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Abstract 1
ABSTRACT
This study evaluated commercially available tests of thyroid function in dogs. The 
diagnostic utility of these tests for hypothyroidism are reported, as are the epidemiological, 
clinical, biochemical and haematological features of the disease. The clinical and 
clinicopathological changes associated with treatment for hypothyroidism are reported and 
a strategy for therapeutic monitoring is provided. The value of thyroid function tests as 
prognostic markers in non-thyroidal illness (NTI) is evaluated.
Commercial kit assays for total 3,5,3',5'- tetraiodothyronine (thyroxine, T 4 ) ,  free T 4 ,  
total 3,5,3'-triiodothyronine (T3), endogenous canine thyrotropin (thyroid stimulating 
hormone, TSH) (cTSH) and thyroglobulin autoantibodies (TgAb) were successfully 
validated for use with canine serum and subsequently evaluated in 140 dogs with clinical 
signs suggestive of hypothyroidism. Hypothyroidism was confirmed (n=52) or excluded 
(n=8 8 ) based on the results of bovine TSH response tests. Median circulating total T4 (4.7 
nmol/L), free T4 (3.22 pmol/L) and total T3 (1.32 nmol/L) concentrations were significantly 
decreased and cTSH (1.38 ng/ml) significantly increased in hypothyroid dogs compared to 
the corresponding values of 20.1 nmol/L, 13.84 pmol/L, 2.38 nmol/L and 0.27 ng/ml, 
respectively in euthyroid dogs with NTI. Optimal diagnostic cut-off values for total T4, free 
T 4 ,  total T 3  and cTSH for the confirmation of hypothyroidism were 14.8 nmol/L, 6 . 6 6  
pmol/L, 1.77 nmol/L and 0.69 ng/ml, respectively. The corresponding test sensitivities and 
specificities for hypothyroidism were 0.96 and 0.70 (total T 4 ) ,  0.81 and 0.93 (free T 4 ) ,  0.76 
and 0.80 (total T 3 ) ,  and 0.79 and 0.82 (cTSH), respectively. Transient increases in cTSH 
values in euthyroid dogs were usually due to recovery from NTI or the recent use of 
sulphonamide-containing drug therapy. Concurrent illness may reduce cTSH 
concentrations into the euthyroid range in hypothyroid dogs.
No age, gender, neutering status or breed predilections for hypothyroidism were 
identified. Although hypothyroidism occurred in dogs of any age, it was rare in animals less 
than two years old. Evaluation of breed and pedigree status was hindered by inherent biases 
within the population studied. However, the most commonly affected breed-types were 
retrievers, spaniels, terriers, crossbreeds and doberman pinschers although these were also 
common amongst the dogs with NTI. No effect of pedigree status on the likelihood of 
developing hypothyroidism was identified. The most common clinical features associated 
with hypothyroidism were metabolic signs (85 % cases), particularly lethargy (77 %), 
weight gain (42 %) or exercise intolerance (27 %), and dermatological signs (79 %), 
particularly hair thinning (56 %), poor coat quality (29 %), hyperpigmentation (19 %) and 
superficial pyoderma (15 %). Concurrent metabolic and dermatological signs occurred in 
67 % cases. The most common routine biochemical and haematological abnormalities 
compared with the laboratory reference range were increases in circulating triglyceride ( 8 8  
% cases), cholesterol (78 %) and fructosamine (43 %) concentrations and reduced red 
blood cell count (40 %). However similar abnormalities frequently occurred in euthyroid 
dogs and the routine tests which most efficiently confirmed hypothyroidism were reduced 
red blood cell count and increased fructosamine values.
Successful clinical resolution of hypothyroidism was achieved by once daily 
administration of synthetic L-thyroxine therapy. Metabolic signs usually improved within 
two weeks after starting therapy whereas dermatological improvements took longer. Mean 
body weight decreased by 1 0  %: ifflfeate)l cases during the first three months o f therapy. 
Most dogs were essentially clinically Wrnial within 13 weeks of starting therapy. Six hour 
post-pill total T4 concentrations were a reliable method of objectively assessing therapeutic 
control. Corresponding mean values in well controlled cases were 55 nmol/L whereas 
values less than 35 nmol/L were usually associated with inadequate clinical improvement. 
Circulating cTSH estimation was of limited utility for therapeutic monitoring although
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increased concentrations usually predicted the need for an increase in therapy. 
Improvements in numerous biochemical and haematological parameters occurred during 
therapy and were consistent with metabolic normalisation. However, only creatinine 
estimation could be used to differentiate between dogs which were adequately or 
inadequately clinically controlled. Iatrogenic thyrotoxicosis occasionally occurred but was 
uncommon and easily treated.
Circulating TgAb was negative, equivocal or positive in 19 (45 %), eight (19 %) 
and 15 (36 %) of 42 hypothyroid, 55 (79 %), 11 (16 %) and four ( 6  %) of 70 healthy, and 
72 (94 %), five ( 6  %) and none, of 77 euthyroid dogs with NTI, respectively. TgAb 
positive and equivocal results were significantly more common in hypothyroid than 
euthyroid dogs. Two of four apparently healthy TgAb-positive dogs had additional 
biochemical abnormalities consistent with profound primary hypothyroidism. The high 
prevalence o f false-positive TgAb results obtained in previous reports was not a significant 
problem with the method evaluated, and a TgAb positive result was highly suggestive of 
thyroid disease.
Clinical features, and thyroid hormone parameters were determined in 205 dogs 
with varying types and severity of illnesses. Mean (± standard deviation (s.d.)) age (years) 
was significantly lower in dogs which made a full recovery (5.6 ± 4.3) compared to those 
which were made a partial recovery (7.4 ±3.7 years) or which were euthanatised (7.6 ±3.6 
years). Dogs with acute diseases were significantly less likely to survive than those with 
chronic illnesses. Dogs with neoplasia were significantly less likely to survive than other 
dogs, whereas orthopaedic cases were significantly more likely to make a full recovery. The 
most common pattern of thyroid hormone abnormalities was reduced total T3 alone 
(approximately 40 % cases) or concurrently reduced total T4 and total T3 (approximately 
30 % cases) concentrations. Reduction in total T4 values alone was rare. Circulating total 
and free T4 concentrations were significantly decreased by certain drug therapies but these 
did not influence prognosis. Circulating total T4, free T4 and total T3 were significantly 
decreased in dogs that died compared to those which survived. The magnitude of 
depression was inversely correlated to the likelihood of survival. The maintenance of 
normal circulating total T3 concentrations was a strong predictor that an animal would 
survive.
This clinical, clinicopathological and epidemiological study has greatly increased the 
knowledge and understanding of canine thyroid function in hypothyroidism and NTI. The 
findings have improved the ability to diagnose, treat and prognosticate, and have opened 
the door for future research.
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CHAPTER 1 
INTRODUCTION
1.1 BACKGROUND
Hypothyroidism is the clinical syndrome caused by reduced circulating concentrations of 
the active thyroid hormones T3 and T4. It is widely acknowledged as one o f the most 
common endocrine diseases affecting dogs. In dogs, hypothyroidism usually results from 
primary thyroid gland failure, caused by either lymphocytic thyroiditis or idiopathic atrophy 
(Kemppainen & Clark, 1994). Central hypothyroidism, whereby inadequate thyrotropin 
(thyroid stimulating hormone, TSH) secretion causes thyroidal insufficiency also 
occasionally occurs in dogs.
In humans, the diagnosis of primary hypothyroidism can be accurately and reliably 
achieved by measurement of circulating free (non protein-bound) T4 and human TSH 
concentrations (Stockigt, 1996). By contrast, achieving a reliable diagnosis of canine 
hypothyroidism is fraught with difficulty. Measurement of circulating total T4 concentration 
is often recommended but is complicated by the overlap of results in hypothyroidism, in 
health and in NTI (Belshaw & Rinjberk, 1979; Nelson, Ihle, Feldman & Bottoms, 1991; 
Peterson, Melian & Nichols, 1997; Scott-Moncrieff, Nelson, Bruner & Williams, 1998). 
Free T4 is considered to be the principal determinant of cellular hormone activity and 
consequently should provide a more accurate indicator of true thyroid status (Robbins & 
Rail, 1957). However, estimation of free T4 can be performed by a variety of techniques 
and the most widely used of these methods in veterinary medicine have been severely 
criticised on both theoretical and practical grounds (Ekins, 1985). Measurement of free T4 
by tracer equilibrium dialysis is considered to be the gold standard method but this 
technique is cumbersome and unsuitable for most veterinary laboratories.
Recently assays for cTSH, free T4 measured by a modified equilibrium dialysis kit 
technique, and TgAb have become commercially available. At the commencement of this 
study, there were no reports regarding cTSH measurement in the investigation of 
spontaneous hypothyroidism; very limited data had been published on reliably measured 
free T4 concentrations in suspected hypothyroid dogs; and no reports of the clinical utility 
of TgAb estimation for hypothyroidism using the recently commercialised assay were 
available. In particular, very little is known about the effect o f non-thyroidal factors such as 
NTI or commonly used drug therapies on these tests. During the course of this study, 
Jensen, Iverson, Hoier, Kristensen & Henriksen, (1996) reported relatively poor diagnostic
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sensitivity of the cTSH assay for hypothyroidism but thyroid function itself was not reliably 
studied. Peterson et al., (1997) documented hypothyroidism in 54 dogs, and reported 
improved diagnostic accuracy o f free T4 by modified equilibrium dialysis compared to total 
T4 measurement. Peterson et al, (1997) also evaluated the cTSH assay but reported 
relatively poor sensitivity for hypothyroidism. Scott-Moncrieff et al, (1998) evaluated the 
same assay as Peterson et al., (1997) with broadly similar conclusions, but cases with 
borderline thyroid function based on TSH response tests were excluded from that study. 
Nachreiner, Refsal, Graham, Hauptman & Watson, (1998) evaluated a kit for TgAb 
estimation but the study was laboratory based and only limited clinical information was 
available from the cases.
Epidemiological information on canine hypothyroidism worldwide is sparse, and as 
it applies to the UK specifically, essentially non-existent. Previous studies of the disease 
have been limited by variable or poor quality methods for reliably confirming 
hypothyroidism, and studies performed elsewhere cannot necessarily be presumed to reflect 
the pattern of hypothyroidism in the population of dogs in the United Kingdom (UK) at this 
time.
Another consequence of the difficulties encountered in reliably confirming 
hypothyroidism, is that published data of the clinical and clinicopathological features of the 
disease are often sparse and must be interpreted cautiously. Hypercholesterolaemia and a 
mild anaemia are commonly reported in hypothyroidism (Panciera, 1994). However, their 
relative frequency in dogs with clinically similar NTI has not been reported. Therefore, the 
diagnostic utility of these and other routine biochemical and haematological parameters for 
hypothyroidism remains unclear.
Canine hypothyroidism is usually treated by oral administration of a synthetic 
thyroid hormone supplement. However, the dosing regime is controversial and 
recommendations vary among authors. Similarly, guidelines for therapeutic monitoring vary 
between reports and are largely empirical. Furthermore, there is a paucity of data regarding 
the changes which occur in biochemical and haematological parameters following the 
institution o f therapy for hypothyroidism. Neither has the correlation of endocrine or 
routine clinicopathological parameters with clinical outcome been reliably studied in dogs. 
Consequently there are no scientifically-based objective guidelines for treating and 
monitoring canine hypothyroidism.
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1.2 PROJECT AIMS
It was against this background that the present study was performed. The project aims 
were:
To fully validate commercially available total T4, free T4 by modified equilibrium dialysis, 
total T3 , cTSH, and TgAb assays for use with canine serum.
To evaluate the potential role of differential positive rate analysis and receiver operating 
characteristic curves in the study of diagnostic tests of canine thyroid function.
To evaluate the diagnostic utility of these assays in the investigation of dogs with suspected 
spontaneous hypothyroidism, and to produce guidelines for their routine use and 
interpretation. Furthermore, to study these tests in a population of dogs with a variety of 
NTI to provide additional data on the test performances in a clinical setting.
To identify clinical and clinicopathological characteristics of canine hypothyroidism and by 
comparison with the equivalent results from dogs with clinically similar NTI, identify the 
most reliable predictors of hypothyroidism. Furthermore, to identify clinical and 
epidemiological characteristics associated with hypothyroidism
To determine objective therapeutic guidelines for canine hypothyroidism and to evaluate 
the role of both endocrine tests and routine biochemical and haematological tests in 
monitoring dogs receiving thyroid hormone replacement therapy.
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CHAPTER 2 
GENERAL MATERIALS AND METHODS
2.1 CLINICAL MATERIAL
The initial case material comprised a series of dogs referred to the University of Glasgow 
Veterinary School Department of Veterinary Clinical Studies (DVCS) for investigation of 
clinical signs or clinicopathological abnormalities suggestive of hypothyroidism. All cases 
were registered with the DVCS at the time of their first consultation and assigned a unique 
permanent six figure hospital number. Details of the owner, patient and referring veterinary 
surgeon were recorded to the hospital database and updated during subsequent visits. The 
data recorded are listed in Appendix 1.
During the initial consultation relevant historical details were recorded in the 
animal's case notes including the type and duration of clinical signs, current and previous 
drug therapies, previous ancillary test results, and response to any previous therapies. A full 
physical examination was performed and the findings similarly recorded. If hypothyroidism 
remained a possible diagnosis, owner consent for further investigation was ascertained and 
the animal was hospitalised. Providing the animal had been subjected to an overnight fast, 
blood samples were collected by jugular venipuncture into appropriate tubes for further 
analyses which included all or a selection of the following; routine haematology, routine 
biochemistry, total T4, endogenous cTSH, free T4 measured by equilibrium dialysis, total T3 
and TgAb. A bovine TSH response test was then performed in each case. The result of this 
test was used to categorise the case as either hypothyroid or euthyroid.
Hypothyroidism was excluded in dogs with a post-TSH serum total T4 
concentration in excess of 30 nmol/L and which was at least 1.5 times greater than the 
basal total T4 concentration. In these cases additional diagnostic tests were performed as 
required to identify the cause of disease. Hypothyroidism was confirmed in dogs with a 
post-TSH total T4 concentration < 20 nmol/L. These criteria are similar to those most 
recently used by Peterson et al., (1997) and Scott-MoncriefF et al, (1998). Additional 
criteria were used to classify those dogs with a post-TSH total T4 concentration which was 
between 20 and 30 nmol/L and which had shown an increase o f at least 1.5 times the basal 
concentration. These additional criteria included follow-up measurement o f thyroid
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hormones, histopathological examination of thyroid tissue and complete recovery from a 
NTI without the need for thyroid hormone supplementation.
In dogs in which hypothyroidism was excluded based on the above results 
appropriate additional ancillary tests (urinalysis, diagnostic imaging, electrocardiography, 
skin scraping, dynamic adrenal function testing etc.) were performed to establish a 
diagnosis. These animals were usually transferred to other clinicians in the DVCS for such 
investigations. If  thyroid status was equivocal after the initial tests, three to six month 
intervals were allowed elapse and the case subsequently reviewed and classified. In dogs in 
which hypothyroidism was confirmed treatment was instituted with L-thyroxine sodium 
(Soloxine, Daniels Pharmaceuticals) @ 0.02 mg/kg body weight given once daily in the 
morning. Owners were requested to return for repeat examinations two, six and 12 weeks 
after the start of treatment unless otherwise indicated. At each repeat examination the 
changes in clinical details were recorded and blood collected six hours after T4 
administration for total T4 and cTSH estimation and routine biochemical and 
haematological analyses. The dosage of L-thyroxine was subsequently adjusted based on 
the clinical and clinicopathological response. If there was resolution of the clinical signs, 
and acceptable and stable clinicopathological results by the 1 2  week examination, cases 
were discharged from the DVCS and referred back to their primary veterinary surgeon for 
future monitoring. Any dogs who were not adequately controlled by the 12 week check-up 
continued to return to the DVCS until adequately treated.
Assessment of total T4, free T4, total T3, cTSH and TgAb was also performed in 
serum and plasma samples collected from a series of dogs hospitalised at the DVCS with 
various NTI (Chapter 8 ). This group comprised animals being blood sampled by the 
attending clinician in the DVCS as part of routine diagnostic or monitoring evaluation. 
Dogs with a wide range of types and severity of illnesses were included but only if there 
was a sufficient volume of sample spare to perform subsequent thyroid hormone analyses. 
Clinical and historical information, and outcome of these cases was obtained by 
interrogation of the relevant clinician and when necessary by examination o f the laboratory 
submission form, hospital case notes and the letters o f referral. The diagnosis assigned to 
these cases was the one considered most likely by the attending clinician. Further details on 
the method o f clinical information recording in these cases is provided in Chapter 8 .
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2.2 ROUTINE HAEMATOLOGICAL ANALYSES
Blood was collected into plastic tubes containing tri-potassium ethylenediamine tetra-acetic 
acid (EDTA) anticoagulant and analysed within four hours of collection using an 
automated MINOS-Vet haematology analyser (ABX, Montpellier). Buffered saline was 
used as a diluent and potassium cyanide as a lysing agent as described by the manufacturer. 
A blood film was prepared on a glass slide and stained with May-Grunwald-Geimsa's stain. 
The differential white blood cell count was performed by counting and classifying at least 
200 cells using an extended battlement technique. Measured and calculated parameters are 
listed in Appendix 2.
2.3 ROUTINE BIOCHEMICAL ANALYSES
Blood was collected into plastic tubes containing either lithium heparin (all routine 
measurements except glucose) or fluoride oxalate (glucose measurement) anticoagulant 
and analysed within four hours of collection. The parameters measured and the analysers 
used are listed in Appendix 3. Quality control (QC) procedures included daily analysis of 
commercial QC samples including regional quality control (RQC) (Scottish Antibody 
Production Unit (SAPU)), Pathonorm (Biostat) and Set-Point Calibrator Universal 
(Bayer), as well as monthly analysis of Veterinary Sample Exchange (VSE) scheme QC 
material.
2.4 BOVINE THYROTROPIN RESPONSE TEST
A bovine TSH response test was carried out in the initial cases by collection of blood for 
total T4 estimation immediately before and six hours after the intravenous administration of 
0.1 international unit (i.u.) TSH (Thyrotropic Hormone, Sigma Chemical Company) per kg 
body weight (maximum dose 5 i.u. per dog). Serum total T4 estimations were performed on 
each sample in the same assay run to avoid inter-assay variation.
2.5 THYROID HORMONE ANALYSES
All plain (uncoated) tubes used for hormone assays were polypropylene highly-transparent
4.5 ml tubes (Coombs-Tube, catalogue number 57.477.500, Starstedt). The pre-TSH 
sample was used for all hormone measurements other than the post-TSH total T4 
estimation.
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Total Thyroxine
Serum total T4 concentrations were measured using a commercial magnetic separation 
competitive radioimmunoassay (RIA) kit (MAGIC T4, Chiron Diagnostics). The materials 
provided with the kit included one vial of rabbit anti-T4 antibody (Ab) covalently bound to 
magnetic particles and suspended in phosphate buffered saline (PBS), one vial of 125I- 
labelled T4 tracer (less than 216 kilo Becquerels (KBq) radioactivity per vial) dissolved in 
PBS, and she pre-prepared T4 standards in human serum at concentrations of approximately 
0, 32, 64, 129, 193 and 386 nmol/L. All samples, standards and reagents were allowed to 
come to room temperature prior to use. The assay was performed according to the 
manufacturers instructions with the addition of 8  nmol/L and 16 nmol/L standards prepared 
by dilution of the supplied standards with the zero standard, to increase the working range 
of the assay.
Plain tubes were labelled in duplicate for standards, controls and patient samples 
and two tubes were labelled for total count (TC) measurement. 25 pi of either standard, 
control or patient serum plus 100 pi of tracer and 500 pi anti-T4 Ab was added to each 
tube. All tubes were incubated at room temperature for one hour and then placed in a 
magnetic separation unit (MAGIC, Chiron Diagnostics) for three minutes before decanting 
and blotting. The remaining radioactivity was measured in counts per minute (cpm) with a 
gamma counter (COBRA II Auto-Gamma, Packard BioScience) and compared with those 
of the standards to allow estimation of the total T4 concentration in the original patient 
sample.
Free Thyroxine
A modified direct dialysis kit (Free T4 by Equilibrium Dialysis, Nichols Institute 
Diagnostics) was used for free T4 estimations. The materials provided with the kit included 
100 polystyrene tubes coated with anti-T4 Ab, one vial of 125I-labelled T4 tracer (less than 
270 KBq radioactivity per vial) in HEPES buffer, six standards in HEPES buffer at batch- 
specific concentrations of approximately 0, 3.1, 8.0, 23.2, 55.3 and 124.8 pmol/L after 
reconstitution with 6.0 ml deionised water, one vial o f wash solution concentrate in PBS, 
one vial of dialysis buffer, and 40 disposable Nelson Dialysis Cells composed o f an outer 
dialysate vial and an inner membrane cylinder. The assay was performed according to the 
manufacturers instructions.
Dialysate vials were labeled in singlicate for all control and patient samples. The 
membrane cylinder was removed, 2.4 ml dialysis buffer added to the dialysate vial and the
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membrane cylinder replaced. 2 0 0  pi of patient sample or control was added to the 
appropriate membrane cylinders and the cells were sealed with parafilm (NESCOFILM, 
Nippon Shoji Kaisha Ltd.) and incubated for 16-18 hours at 37 ± 0.5°C in a water bath 
(SS40-A2, Grant Instruments). After incubation the membrane cylinders were immediately 
removed from the dialysate vials prior to RIA.
The coated tubes were labelled in duplicate for standards, control and patient 
sample dialysates. Two plain tubes were labelled as TC tubes and two as non-specific 
binding (NSB) tubes. 800 pi of standard or dialysates and 50 pi of tracer was added to 
appropriate tubes. These were vortexed and sealed with parafilm and incubated at 37 ± 
0.5°C in a water bath (SE15, Grant Instruments). After incubation all tubes except the TC's 
were decanted and washed twice each with 2 ml of wash solution. After thorough draining 
the remaining radioactivity was measured as for total T4 . Comparison of the test sample 
counts with those of the standards allowed estimation of the free T4 concentration in the 
original patient sample.
Total Triiodothyronine
Serum total T3 concentrations were measured using a commercial magnetic separation 
competitive RIA kit (MAGIC T3, Chiron Diagnostics). The materials provided with the kit 
included one vial of rabbit anti-T3 Ab covalently bound to magnetic particles and suspended 
in PBS, one vial of 125I-labelled T3 tracer (less than 81 KBq radioactivity per vial) dissolved 
in PBS, and seven pre-prepared T3 standards in human serum at concentrations of 
approximately 0, 0.38, 0.77, 1.54, 3.08, 6.16 and 12.32 nmol/L. All samples, standards and 
reagents were allowed to come to room temperature prior to use and the assay was 
performed according to the manufacturers instructions.
Plain tubes were labelled in duplicate for standards, controls and patient samples 
and two tubes were labelled for TC measurement. 50 pi of either standard, control or 
patient serum plus 100 pi of tracer and 500 pi anti-T3 Ab was added to each tube. All tubes 
were incubated at room temperature for two hours and then placed in a magnetic 
separation unit for five minutes before decanting and blotting. After thorough draining the 
remaining radioactivity was measured as for total T 4 .  Comparison of the test sample counts 
with those of the standards allowed estimation of the total T3 concentration in the original 
patient sample.
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Thyrotropin
Endogenous serum cTSH was measured using a commercial immunoradiometric (IRMA) 
assay (Canine TSH IRMA, Diagnostic Products). The materials provided with the kit 
included 100 polystyrene tubes coated with murine anti-cTSH monoclonal Ab, two vials of 
125I-labelled anti-cTSH rabbit polyclonal Ab tracer (less than 270 KBq radioactivity per 
vial), seven cTSH standards prepared in cTSH-free canine serum at batch-specific 
concentrations o f approximately 0, 0.15, 0.30, 0.60, 1.5, 4.0 and 12.0 ng/ml, and one vial 
of concentrated buffered saline solution. All samples, standards and reagents were allowed 
to come to room temperature prior to use. The assay was performed according to the 
manufacturers instructions.
The coated tubes were labelled in duplicate for standards, controls, test samples and 
two plain tubes were labelled for TC estimation. 100 pi of standard, control or patient 
serum and then 1 0 0  pi of tracer was added to all tubes prior to shaking at room 
temperature on a rack shaker (DPSR2, Diagnostic Products) at 200 strokes per minute for 
three hours. All tubes except TC's were decanted and washed twice each with 2 ml o f wash 
solution. After thorough draining the remaining radioactivity was measured as for total T4 . 
Comparison o f the test sample counts with those o f the standards allowed estimation o f the 
cTSH concentration in the original patient sample.
Thyroglobulin Autoantibodies
A commercial enzyme linked immunosorbent assay (ELISA) kit (Canine thyroglobulin 
autoantibody immunoassay kit, Oxford Laboratories) was used to assess TgAb status. The 
materials provided with the kit included one 96-well microtitre plate pre-coated with canine 
thyroglobulin (Tg), one vial of horseradish peroxidase (HRP)-conjugated rabbit anti-canine 
immunoglobulin G (IgG), one vial each of TgAb positive and negative reference serum, one 
vial of phosphate buffer, one vial of 3,3',5,5'-tetramethylbenzidine (TMB) enzyme substrate 
and one vial o f wash buffer. The assay was performed according to the manufacturers 
instructions.
Samples and standards were diluted 1:100 with buffer and 100 pi was added to 
appropriate wells and incubated at room temperature for at least two hours. All test 
samples were measured in duplicate and standards in hexuplicate. Four wells were left 
empty as blanks. After incubation each well was washed three times and 100 pi of anti­
canine IgG was added. After a further one hour incubation period the wells were washed 
three times and 200 pi enzyme substrate was added. After a 10 minute incubation period 50
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pi IN sulphuric acid stop solution was added to each well and the optical densities (o.d.) 
immediately read at 450 nm using a commercial plate reader (MRX Microplate Reader, 
Dynex Technologies (UK) Ltd.). Test sample o.d.'s less than the mean plus twice the s.d. of 
the negative standard were considered negative. Test sample o.d.'s greater than twice the 
mean value of the negative standard were considered positive. Those samples with o.d.'s 
between these limits were considered equivocal.
2.6 DATABASE INTERROGATION
The hospital computer system operated by the DVCS over the relevant period of this study 
was used to record animal details of all cases referred to the University of Glasgow 
Veterinary School. These data were used for the generation of the hospital control group 
used in Chapter 5. Data from proven hypothyroid and euthyroid groups was directly stored 
using standard personal computer (PC) compatible Microsoft software. The hospital 
system was operated from a Jarogate Sprite 386 (Jarogate) and used relational database 
software (Dataflex, Data Access Corporation) running on a CP/M operating system. 
Terminals for case data entry were located within the case reception office. Additional links 
via a local network allowed transfer o f data between the central animal file and the 
Department of Veterinary Pathology which included haematology data. The central animal 
file itself stored relatively few details on each case, namely hospital number, animal name, 
gender, date of birth and date first seen. However this file contained references to other 
files which were used for storage of data relating to species, breed, owner, staff member 
and referring veterinary surgeon. Consequently accessing the central animal file directly 
allowed interrogation o f numerous additional files with the appropriate case information. 
The interrogation of the system was performed by executing the “query database” function 
available within Dataflex. This function allowed the selection of the desired case details 
which could be saved in a delimited form to an external file. Each query was defined by 
case and temporal parameters and stored to PC in a compatible format using a commercial 
computerised spreadsheet programme (Microsoft Excel for Windows 95, version 7.0a, 
Microsoft Corporation). This allowed additional and more convenient Windows-based data 
interrogation at a later date.
2.7 DATA STORAGE
Microsoft Excel spreadsheets were used for storage, sorting, retrieval and transfer of 
clinical, haematological, biochemical and endocrinological data o f the proven hypothyroid
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and euthyroid groups. Data were arranged in rows on a single spreadsheet primarily in 
alphabetical order of the owner's name, and secondarily in order of visit date. Each dog- 
visit therefore resulted in the addition o f another row of information containing relevant 
data as detailed in Appendix 4. This method of data storage facilitated retrieval and transfer 
to computerised statistical packages for subsequent analyses.
Data from cases used in Chapter 8  were collected by manual storage of various 
parameters to a blank template as shown in Appendix 5. Each hard copy was recorded and 
stored in numerical order as determined by the date of sample receipt. Many of the 
parameters such as age, breed, case number, date of sample and gender could be recorded 
directly from the sample submission form accompanying the relevant sample. Additional 
clinical information was obtained by interrogation of the attending clinician. A 
computerised database (Microsoft Access for Windows 95 version 7.00, Microsoft 
Corporation) was then used to store the data on PC. A file was produced which allowed 
storage of the appropriate parameters. This was interrogated by the design of appropriate 
query actions within the software.
2.8 DATA MANIPULATION 
Diagnostic Sensitivity and Specificity
The diagnostic performance of the tests used in the investigation of hypothyroidism 
(Chapters 4 and 5) were evaluated in terms of their sensitivity and specificity (Table 1). 
Diagnostic sensitivity was defined as the probability that a test or procedure was positive 
when the disease was present and the specificity as the probability that the test or 
procedure was negative when the disease was not present (Griner, Mayewski, Mushlin & 
Greenland, 1981). Individuals with a result equal to the cut-off were considered diseased 
(Jensen, 1994).
.. . . . . .  True positivesDiagnostic sensitivity = _  — —*— ——True positives + false negatives
.. True negativesDiagnostic specificity = _  — :----- n —True negatives + false positives
Table 1. Calculations used to determine diagnostic sensitivity and specificity
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Production of Receiver Operating Characteristic (ROC) Curves and Calculation of 
the Differential Positive Rate (DPR)
The performance of the test under investigation across the range of possible cut-off values 
was represented graphically by generating a receiver operating characteristic (ROC) curve 
(Figure 1). A ROC curve is a graph which plots the sensitivity on the y-axis against 1- 
specificity on the x-axis throughout the range of possible test cut-off values. All ROC 
curves pass through the points 0 , 0  (sensitivity = 0 , specificity = 1 ) and 1 , 1  (sensitivity = 1 , 
specificity = 0). A perfect test (i.e. sensitivity and specificity both = 1) extends to the upper 
left hand comer of the graph (position 0 , 1 ) whereas a test with no ability to differentiate 
healthy from diseased individuals is a straight line with a slope of 1 extending from the 
origin (position 0,0) to the top right comer (position 1,1) of the graph. ROC curves for 
several diagnostic tests can be visually compared with the line located furthest towards the 
top left hand comer of the graph being the generally better test. However, a more objective 
assessment can be made by calculation of the area under the curve (W). The W of a perfect 
test equals 1 whereas a test in which W is not significantly different from 0.5 (a straight line 
from position 0 , 0  to 1 , 1 ) has no determinable ability to differentiate healthy from diseased 
individuals (Jensen, 1994). The W was calculated for all endocrine tests under 
investigation.
Sensitivity
1
0 0 1
1 -specificity
Figure 1. Representation of a Receiver Operating Characteristic (ROC) curve. Line “A” 
represents a diagnostically perfect hypothetical test. Line “B” represents a hypothetical test 
with intermediate performance characteristics. Line “C” represents a hypothetical test with 
no ability to differentiate affected from unaffected patients.
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The cut-off value of the test associated with the greatest combined sensitivity and 
specificity was identified by calculation o f the differential positive rate (DPR) across the 
range of possible cut-off values. The DPR corresponds to the sensitivity minus (1- 
specificity) (Ward, 1986). The computational data for DPR analysis and ROC curve 
construction including calculation of diagnostic sensitivity and specificity were generated 
by use of formulae constructed within Microsoft Excel. These are outlined in Appendix 6 . 
ROC curve data were produced according to the method of Jensen, (1994) and then copied 
to a computerised graphical package (PowerPoint for Windows 95 version 7.0b, Microsoft 
Corporation). Graphs of the diagnostic sensitivity, specificity and DPR were also produced 
with Microsoft PowerPoint.
2.9 STATISTICAL ANALYSES
All statistical calculations were performed using MINI TAB 9.2 for Windows (Minitab Inc.) 
or MedCalc Demo Version 4.16e for Windows 95 (Frank Schoonjans). Additional details 
of the statistical methods used are given in appropriate chapters. A probability (p) value 
less than 5 % (p < 0.05) was considered significant.
2.10 SELECTION OF CLINICAL CONTROL POPULATIONS
For the purposes of this study and particularly the investigations outlined in Chapter 5, 
three groups of dogs were used as the clinical control groups. Each group was chosen for a 
separate and specific purpose. This is discussed in detail in Chapter 5. The first control 
group, referred to as the euthyroid group, consisted o f those dogs investigated for 
hypothyroidism but subsequently classified as euthyroid. This group was used to identify 
the characteristics which separated truly hypothyroid dogs from dogs with diseases 
mimicking hypothyroidism. The second control group, referred to as the hospital group, 
consisted of all dogs other than the hypothyroid or euthyroid groups, with complete data 
for age, breed and sex referred to the DVCS during the study period. These data were 
obtained by interrogation of the hospital computer system as previously described. If dogs 
were seen on more than one occasion during this interval only data from the first visit was 
used for statistical analyses. The hospital group was used to allow comparison of results 
with other studies, most of which used the equivalent cases as control populations. The 
third control group, referred to as the external group, consisted o f data obtained from the 
Kennel Club (KC). These data consisted of the number of dogs of each breed first 
registered with the KC during the period 1994-1997 inclusive.
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2.11 SELECTION OF CLINICOPATHOLOGICAL CONTROL POPULATIONS
The nomenclature used to compare the routine clinicopathological results of the 
hypothyroid and other dogs discussed in Chapter 5 was as recommended by Grasbeck, 
Siest, Wilding, Williams & Whitehead, (1979). For the purposes of this study and 
particularly the investigation outlined in Chapter 5, the clinicopathological results from 
hypothyroid dogs were compared with two reference sample groups. The first was the 
laboratory reference range which allowed comparison of results with the findings of 
previous studies. The laboratory reference range was generated by a variety of methods 
which included analysis of samples from “healthy” dogs, clinical experience gained from the 
analysis of results from dogs referred to the DVCS, and the use of broadly accepted so- 
called “normal” values derived from the literature. The second reference sample group was 
all the dogs investigated for suspected hypothyroidism but in which the diagnosis was 
excluded, i.e. the euthyroid group. The reference distribution was considered to be all the
thclinicopathological results from these cases. The reference limits were defined as the 2.5 
and 97.5th percentiles of the reference distribution values. Results were considered 
abnormal if they were above or below the upper and lower reference limits, respectively.
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CHAPTER 3
VALIDATION OF ASSAYS USED TO ASSESS THYROID FUNCTION
3.1 LITERATURE REVIEW 
Assay validation
The reliability of an assay should be demonstrated prior to its adoption for routine use 
because although most QC procedures will identity changes in the performance of an 
analytical method, no system of QC can improve a fundamentally unsound technique 
(Buttner, Borth, Boutwell, Broughton & Bowyer, 1980a). The principal features which 
require evaluation in assay validation studies are precision, accuracy, specificity and 
detectability often expressed as “sensitivity” (Robinson, 1988; McLauchlan & Gowenlock, 
1988). This is known as the “PASS” validation of a method. Precision includes inter-assay 
and intra-assay precision; accuracy is usually determined by assay of reference samples or 
by spiking of samples; specificity is evaluated by cross-reactivity or parallelism studies, and 
sensitivity can be determined using a number o f methods. The PASS scheme is outlined 
below. In addition, consideration should also be given to the practicality of a method such 
as speed, cost, skills required and safety (Seneviratne, 1988).
The precision of a method is an assessment of its repeatability. This encompasses 
both within-run (intra-assay) precision and between-day (inter-assay) precision. The 
number of samples used for precision estimation is arbitrary, although 2 0  replicates 
spanning the range of clinical relevance has been suggested to be adequate (Buttner et al., 
1980a; Seneviratne, 1988). The mean, s.d. and the coefficient of variation (c.v.) defined as 
the ratio o f the s.d. to the mean expressed as a percentage should be quoted. There are no 
standard performance criteria applicable to all assays since these vary depending on the 
clinical interpretation o f results across the range o f possible values. However, for 
radioimmunoassays intra-assay c.v.'s up to approximately 1 0  % and inter-assay c.v.'s not 
exceeding 15 % are often broadly acceptable (Hunter, 1978).
The accuracy of an assay is the agreement between the mean estimate of a quantity 
and its true value. However the true value o f biological specimens is rarely known. 
Consequently, comparison of the method with other techniques, ideally a definitive method 
but more usually a reference method, is commonly used as an indicator o f accuracy as is the
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ability of the technique to recover a known amount of added material (Buttner et al.,
1980a; Robinson, 1988).
Most analytical methods show some lack of specificity commonly due to cross­
reactivity with other analytes. Indeed the assessment of specificity is rather open-ended 
since an infinite number of molecules, drugs, food-stuffs etc. may potentially interfere with 
an assay. Nevertheless the use of immunoassays is generally associated with relatively high 
specificity due to the highly specific nature of the antigen-antibody interaction. Ideally, 
specificity is demonstrated by the measurement of analyte in a sample to which various 
structurally similar compounds have been added. Under these conditions, a highly specific 
assay will show no significant increase in apparent concentration whereas the concentration 
is likely to increase if there is significant cross-reactivity. However, in practice this can be 
technically awkward depending on the group of substances under test. Therefore as an 
alternative, the specificity of an assay can be evaluated by demonstration o f linearity under 
dilution using a diluent known not to contain the analyte. This technique is straightforward 
particularly in the case of drug assay studies and therefore is widely used. However, when 
measuring biological entities, such as hormones, obtaining serum which is devoid of the 
analyte but otherwise identical to the test samples is more difficult. Collection of samples 
from patients with genetic deficiencies of particular hormones may be used for this purpose 
but clearly these are difficult to regularly obtain. Serum from the relevant species can be 
stripped of hormone for example by charcoal adsorption (Stockhill, 1979). However this 
process also results in removal o f other hormones and can be complicated by the 
persistence of charcoal fines within the serum. An alternative method of hormone 
extraction from serum in which serum is passed through suspended dowex resin was 
reported by Salter, (1979). The addition of radiolabelled hormone to the serum prior to 
processing and subsequent assessment of the radioactivity remaining after extraction allows 
confirmation that all the hormone has been removed. This method is inexpensive and avoids 
the problem of charcoal fines. The use of assay “zero standards” as the diluent in 
parallelism studies is often used as an alternative to hormone stripped serum. A 
disadvantage is that the measured concentration of any analyte will usually decrease in a 
linear manner irrespective of the analyte being measured, as long as the diluent is free of 
that substance. The use of protein-free diluents such as zero standards, will also influence 
protein binding in the resultant samples and potentially interfere with total and particularly 
free hormone assays. This is particularly important in samples containing inhibitors of 
protein binding. This issue is discussed in more detail in Chapter 8 . Therefore given all of
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these, while the absence of parallelism usually indicates poor assay specificity, its presence 
does not guarantee it. The specificity of an assay can also be evaluated by demonstrating an 
appropriate biological response. For example a rise in circulating cTSH concentration 
following administration of the tripeptide, thyrotropin releasing hormone (TRH), or 
increase in total T4 after cTSH administration would be supportive o f assay specificity 
(Belshaw & Rijnberk, 1979). However this method is certainly not definitive. The method 
or methods ultimately used depends on the balance between the available resources and the 
purposes of the validation.
The detectability of an assay is its ability to detect small quantities of a measured 
component. Whilst this has no numerical value, the corresponding measured quantity is the 
limit of detection (LoD) which is the smallest single result that with a stated probability, 
usually 95 %, can be distinguished from a suitable blank (Buttner, Borth, Boutwell, 
Broughton & Bowyer, 1980b). Determination of the LoD allows comparison between 
methods, helps avoid regular misuse of an assay at values near or lower than the LoD, and 
recognises those results which should be reported as 'less than [LoD]'. Several methods of 
estimation of the LoD have been reported. The International Federation of Clinical 
Chemistry (IFCC) recommends repeated analysis of a suitable blank known not to contain 
the analyte and calculation of the LoD as the mean plus 2.6 s.d. of the blank result (Buttner 
et al., 1980a). Alternatively, the LoD o f an assay can be determined by the construction of 
precision profiles. This technique enables estimation of the lowest concentration of an 
analyte associated with an acceptable level of assay imprecision (Wilkinson, Rae, 
Thompson, Toft, Spencer & Beckett, 1993; Ekins & Edwards, 1997). This approach 
allows the varying clinical applications of assays to be accommodated without a rigid 
criteria being applied to all systems. Since the method relies upon the loss of precision 
which occurs at extremes of the standard curve it can also be used to determine the upper 
end of the analytical range of a method. Alternatively, the concentration of hormone 
producing a change in binding of a predetermined value (e.g. 2  s.d. greater than the 
maximal binding) has been used as corresponding to the LoD (Torres, McKeever & 
Johnston, 1991; Panciera & Post, 1992; Peterson et al, 1997). Some workers prefer to cite 
the concentration of the lowest available standard as the LoD (Thoday, 1986). However, 
this is likely to be an unnecessarily conservative approach particularly given the 
sophisticated computer modeling packages now available for standard curve extrapolation 
(Robinson, 1988).
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Validation of assays used to assess canine thyroid function
Numerous publications reporting on the laboratory or clinical performance of thyroid 
hormone and clinically related assays exist in the human and veterinary literature. It is 
outwith the scope of this thesis to attempt a review of all such reports. Therefore, a 
selection of those considered to be either of most historical interest, or particularly relevant 
to the work outlined herein were chosen for a more detailed review.
Total thyroxine
The most widely investigated diagnostic assays designed to assess canine thyroid function 
are total T4 RIA's. These are usually manufactured for use with human serum but are 
reliable when used with canine samples because of the inter-species cross reactivity of T4 
(Feldman & Nelson, 1996). However, serum total T4 concentration in the dog is 
approximately 25 % o f that encountered in humans (Kaptein, Hays & Ferguson, 1994) and 
therefore most procedures are modified by dilution of the standards to facilitate the 
measurement of lower concentrations (Panciera & Post, 1992; Hall, Campbell, Chambers & 
Davis, 1993; Torres et ah, 1991).
One of the first large studies on the use of thyroid hormone RIA’s in veterinary 
medicine was reported by Belshaw & Rijnberk, (1979). Charcoal based magnetic 
separation RIA’s for total T4 and total T3 estimation in canine serum were used. The 
assay’s were in-house methods using 125I-labelled T4 and T3 (New England Nuclear), T4 
and T3 rabbit antisera (Nichols Institute) and pre-supplied T4 and T3 standards (Sigma 
Chemical Co.). However only limited assay validation data were reported and the authors 
concentrated mainly on clinical validation o f the methods.
Reimers, Cowan, Davidson & Colby, (1981) evaluated a human derived coated- 
tube total T4 RIA (Autopak, Micromedic Systems) for use with canine serum and gave a 
full and comprehensive report on their methods and results. The assay was modified for 
canine serum by dilution o f the lowest standard 1 : 2  with zero standard to improve the assay 
LoD. Intra-assay precision was evaluated by the repeated measurement of two samples on 
10 occasions in a single assay. Inter-assay precision was evaluated by the repeated 
measurement of three samples in 20 consecutive assay runs. Intra-assay c.v.’s were 5.8 and
7.6 % at mean total T4 concentrations of 8.89 and 44.27 nmol/L, respectively. Inter-assay 
c.v.’s were 16.4, 7.1 and 4.0 % at mean total T4 concentrations of 8.62, 25.35 and 54.31 
nmol/L, respectively. Accuracy was determined by adding known amounts (determined 
gravimetrically) of purified T4 to serum samples containing previously measured
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endogenous total T4 and measuring the final concentration obtained. The recovery slope 
had an r value of 0.997 and an intercept of -0.17 based on analysis of three samples. 
However the individual results were not provided. The LoD was determined by calculation 
of the lower 95 % confidence limit of percentage binding of the zero standard based on 10 
measurements. This was reported to be 2.19 nmol/L. Specificity was comprehensively 
evaluated by the production of a standard inhibition curve, assessment of cross-reactivity 
with chemically similar compounds and by reproducing previously observed biological 
responses in-vivo. The individual results of the dilutional study were not provided, but 
visual analysis of the inhibition curve confirmed a parallel response following dilution with 
the supplied standards. The relative cross-reactivity (T4 being allocated a value of 1) with 
both T3 and 3,3’,5'-T3 (reverse-T3, rT3) was 0.064 and was negligible with various other 
similar compounds. An appropriate increase in total T4 was documented following the 
administration of TSH (unspecified protocol) and an appropriate decrease was reported 24 
hours following thyroidectomy in cats.
Peterson, Ferguson, Kintzer & Drucker, (1984) evaluated an in-house human total 
T4 RIA for use with canine serum. A commercial anti-T4 antibody (Endocrine Sciences, 
Tazana) was used in the assay but the separation method of bound from unbound hormone 
was not specified. The intra-assay c.v. was 5.6 %, and the inter-assay c.v. was 5.8 %. Both 
estimates of precision were based on six samples but the mean concentrations of these were 
not provided. Mean ± standard error of the mean (s.e.m.) recovery of hormone added to 
hormone-free (charcoal stripped) serum was 98.1 ± 6.8 % (n=6), 102 ± 3.3 % (n=6), 94.8 
± 2.9 % (n=6) and 89.8 ± 1.9 % (n=6) at mean concentrations of 10.04, 20.08, 40.15 and 
80.44 nmol/L, respectively, giving an average o f 96.2 + 2.2 %. However, the method used 
to confirm the quantity of hormone added to each sample was not provided. Parallelism 
was confirmed by the measurement of total T4 in 75, 50 and 25 % dilutions o f a sample 
with charcoal stripped serum. The resulting mean ± s.e.m. serum concentrations were 71.3 
± 1.4 % (n=6), 50 ± 2.5 % (n=7), and 21.6 ± 0.8 % (n=6) of the undiluted sample 
concentration, respectively. Assessment o f the specificity of the assay was based on the 
manufacturers data which reported cross-reactivity with total T3 and rT3 as 0.3 and 2.0 % 
respectively. The LoD was reported to be 2.57 nmol/L although the method of calculation 
was not provided. The upper end of the working range was reported to be 643.5 nmol/L.
Panciera & Post, (1992) evaluated a commercially available coated tube human 
total T4 RIA (Coat-A-Count total T4, Diagnostic Products) for use with canine serum. The 
assay was performed according to the manufacturers instructions other than an additional
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standard was prepared by 1 : 1  dilution o f the lowest supplied standard with the zero 
standard to increase the working range. Intra-assay precision was determined by the 
repeated measurement of low, normal and high thyroid hormone pools each on 1 0  
occasions within a single assay. The low pool was collected from hypothyroid dogs and the 
high pool was obtained from dogs following the administration of TSH. Intra-assay c.v.’s 
were 9.1, 8.5 and 10.0 % at mean concentrations of 10.8, 30.9 and 80.9 nmol/L, 
respectively. The inter-assay c.v. was reported to be 14 %. However no information 
regarding the method of calculation or the concentration at which it was estimated was 
provided. Accuracy was determined by recovery of added hormone to the low hormone 
pool. Following the addition of 12.87, 51.48 and 128.7 nmol/L T4 , 103, 96 and 95 % o f the 
respective expected concentrations were measured. The LoD of the assay was calculated as 
the point of 90 % binding on the standard curve and reported to be 0.6 nmol/L. Specificity 
was assessed by dilution of the high pool with the zero standard supplied with the kit. In 
1:2, 1:4 and 1: 8  dilutions, 97, 77 and 72 % o f the respective expected concentrations were 
measured. No reference was made by the authors of this paper to the apparent lack of 
parallelism in the dilutional study or the estimated LoD which is considerably lower than in 
most similar studies.
Recently, Peterson et al, (1997) evaluated a widely used canine coated tube total 
T4 RIA (Coat-A-Count Canine T4, Diagnostic Products). The assay is specifically 
manufactured for use with canine serum by inclusion of calibrators produced with canine 
serum to minimise variation in protein binding between species. The assay is also optimised 
for use with canine samples, to facilitate the measurement of the lower thyroid hormone 
concentrations in this species. Intra-assay precision was determined by assaying six 
replicates o f four pooled canine serum samples, and inter-assay precision was determined 
by assaying four pooled samples on four consecutive days. In each case the pooled samples 
ranged from low to slightly high total T4 concentrations but actual values were not 
provided. Surprisingly, only a single result for both the intra-assay c.v. (8.0 %) and inter­
assay c.v. (5.0 %) was actually reported. Whilst the description of the method of estimating 
precision was therefore rather ambiguous it is likely that the quoted values represented the 
mean c.v. of the four hormone pools. This is an unsatisfactory method o f reporting 
validation data because the mean precision value may lie within acceptable limits despite 
unacceptably poor c.v.’s at various points of clinical importance on the standard curve. 
Accuracy was not assessed. The LoD was defined as the apparent concentration of total T4 
that produced a change in binding two s.d. greater than that of the zero standard and was
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reported to be 2.5 nmol/L. Specificity was evaluated by dilution of a pooled sample of high 
total T4 concentration. Parallelism of the standard curve was reported but the data were not 
provided.
Free thyroxine
The issue of free T4 estimation is controversial and is discussed more fully in Chapter 4. 
Only methodologies which are considered to be genuinely free hormone techniques will be 
reviewed. All free T4 assays are manufactured primarily for use with human samples. 
However these are usually considered to be applicable for use with canine samples.
Ferguson & Peterson, (1992) reported the use of a modified equilibrium dialysis 
technique for free T4 measurement in canine serum based on an original human study of 
Sterling & Brenner, (1966). In brief, this method involved the addition of predialysed 1 25I- 
T4 in bovine serum albumin (BSA) to undiluted canine serum. The serum was then dialysed 
against a standard buffer for 16-20 hours. Following dialysis, the tracer was precipitated 
with a magnesium precipitation solution and separated by repeated centrifugation and 
washing of the precipitate. The free T4 fraction was then determined and the free T4 
concentration calculated as the total T4 concentration multiplied by the free T4 fraction. 
The intra-assay and inter-assay c.v.’s reported were 8.2 and 16.6 %, respectively. 
However, no information was provided regarding the method o f estimation of the assay 
precision or the mean free T4 concentrations at which they were calculated. This method 
was time consuming and technically awkward and was not considered to be of value in a 
routine clinical setting.
Nelson & Tomei, (1988) designed a re-usable dialysis cell and a complex buffer 
which allowed dialysis of human serum samples. Free T4 concentration was then directly 
measured on the dialysate using an ultrasensitive T4 RIA. Intra-assay precision was 
assessed by dialysis of a single serum pool in 57 cells. The intra-assay c.v. was 5.3 % at a 
mean free T4 concentration of 19.30 pmol/L. Inter-assay precision was assessed by dialysis 
of a separate single pooled serum sample on 57 different days over a four month period. 
The dialysed sample inter-assay c.v. was 6.9 % at a mean free T4 concentration of 23.17 
pmol/L. The inter-assay precision o f the RIA was also evaluated on the same 57 days by 
repeated RIA measurement of a separate pooled dialysate. The dialysate inter-assay c.v. 
was 7.4 % at a mean free T4 concentration of 18.02 pmol/L. The variability was similar for 
both the serum pool (subjected to dialysis followed by RIA on each of the 57 occasions) 
and the dialysate pool (subjected to only RIA on each o f the 57 occasions) suggesting that
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the dialysis step added little to the variability in results. No data on assay accuracy or 
specificity of the RIA was supplied. However, the normal recovery test used for assessing 
accuracy cannot be applied to the determination of free T4 prior to dialysis, because the free 
T4 concentration depends both on the quantity of T4 added and on the affinity and 
concentration of binding proteins present (Helenius & Liewendahl, 1983). The putative 
working range of the assay defined as the free T4 concentration corresponding to 90 % 
(LoD) and 13 % (upper limit) of the binding of the zero standard was 2.57 to 164.74 
pmol/L, respectively. Additional validation work included an assessment of the effect of 
repeated freeze-thaw cycles and prolonged storage o f frozen samples on measured free T4 
concentration. A pooled sample frozen for over three months (temperature not provided) 
showed no significant alteration in free T4 concentration. Similarly, 10 repeated freeze-thaw 
cycles did not result in any significant change in free T4 concentration. This method was 
subsequently developed into a commercially applicable kit form suitable for routine 
laboratory use (Free T4 by Equilibrium Dialysis, Nichols Institute Diagnostics).
Panciera & Post, (1992) evaluated the above equilibrium dialysis kit for use with 
canine serum. Intra-assay precision was determined by the repeated measurement of free T4 
in three serum pools collected from hypothyroid dogs (low pool), healthy dogs (medium 
pool) and following administration of exogenous TSH to healthy dogs (high pool) each on 
10 occasions. Intra-assay c.v.’s were reported to be 19.7, 7.3 and 10.8 % at mean 
concentrations of 0.57, 1.89 and 4.27 pmol/L, respectively. However the mean values 
reported are exceptionally low compared to all other similar human or veterinary reports 
and were almost certainly misquoted. It is possible that the values actually correspond to 
conventional units (ng/dl) rather than Systeme International d’Unites (SI) units which are 
considered preferable. Assuming this to be the case, the mean free T4 concentrations in the 
low, normal and high pools were most likely 7.34, 24.32 and 54.95 pmol/L, respectively. 
These figures would be much more in keeping with other published values. The inter-assay 
c.v. was reported to be 17 %. However no indication o f the free T4 concentration to which 
this value refers, or the method of calculation was provided. Accuracy of the RIA was 
assessed by the addition of T4 standards (supplied with the kit) to the dialysate. Recovery 
rates were 91, 120 and 111 % of the respective expected concentrations at increasing 
concentrations of added T4. The assay LoD was defined as the point of 90 % total binding 
on the standard curve and reported to be 0.24 pmol/L respectively. Again, it is likely that 
the units were misquoted and the true value was therefore probably 3.09 pmol/L. Assay 
specificity was assessed by dilution o f the high thyroid hormone serum pool in the ratios
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1:2, 1:4 and 1:8 with the zero standard supplied with the kit. However, 122, 119, 145 and 
115 % of the respective expected concentrations were reported as the results but the actual 
data were not provided. It is unclear from the manuscript, but appears that the serum 
samples were diluted then dialysed. There was no explanation provided to justify either the 
publication of four results from only three dilutions, or the particularly elevated value of 
145 %. Once again it seems likely that problems in production of the manuscript of that 
study were at least in part responsible for the confusing data published.
Peterson et al, (1997) evaluated the same commercial dialysis free T4 methodology 
as Panciera & Post, (1992) and determined intra-assay precision by repeated measurement 
of four pooled serum samples ranging from low to slightly high free T4 concentration six 
times within a single assay. The inter-assay precision was determined by repeated 
measurement of the same four pooled samples on four separate days. The intra-assay and 
inter-assay c.v.’s were reported to be 11.1 and 9.5 %, respectively. As was the case for the 
total T4 assay validation results published in that study, these figures are assumed to be an 
average of the c.v.’s from all the pooled samples. Once again, this is an unsatisfactory 
method of result reporting. No assessment of assay accuracy was made. The LoD, defined 
as the concentration of free T4 that produced a change in binding two s.d. greater than that 
of the negative control samples, was 2.0 pmol/L. Specificity was demonstrated by serial 
dilution of a high free T4 concentration serum sample with the assay zero standard. The 
curve produced was reported to be parallel to the standard curve but the data were not 
provided. Although it is not completely clear from the manuscript, the authors apparently 
diluted serum samples then performed the dialysis. Assuming this to be the case, there is no 
explanation offered by the authors to explain a parallel free T4 response to the standard 
curve. As discussed in chapter 4, this would not be expected o f a true free hormone assay. 
As with the report by Panciera & Post, (1992), the poor description o f the precise 
technique used for the assay validation, makes interpretation of the results and author’s 
conclusions more difficult.
Total triiodothyronine
Reimers, Mummery, McCann, Cowan & Concannon, (1984) evaluated a human derived 
coated-tube total T3 RIA for use with canine serum. Intra-assay precision was evaluated by 
the repeated measurement of two samples on 10 occasions in a single assay. Inter-assay 
precision was evaluated by the repeated measurement of three samples in 2 0  consecutive 
assay runs. Intra-assay c.v.’s were 12.8 and 7.6 % at mean total T3 concentrations of 0.72
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and 2.03 nmol/L, respectively. Inter-assay c.v.’s were 12.2, 14.0 and 11.6 % at mean total 
T3 concentrations of 1.26, 1.65 and 2.66 nmol/L, respectively. Accuracy was determined by 
adding known amounts (determined gravimetrically) of purified T3 to serum samples 
containing endogenous total T3 and measuring the final concentration obtained. The 
recovery slope had an r value of 0.993 and an intercept of -0.19 based on analysis of three 
samples. However the individual results were not provided. The LoD was determined by 
calculation o f the lower 95 % confidence limit o f percentage binding of the zero standard 
based on 10 measurements. This was reported to be 0.22 nmol/L. Specificity was evaluated 
by the production of a standard inhibition curve and assessment of cross-reactivity with 
chemically similar compounds. The individual results of the dilutional study were not 
provided, but visual analysis of the inhibition curve confirmed a parallel response following 
dilution with the supplied standards. The relative cross-reactivity ( T 3  being allocated a 
value of 1 ) was 0.0013 with total T4, 0.0019 with 3,5-diiodothyronine (3 ,5 -T2), 0.0001 
with rT3 and was negligible with various other similar compounds.
Peterson et ai, (1984) evaluated an in-house total T3 RIA for use with canine 
serum using a method designed by Lieblich & Utiger, (1972). Anti-T3 Ab was prepared by 
repeated immunisation of rabbits with T3-BSA conjugate. Commercially available 
radiolabelled T3 (Sigma Chemical Co.) was used and separation of bound from unbound 
hormone was achieved by precipitation using goat anti-rabbit IgG followed by 
centrifugation. The intra-assay c.v. was 6 . 6  %, and the inter-assay c.v. was 13.4 %. Both 
estimates of precision were based on repeated measurement of five samples but the mean 
concentrations of these were not provided. Mean (± s.e.m.) recovery o f hormone added to 
stripped serum was 113.2 ± 4.9 % (n=4), 97.7 ± 7.8 % (n=4), 110.3 ± 2.0 % (n=4) and
101.7 ± 4.4 % (n=3) at mean total T3 concentrations o f 0.48, 0.96, 1.92 and 3.85 nmol/L, 
respectively. However, the method used to confirm the quantity of hormone added to each 
sample was not provided. Parallelism was confirmed by the measurement o f total T3 in 75, 
50 and 25 % dilutions of a sample with stripped serum. The resulting mean (± s.e.m.) 
serum concentrations were 78.8 ± 3.0 % (n=6 ), 55.8 ± 2.3 % (n=6 ) and 24.7 ± 1.0 % (n=5) 
of the undiluted sample, respectively. The LoD was reported to be 0.12 nmol/L although 
the method of determination was not provided. The upper end o f the working range was 
reported to be 7.7 nmol/L.
Panciera & Post, (1992) evaluated a commercially available coated tube human 
total T3 RIA for use with canine samples. Intra-assay precision was determined by the 
repeated measurement of low, normal and high thyroid hormone pools each on 1 0
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occasions within a single assay. The serum pools were collected as described for total T4 . 
Intra-assay c.v.’s were 11.1, 9.9 and 6.5 % at mean total T3 concentrations of 0.49, 1.76 
and 2.83 nmol/L, respectively. The inter-assay c.v. was reported to be 11 %. However, no 
information regarding the method of calculation or the concentration at which it was 
estimated was provided. Accuracy was determined by recovery of added hormone (using 
supplied kit standards) to the low hormone pool. Following addition of approximately 0.31, 
0.77 and 1.54 nmol/L T 3 ,  92, 90 and 97 % o f the respective expected concentrations were 
measured. The LoD of the assay was calculated as the point o f 90 % binding on the 
standard curve and reported to be 0.26 nmol/L. Specificity was assessed by dilution of the 
high pool with the zero standard supplied with the kit. In 1:2, 1:4 and 1:8 dilutions, 107, 
109 and 114 % of the respective expected concentrations were measured.
Recently, Peterson et al, (1997) evaluated a coated tube total T3 RIA designed for 
use with canine serum (Coat-A-Count Canine T3, Diagnostic Products). The assay is 
specifically manufactured for use with canine serum by inclusion o f calibrators produced 
with canine serum to minimise variation in protein binding between species. The assay is 
also optimised for use with canine samples. Intra-assay and inter-assay precision were 
determined using the same protocol as described for total T4 in the same study. The intra­
assay and inter-assay c.v.’s were reported to be 6.2 and 3.4 %, respectively. However the 
ambiguities and assumptions discussed earlier remain applicable. Accuracy was not 
assessed in this study. The LoD was defined as the apparent concentration of total T3 that 
produced a change in binding two s.d. greater than that of the zero standard. The LoD was 
reported to be 0.2 nmol/L. Specificity was evaluated by dilution of a pooled sample of high 
total T3 concentration. A parallel curve was reported but the data were not provided.
Thyrotropin
The measurement of endogenous serum cTSH has been attempted for nearly 20 years. 
Until recently, like total T4 and total T3 methods, most reports concerned the use of human 
assays. However, unlike the iodothyronines, the cross reactivity of the human and canine 
TSH molecules, most probably the (3-subunit, was inadequate and consequently these 
assays were of little diagnostic value in the dog (Larsson, 1981). Similarly, early assays 
purporting to be canine-specific were of little clinical value. The cTSH assay produced by 
Quinlan & Michaelson, (1981) was unable to detect cTSH concentrations less than 1.25 
ng/ml which is inadequate for routine use. The assay evaluated by Rachofsky, Chester & 
Hightower, (1988) had a LoD of 1.5 ng/ml and the results from dogs investigated for
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hypothyroidism were no more predictive of a favourable response to thyroid hormone 
replacement therapy (THRT) than total T4 estimations alone. More recently a new range of 
commercial cTSH kit assays have been released. The three methodologies currently 
available are IRMA, chemiluminescent and ELISA techniques. The methods were all 
released simultaneously by the manufacturer and differ only in the signalling method used, 
the cTSH antibody being equivalent between methods. A review of the reports of 
validation of these assays is provided.
Williams, Scott-Moncrieff, Bruner, Sustarsic, Panosian-Sahakian, Unver & Said El 
Shami, (1996) reported the results o f validation of the IRMA assay for cTSH. Intra-assay 
and inter-assay precision were assessed by measurement of cTSH in three serum samples 
each on 20 occasions within a single assay, and in 20 different assays respectively. The 
intra-assay c.v. was 3.8, 2.3 and 2.4 % at mean cTSH concentrations of 0.26, 0.88 and 4.6 
ng/ml, respectively. The inter-assay c.v. was 3.8, 3.3 and 2.1 % at mean cTSH 
concentrations of 0.26, 0.92 and 4.7 ng/ml, respectively. Accuracy was assessed by the 
addition of three different solutions o f cTSH (9.8, 39.0 and 78.0 ng/ml) to each of three 
serum samples in the ratio 19:1. The method of calculation of the cTSH concentrations in 
these spiking solutions was not reported, but presumably standard solutions used for assay 
development were employed. Measured cTSH values in spiked samples were between 95 
and 110 % of the expected concentrations. The LoD was defined as the cTSH 
concentrations that produced a change in binding two s.d. greater than that of the zero 
standard. The upper working limit was defined as the cTSH concentration that produced a 
change in binding greater than two s.d. from the maximum observed. The working range of 
the assay was reported as 0.01 to 12.0 ng/ml. Assay specificity was assessed by dilution of 
three samples 1:1, 1:3, 1:7 and 1:15 with the zero calibrant. Observed cTSH concentrations 
in diluted samples were between 97 and 109 % of the expected values. Specificity o f the 
assay was also inferred from the biological response in six beagle dogs in which 
hypothyroidism was induced by radiothyroidectomy, and subsequently treated with
standard THRT. Confirmation of thyroid status was achieved by estimation o f total T4 
concentrations before and after exogenous TSH administration. Circulating cTSH
concentrations increased by approximately 35 fold 21 days after induction of
hypothyroidism and returned to values not significantly different to the original
concentrations within 14 days after starting THRT. The mean cTSH concentrations were 
approximately 0.1 ng/ml prior to radiothyroidectomy, peaking at approximately 4 ng/ml 28
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days after radiothyroidectomy, and decreasing to less than 1 ng/ml after institution of 
THRT. However, the actual data were not provided other than in graphical form.
Jensen et al, (1996) also validated the cTSH IRMA assay although in considerably 
less detail. Intra-assay and inter-assay c.v.’s were reported to be 10.6 and 9.7 %, at cTSH 
concentrations between 0.05 to 0.85 ng/ml, respectively. However, the protocol was not 
provided. Assay accuracy was evaluated by the addition of 75 pi of each of the calibrators 
into 425 pi aliquots of a serum pool with a measured cTSH concentration of 0.15 ng/ml. 
This left the serum matrix relatively unaffected, and cTSH was recovered in a linear and 
proportional manner. The assay LoD was not independently assessed. Analytical specificity 
was evaluated by the serial dilution o f two samples with normal (0.07 ng/ml) and elevated 
(0.85 ng/ml) cTSH concentrations, using the zero standard as the diluent. The curve 
obtained was not parallel to that of the standard curve and the authors suggested that this 
may have been related to differences in matrix composition between the canine samples and 
the zero calibrant. The authors reported that there was no significant difference in cTSH 
concentration in paired samples of serum or heparinised plasma from both normal and 
hypothyroid dogs, although the data were not provided.
Meij, Mol & Rijnberk, (1996) evaluated the same cTSH IRMA assay and reported 
intra-assay and inter-assay c.v.’s of 2.4 and 3.9 %, at mean cTSH concentrations of 4.6 and
3.6 ng/ml, respectively. No assessment o f accuracy was made. The LoD was reported to be 
0.03 ng/ml although the protocol for estimation was not provided. Negligible cross 
reactivity with canine leutenising hormone (LH) and follicle stimulating hormone (FSH) 
was reported but the supporting data were not provided.
Peterson et al, (1997) evaluated the same cTSH IRMA assay for use with canine 
serum. Intra-assay and inter-assay precision were determined using the same protocol as 
described for total T4 in the same paper. The intra-assay and inter-assay c.v.’s were 
reported to be 4.7 and 2.5 %, respectively. As described under total T4 and total T3 the 
ambiguities and assumptions discussed earlier apply. Accuracy was not assessed in this 
study. The LoD was defined as the apparent concentration o f cTSH that produced a 
change in binding two s.d. greater than that o f the zero standard. The LoD was reported to 
be 0.01 ng/ml. Specificity was evaluated by dilution o f a pooled sample of high cTSH 
concentration. A parallel curve was reported but the data were not provided.
Scott-Moncrieff et al, (1998) evaluated the chemiluminescent enzyme 
immunoassay for cTSH. Intra-assay c.v.’s were reported to be 5.9, 3 and 6 . 8  % at mean 
cTSH concentrations o f 0.07, 0.13 and 1.80 ng/ml, respectively. Inter-assay c.v.’s were
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reported to be 7.0 and 4.8 % at mean cTSH concentrations of 0.30 and 2.90 ng/ml, 
respectively. However, no details of the number of samples or protocols for the precision 
studies were provided. No accuracy data were provided. The LoD was reported to be 0.05 
ng/ml but the method of estimation was not provided. A clinical reference range was 
reported as less than 0.65 ng/ml based on analysis of samples from 62 healthy dogs. 
However, no additional information on the method o f calculation was provided.
Ramsey, Evans & Herrtage, (1997) evaluated the ELISA method for cTSH 
estimation. Intra-assay precision was evaluated by testing two samples 10 times on two 
separate occasions. The intra-assay c.v. was reported to be less than 5 % but the actual 
value was not provided. Inter-assay precision was evaluated by repeated estimation of 
control samples in different assays. The inter-assay c.v. was reported to be 14, 18, 8.0 and 
5.0 % at mean cTSH concentrations of 0.17, 0.29, 1.24 and 2.67 ng/ml, respectively. 
However the number of assays over which the precision was evaluated was not specified. 
Accuracy was not assessed. The LoD was determined by estimation of cTSH in 10 blank 
samples and reported to be 0.01 ng/ml. However the method of calculation was not 
provided. Assay specificity was not evaluated. The inter-assay c.v’s reported for reference 
range cTSH concentrations were markedly higher in this study than in any other report of 
cTSH assay validation. The difference is presumably related to the different signalling 
technique between the methods and indicate that the IRMA (Williams et al., 1996; Jensen 
et al., 1996; Meij et al., 1996; Peterson et al., 1997) and chemiluminescent (Scott- 
Moncrieff et al., 1998) techniques are considerably more reproducible than the ELISA 
method.
Thyroglobulin autoantibodies
Nachreiner et al., (1998) evaluated a commercially available ELISA for canine TgAb 
estimation (Canine thyroglobulin autoantibody immunoassay kit, Oxford Laboratories). All 
o.d. results were expressed as a percentage of negative control sample. Unfortunately, the 
description of the method of determination of precision was unclear. Apparently, the intra­
assay c.v. was calculated by the repeated analysis of two replicates at the beginning and end 
of eight assay runs. The intra-assay c.v. from each run was calculated and then the average 
figure for all runs subsequently determined. Using this approach, the intra-assay c.v. was 
reported to be 7.6 %. This approach is unusual. The inter-assay c.v. was calculated as the 
variation in a single sample o.d. over 1 0  consecutive assay runs when expressed as a 
percentage of the positive control. The inter-assay c.v. was reported to be 26.5 %.
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Quantitative evaluation of assay accuracy is more difficult with this type o f methodology 
since the results are reported as an o.d. relative to a qualitatively defined standard sample 
to which an absolute concentration o f TgAb is not assigned. The LoD of the assay was not 
evaluated. Given the quantitative nature of the results, and the method o f sample result 
categorisation (i.e. based on relative o.d. compared to the negative control) the assay is less 
amenable to this type of analysis and the absence of a standard curve makes the 
differentiation o f the LoD from a zero result more difficult. In addition the clinical utility of 
this assay is such that the differentiation of low from negative results is o f no practical 
relevance. This is presumably why the LoD was not determined. Assay specificity was 
functionally evaluated by comparison of thyroid histopathology from eight dogs with, and 
10 dogs without, a positive TgAb result. All TgAb positive cases had evidence of mild to 
diffiise lymphocytic thyroiditis whereas all dogs negative for the autoantibody had no 
evidence of thyroiditis. Specificity was also functionally evaluated by the measurement of 
TgAb in serum from 146 dogs with a variety of non-thyroidal diseases. Eight (5 %) cases 
were TgAb positive confirming a relatively high functional specificity of the assay.
Iverson, Jensen, Hoier, Skydsgaard & Kristensen, (1998) developed and validated a 
separate TgAb ELISA from that reported by Nachreiner et al., (1998). In each assay run, 
samples from a single dog with hypothyroidism and lymphocytic thyroiditis, and two dogs 
without hypothyroidism or thyroiditis were measured in quadruplicate. A “K” value was 
calculated for each run, defined as the difference between the o.d. from the hypothyroid 
sample and the mean o f the two normal samples. Each test sample was expressed as an “Ab 
score”. The Ab score was defined as the test sample o.d. expressed as a percentage of the 
K value. Intra-assay precision was evaluated by analysis of three samples (low, medium and 
high Ab scores) at least 15 times in a single assay run. Inter-assay precision was evaluated 
by repeated measurement o f the samples from the control dogs in 15 different assay runs. 
Intra-assay c.v.’s were 3.2, 4.9 and 2.0 % in the low, medium and high Ab score samples, 
respectively. Inter-assay c.v’s were 4.6, 7.3 and 9.9 % for the corresponding samples, 
respectively. Accuracy was not evaluated. The LoD was calculated as the zero value (NSB) 
plus two s.d. o f the results o f 13 duplicate analyses from samples with an Ab score less 
than 7.5 %. The LoD was reported to be 5.6 %. Assay specificity was comprehensively 
evaluated by estimation o f TgAb in eight samples from TgAb positive dogs, before and 
following immunoglobulin precipitation with polyethyleneglycol 6000 (PEG). In addition, 
TgAb positive samples were incubated with purified Tg and re-analysed for the 
autoantibody. TgAb was estimated in another series of samples before and following
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incubation with buffer to which either T3 or T4 had been added. Samples incubated with 
either PEG or Tg had a significant and almost complete reduction in assay signal 
confirming the assay’s specificity for TgAb. Samples incubated with T3 or T4 showed a 
significant but smaller reduction in TgAb result, with those incubated with T3 showing the 
greatest changes. The explanation for this is less clear, but may be attributable to the 
presence of T3 autoantibodies (T3Ab) or T4 autoantibodies (T4Ab) in some o f the serum 
samples. T3Ab and T4Ab are believed to be subsets of TgAb that recognise particular 
epitopes on the Tg molecule (Gaschen, Thompson, Beale & Keisling, 1993). Alternatively 
changes in sample matrix following the addition of the buffer medium may have been 
responsible. Unlike the kit evaluated by Nachreiner et al, (1998), the method studied by 
Iverson et al, (1998) has not yet been made commercially available.
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All of the kits used to assess thyroid function in this study were commercially available 
immunoassays and were supplied with details of the manufacturers own validation data. 
However, not only were some of the kits designed for human sera, but previous reports of 
diagnostic and validation performance of many thyroid function tests have often been 
incomplete and occasionally produced conflicting information. Consequently, an 
assessment of technical validity and reliability for each assay was considered necessary 
prior to diagnostic use. The principal objectives when validating each assay were as 
adopted by the IFCC (Buttner et al., 1980a). This consisted of confirmation of their 
practicality for routine laboratory use and assessment of their reliability characteristics 
namely precision, accuracy, specificity and detectability when used with canine sera. The 
assessment of certain validation characteristics was not always practical and when possible 
these data were obtained from the available literature. Validation of the TgAb assay in 
particular was more limited due to the qualitative nature o f the assay results as discussed.
3.3 MATERIALS AND METHODS
Sample Collection
Blood samples used for the validation studies were collected and stored from dogs referred 
to the DVCS as described in Chapter 2. A number o f healthy dogs were also blood sampled 
as part of a routine health check programme. When the sample volume permitted, these 
samples were also stored for inclusion in the validation experiments. A number of these 
samples were aliquoted prior to freezing to avoid repeated freeze thaw cycles during inter­
assay precision studies.
General Statistics
When calculating the LoD of each assay, raw data (cpm) were used for statistical analysis 
before being converted to an equivalent LoD by calculation of the mean - 2.6 s.d. (mean +
2.6 s.d. in the case of cTSH) of the blank value as described by Buttner et al, (1980a). Pre 
and post-gonadotropin releasing hormone (GnRH) stimulation cTSH concentrations were 
compared using a paired t-test.
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Specific Assay Validations
Total Thyroxine
Total T 4  was measured with a commercial competitive RIA (MAGIC T 4 ,  Chiron 
Diagnostics) as described in Chapter 2. Intra-assay precision was determined by the 
repeated measurement of 10 duplicates of three samples with varying total T4 concentration 
(low, intermediate and high) in a single assay run. Inter-assay precision was determined by 
the repeated measurement of three samples (low, intermediate and high) in duplicate in 1 0  
consecutive assay runs. Specificity was determined by measurement of total T4 in serial 20 
% dilutions of a single sample (original concentration 21.2 nmol/L) using the zero standard 
supplied with the kit as the diluent. Assay cross-reactivity data were provided by the 
manufacturer. The LoD was determined by repeated measurement of total T4 in 20 
replicates of the zero standard supplied with the kit.
Free Thyroxine
Free T4 was measured using a commercial modified dialysis technique (Free T4 by 
Equilibrium Dialysis, Nichols Institute Diagnostics) as described in Chapter 2. Intra-assay 
precision was determined by the repeated measurement of 1 0  duplicates of three samples 
with varying free T4 concentration (low, intermediate and high) in a single assay run. Inter­
assay precision was determined by the repeated measurement of three samples (low, 
intermediate and high) in duplicate in six consecutive assay runs. Specificity was 
determined by measurement of free T4 in serial dilutions of a single dialysate using the zero 
standard supplied with the kit as the diluent. Assay cross-reactivity data were provided by 
the manufacturer. The LoD was determined by repeated measurement of free T4 in 20 
replicates of the zero standard supplied with the kit.
Total Triiodothyronine
Total T3 was measured with a commercial competitive RIA (MAGIC T3, Chiron 
Diagnostics) as described in Chapter 2. Intra-assay precision was determined by the 
repeated measurement of 10 duplicates of three samples with varying total T3 concentration 
(low, intermediate and high) in a single assay run. Inter-assay precision was determined by 
the repeated measurement of three samples (low, intermediate and high) in duplicate in four 
consecutive assay runs. Specificity was determined by measurement o f total T3 in serial 
dilutions of a single sample using the zero standard supplied with the kit as the diluent. 
Assay accuracy and cross-reactivity data were provided by the manufacturer. The LoD was
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determined by repeated measurement of total T3 in 2 0  replicates of the zero standard 
supplied with the kit.
Thyrotropin
Circulating cTSH was measured with a commercial assay (Canine TSH IRMA, Diagnostic 
Products) as described in Chapter 2. Intra-assay precision was determined by the repeated 
measurement of 10 duplicates of three samples with varying cTSH concentration (low, 
intermediate and high) in a single assay run. Inter-assay precision was determined by the 
repeated measurement of three samples (low, intermediate and high) in duplicate in 1 0  
consecutive assay runs. Specificity was determined by measurement of cTSH in serial 
dilutions of a single sample using the zero standard supplied with the kit as the diluent. 
Cross reactivity with similar molecules (LH and FSH) was assessed by measurement of 
cTSH in sera collected from three entire female dogs prior to and 60 minutes following the 
intravenous administration of 0.32 pg GnRH analogue (Receptal, Hoechst Roussel Vet). 
Assay accuracy data were provided by the manufacturer. The LoD was determined by 
repeated measurement of cTSH in 20 replicates of the zero standard supplied with the kit.
Thyroglobulin Autoantibody
TgAb was measured with a commercial assay (Canine thyroglobulin autoantibody 
immunoassay, Oxford Laboratories) as described in Chapter 2. Intra-assay precision was 
assessed by the repeated measurement of 2 0  replicates of each of two samples with either 
negative or positive TgAb status. Inter-assay precision was assessed by the repeated 
measurement in duplicate of each o f three samples with negative, equivocal and positive 
TgAb status in six consecutive assay runs. Precision was assessed by both quantitative and 
qualitative methods. Quantitative assessment of the validation samples was performed by 
determination of the c.v.'s from each o.d. when expressed as a percentage of the negative 
control value. Qualitative assessment of the results was made by examination of the 
precision with which validation samples were correctly classified as either positive, negative 
or equivocal. Classification of samples was as recommended by the kit manufacturer as 
described in Chapter 2.
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3.4 RESULTS 
Total Thyroxine
Intra-assay precision results are summarised in Appendix 7. Inter-assay precision results are 
summarised in Appendix 8 . Linearity under dilution results are summarised in Appendix 9. 
Results of LoD determination are summarised in Appendix 10. Cross reactivity o f the assay 
was 2.7 % with tetraiodothyroacetic acid, 4.5 % with L-triiodothyronine and 0.11 % with 
D-triiodothyronine.
Free Thyroxine
Intra-assay precision results are summarised in Appendix 11. Inter-assay precision results 
are summarised in Appendix 12. Linearity under dilution results are summarised in 
Appendix 13. Results o f LoD determination are summarised in Appendix 14. Cross­
reactivity was less than 0.05 % with each of D-thyroxine, T3 and rT3.
Total Triiodothyronine
Intra-assay precision results are summarised in Appendix 15. Inter-assay precision results 
are summarised in Appendix 16. Linearity under dilution results are summarised in 
Appendix 17. Results of LoD determination are summarised in Appendix 18. Cross 
reactivity of the assay was 0.2 % with tetraiodothyroacetic acid, 0.14 % with D-thyroxine 
and 0.12 % with L-thyroxine. Mean recovery of T3 from spiked samples was 103.1 % with 
a range of 96.3 to 118.3 %.
Thyrotropin
Intra-assay precision results are summarised in Appendix 19. Inter-assay precision results 
are summarised in Appendix 20. Linearity under dilution results are summarised in 
Appendix 21. Results o f LoD determination are summarised in Appendix 22. Serum cTSH 
concentration (mean ± s.d.) was 0.13 ± 0.01 ng/ml and 0.14 ± 0.07 ng/ml prior to and 
following GnRH administration, respectively. There was no significant difference between 
pre and post-GnRH results suggesting minimal cross reactivity with LH and FSH. 
Recovery of cTSH from spiked samples varied from 95 to 110 % of expected values.
Thyroglobulin Autoantibodies
Quantitative intra-assay precision results are summarised in Appendix 23. Quantitative 
inter-assay precision results are summarised in Appendix 24. Qualitative intra-assay
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precision results are summarised in Appendix 25. Qualitative inter-assay precision results 
are summarised in Appendix 26.
3.5 DISCUSSION
The results o f the validation studies were generally considered good to excellent. Each of 
the methods was practical and with the exception of the free T4 assay could be comfortably 
performed in a single day.
The total T4 assay demonstrated good intra- and inter-assay precision even at low 
values despite extrapolation of the standard curve downwards by dilution of the standards. 
This is similar to the findings of previous studies (Reimers et al, 1981; Peterson et al, 
1984; 1997). Data on the accuracy of the methods was obtained from the available 
literature. This avoided the need for hormone recovery experiments which were considered 
either excessively demanding for the purposes of the current study (total T4 and T3) or 
impractical or impossible given the nature of the analytes being estimated (free T4, cTSH 
and TgAb). In addition, previous reports have clearly demonstrated that human total T4 
assays are usually highly accurate when used with canine serum (Reimers et al, 1981, 
Peterson et al, 1984) The LoD was 4.7 nmol/L which is also similar to that of previous 
studies (Reimers et al, 1981; Eckersall, McEwan & Mooney, 1991; Peterson et al, 1997). 
Specificity was considered adequate with total T4 results between 104 and 112 % of the 
expected values after dilution. These results lie somewhere in-between those reported by 
Panciera, MacEwan, Atkins, Bosu, Refsal & Nachreiner, (1989) and Panciera & Post, 
(1992).
The free T4 kit was the most time consuming and expensive of the assays examined. 
The overnight dialysis incubation required considerable preparation and practically was 
more awkward than the other methods. However, the method was not considered 
prohibitively inconvenient and could be employed within a veterinary laboratory with the 
appropriate facilities. Of particular importance in the performance of the free T4 assay was 
the overnight incubation temperature which had to be accurately controlled. The precision 
studies were considered adequate and although an intra-assay c.v. of 15.7 % at 10.4 
pmol/L is just outwith the guidelines of Hunter, (1978) it was considered adequate given 
the two steps involved. Because of the differences in methodologies for free T4 estimation 
the results of this study should only be compared with reports of equivalent methods. 
Precision results were similar to previous studies (Nelson & Tomei, 1988; Ferguson &
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Peterson, 1992; Panciera & Post, 1992; Peterson et al, 1997) and the LoD was similar to 
that reported by Nelson & Tomei, (1988) and Peterson et al, (1997) despite the different 
methods of calculation. However, the LoD reported by Panciera & Post, (1992) was less 
than 12 % of that found in both the present study and that of Peterson et al., (1997). 
Various errors were present in that paper and the apparent differences in LoD are probably 
simply the result o f the publication of incorrect values as described previously.
The total T3 assay validation results were considered to be excellent. The intra- and 
inter-assay precision results were under 8 % at all concentrations of total T3. This is in 
agreement with previous studies (Kemppainen et al., 1983; Larsson, 1988; Panciera & 
Post, 1992; Peterson et al, 1997). The LoD was 0.14 nmol/L which is very similar to other 
reports despite different methods of calculation (Hall et al, 1993; Li, Chen, Tiller & 
Kunkle, 1986; Reimers, Lawler, Sutaria, Correa & Erb, 1990; Peterson et al, 1997). 
Specificity results were good with 94 to 112 % of the expected concentrations being 
measured following dilution. This is in agreement with Peterson et al, (1997).
The present study found intra-assay precision of the cTSH assay to be excellent 
across the range of clinical relevance supporting the findings of Williams et al, (1996). The 
inter-assay precision was adequate at mean concentrations of 0.40 ng/ml and 2.17 ng/ml 
although the c.v. at 0.13 ng/ml o f 21.9 % was higher than that recommended by Hunter, 
(1978). This imprecision was not considered clinically significant since the accurate 
estimation of elevated cTSH concentrations is of much greater importance than the 
measurement o f low or normal values. Thus, in the clinically relevant region o f the standard 
curve the precision was adequate. The LoD of 0.01 ng/ml is not considered to be 
sufficiently low to identify cases of hyperthyroidism or central hypothyroidism and is similar 
or identical to previous results (Meij et al, 1996; Williams et al, 1996; Peterson et al,
1997) using the same kit. The identification of individuals with subnormal cTSH results is 
therefore not currently possible using this kit. The assay specificity was confirmed by 
demonstration of parallelism under dilution. The results varied from 88 to 108 % of the 
anticipated values which is similar to the findings of Williams et al, (1996). The absence of 
a significant rise in cTSH after administration of GnRH also confirmed the specificity of the 
antibody used in the assay. The cTSH recovery concentrations from spiked samples 
reported by the manufacturer were consistent with good assay accuracy.
The validation of the TgAb assay was less detailed than for the other techniques in 
this chapter since the quantitative classification of results as either positive, negative or 
equivocal is not immediately suited to assessment of characteristics such as LoD or
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dilutional parallelism. Since a numerical value is not assigned to the TgAb result it is 
impossible to assign a quantitative LoD. A value relative to the negative controls could be 
determined for these purposes but the value is of little clinical significance given that only 
abnormally increased TgAb results are of any importance. The intra-assay precision results 
were excellent when considered either based on the qualitative classification o f samples or 
on the c.v.’s of their o.d.'s. However there was discordancy between the quantitative and 
qualitative results obtained during evaluation of inter-assay precision. The o.d. c.v.'s of 
each sample varied from 17 to 31 % and therefore were all inadequate according to 
standard validation criteria (Hunter, 1978). However the precision of actual result 
classification (i.e. either positive, negative or equivocal) was good to excellent. This study 
has demonstrated that the use of relatively broad qualitative categories, in addition to the 
safety margin of the equivocal category provides for good consistency of results despite 
considerable imprecision of o.d.’s within individual categories.
Chapter 4 62
CHAPTER 4
ACHIEVING A DIAGNOSIS OF HYPOTHYROIDISM
4.1 LITERATURE REVIEW 
The Healthy Thyroid Gland
Anatomical and Histological features
In the dog, the thyroid gland is a vascular bilobed structure located lateral to the proximal 
tracheal rings. It weighs 0.04 to 0.4 g/kg body weight and is located deep to the 
stemocephalicus muscle and therefore is not normally palpable. As in humans, accessory or 
ectopic thyroid tissue is common in the dog. Ectopic thyroid is present near the hyoid bone, 
along the cervical trachea or at the aortic base in over 50 % of dogs (Peterson & Ferguson, 
1989; Capen, 1996). The thyroid gland is enclosed within a fibro-elastic capsule from 
which septae penetrate the gland dividing it into variously sized lobules. Blood and 
lymphatic vessels run within this connective tissue network (Wheater & Burkitt, 1987; 
Peterson & Ferguson, 1989). The lobules are composed of numerous follicles of varying 
size. Each follicle consists of a follicular lumen filled with colloid which is surrounded by a 
monolayer of cuboidal epithelial cells bounded by a fenestrated basement membrane. 
Colloid is a viscous gel containing thyroglobulin, a large molecular weight glycoprotein 
which is the precursor of the iodothyronines. The apical surface of the follicular epithelial 
layer has a microvillus structure similar to that of the intestinal brush border and projects 
into the follicular lumen. The outer surface contacts the surrounding blood vessels 
permitting the transfer o f iodide and thyroid hormones between the follicular cells and the 
blood. In the mammalian thyroid gland a second endocrine cell type, C-cells, are found 
immediately below the basement membrane, between the follicular cells and between the 
follicles. These are responsible for the secretion of the polypeptide hormone calcitonin, 
involved in the maintenance o f circulating calcium concentrations. C-cells are functionally 
distinct from the thyroid follicular units.
Synthesis o f Thyroid Hormones
The only function of ingested iodine is the synthesis o f iodothyronines within the thyroid 
gland (Peterson & Ferguson, 1989). This iodine is converted to iodide within the 
gastrointestinal tract before being absorbed into the circulation. A variety of processes, 
collectively known as the iodide transport mechanism are responsible for iodide entry into
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the thyroid follicular cells. This is the first and rate limiting step in iodothyronine synthesis 
and is controlled primarily by the stimulatory effects of TSH (Ferguson, 1984; Vassart & 
Dumont, 1992; Taurog, 1996). The iodide transport mechanism is an active process and 
results in iodide accumulation within the thyroid follicular cytosol in concentrations 
approximately 10 to 200 fold greater than that found in the serum (Peterson & Ferguson, 
1989). Intra-cellular iodide is oxidised to iodine and diffuses through the microvilli into the 
follicular lumen. Here it is incorporated within the tyrosine residues of thyroglobulin to 
form monoiodotyrosine (MIT) and diiodotyrosine (DIT) in a process known as 
organification (Werner, 1982). T3 is produced by the coupling of one MIT with one DIT 
molecule and T4 is produced by the coupling of two DIT molecules (Ferguson, 1984). The 
secretion of thyroid hormones begins with the fusion o f colloid droplets containing 
thyroglobulin to the follicular cells. These are released into the follicular cytosol by 
pinocytosis and endocytosis (Greenspan & Rapoport, 1991; Dunn, 1996). Proteolysis of 
the droplets by lysosomal enzymes then liberates the iodotyrosines MIT and DIT and the 
iodothyronines T3 and T4. Deiodination of T4 to T3 occurs within the thyroid follicular 
cytosol and therefore although the stored ratio of T4 to T3 in the thyroid is approximately 
12:1, the ratio entering the circulation is nearer 4:1 (Panciera, 1990a).
A variety of iodinated substances are released from the thyroid into the circulation 
including iodothyronines, iodotyrosines, iodoproteins and inorganic iodide. However, only 
the iodothyronines T3 and T4 are considered to have any significant biological activity. In 
healthy humans T4 is produced in two to three fold greater quantities, and is cleared from 
the circulation at 1 /20th the rate of T3 (Chopra, 1996). T3 is therefore present in the serum 
at a much lower concentration than T4. In contrast to T4 which is derived entirely from 
thyroidal synthesis and secretion, only 20 % (humans) and 40-60 % (dogs) of circulating T3 
normally originates from direct thyroidal production. The remainder is produced by outer- 
ring deiodination of T4 to T3 by 5'-deiodinase (5-D) in peripheral tissues especially the liver 
and kidneys (Ferguson, 1994; Kaptein et al., 1994). This enzyme is also responsible for the 
conversion o f rT3 to 3,3'-diiodothyronine (3,3-T2). Peripheral deiodination of T4 by 5- 
deiodinase (5-D) results in cleavage o f an inner ring o f the T4 molecule with the production 
of rT3. Because of its largely peripheral synthesis only 20 % o f total body T3 is present 
within the circulation, the remainder being located intracellularly (Kaptein et al., 1994). T3 
is three to five times more metabolically active than T4 leading some to suggest that T4 acts 
essentially as a pro-hormone.
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Two 5-D isoenzymes exist. Type I is found in most tissues particularly liver, 
kidneys, muscle and skin and is responsible for peripheral conversion of T4 to T3 as 
described above. The type II 5-D enzyme is located mainly in the brain, pituitary gland and 
brown smooth muscle and is responsible for the intra-pituitary deiodination of T4 to T3 .
Control of Thyroid Hormone Synthesis and Secretion
Serum thyroid hormone concentrations are principally regulated by a negative feedback 
mechanism. The main stimulus for their synthesis and secretion is a rise in serum TSH 
concentrations which acts by binding to thyroid gland follicular cell surface receptors and 
stimulating cyclic adenosine monophosphate (cAMP) production (Ferguson, 1984; Vassart 
& Dumont, 1992; Rapoport & Spaulding, 1996). The binding of TSH to membrane 
receptors stimulates numerous intracellular pathways within the thyrocyte driving thyroid 
hormone synthesis and release (Rapoport & Spaulding, 1996).
TSH is synthesised and secreted from the pars distalis of the pituitary gland under 
the tonic simulation of TRH. The secretion of TSH from the pituitary is mainly inhibited by 
the negative feedback effect of the thyroid hormones, but a complicated network of 
neuropeptides and neurotransmitters including dopamine and somatostatin also modulate 
TSH release (Scanlon & Toft, 1996). The main inhibitor o f TSH release is circulating free 
T4 which enters the pituitary and is deiodinated to T3 by the type II 5-D isoenzyme. This T3 
acts via pituitary nuclear receptors to inhibit TSH synthesis and secretion by stimulating the 
production of an inhibitory protein and a decrease in the number of pituitary TRH receptors 
(Hinkle, Perrone & Schonbrunn, 1981). Thyroid hormones also inhibit the release of TRH 
by modifying TRH gene expression. This provides an additional mechanism for the 
regulation of TSH and thus thyroid hormone concentrations (Scanlon & Toft, 1996). 
Intrathyroidal mechanisms including the Wolff-Chaikoff blocking effect, altered thyroidal 
sensitivity to TSH and the relative production o f T3 to T4 also modulate thyroid hormone 
synthesis, release and activity, but these are generally only of much relevance during 
periods of abnormal thyroid function. Certainly under normal conditions they are of much 
less importance in the regulation of thyroid function compared to the profound influence of 
circulating TSH concentrations (Scanlon & Toft, 1996; Feldman & Nelson, 1996).
Transport of Thyroid Hormones
The iodothyronines are present in the circulation mainly bound to the plasma proteins 
thyroid hormone binding globulin (TBG), albumin and thyroid hormone binding prealbumin
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(TBPA (transthyretin)). A minor fraction of T3 and T4 is also carried by circulating 
lipoproteins (Robbins, 1996). In the healthy dog, approximately 60 % of T4 is bound to 
TBG, 17 % to TBPA, 12 % to albumin and 11 % to the high density lipoprotein (HDL2) 
(Larsson, Pettersson & Carlstrom, 1985). T3 circulates bound to the proteins in a similar 
fashion. TBG becomes saturated once T4 approaches 150 nmol/L and the other carrier 
proteins are virtually unsaturable (Larsson et al, 1985). The binding affinity for thyroid 
hormones is considerably lower in dogs than in humans and consequently the free hormone 
fraction in dogs is greater than in humans. It is estimated that in canine serum the free or 
unbound fraction of T4 is only 0.1-0.3 % o f the total hormone concentration whilst 
approximately 1 % of total T3 circulates unbound (Furth, Becker, Nunez & Reid, 1968; 
Refetoff, Robin & Fang, 1970; Feldman & Nelson, 1996). In contrast, the free T4 and free 
T3 fractions in humans are only approximately 0.03 % and 0.3 %, respectively. The reduced 
affinity of the thyroid hormones for their carrier proteins in dogs is responsible for the 
considerably more rapid hormone turnover in this species compared with humans. 
Correspondingly, the half life of T4 is between 10 and 16 hours in dogs compared with 
about seven days in humans whilst the half life of T3 in dogs is estimated to be only 
approximately five to six hours (Ferguson, 1994). The various thyroid hormone binding 
proteins vary in their concentration, affinity for thyroid hormones and dissociation rate 
constants. For example whilst TBG is the least abundant o f the three major carrier proteins 
in human serum, it accounts for binding of approximately 70 % o f the T3 and T4 compared 
with only 15-20 % to albumin, and 10-15 % to TBPA both of which are present in greater 
concentrations. In dogs the concentration of serum proteins is considerably lower than the 
corresponding human values. TBG concentration is particularly different between the 
species, with canine values approximating only 15 % of the human concentration. The 
concentration of total thyroid hormone in the dog is correspondingly reduced compared 
with humans (Refetoff et al, 1970; Ferguson, 1994).
Actions of Thyroid Hormones
Thyroid hormones affect most body tissues by interaction with specific nuclear receptors 
although several non-nuclear pathways also exist (Oppenheimer, Schwartz & Strait, 1996). 
The thyroid hormone receptors act largely as transcription factors fimctioning in 
association with a broad range of other nuclear proteins to modify the expression of a 
diverse set of genes. At a cellular level, thyroid hormones therefore influence multiple 
metabolic processes from regulation of mitochondrial oxygen demand to the control of
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protein synthesis. It is not surprising therefore that whilst some actions o f thyroid hormones 
can be demonstrated within minutes to hours of thyroid hormone administration others may 
take weeks or even months to become apparent. The wide ranging biological role of 
thyroid hormones is partly responsible for the variable time required for the development of 
the different clinical signs associated with hypothyroidism and their resolution following 
thyroid hormone replacement therapy.
According to the free hormone hypothesis initially proposed by Robbins & Rail, 
(1957) it is only the non-protein bound hormone that is available for entry into cells with 
the protein bound hormone acting as a passive reservoir of hormone, serving to distribute it 
throughout the circulation. This concept is supported by studies of humans and animals 
with grossly disturbed (increased or reduced) total hormone concentrations resulting from 
genetic abnormalities in their thyroid hormone binding proteins. Such individuals may have 
grossly disturbed total hormone concentrations but relatively unaffected free hormone 
concentrations and do not develop clinical abnormalities consistent with thyroid disease, 
suggesting that the free hormone is ultimately responsible for thyroid status (Robbins, 
1996). However, Pardridge, (1981) demonstrated single pass organ uptake of hormone in 
excess of the free hormone concentrations as determined by equilibrium dialysis. This was 
suggested to indicate protein-mediated tissue-specific hormone uptake. Despite this, the 
steady state uptake remained proportional to, albeit greater than, the free hormone 
concentration.
The Failing Thyroid Gland
Causes of Hypothyroidism 
Primary Hypothyroidism
The most common adult form o f human and canine hypothyroidism is primary or thyroidal 
hypothyroidism (Braverman & Utiger, 1996; Feldman & Nelson, 1996; Rijnberk, 1996). 
Worldwide, the most common cause in humans is chronic dietary iodine deficiency whilst in 
the developed western world it is usually the result o f autoimmune thyroid disease (AITD), 
specifically chronic immune-mediated thyroiditis (Braverman & Utiger, 1996). The use of 
commercial dietary preparations has made iodine deficiency a rare occurrence in the dog. 
Approximately half of all canine cases result from lymphocytic thyroiditis whilst most of the 
remainder are caused by idiopathic thyroidal atrophy (Panciera, 1990a; Ferguson, 1994; 
Kemppainen & Clark, 1994). Primary thyroidal failure occasionally results from neoplastic
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destruction, anti-thyroid medication, radiation therapy, or congenital defects although these 
are rare in dogs (Kemppainen & Clark, 1994; Braverman & Utiger, 1996; Rijnberk, 1996). 
Primary hypothyroidism is associated with subnormal thyroid hormone concentrations. The 
negative feedback which these thyroid hormones normally exert on pituitary TSH synthesis 
and secretion is therefore reduced and primary hypothyroidism is generally associated with 
elevated circulating TSH concentrations.
Histologically, lymphocytic thyroiditis is characterised by multifocal or difluse 
infiltration of the thyroid gland by lymphocytes, macrophages and plasma cells. The 
follicular epithelial cells which are normally cuboidal in appearance become columnar under 
the stimulatory effect of increased TSH concentrations. There is thickening o f the basement 
membrane and replacement of normal thyroid tissue with mature fibrous connective tissue 
(Gosselin, Capen & Martin, 1981a; Lucke, Gaskell & Wotton, 1983; Kemppainen & Clark, 
1994). This process is progressive and it has been suggested that total thyroidal destruction 
may occur over a three to four year period after which time there remains virtually no 
functional thyroid tissue (Belshaw, 1983). It is not until approximately 75 % o f the gland is 
destroyed that functional failure develops and clinical signs of hypothyroidism become 
apparent (Peterson & Ferguson, 1989).
Whilst the aetiology of canine lymphocytic thyroiditis is believed to be immune 
mediated, analogous to the AITD syndrome in humans, the underlying cause is unclear. 
Thyroiditis has been reported to be more prevalent in certain breeds and family lines of 
dogs (Conaway, Padgett & Nachreiner, 1985) and this subject is discussed in detail in 
Chapter 7. Biochemical evidence of thyroiditis is also more common in apparently healthy 
dogs closely related to individuals with evidence of thyroiditis as determined by TgAb 
estimation (Haines, Lording & Penhale, 1984b). It is therefore presumed that 
hypothyroidism resulting from thyroiditis has a genetic component but other predisposing 
factors remain to be identified. Not surprisingly therefore, a breed predisposition to 
hypothyroidism has also been reported in the literature although the populations under test 
and the diagnostic criteria for the confirmation of hypothyroidism have varied between 
reports making this issue less clear. This is discussed in detail in Chapter 5.
Idiopathic thyroidal atrophy is characterised by reduction in follicular size and 
replacement of the normal parenchymal tissue with adipose connective tissue. There is 
degeneration of follicular cells with exfoliation into the colloid and interfollicular area. Like 
lymphocytic thyroiditis the underlying cause of this process is unknown but histologically it 
appears to be a non-inflammatory degenerative process (Gosselin, et al, 1981a). The
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degeneration has been suggested to be the end stage of an autoimmune process (Rijnberk, 
1996). However, histopathological examination o f affected glands rarely demonstrates a 
concurrent inflammatory infiltrate which has been suggested to indicate that the aetiology 
differs from that of lymphocytic thyroiditis (Gosselin et al, 1981a).
Central Hypothyroidism
Spontaneous secondary or central hypothyroidism reputedly accounts for under 5 % of 
adult cases and is caused by a failure of normal TSH secretion by the thyrotropic cells of 
the pituitary gland (Feldman & Nelson, 1996). The absence of thyroidal stimulation results 
in atrophic degeneration of the thyroid characterised by follicular distention and flattening 
of the follicular epithelium. This can be distinguished from the changes typical o f the more 
common primary idiopathic thyroidal atrophy (Rijnberk, 1996). The most common 
spontaneous cause of central hypothyroidism in the dog is believed to be a tumour within 
or adjacent to the pituitary (Rijnberk, 1996). However there are few reports of this type of 
hypothyroidism in adult dogs (Chastain, Riedesel & Graham, 1979). More commonly 
central hypothyroidism results from suppression o f pituitary TSH secretion by exogenous 
glucocorticoid administration or spontaneous hyperadrenocorticism (Peterson et al., 1984). 
However, this is usually a temporary and reversible condition in which treatment of the 
underlying cause is curative and thyroid hormone supplementation is not required (Peterson 
et al, 1984).
Diagnosing Hypothyroidism
The diagnosis of hypothyroidism in humans is relatively straightforward with the 
measurement of serum free T4 and endogenous TSH concentrations providing a highly 
sensitive and specific assessment of thyroid status (Stockigt, 1996). By contrast the 
diagnosis of this disease in the dog is controversial and is frequently the cause of 
considerable confusion. A variety o f tests to confirm canine hypothyroidism have been 
employed, most of which have their origins in human medicine and this in itself has 
sometimes been responsible for their poor performance. In addition, various technical 
problems inherent in some o f the commonly used assays, and the variation in diagnostic 
classification criteria employed between reports has perplexed both practitioners and 
researchers alike.
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Clinical and Routine Clinicopathological Features
There are various well recognised laboratory abnormalities associated with hypothyroidism 
although these abnormalities are non-specific findings and their presence or absence cannot 
confirm or exclude a diagnosis of hypothyroidism. Similarly, the historical and clinical 
abnormalities are both variable and non-specific for the disease. This subject is discussed in 
detail in Chapter 5.
Thyroid Hormone Concentrations
This review will briefly summarise the major tests used to diagnose hypothyroidism, and 
discuss in more detail those reports where the performance of these tests is compared.
Total Thyroxine
The principal product of the thyroid gland is T4 and basal serum total T4 estimation has 
traditionally been the mainstay of the diagnosis of canine hypothyroidism (Panciera, 
1990b). As described in Chapter 3, there is good cross reactivity o f T4 between most 
species making the commercially available human total T4 assays suitable for use with 
canine samples once modified to allow measurement of the lower circulating concentrations 
in the dog (Belshaw & Rijnberk, 1979; Li et al, 1986; Panciera et al, 1989).
There is universal agreement that circulating total T4 is usually subnormal in 
hypothyroidism. Belshaw & Rijnberk, (1979) confirmed hypothyroidism in 48 dogs using 
either a modified TSH stimulation test based on 131I uptake before and after TSH 
administration, or gamma camera visualisation of the thyroid glands 30 minutes after 
pertechnetate administration. Total T4 was measured as described previously. Reference 
limits were defined as the 2.5th and 97.5th percentiles of results from 126 healthy dogs and 
results were considered abnormal if they were outwith the central 90th percentile of this 
reference distribution. All hypothyroid dogs had subnormal total T4 results.
Nelson et al, (1991) reported resting circulating total T4 concentrations that were 
below the laboratory reference limits in 50 of 51 (98 %) hypothyroid dogs categorised by 
TSH response testing (total T4 measurement immediately before and six hours after the 
intravenous administration of 0.1 i.u./kg body weight exogenous TSH). The method used 
for total T4 estimation was a human RIA kit (Clinical Assays) previously validated for use 
with canine serum by Evinger, Nelson & Bottoms, (1985). One hypothyroid dog had an 
inappropriate total T4 value of 39.9 nmol/L. The authors attributed this result to the 
presence of T4Ab and confirmed lymphocytic thyroiditis in that individual.
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A number of reports have simultaneously evaluated multiple tests of thyroid 
function including total T4 and these are summarised below.
Peterson et al, (1997) and Scott-Moncrieff et al, (1998) both used the same TSH 
response test protocol to confirm hypothyroidism (circulating total T4 measurement 
immediately before and six hours after administration o f 0.1 i.u. TSH/kg body weight). 
Peterson et al, (1997) reported depressed circulating total T4 in 48 of 54 (89 %) 
hypothyroid dogs, and Scott-Moncrieff et al, (1998) reported subnormal basal total T4 
concentrations in all of 16 hypothyroid dogs. Both studies measured total T4 using a coated 
tube RIA (Coat-A-Count Canine T4, Diagnostic Products). Peterson et al, (1997) 
generated a reference range for total T4 by selecting the 5th to 95th percentiles o f all results 
from 150 healthy dogs. Results outwith this range were considered abnormal. Scott- 
Moncrieff et al, (1998) used a laboratory reference range to interpret the test results. 
Whilst six of the hypothyroid dogs reported by Peterson et al, (1997) had total T4 values 
within or above the reference range, three of these cases had spuriously elevated results 
caused by T4Ab whilst in the remaining three cases concentrations were in the low-normal 
range. Thyroid hormone autoantibodies cause spurious results with most thyroid hormone 
immunoassays. The type of interference depends on the method of separation of bound 
from unbound hormone employed in the assay system but in most commercial kits this 
usually causes artefactually elevated results. The presence o f antibodies to the hormone in a 
competitive assay system allows binding of the tracer to the endogenous Ab. This tracer- 
Ab complex cannot compete with endogenous hormone for assay binding sites and 
following removal of unbound hormone and the tracer-Ab complexes there is an artefactual 
increase in the measured hormone concentration.
Whilst the diagnostic sensitivity of total T4 estimation for hypothyroidism is 
undoubtedly high, the specificity of this analyte is particularly poor for a variety o f reasons. 
First, normal random fluctuation in total T4 concentrations occurs in healthy dogs and 
subnormal values are a common occurrence during health. Kemppainen & Sartin, (1984) 
measured serum total T4 at 20 minute intervals from 11 euthyroid dogs using an 
unspecified RIA (Diagnostic Products). There was episodic fluctuation of secretion in all 
dogs which had no predictable pattern. No indication of the number of dogs with, or the 
definition of, “subnormal” results, was provided by the authors. More recently, Miller, 
Nelson, Scott-Moncrieff, Neal & Bottoms, (1992) performed serial total T4 estimation 
using an unspecified RIA (Clinical Assays) over a 12 hour period in 20 clinically healthy 
euthyroid dogs and reported subnormal (less than the laboratory reference value, i.e. 20
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nmol/L) total T4 concentrations in 10 of the animals on at least one occasion. Second, there 
is a progressive decline in mean serum total T4 concentrations with increasing age such that 
juvenile dogs less than three months of age have total T4 concentrations approximately two 
to five times that of adults. Reimers et al, (1990) documented a statistically significant 
decrease in total T4 values (unspecified RIA, ICN Biomedicals/Micromedic Systems) with 
age in 1048 dogs categorised as one of six age groupings between one week and 11 years. 
Mean (± s.e.m.) total T4 concentrations were 39.1 ± 0.6 nmol/L (one to six weeks of age), 
25.0 ± 0.6 nmol/L (six to 12 weeks), 25.1 ± 0.5 nmol/L (three to six months), 24.4 ± 0.8 
nmol/L (six to 12 months), 22.1 ± 0.6 nmol/L (one to six years) and 19.3 ± 0.6 nmol/L (six 
to 11 years) in the various groups. Third, the same study also evaluated the effect of breed 
size on serum total T4 concentrations and identified lower values in medium (25.0 ± 0.5 
nmol/L) and large-breed (26.1 ± 0.4 nmol/L) dogs compared with small breed (31.5 ±0.8 
nmol/L) dogs. Gaughan, Bruyette & Jordan, (1996) also demonstrated an effect of breed 
on total T4 concentration (unspecified method) with greyhounds having significantly 
depressed values compared with non-greyhound pet dogs.
The influence of gender on thyroid hormone concentrations has been evaluated in 
several studies with conflicting results. Le Roux, (1983) demonstrated that mean (± s.d.) 
total T4 concentrations (30.6 ± 5.6 nmol/L) were significantly lower in female dogs 55 
weeks following ovariectomy compared to those which had received a sham ovariectomy 
(39.5 ± 12.1 nmol/L). A similar effect has also been reported in male dogs following 
castration (Ganong & Junker, 1955). Gosselin, Capen, Martin & Targowski, (1980) 
reported no effect of hyperoestrogenism on total T3 or T4 concentrations (unspecified RIA) 
in six dogs. Reimers et al, (1984) evaluated circulating total T4 and total T3 concentrations 
using coated-tube RIA’s (Autopak, Micromedic systems) in five anoestrus, five pro- 
oestrous, five dioestrous, five pregnant and five lactating beagle bitches and five male dogs. 
Total T4 concentrations were significantly increased in dioestrous and pregnant bitches and 
total T3 was significantly increased in dioestrous bitches compared with each other group 
of dogs. Unfortunately, summary mean values were not provided for each group, but 
broadly speaking, mean total T4 concentrations were approximately 30 nmol/L and 25 
nmol/L during dioestrus and pregnancy, respectively, compared with approximately 15 
nmol/L during most other stages of the oestrus cycle. Similarly, mean total T3 
concentrations were approximately 1.5 nmol/L during dioestrus compared with 
approximately 0.92 nmol/L during most other stages of the oestrus cycle. There were no 
significant differences between other groups suggesting that progesterone dominated
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phases of the oestrous cycle are associated with increased thyroid hormone concentrations. 
The effect of gender on thyroid hormones was also evaluated by Kemppainen & Sartin, 
(1984) who reported significantly lower mean (± s.d.) total T4 concentrations in intact male 
(15.4 ± 3.6 nmol/L) compared with anoestrus intact female (20.7 ± 3.6 nmol/L) dogs. 
Whilst the magnitude of variation in thyroid hormone concentrations between reproductive 
groups is greater in the report by Reimers et al, (1984) than in the study by Kemppainen & 
Sartin, (1984), both studies have groups with mean results of approximately 15 nmol/L. 
Using most conventional criteria these results are bordering on “subnormal” and therefore 
reproductive factors apparently have the potential to be of clinical relevance. Reimers et al, 
(1990) reported no significant difference in mean (± s.e.m.) circulating total T4 
concentrations in 517 male dogs (26.8 ± 0.5 nmol/L) compared with 557 females (27.2 ± 
0.5 nmol/L) although no account was taken of the stage of the reproductive cycle in the 
female animals. The reason for the difference in results between some of these studies is 
unclear.
Based on the above studies evaluating the effects o f random fluctuation, age, breed 
and gender on circulating thyroid hormone concentrations it is clear that normal 
physiological mechanisms in the healthy dog exist which cause considerable variation in 
total T4 concentrations.
The overlap which exists between hypothyroid dogs and dogs with NTI and those 
receiving certain drug therapies is even greater than the overlap with healthy dogs. This 
subject is discussed in detail in Chapter 8 . This further reduces the diagnostic specificity of 
total T4 measurement for hypothyroidism.
Given the various factors other than hypothyroidism capable of decreasing total T4 
concentrations, estimation of this analyte is only truly diagnostic if concentrations are 
within the reference range in which case hypothyroidism can generally be excluded.
Total Triiodothyronine
Serum total T3 estimation is infrequently performed in the evaluation of hypothyroidism 
since the overlap o f results from euthyroid dogs with NTI and hypothyroid dogs tends to 
be even greater than that reported for total T4 (Panciera, 1994). Using the diagnostic 
criteria outlined above, Belshaw & Rijnberk, (1979) reported plasma total T3 to be of about 
equal value to that of total T4 in discriminating between 126 healthy and 48 hypothyroid 
dogs. Thyroid hormones were measured using charcoal separation RIA methods with 
unspecified commercial T4 and T3 antisera (Nichols institute) and labelled hormones
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(Sigma). However, measurement of total T3 from dogs with clinical disease reduces its 
diagnostic specificity for hypothyroidism.
Nelson et al., (1991) reported that mean (± s.d.) total T3 was not significantly 
different between 51 hypothyroid (0.77 ± 0.77 nmol/L), 62 healthy (1.08 ± 0.46 nmol/L) 
and 59 euthyroid dogs with one of eight categories o f NTI. The method used for total T3 
estimation was a human RIA kit (Clinical Assays) previously validated for use with canine 
serum by Evinger et al., (1985). Cases were categorised using a combination of clinical 
signs, TSH response tests, thyroid gland histopathological examination, response to therapy 
and case follow up. Mean thyroid hormone results from the NTI cases were categorised 
into each of the eight types of diseases but an overall mean value was not provided for 
these dogs. Nevertheless, total T3 concentrations ranged from 0.15 to 3.07 nmol/L in the 
dogs with NTI, compared with 0.15 to 1.84 nmol/L (healthy dogs) and 0.15 to 2.76 nmol/L 
(hypothyroid dogs).
Miller et al., (1992) determined total T3 concentration using the same method as 
Nelson et al., (1991) in 19 hypothyroid, 20 healthy and 18 euthyroid dogs with atopic 
dermatitis, categorised by TSH response tests and reported no significant difference in 
results between the three groups. Overall mean total T3 concentrations for each group were 
not provided, since the study was designed to evaluate the effect of time of sampling on 
hormone concentration, and consequently reported the mean values at each individual time 
point during the study. Random fluctuation of total T3 was common with 14 of 20 healthy 
euthyroid, and 15 of 18 sick euthyroid dogs (with atopic dermatitis) having a subnormal 
concentration (less than the laboratory reference value, i.e. <1 .0  nmol/L) on at least one 
occasion over a 12 hour sampling period.
Recently, Peterson et al, (1997) reported a median total T3 concentration of 1.4 
nmol/L in 31 hypothyroid dogs which was not significantly different to 1.5 nmol/L in 135 
healthy or 1.2 nmol/L in 38 euthyroid dogs with NTI. Total T3 was measured using a 
coated tube RIA (Coat-A-Count Canine T3, Diagnostic Products) and cases were 
categorised based on the results of TSH response tests. In that study, subnormal total T3 
results occurred in only three hypothyroid dogs although five of the 31 cases had elevated 
results due to autoantibody interference.
Several factors are presumed to be responsible for the poor diagnostic performance 
of total T3 estimation in hypothyroidism. First, the thyroid gland itself is responsible for the 
secretion of only approximately half o f circulating T3. Consequently, the measurement of 
circulating total T3 is a relatively insensitive method with which to evaluate changes in
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thyroid gland function. Second, most T3 is produced peripherally within the tissues by 5' 
deiodination of T4 Consequently, any changes in the rate of peripheral T3 production, such 
as occurs in NTI, will alter circulating total T3 concentration but not necessarily reflect 
thyroid gland function. This may contribute to the poor correlation of circulating total T3 
concentration and thyroid gland function. Third, the failing thyroid gland is associated with 
an increase in endogenous TSH concentration. This stimulates the preferential thyroidal 
secretion of T3 instead of T4 (Peterson & Ferguson, 1989; Panciera, 1990a). This 
presumably helps maintain circulating total T3 concentrations and therefore metabolic 
activity in the face o f impending failure (Lum, Nicoloff, Spencer & Kaptein, 1984). 
However, as a consequence of this, decreases in circulating T3 values, particularly in the 
early stages of thyroid dysfunction, are inconsistent.
Free Thyroid Hormones
The measurement of free thyroid hormone concentrations should in theory at least, offer 
considerable advantages over total hormone estimations. Assuming the free hormone 
hypothesis to be broadly correct, free hormone is the metabolically active fraction available 
for tissue uptake and therefore should provide the most accurate assessment of cellular 
thyroid status (Robbins & Rail, 1957). Additionally, measurement of free hormone 
concentration is theoretically unaffected by the presence of thyroid hormone 
autoantibodies, the presence of protein binding inhibitors, or alteration in the concentration 
and/or affinity of thyroid hormone binding proteins, all o f which interfere with total T4 
estimation. The close correlation between free T4 concentrations and metabolic status has 
resulted in its measurement being used as the gold standard test of thyroid function in 
humans (Ekins, 1985).
An indirect assessment of free T4 concentration, the free thyroxine index (fT4I) has 
been widely used in humans, and more briefly in dogs (Kallfelz, 1968; Kallfelz & Erali, 
1973). The fT4I is the product o f the thyroid hormone binding ratio (THBR) and circulating 
total T4 concentration. The THBR, previously known as the “ T 3  resin sponge uptake test” 
is based on the in-vitro competition between plasma proteins and an ion exchange or a 
charcoal resin matrix for endogenous serum thyroid hormones and added T3 tracer. 
Radiolabelled T3 is used in preference to T4 because it has a lower affinity for human TBG 
and therefore equilibrates more rapidly in vitro. The degree of tracer binding to the resin is 
inversely proportional to the concentration of unoccupied protein binding sites and their 
affinity for thyroid hormones. In humans the THBR often correlates reasonably accurately
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with free T4 concentrations as measured by dialysis (Ferguson, 1994). Unfortunately the 
fT4  is very insensitive to changes in thyroid status in dogs largely due to the much lower 
concentration and affinity of circulating TBG for thyroid hormones in dogs compared to 
humans. Consequently the use of the THBR and fTJ have been discarded in the dog.
Currently the measurement of so-called free T4 is usually performed by either 
dialysis, ultrafiltration, or free hormone RIA methods. Direct immunoassay has been by far 
the most commonly used method. However many of these techniques have been severely 
criticised on theoretical and practical grounds and reports of their validation and clinical 
performance have caused both confusion and controversy (Ekins, 1983; Alexander, 1986). 
A comprehensive review of the practical and physicochemical properties of the available 
methodologies has been previously reported by Ekins, (1987; 1993).
Three “free hormone” RIA methods have been utilised for the measurement of 
thyroid hormones in humans, namely the “labelled hormone antibody uptake”, “labelled 
hormone back titration” and “labelled analogue” techniques.
The labelled hormone antibody uptake method relies upon estimation of total 
sample hormone concentration followed by the estimation of the fraction of the hormone 
which binds to exogenous antibody. This is in essence similar to the traditional fT4I 
estimates. The principal disadvantage of this technique is that the amount o f hormone being 
removed from the assay system and incorporated in the antibody-ligand complex is 
relatively large. This results in progressive dissociation o f previously bound hormone much 
as occurs during sample dilution discussed below. This feature can be responsible for 
erroneous values in situations such as the presence of thyroid hormone protein binding 
inhibitors (THBI).
The labelled hormone back titration method is a two step procedure. First solid- 
phase antibody is incubated with the sample allowing the ligand to bind. The antibody is 
then removed and washed, and then incubated in the presence of labelled hormone. The 
labelled hormone attaches to any unoccupied antibody binding sites allowing inference of 
the free hormone binding and therefore concentration. This method is not subject to the 
problems encountered with the single step “analogue” assays described below, and the 
validity o f this method is not questioned. However, this methodology has been subject to 
unacceptable intra-assay drift arising from the variable sequential incubation time from one 
sample to the next. This effect can be minimised by the selection of an antibody with 
appropriate reaction kinetics but nevertheless has proved to be a problem in practice.
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By far the most widely used method over the previous 20 years has been the 
labelled analogue RIA's in which a labelled T4 analogue competes with endogenous free T4 
for a limited number of solid-phase Ab binding sites (Montgomery, Nelson, Ferguson & 
Feldman, 1991; Nelson et al, 1991; Paradis, Page, Lariviere & Fontaine, 1996). Whilst the 
theoretical basis for the technique is perfectly sound, the assays rely upon the absence of 
any interaction between the labelled T4 analogue and endogenous serum proteins. However 
it is now clear that in practice this fundamental requirement is not met (Stockigt, DeGaris, 
Csicsmann, Barlow, White & Hurley, 1981; Bayer, 1983; Ekins, 1985). The main effect of 
binding o f the analogue to serum proteins is the potential to change the concentration of 
analogue which is available for antibody binding. Clearly the greater the binding of labelled 
analogue to endogenous serum proteins, the lower the concentration of analogue available 
for binding to the anti-T4 antibody. Similarly any reduction in the concentration of binding 
proteins or their affinity for the analogue, increases the free analogue concentration and 
consequently competition between analogue and endogenous hormone. This causes a 
decrease in the measured free hormone concentration.
The presence of THBI in NTI causes displacement o f hormone from binding 
proteins and therefore, free T4 concentration increases. This has been confirmed using 
equilibrium dialysis techniques (Chopra, Solomon, Hepner & Morgenstein, 1979a). This is 
typically a short-lived phenomenon since the absolute free T4 concentration re-equilibrates 
fairly rapidly as TSH production and consequently total T4 values decrease, returning free 
T4 concentration to normal despite an increased free hormone fraction. However, when 
using analogue methods in which there is significant interaction between the analogue and 
endogenous proteins, the presence of THBI also displaces analogue from the protein, 
thereby increasing the competitive effect of the analogue for assay Ab. This artefactually 
reduces the measured free T4 concentration compared to the “normal” results obtained with 
that assay. In clinical situations such as chronic NTI in which THBI are present (Chopra, 
Chua Teco, Nguyen & Solomon, 1979b), the measured free T4 value depends largely on 
the interaction of analogue and serum proteins and frequently bears little relation to the true 
free hormone concentration. This is the principal reason why one step analogue assays are 
unreliable when used in cases with NTI. Whilst the increase in true free T4 fraction and 
reduction o f analogue-protein binding can be anticipated, the magnitude of the effects of 
THBI cannot be determined without knowledge of the relative interaction of both THBI 
and analogue for each of the binding proteins in the serum samples and the kit reagents. 
Since the latter is unknown, and almost certainly different between each of the analogue
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assays, the kits’ response to these competitors cannot be accurately predicted. 
Furthermore, species differences in normal binding proteins may potentially alter results 
depending on the relative affinity of the analogue for different proteins.
Various chemical blockers have been added to the analogue systems in an attempt 
to prevent binding of the labelled analogue with plasma proteins (Witherspoon, El Shami, 
Shuler, Neely, Sonnemaker, Gilbert & Alyea, 1988). However, these modifications have 
been found to be broadly cosmetic and have not been effected by identifying an analogue 
with the desired physicochemical characteristics, but by altering the other assay 
components to give broadly correct results in a number of specific clinical situations 
(especially pregnancy which is associated with markedly elevated TBG concentration in 
humans). Using one such assay (Amerlex FT4 RIA, Amersham) Bayer, (1983) 
demonstrated that measured free T4 results in hormone-free serum were in fact directly 
proportional to the concentration of albumin in the samples.
Further doubt has been cast on the validity o f the analogue assays based on results 
of experimental dilutional studies. When serum is diluted with an aqueous inert diluent 
there is a net dissociation of bound hormone resulting in an approximate maintenance of the 
free hormone in the diluted medium. Dilution therefore causes a reduction in the total 
hormone concentration far in excess of the reduction in free hormone concentration. Near 
constancy of assay results in the face of serum dilution is now widely regarded as the 
classic test of free T4 assay validity. Dilution of samples in this manner, results in depletion 
of the free hormone pool to an extent dependent on the normal proportion of bound and 
free hormone. In the case of T4 specifically, dilutions in the order of 500 to 1000 result in 
imperceptible decreases in free T4 measured by dialysis methods (Ekins, 1987). In the case 
of less highly protein bound hormones such as T3 (approximately 1 % free) or steroids (up 
to 10 % free) the same dilution will have an effect that is orders of magnitude greater. A 
similar variation in free hormone depletion as a consequence of dilution may be expected 
when comparing results from humans and dogs, since the free T4 fraction is approximately 
three fold greater in dogs. Nevertheless, the relative free T4 fraction in dogs remains 
minimal and under normal circumstances, assuming no indirect dilution effects such as 
those discussed above, dilution is thus of little consequence in this species. The extent of 
dilution inherent within an assay system should therefore take account of the maximum 
“permissible” dilution factor, depending on the species and hormone being evaluated. This 
potential error arises in all free hormone methodologies, not simply analogue techniques.
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However, the failure of analogue methods to pass this “dilution test” provides further 
evidence that they are not truly free hormone assays (Ekins, 1985).
The effect of dilution of samples containing THBI prior to free T4 estimation using 
an analogue methodology is complicated. Dilution o f the sample will alter the effects 
exerted by the THBI. In general, if a THBI interacts with protein binding sites with a lower 
affinity than does the endogenous hormone, dilution will tend to reduce the effects of the 
THBI. This will typically reduce the measured free T4. However, if the THBI reacts with 
the binding sites with a higher affinity than the hormone, the converse applies (Ekins, 
1985). Clearly the one-step analogue method remains fundamentally incorrect and liable to 
artefact (Ekins, 1985). Consequently whilst analogue assays tend to give results which 
correlate with free T4 measured by equilibrium dialysis in healthy patients, they are 
consistently lower when used in cases with NTI and their use is now discouraged (Ekins, 
1985; Montgomery et al, 1991; Ferguson, 1994).
The reference techniques for free hormone measurement are equilibrium dialysis 
and ultrafiltration. However there remain practical difficulties associated with both of these 
methods. Ultrafiltration in particular is not suitable for routine clinical use and consequently 
is not widely commercially used for thyroid hormone estimations (Schussler & Plager, 
1967). Ultrafiltration does have the advantage that it can be performed without sample 
dilution and is therefore not associated with some of the problems inherent in the
conventional RIA and dialysis techniques. However, ultrafiltration is complicated by the
presence of any non-filtrable THBI which if confined to the protein-containing filtrand will 
have the same effects described below.
Dialysis techniques rely on bringing the serum (“dialysand”) into contact with a 
buffer (“dialysate”), the two being separated by a membrane which is permeable to free 
hormone but not to the hormone binding proteins. Free hormone passes through the 
membrane causing dissociation of protein-bound hormone to maintain the thermodynamic 
equilibrium within the system. Once a state of equilibrium is reached the concentration of 
free hormone on both sides of the membrane is identical. Measurement of free hormone in
the dialysate by either direct or indirect methods can then be performed without the
complicating effect of endogenous proteins. Indirect measurement of dialysate hormone 
concentration was first performed by Sterling & Hegedus, (1962). This method relies on 
estimation of the total hormone in the sample, for example by conventional RIA, followed 
by measurement of the fraction of hormone which appears in the dialysate. This is achieved 
by the addition of tracer to the original sample prior to dialysis, and calculation of the
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percentage radioactivity which is ultimately dialysed. The principal limitation of this 
approach has been associated with impurities within the radioactive tracer. Such impurities 
enter the dialysate and contribute to a falsely elevated free T4 estimation. This is of 
particular importance in the case of the thyroid hormones since the free hormone fraction is 
normally extremely small. The presence of even small quantities of non-T4 tracer therefore 
causes a considerable relative overestimation of free T 4 .  As a consequence of the problems 
associated with tracer impurities, direct dialysate hormone measurement were subsequently 
developed. Ellis & Ekins, (1973) reported a direct dialysis method for free T4 and free T3 
estimation. This was apparently designed using highly specific antisera and computer 
optimisation techniques to maximise the sensitivity of the assay. However, no further 
validation data were provided. Free T4 results ranged from 32.2 to 51.5 pmol/L in healthy 
individuals. Subnormal results in hypothyroidism, and increased concentrations in 
thyrotoxicosis were reported but detailed data o f results or categorisation methods were 
not provided. Helenius & Liewendahl, (1983) designed a method of sample dialysis 
followed by direct RIA o f free hormone in the dialysate utilising disposable dialysis cells. 
These were manufactured from thermoplastic resin which had minimal absorptive capacity 
for T4 yet, unlike glass, was sufficiently inexpensive to allow mass production of the cells in 
a disposable format. The dialysis cells containing 100 pi sample and 400 pi buffer were 
incubated for 18 hours at 37°C on a rack shaker. The dialysis membrane was manufactured 
from Visking tubing (molecular mass cut off 6000). Direct competitive RIA of the dialysate 
was then performed on 600 pi dialysate using commercial T4 antibody (International 
Laboratory Services) and 125I labelled T4. Bound and unbound hormone were separated 
using PEG precipitation. The assay was compared with a number of non-dialysis 
commercial free T4 methods, and generally gave results which were greater than obtained 
with the other methods, particularly in cases with NTI. Nelson & Weiss, (1985) developed 
a highly sensitive T4 RIA to allow the direct determination of free T4 in dialysates. The 
assay was designed to maintain the pH and concentration of ions known to affect T4 
binding to serum proteins by the combined use of HEPES buffer and HEPES acid 
(Calbiochem-Behring). Progressive serum dilution prior to dialysis resulted in a decrease in 
measured free hormone in patients with NTI but not in serum from healthy individuals. The 
magnitude of the decrease in the patients with various NTI varied widely and was not 
predictable. Nelson & Tomei, (1988) evaluated a similar dialysis method to that reported 
earlier by Helenius & Liewendahl, (1983) utilising the sensitive RIA described by Nelson & 
Weiss (1985). The working range of the assay was reported to be 2.6 to 164.7 pmol/L with
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a reference range of 10.3 to 34.7 pmol/L. Free T4 concentrations were reported to be 41.2 
to 615.2 pmol/L in hyperthyroidism, 11.6 to 34.7 pmol/L in excess TBG and familial 
dysalbuminaemic hyperthyroxinaemia, less than 2.6 to 9.0 pmol/L in hypothyroidism, 11.6 
to 32.2 pmol/L in severe TBG deficiency, and 10.3 to 45.0 pmol/L in various NTI. The 
cells designed for this purpose were modified and ultimately became commercially available 
in kit form (Free T4 by Equilibrium Dialysis, Nichols Institute Diagnostics).
Ferguson & Peterson, (1992) evaluated a free T4 method which was a modification 
of the indirect dialysis technique reported by Sterling & Brenner, (1966). Serum was 
collected from 42 dogs with hyperadrenocorticism and 103 healthy dogs. The mean (± 
s.e.m.) free T4 concentration was significantly lower in the dogs with hyperadrenocorticism 
(16.9 ± 2.3 pmol/L) compared with the healthy dogs (23.6 ± 1 . 0  pmol/L). The free T4 
fraction was significantly higher in the dogs with hyperadrenocorticism (0.15 ± 0.018 %) 
compared with the healthy dogs (0.09 ± 0.003 %) indicative of a reduction in serum protein 
binding.
Panciera & Post, (1992) evaluated the effect of trimethoprim and sulphadiazine 
medication on free T4 concentrations determined using a modified equilibrium dialysis kit 
method (Free T4 by Equilibrium Dialysis, Nichols Institute Diagnostics) in 12 healthy adult 
beagle dogs. Whilst no effect of the drug at standard therapeutic doses was recognised, 
apparently random decreases in free T4 concentration occasionally occurred. The actual 
free T4 concentrations in the treated and control groups were difficult to determine due to 
the errors in the manuscript discussed in Chapter 3.
Scott-Moncrieff, Nelson, Ferguson & Neal, (1994) determined circulating free T4 
concentrations using the same kit method as Panciera & Post, (1992) in 31 healthy, 11 
hypothyroid and 32 euthyroid dogs with NTI. Cases were categorised based on history, 
physical examination, TSH stimulation tests and the need for thyroid hormone replacement 
therapy. Mean (± s.d.) free T4 concentration was significantly higher in the healthy (25.74 ± 
10.3 pmol/L) dogs compared to the hypothyroid (2.57 ± 2.57 pmol/L) animals. The 
euthyroid group with NTI were categorised into those with hyperadrenocorticism (n=10), 
obesity (n=9), hypoalbuminaemia (n=8 ) and megaoesophagus (n=5). Only those dogs with 
hyperadrenocorticism had free T4 concentrations significantly lower than the healthy 
animals. The accuracy o f free T4 for correctly identifying cases as either hypothyroid or 
euthyroid was 0.85.
Peterson et al., (1997) evaluated the same free T4 method in 54 dogs with 
hypothyroidism, 54 dogs with various NTI and 150 clinically healthy dogs. Cases were
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categorised based on the results of bovine TSH response tests (total T4 estimation prior to 
and six hours following the intravenous administration of 0.1 i.u. TSH/kg body weight). 
Median free T4 concentrations were significantly lower in the hypothyroid dogs (2 pmol/L) 
compared to the euthyroid dogs with NTI (20 pmol/L) and the healthy dogs (22 pmol/L). 
Fifty three of the 54 (98 %) hypothyroid dogs had free T4 concentrations less than the 
reference range (derived from the healthy dogs as indicated above) compared to only four 
o f the 54 (7 %) euthyroid dogs. The diagnostic sensitivity, specificity and accuracy of free 
T4 estimation for hypothyroidism was 0.98, 0.93 and 0.95, respectively.
Thyrotropin
In human medicine, the measurement of circulating TSH concentration generally provides 
an accurate indication of fimctional thyroid status due to the exquisite sensitivity of the 
pituitary thyrotrophs to changes in circulating free T4 concentration. In fact when plotted 
together, TSH is usually depicted on a logarithmic scale because of its dramatic response to 
changes in serum free T4 (Stockigt, 1996). The human TSH assays currently used are third 
generation assays and are both extremely sensitive and accurate. These assays are not only 
capable of distinguishing low, normal and high values, but can differentiate the low values 
found in NTI from the very low values associated with thyrotoxicosis (Spencer, LoPresti, 
Patel, Guttler Eigen, Shen, Gray & Nicoloff, 1990).
Chastain, (1978) first reported on the use of a human TSH assay as a diagnostic test 
for canine hypothyroidism using 14 clinically healthy and five suspected hypothyroid dogs. 
Four of the hypothyroid group had clinical signs consistent with hypothyroidism, and a 
subnormal total T4 response to TSH administration. One other dog was categorised as 
hypothyroid based on a subnormal basal total T4 concentration alone. The study found no 
correlation of cTSH results with categorisation, and concluded that the cross-reactivity of 
the cTSH molecule, most likely the [3-subunit with the antibody used in the assay, was 
insufficient to be clinically usefiil. In a larger series of dogs Larsson, (1981) investigated a 
human based assay in which the cTSH Ab was derived from sheep. Bovine TSH response 
tests were used to classify cases, and confirmed hypothyroidism in 40 o f 150 dogs 
investigated. The mean (± s.d.) cTSH concentration in the hypothyroid group (9.49 ± 6.73 
pU/ml) was significantly higher than in a random selection o f 20 o f the euthyroid dogs (3.5 
± 1.67 pU/ml). However, there was marked overlap of results between euthyroid and 
hypothyroid dogs reducing the diagnostic utility of the assay. In the same study TRH 
response testing was performed in eight dogs and revealed minimal increase in cTSH
Chapter 4 82
concentrations. This was interpreted as an indication o f inadequate cross-reactivity o f the 
Ab used in the assay. Quinlan & Michaelson, (1981) reported the use of a supposedly 
canine-specific cTSH assay based on rabbit derived cTSH Ab in dogs following 
propylthiouracil (PTU) administration and x-irradiation. However, the validation data 
provided in that report was limited and the method was not made commercially available. 
Rachofsky et al, (1988) investigated a separate species-specific assay in 79 suspected 
hypothyroid dogs. Most of the cases were categorised based on their clinical response to T4 
supplementation. However, the results indicated that cTSH estimation either alone or in 
conjunction with total T4 measurement was no more predictive o f a favourable response to 
T4 replacement therapy than a basal total T4 estimation alone.
Recently Williams et al, (1996) reported the development and laboratory validation 
characteristics of an IRMA assay for cTSH measurement (Canine TSH IRMA, Diagnostic 
Products). Canine cTSH was isolated from canine pituitary glands and purified by means of 
immunoaffinity chromatography using a highly specific monoclonal antibody. The 
polyclonal rabbit anti-cTSH antibody used in the assay was then produced by immunisation 
of rabbits with the cTSH and performing immunoaffinity chromatography on the rabbit 
serum. In the assay, sample cTSH is sandwiched between polyclonal anti-cTSH antibody in 
the liquid phase, and specific monoclonal anti-cTSH antibody immobilised on the inside of 
the reaction tubes. The authors reported significant elevations in serum cTSH 
concentration in six dogs 14 days after experimental radiothyroidectomy. Thyroid status 
was confirmed by bovine TSH response testing prior to and following radiothyroidectomy. 
Following T4 replacement therapy cTSH concentrations decreased and were not 
significantly different to the baseline values within 14 days of commencing therapy. The 
results were consistent with expected changes, although actual cTSH concentrations were 
not provided. Following the development of the cTSH antibody, it has subsequently been 
commercialised and is now widely available in several kit forms including the IRMA.
Jensen et al, (1996) evaluated the same assay in five hypothyroid dogs, and 11 
dogs with various dermatological conditions. Cases were categorised as hypothyroid or 
euthyroid with NTI by thyroid gland biopsy examination. In addition 13 healthy dogs were 
studied. Median (range) cTSH concentration was 0.18 pg/L (0.16-0.72) in the hypothyroid 
dogs which was significantly greater than 0.09 pg/L (0.05-0.53) in the euthyroid dogs with 
NTI and 0.09 pg/L (0.06-0.34) in the healthy dogs. However, there was considerable 
overlap of results between the three groups. This may have been related to the classification 
of cases since the presence of thyroid pathology in itself is not confirmatory of functional
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failure and no assessment of thyroid reserve was performed in the study. Furthermore, only 
a small number of putatively hypothyroid dogs were studied. Jensen et al, (1996) 
suggested that the reference range cTSH concentrations in the dogs with histopathological 
evidence consistent with hypothyroidism may have been the result o f exhaustion of the 
pituitary gland’s ability to synthesise and release cTSH. Variation in cTSH isoforms, or 
“microheterogeneity” was also suggested as a possible explanation for the discordant 
results.
Peterson et al, (1997) evaluated the same cTSH IRMA kit in 150 healthy, 54 
hypothyroid and 54 euthyroid dogs with NTI. Bovine TSH response testing was use to 
differentiate hypothyroidism from euthyroidism with NTI. Median serum cTSH was 
significantly greater in the hypothyroid (1.5 ng/ml) compared to both clinically healthy 
(0.19 ng/ml) and euthyroid with NTI (0.28 ng/ml) cases. However “normal” cTSH results, 
defined from reference limits generated as described above for total T4 , occurred in 13 of 
54 (24.1 %) hypothyroid dogs and elevated cTSH concentrations were reported in 4 of 54 
(7.6 %) euthyroid dogs with NTI giving a sensitivity and specificity for hypothyroidism of 
0.76 and 0.93, respectively. Possible explanations provided by the author for reference 
range cTSH concentrations in hypothyroid dogs included central hypothyroidism, the 
presence of undetectable isoforms of cTSH or a variance between the immunological 
concentrations and biological activity of the cTSH present. No suggested explanation for 
the increased cTSH concentrations in the euthyroid dogs was provided.
Ramsey et al, (1997) recently investigated an ELISA for cTSH (Canine TSH 
ELISA, Diagnostic Products). In that study dogs were categorised as either euthyroid, 
“sick euthyroid”, hypothyroid or hypothyroid on non-thyroidal therapy based on clinical 
signs, total T4 concentration and TRH stimulation test results. The reference range was 
defined as the 2.5th to 97.5th percentile values of the results from the euthyroid group. The 
reference range quoted was 0 to 0.41 ng/ml. Serum cTSH concentrations were elevated in 
two o f 41 euthyroid, five of 16 sick euthyroid, six o f nine hypothyroid, and one of six 
hypothyroid dogs on non thyroidal therapy. However, cases were predominantly classified 
based on the results of TRH response tests which are known to be very poorly specific for 
hypothyroidism (Frank, 1996). Ramsey et al, (1997) suggested that down regulation of the 
pituitary thyrotrophs as a result o f chronic hypothyroidism, or alternatively, central 
hypothyroidism may have been responsible for the discordantly low cTSH concentrations in 
the putatively hypothyroid group.
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Scott-Moncrieff et al, (1998) evaluated the same cTSH IRMA assay as Peterson et 
al., (1997) in samples from 62 healthy, 16 hypothyroid and 33 euthyroid dogs with various 
NTI categorised based on TSH response tests. Cases with equivocal response test results 
were excluded from the study. A reference range for cTSH was generated from the 5th to 
95th percentile of results from healthy dogs, and reported to be 0.02 to 0.45 ng/ml. Median 
(range) cTSH concentrations were 0.10 ng/ml (0.01 to 0.75) in the healthy dogs, 0.47 
ng/ml (0.07 to 2.06) in the hypothyroid dogs and 0.18 ng/ml (0.01 to 2.29) in the euthyroid 
dogs with NTI. Circulating cTSH concentrations were significantly different between each 
of the three groups. Four o f 33 (12 %) euthyroid dogs, and six of 16 ( 38 %) hypothyroid 
dogs had unexpectedly increased and decreased cTSH concentrations, respectively. The 
diagnostic sensitivity and specificity for hypothyroidism were 0.63 and 0.88, respectively. 
Possible explanations for the discordant cTSH results proposed by the authors included 
diurnal fluctuation in cTSH, central hypothyroidism, concurrent drug administration, 
concurrent disease or decreased pituitary secretion of cTSH in cases with chronic 
hypothyroidism.
From the studies outlined above, it is clear that cTSH measurement alone is neither 
entirely sensitive or specific for hypothyroidism, and several explanations for discordant 
results in both euthyroid and hypothyroid dogs have been proposed (Campbell et al, 1996; 
Jensen et al, 1996; Peterson et al, 1997, Ramsey et al, 1997; Scott-Moncrieff et al,
1998). However, currently there is relatively little data to help identify causes of 
discordancy. Many normal physiological characteristics, such as the effect of age, breed and 
sex on cTSH have not yet been evaluated. Bruner, Scott-Moncrieff & Williams, (1998) 
determined cTSH concentrations, using the same IRMA assay described above, in six 
healthy dogs, six radiothyroidectomised adult beagle dogs before and during THRT, and in 
six dogs with spontaneous hypothyroidism every two hours from 8am for 12 hours. Dogs 
were cateogrised according to clinical signs, circulating endogenous cTSH concentration 
and total T4 concentration before and after TRH administration. The cTSH concentrations 
from the spontaneously hypothyroid dogs were estimated using the chemiluminescent 
technique (Immulite Canine TSH, Diagnostic Products). Mean (± s.d.) cTSH concentration 
in the healthy, untreated radiothyroidectomised, treated radiothyroidectomised and 
spontaneously hypothyroid dogs were 0.11 ± 0.08, 3.31 ± 1.30, 0.08 ± 0.07 and 0.55 ± 
0.27 ng/ml respectively. There were no significant differences within groups between time 
points. All cTSH concentrations from the healthy dogs and treated radiothyroidectomised 
dogs were within the reference range. All cTSH concentrations from the untreated
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radiothyroidectomised were above the reference range. Fifteen of 41 (37 %) samples from 
the spontaneously hypothyroid dogs had cTSH concentrations greater than the reference 
range, whereas the remaining 26 (63 %) results were within the reference range. In one dog 
with naturally occurring hypothyroidism, cTSH concentration was within the reference 
range at all time points contributing to these results. The authors suggested that central 
hypothyroidism or the presence of undetectable isoforms of cTSH may have been 
responsible for the results in this case. None o f the spontaneously hypothyroid dogs had 
cTSH concentrations outwith the reference range at every time point. However, the 
fluctuations in cTSH concentrations in these dogs was apparently random. The authors 
concluded that this phenomenon may in part explain the reduced diagnostic sensitivity of 
cTSH for hypothyroidism and suggested that repeated sampling for cTSH measurement 
may be of value in suspected hypothyroid dogs.
Amongst the recent reports of the IRMA cTSH assay performance, there is 
widespread agreement that the LoD of the assay is in the region of 0.01 ng/ml which is 
inadequate to differentiate between “normal” and low values. This is supported by the data 
presented in Chapter 3. The current generation o f cTSH assays therefore appear unable to 
confirm central hypothyroidism or be accurately used for therapeutic monitoring purposes.
Thyroglobulin Autoantibodies
The demonstration of circulating autoantibodies to thyroglobulin (TgAb) has been 
suggested to be useful in the confirmation of thyroiditis in the dog. This subject is discussed 
in detail in Chapter 7.
Dynamic Thyroid Function Testing 
TSH response Test
The most definitive test for the confirmation o f hypothyroidism in the dog is the bovine 
TSH response test (Larsson, 1988; Peterson & Ferguson, 1989; Panciera, 1990b; 
Ferguson, 1994; Feldman & Nelson, 1996). The principle behind the test is that 
administration of a supraphysiological dose of exogenous TSH causes maximal stimulation 
of the thyroid gland. This test therefore provides an assessment of thyroid secretory reserve 
(Peterson & Ferguson, 1989; Ferguson, 1994). Whilst both drug therapy and NTI can 
cause a reduction in the thyroid gland’s response to exogenous TSH, this test is affected 
less than any other commonly available technique and accurate identification of
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hypothyroidism is possible in most cases (Torres et al, 1991; Feldman & Nelson, 1996; 
Frank, 1996).
Various protocols and interpretations of TSH response tests have been advocated in 
the literature. Belshaw & Rijnberk, (1979) compared serum total T4 concentrations two, 
four, eight and 10 hours after the intravenous administration of 10 i.u. TSH in 30 dogs and 
concluded that the eight hour sample gave the highest and most consistently elevated total 
T4 concentration. Gosselin et al, (1980) reported maximal total T3 and total T4 
concentrations eight hours after the intramuscular administration of 0.1 or 0.2 i.u. / 5 lbs 
body weight bovine TSH but 12 hours after the administration of 1 i.u. / 5 lbs body weight. 
Lorenz & Stiff, (1980) adopted an unusual protocol whereby blood was collected for 
serum total T4 estimation mid-morning and 0.4 i.u. TSH/kg body weight was then 
administered at 10pm that evening. The following day another sample for total T4 
estimation was collected for comparison. A failure to double serum total T4 concentration 
was considered confirmatory of hypothyroidism. Chastain, (1982) recommended sampling 
before and eight hours after intravenous administration of 5 i.u. or 10 i.u. TSH to dogs less 
than or greater than 5 kg body weight, respectively. Reimers, Concannon & Cowan, (1982) 
administered 5 i.u. TSH intravenously and reported peak total T4 concentrations 4.5 hours 
later. However in that study no samples were collected after the 4.5 hour sampling time. 
The same study confirmed simultaneous administration of adrenocorticotropin (ACTH) and 
TSH had no significant effect on the magnitude of total T4 increase. Oliver & Waldrop, 
(1983) administered either 2.5 i.u. or 5 i.u. TSH to dogs intravenously and reported 
significant increases in total T4 by three hours after TSH administration with peak total T4 
concentrations occurring after five to seven hours. There was no significant difference in 
total T4 results between the two doses used. Kemppainen, Thompson, Lorenz, Munnell & 
Chakraborty, (1983) administered 0.4 i.u. TSH/kg body weight intravenously and collected 
serum for total T4 measurement four hours later. Mean ± s.e.m. increase in total T4 was 63 
± 6.4 nmol/L in 10 healthy control dogs. Oliver & Held, (1985) evaluated the total T3 and 
T4 response to 0.2 i.u. TSH/kg body weight administered intravenously to 10 clinically 
healthy dogs. There was a significant increase in total T3 concentration within 30 minutes 
of TSH administration and had doubled the baseline value within 60 minutes. The total T4 
concentration was significantly increased within 60 minutes of TSH administration, and had 
doubled by 90 minutes. Whilst the total T3 response to TSH administration was therefore 
more rapid than that that of total T4, the peak thyroid hormone concentrations were 
reached four hours post-TSH administration. Whilst the authors suggested that the early
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measurement of post-TSH T3 may therefore assist in a more rapid evaluation of thyroid 
gland function, such a protocol remains less robust than measurement of peak post-TSH 
total T4 concentration. Paradis, Lepine, Lemay & Fontaine, (1991) administered 2 i.u. 
bovine TSH per dog and collected samples for total T4 estimation at zero and four hours. 
The authors recommended that post-TSH total T4 concentration should increase by at least 
24 nmol/L from the basal value, or should be > 45 nmol/L to exclude hypothyroidism. 
Beale, Keisling & Forster-Blouin, (1992) collected samples for total T4 estimation before 
and six hours after the administration of either 2.5 or 5 i.u. TSH to dogs less or greater 
than 20 kg body weight, respectively. Dogs were considered euthyroid if the post-TSH 
total T4 concentration exceeded 38.6 nmol/L. Paradis, Laperriere & Lariviere, (1994) 
administered 0.1 i.u. TSH/kg body weight to 18 healthy dogs and reported a good total T4 
response at both four and six hours post-TSH. The same study also confirmed that storage 
of frozen reconstituted TSH at -20°C for up to 200 days had no significant effect on its 
biological activity in-vivo. Sparkes, Gruffydd-Jones, Wotton, Gleadhill, Evans & Walker, 
(1995) assessed the response of serum total T4, total T3 and free T4 at two, four, five, sue, 
seven, eight and 10 hours after the intravenous administration o f 1 i.u., 3 i.u. and 5 i.u. 
bovine TSH to six healthy beagles. The method used for “free” hormone estimation was a 
single step analogue radioimmunoassay and therefore as discussed above, these results can 
not be considered as an accurate estimation of the genuine free hormone concentration. 
The peak total T3 and total T4 concentrations occurred six hours after 1 i.u. and 3 i.u. TSH 
and at five and eight hours after 5 i.u. TSH administration, respectively. The total T4 
response to TSH was greater and more consistent than that of total T3. The optimal time 
for total T4 measurement was reported to be six hours post-TSH. Recently Peterson et al, 
(1997) excluded hypothyroidism if serum total T4 increased by at least 1.5 times the basal 
concentration to a value in excess o f 25 nmol/L six hours after administration of 0.1 i.u. 
TSH/kg body weight. Hypothyroidism was confirmed if the post-TSH total T4 result was 
less than 20 nmol/L. Scott-Moncrieff et al, (1998) used the same protocol and confirmed 
hypothyroidism if the post-TSH total T4 concentration was less than 19.3 nmol/L and 
excluded it in those with a value greater than 32 nmol/L.
Whilst it is clear that a variety of protocols for both performing and interpreting the 
TSH response test have been used, the studies outlined above have improved the 
understanding of the most efficient and effective means of performing the test. 
Consequently there is now a more consistent approach between workers with 0.1 i.u./kg 
body weight bovine TSH administered intravenously and sampling for total T4 at zero and
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six hours being generally adopted (Panciera, 1994; Frank, 1996; Peterson et al., 1997; 
Scott-Moncrieff et al, 1998). This protocol is practical, provides maximal thyroidal 
stimulation and therefore allows optimal assessment o f thyroid reserve. Recommendations 
on the interpretation of the thyroid hormone results have also become more standardised 
with values less than approximately 20 nmol/L and greater than approximately 30 nmol/L 
being confirmatory of hypothyroidism or euthyroidism respectively (Peterson et al., 1997; 
Scott-Moncrieff et al, 1998). In addition most workers now also require a relative increase 
in total T4 results usually in the order of at least 50 % of the basal value. This avoids the 
potential misclassification of cases which would occur in those hypothyroid individuals with 
spurious elevated total T4 concentrations resulting from circulating T4Ab. Whilst earlier 
studies have solely recommended the use of a percentage increase in total T4 irrespective of 
the absolute hormone concentrations for the confirmation or exclusion of hypothyroidism, 
this approach is unreliable in cases with very low resting basal total T4 concentrations in 
which a small and clinically insignificant increase could be misinterpreted as a “normal” 
response.
However, there is currently no TSH preparation licensed for diagnostic use in the 
dog and consequently it is difficult to obtain this product in veterinary practice. In addition, 
bovine TSH is relatively expensive and therefore its use is generally reserved for research 
purposes.
TRH Response Test
Because of the cost and availability problems associated with TSH response testing, the 
TRH response test has been used to confirm hypothyroidism (Jacobs, Lumsden & Willet, 
1987; Ramsey et al, 1997). However, the thyroidal response to exogenous TRH is 
considerably lower and more variable than that obtained with TSH particularly in cases 
with NTI. Lothrop, Tamas & Fadok, (1984) collected serum for total T4 estimation 
immediately before and six hours following the intravenous administration of 2  pg/kg to 
200 pg/kg TRH in 31 healthy adult dogs. A significant elevation in total T4 was reported 
which peaked at six hours post-TRH. Increased doses o f TRH were found to increase the 
duration but not the peak concentration of total T4 response. Side effects were reported at 
all doses greater than 1 0 0  pg/kg and included salivation, urination, defaecation, vomition, 
pupillary constriction, tachycardia and tachypnoea. At a TRH dose of 100 pg/kg, 12 o f the 
healthy animals had a total T4 response that was less than 1 . 8  times the basal concentration.
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Sparkes et al., (1995) evaluated the total T4  and total T3 responses to intravenous 
administration of 100 fig, 200 pg, 300 pg and 600 pg TRH in six healthy adult beagles. 
Circulating hormone concentrations were determined immediately before and two, five, six, 
seven and eight hours after TRH administration. Mean total T4 concentrations were 
significantly increased at all sample times after TRH administration irrespective o f the dose 
used although on an individual basis an increase in total T4 concentrations of less than 50 % 
basal value was not uncommon. The total T3 response to TRH was even more variable with 
few post-injection samples being significantly different to baseline results. Peak total T4 
occurred four hours after 100 pg, and 200 pg TRH and five hours after 300 pg and 600 pg 
TRH had been given. In the same study, bovine TSH response tests were performed as 
described previously. The magnitude of response o f total T4 and total T3 to TSH was 
significantly greater than that to TRH.
Frank, (1996) compared TSH response tests (total T4 measurement before and six 
hours after intravenous administration of 0.1 i.u./kg bovine TSH; maximum dose 5 i.u.) and 
TRH response tests (total T4 measurement before and six hours after intravenous 
administration of 50 pg/kg equine TRH; maximum dose lmg) in five healthy dogs and 22 
dogs with various dermatological complaints. The clinical cases were categorised as either 
hypothyroid (n=6 ), or euthyroid with dermatological disease (n=17) based on the TSH 
response test results. In the group o f healthy dogs, post-TRH total T4 concentrations 
ranged from 23.8 to 32.5 nmol/L compared to 43.9 to 64.2 nmol/L following TSH 
administration. Amongst the euthyroid dogs with dermatological disease, post-TRH total 
T4 concentrations ranged from 14.6 to 45.0 nmol/L compared to 34.0 to 91.3 nmol/L 
following TSH administration. The mean response to TSH was significantly greater than 
that to TRH in both healthy and euthyroid dogs with NTI. Six of 22 euthyroid dogs with 
dermatological disease and normal total T4 responses to TSH had no or minimal total T4 
response to TRH administration. There was a numerical although not statistically 
significant increase in the mean post-TRH total T4 concentration in these dogs after 
treatment of their skin disease. The specificity of the TRH response test for hypothyroidism 
was therefore only 0.73. The smaller and more variable total T4 response to TRH compared 
to TSH may have resulted from the effect o f other factors which modulate TSH control. 
Irrespective, the author’s conclusion was that compared to the TSH response test, in a 
clinical setting TRH response testing is an unreliable tool for the confirmation of 
hypothyroidism and can only reliably be used to exclude the disease.
Chapter 4 90
TSH response to TRH
In humans the sensitivity of the pituitary thyrotrophs to TRH administration tends to be 
increased during primary hypothyroidism and decreased during NTI (Kaptein, Grieb, 
Spencer, Wheeler & Nicoloff, 1981; Sumita, Ujike, Namiki, Watanabe, Kawamata, 
Watanabe & Satoh, 1994). Therefore the TSH response to TRH administration can provide 
valuable information regarding thyroid status. Since the development of a valid cTSH 
assay, several studies have also evaluated this test for use in dogs.
Meij et al, (1996) reported the TSH response to 10 pg/kg body weight TRH 
administered intravenously in eight healthy beagles. Mean ± s.e.m. resting cTSH 
concentrations were 0.14 ± 0.02 ng/ml (range 0.07 to 0.27 ng/ml) which was significantly 
lower than that of the 10 minute post-TRH cTSH concentration of 1.26 ± 0.22 ng/ml. A 
slightly reduced TSH response to TRH was observed when TRH was administered 
concurrently with other hypothalamic releasing hormones, namely corticotrophin releasing 
hormone, growth hormone releasing hormone and gonadotrophin releasing hormone. That 
study provided a basis for further assessment of the responsiveness of the pituitary gland to 
TRH in states of thyroidal and non thyroidal disease.
Ramsey & Herrtage, (1997) examined the cTSH response to TRH in an unspecified 
number of dogs from approximately 50 which were being investigated for hypothyroidism. 
That study reported no clear distinction in response between the hypothyroid and euthyroid 
dogs. The classification of cases as either hypothyroid or euthyroid with NTI relied on the 
results of TRH response tests and therefore the classification of cases is questionable.
Scott-Moncrieff & Nelson, (1998) investigated the cTSH response to TRH 
administration in 13 healthy, 20 hypothyroid and 18 euthyroid dogs with NTI. 
Hypothyroidism or euthyroidism was confirmed based on TRH response tests, endogenous 
cTSH concentration and response to thyroid hormone replacement therapy. The cTSH 
concentration 30 minutes following TRH administration in the hypothyroid group (median 
1.45; range, 0.17-4.2 ng/ml) was significantly greater than in the euthyroid group (median 
0.57; range, 0.17-1.6 ng/ml), but not significantly different to the healthy dogs (median 
0.69; range, 0.4-1.6 ng/ml). As a percentage of the basal cTSH concentration, the increase 
in cTSH was significantly lower in the hypothyroid dogs (median 24 %; range, -21-134 %) 
compared to both the euthyroid (median 167 %; range, 69-1800 %) and he&lthy (median 
207 %; range, 25-2200 %) groups. Using a > 100 % increase in cTSH concentration aftar 
TRH administration as a cut-off for the exclusion o f hypothyroidism, the diagnostic 
sensitivity, specificity and accuracy were 0.85, 0.94 and 0.90, respectively. The authors
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concluded that whilst the test did discriminate between hypothyroid and euthyroid dogs, it 
was of little advantage over a basal cTSH and either total or free T4 estimation. The reason 
for the differences in cTSH response to TRH between dogs and man is currently unclear.
Therapeutic Trial
The confirmation of a diagnosis of hypothyroidism by demonstrating an appropriate 
clinical response to T4 replacement therapy, holds initially at least, considerable appeal. 
This approach is simple and rapid and avoids the problems associated with laboratory 
testing. However, T4 therapy can be associated with non-specific clinical responses which 
can create the impression of a genuine response to treatment and a failure to respond to 
supplementation may result from factors other than an erroneous diagnosis.
Gunaratnam, (1986) determined the rate of hair growth at various sites in healthy 
crossbreed dogs and found a significant increase in the rate of growth following therapy 
with either oral (20 pg/kg/day) or topical L-thyroxine preparations. Clearly the 
demonstration of a clinical response to T4 therapy is therefore not in itself confirmatory of 
hypothyroidism. Considerable individual variation also exists in the pharmacokinetics of 
thyroid hormones in vivo, and a suitable dosage for one dog may not be appropriate for 
another individual. This may be misinterpreted as a failure to respond to therapy. This is 
discussed in Chapter 6 . Circulating concentrations of thyroid hormones may vary by as 
much as four-fold in different dogs receiving similar doses of thyroxine, whilst 
levothyroxine doses between 11-44 pg/kg/day have been required to obtain optimal 
circulating concentrations in different individuals (Nachreiner, Refsal, Ravis, Hauptman, 
Rosser & Pedersoli, 1993). The same study demonstrated that the pharmacokinetics of T4 
were fairly constant within an individual, but varied considerably between individual dogs.
A marked drawback in the use of T4 therapy as a diagnostic tool, results from the 
affect that the medication will have on subsequent tests of thyroid function. Panciera et al, 
(1989) studied the effect of exogenous T4 therapy at a dose recommended for treatment of 
hypothyroidism in 10 euthyroid beagles. Severely suppressed total T4 response to 
exogenous TSH administration occurred within four weeks of starting therapy and 
remained so until at least four weeks after the cessation of treatment. Inappropriate T4 
replacement therefore delays and confuses any subsequent tests o f thyroid status.
In the situation where no other diagnostic options are available, it has been 
recommended that T4 replacement therapy be used as a diagnostic tool under strict 
conditions. Ferguson, (1994) suggested that an objective criterion by which the success of
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the therapy will be judged (such as regrowth o f at least 50 % hair coat) and a time limit 
over which the dog will be re-evaluated be used. In the case of an appropriate clinical 
response, it was suggested that therapy should then be stopped and the case monitored for 
a return of the clinical signs. Resolution of these signs following re-institution of thyroid 
hormone therapy could then be considered confirmatory of the diagnosis. The main 
difficulty with his approach in practice is the understandable reluctance o f dog owners to 
stop therapy in a responding animal.
The changes in thyroid hormone metabolism associated with NTI are presumed to 
be protective mechanisms aimed at reducing metabolic requirements and avoiding 
catabolism of tissue reserves. Over-riding this mechanism with T4 supplementation may 
therefore be detrimental and should be avoided. Brent & Hershman, (1986) demonstrated 
no improvement in clinical outcome in patients with severe NTI following T4 replacement 
and Little, (1985) demonstrated an increase in mortality in rats with experimentally induced 
NTI. Although equivalent canine studies have not yet been reported, it seems prudent to 
ensure a confident diagnosis of hypothyroidism whenever possible prior to instituting 
thyroid hormone replacement therapy.
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4.2 INTRODUCTION
There is no doubt that the single most reliable method for confirming canine 
hypothyroidism is the bovine TSH response test. However, this test is not suitable for 
widespread use in general practice. A range of commercial diagnostic tests including kits 
for cTSH, free T4 by dialysis and TgAb have recently become available. However, there is 
conflicting evidence regarding the diagnostic accuracy of these newer tests (Jensen et al, 
1996; Peterson et al, 1997; Ramsey et al., 1997; Scott-Moncrieff et al, 1998). There is 
also little data to indicate causes of apparently discordant results. The objectives of this 
study were to determine if a single test or combination of tests suitable for analysis in a 
single blood sample could be used in the diagnosis of hypothyroidism with an accuracy 
approaching that of the “gold standard” bovine TSH response test, and identify the optimal 
testing strategy in dogs with suspected hypothyroidism.
4.3 MATERIALS AND METHODS 
Case Material
The case material comprised a series of 140 dogs referred to the DVCS for investigation of 
clinical signs or routine laboratory features consistent with adult onset spontaneous 
hypothyroidism as described in Chapters 2 and 5. Dogs were classified as either euthyroid 
or hypothyroid based on the results of TSH response tests as described in Chapter 2.
Assays
Serum total T4, total T3, free T4 and cTSH were measured using commercially available 
assays as described in Chapter 2.
Receiver Operating Characteristic Curves and Differential Positive Rate Analysis
The diagnostic performance of the total T4, total T3, free T4 and cTSH assays both 
individually and for some parameters in combination with each other, were evaluated by 
DPR and ROC curve analysis which were calculated and graphically represented as 
described in Chapter 2. Specifically, DPR analysis was used to determine optimal cut-off 
values, and ROC curve analysis to compare the performance between tests.
Statistical Analyses
A Mann-Whitney U test was used for comparison o f hormone results between hypothyroid 
and euthyroid groups. For all statistical analyses, results less than the LoD of an assay were 
arbitrarily assigned a value equal to the LoD.
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4.4 RESULTS 
Case Material
Hypothyroidism was confirmed in 52 dogs (mean age 7.6; range 3-13 years) containing 23 
male (5 neutered) and 29 female (15 neutered) animals. Results of the TSH response tests 
were equivocal in three of these cases. Further details of these animals are provided in 
Appendix 27. Mean ± s.d. post TSH total T4 concentration in the remaining 49 dogs was
8.2 + 5.5 nmol/L. Euthyroidism was confirmed in 88 dogs (mean age 7.3; range 1-14.5 
years) of which 49 were male (10 neutered) and 39 female (22 neutered). Results of the 
TSH response tests were equivocal in nine of these cases. Further details of these animals 
are provided in Appendix 27. Mean ± s.d. post TSH total T4 concentration in the remaining 
79 dogs was 65.3 ± 32.1 nmol/L. No adverse reactions to intravenous bovine TSH 
administration were recognised in any of the dogs.
Hormone Results
The results of the hormone analyses from the hypothyroid and euthyroid groups are 
summarised in Tables 2 and 3, respectively. Individual case data are provided in 
Appendices 29 and 30.
Total T4 
(nmol/L)
Total T3 
(nmol/L)
Free T4 
(pmol/L)
cTSH
(ng/ml)
Mean 7.3 1.50 4.86 2.03
s.d. 4.2 0.75 3.10 2.31
Median 4.7 1.32 3.22 1.38
25th Percentile 4.7 1.03 3.22 0.73
75th Percentile 10.2 1.79 4.93 2.62
Minimum 4.7 0.25 3.22 0.01
Maximum 21.2 23.49f (3.88) 12.39 12.3
Table 2. Circulating concentrations of total T4, total T3, free T4 and cTSH obtained from 
52 hypothyroid dogs.
T Total T3 concentration of 23.49 nmol/L was attributed to the presence of T3Ab and was 
not used in calculations. The next highest result in this group was 3.88 nmol/L.
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Total T4 
(nmol/L)
Total T3 
(nmol/L)
Free T4 
(pmol/L)
cTSH
(ng/ml)
Mean 21.9 2.33 16.32 0.41
s.d. 1 1 . 2 0.75 8.94 0.45
Median 2 0 . 1 2.38 13.84 0.27
25th Percentile 13.4 1.83 10.42 0.13
75th Percentile 27.5 2.82 21.29 0.54
Minimum 4.7 0.78 3.22 0 . 0 1
Maximum 60.5 4.71 51.25 2.65
Table 3. Circulating concentrations of total T4, total T 3 ,  free T 4  and cTSH results obtained 
from 8 8  euthyroid dogs.
Total T4
DPR data for total T4 are illustrated in Figure 2. The ROC curve of total T4 results is 
illustrated in Figure 3.
Median basal serum total T4 was significantly (pO.OOOl) lower in the hypothyroid 
compared with the euthyroid dogs. DPR analysis indicated an optimal cut-off value of 7.6 
nmol/L for confirmation of hypothyroidism resulting in a sensitivity, specificity and DPR of 
0.71, 0.97 and 0.68, respectively. The DPR remained relatively constant across a range of 
values from approximately 6  to 15 nmol/L indicating that a cut-off anywhere within this 
range would provide similar overall test performance. Because basal total T4 measurement 
is generally used as a screening test for hypothyroidism, a cut-off value associated with a 
greater diagnostic sensitivity was considered more desirable. Examination of the range of 
DPR values identified 14.8 nmol/L as a suitable cut-off value and this was selected for the 
confirmation of hypothyroidism. This value was associated with a sensitivity, specificity and 
DPR of 0.96, 0.70 and 0.67, respectively. The area under the ROC curve was 0.919.
Two hypothyroid dogs had total T4 concentrations greater than 14.8 nmol/L. One 
of these cases had an elevated cTSH value (6.3 ng/ml), subnormal free T4 (6 . 6 6  pmol/L) 
concentration and negligible response to TSH administration. The remaining case had an 
equivocal total T4 response to TSH administration and had reference range free T4 (12.39
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pmol/L) and cTSH (0.57 ng/ml) concentrations, but hypothyroidism was supported by 
histopathological evidence of autoimmune thyroiditis. This case had been presented to the 
DVCS for investigation of musculoskeletal illness, not considered to be related to the 
hypothyroidism, during which time the evidence of thyroid disease became apparent. 
However the case was almost certainly in the very earliest stages of hypothyroidism and it 
is unlikely that this cases would have been presented to a veterinary surgeon for 
investigation of signs primarily related to hypothyroidism at the time the diagnosis was 
confirmed.
Twenty six euthyroid dogs had subnormal total T4 concentrations. Of these cases, 
cTSH was within the reference range in 21 and was increased in five. Free T4 concentration 
was measured in four of these five dogs and found to be in the euthyroid range in each 
case. Free T 4  was measured in 22 of the 26 euthyroid cases with subnormal total T 4 ,  and 
was subnormal in only five. The cTSH concentration was within the reference range in all 
five of these dogs.
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Figure 2. Differential positive rate (DPR) curve demonstrating the change in diagnostic 
sensitivity, specificity and DPR of total T4 for hypothyroidism across a range o f possible 
diagnostic cut-off values.
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Figure 3. Receiver operating characteristic (ROC) curve for total T4 in distinguishing 
hypothyroid from euthyroid dogs. See Figure 1 for interpretation.
Total T3
DPR data for total T3 are illustrated in Figure 4. The ROC curve of total T3 results is 
illustrated in Figure 5.
Median serum total T3 was significantly (p<0.0001) lower in the hypothyroid 
compared with the euthyroid dogs. DPR analysis indicated an optimal cut-off value of 1.77 
nmol/L for confirmation of hypothyroidism resulting in a sensitivity, specificity and DPR of 
0.76, 0.80 and 0.56, respectively. The area under the ROC curve was 0.805.
Eleven hypothyroid dogs had total T3 concentration greater than 1.77 nmol/L. One 
of these results was extremely elevated (23.49 nmol/L) consistent with interference by T3 
autoantibodies, an assumption which was supported by the presence of TgAb in this case 
(Chapter 7). This total T3 result was excluded from all further analyses. Nine, nine and 
seven of the 11 dogs had total T4, free T4 and cTSH results within the “hypothyroid” 
ranges, respectively.
Fifteen euthyroid dogs had a total T3 concentration less than 1.77 nmol/L. Of these 
cases, basal total T4 was normal in nine, and free T4 and cTSH were normal in 14.
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Figure 4. Differential positive rate (DPR) curve demonstrating the change in diagnostic 
sensitivity, specificity and DPR of total T3 for hypothyroidism across a range of possible 
diagnostic cut-off values.
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Figure 5. Receiver operating characteristic (ROC) curve for total T3 in distinguishing 
hypothyroid from euthyroid dogs. See Figure 1 for interpretation.
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Free T4
DPR data for free T4 are illustrated in Figure 6 . The ROC curve of free T4 results is 
illustrated in Figure 7.
Median serum free T4 was significantly (p<0.0001) lower in the hypothyroid 
compared with the euthyroid dogs. DPR analysis indicated an optimal cut-off value of 6 . 6 6  
pmol/L for confirmation of hypothyroidism resulting in a sensitivity, specificity and DPR of 
0.81, 0.93 and 0.74, respectively. The area under the ROC curve was 0.933.
Eight hypothyroid dogs had free T4 concentrations greater than 6 . 6 6  pmol/L. These 
included the five dogs with the greatest post-TSH total T4 concentration amongst the 
hypothyroid group. Of these eight dogs, total T4 was depressed and cTSH was 
concurrently increased in seven. The remaining eighth case was the dog with reference 
range total T4 concentration and musculoskeletal disease referred to previously. Total T3 
was estimated from seven cases with hypothyroidism and normal free T4 concentration and 
was subnormal in five of them.
Six euthyroid dogs had free T4 concentrations less than 6 . 6 6  pmol/L. These 
included one dog with hyperadrenocorticism, three who had recently received various 
medications including glucocorticoids, phenobarbitone and non-steroidal anti-inflammatory 
drugs (NSAID), and two dogs with testicular neoplasia. Total T4 results were within the 
hypothyroid range in five of these cases. Circulating cTSH results were within the 
euthyroid range in all cases. Total T3 results were normal in all but one dog.
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Figure 6 . Differential positive rate (DPR) curve demonstrating the change in diagnostic 
sensitivity, specificity and DPR of free T4 for hypothyroidism across a range of possible 
diagnostic cut-off values.
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Figure 7. Receiver operating characteristic (ROC) curve for free T4 in distinguishing 
hypothyroid from euthyroid dogs. See Figure 1 for interpretation.
Endogenous TSH
DPR data for cTSH are illustrated in Figure 8. The ROC curve o f cTSH results is 
illustrated in Figure 9.
Median serum cTSH was significantly (p<0.0001) greater in the hypothyroid 
compared with the euthyroid dogs. DPR analysis indicated an optimal cut-off value of 0.69 
ng/ml for confirmation of hypothyroidism resulting in a sensitivity and specificity and DPR 
of 0.79, 0.82 and 0.61, respectively. The area under the ROC curve was 0.816.
Eleven of the 52 hypothyroid dogs had cTSH results less than 0.69 ng/ml. 
Concurrent illness was identified in eight of these cases and included diabetes mellitus 
(n=2), hyperadrenocorticism (n=l), encephalitis (n=T), orthopaedic disease (n=l), dilated 
cardiomyopathy (n=l), idiopathic hyperchylomicronaemia (n=l) and gastrointestinal 
disease (n=l). Of the remaining three cases, the cTSH result approached the LoD of the 
assay, consistent with central hypothyroidism, in only one case (0.02 ng/ml). Further 
studies performed in this case are detailed in Appendix 28. and were consistent with a 
possible diagnosis of central hypothyroidism. No known cause of the reference range cTSH 
concentration was identified in the remaining two individuals. In one of these two dogs free 
T4 was undetectable. No additional diagnostic test results were available in the solitary 
remaining case. Free T4 was measured in eight o f the hypothyroid cases with discordant
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cTSH concentrations and found to be below the assay LoD in seven o f them. Total T3 
values were also measured in eight of the dogs, and were in the hypothyroid range in four.
Sixteen euthyroid dogs had cTSH concentrations greater than 0.69 ng/ml. Five of 
these cases were recovering from a known NTI and three had a history of recent use of 
sulphonamide-containing medication. Basal total T4 concentration was greater than 14.8 
nmol/L in 11 of the discordant euthyroid cases. In two of the remaining five dogs total T4 
and cTSH returned to normal at a later date including one dog who was recovering from 
hypoadrenocorticism at the time of testing. In the remaining three cases no cause of the 
elevated cTSH was identified. Free T4 was measured in 15 o f the 16 euthyroid cases with 
elevated cTSH values, and was within the euthyroid range in all of them. Total T3 was 
measured in 13 of the discordant euthyroid cases and was within the euthyroid range in 12 
of them.
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Figure 8 . Differential positive rate (DPR) curve demonstrating the change in diagnostic 
sensitivity, specificity and DPR of endogenous thyrotropin (cTSH) for hypothyroidism 
across a range o f possible diagnostic cut-off values.
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Figure 9. Receiver operating characteristic (ROC) curve for endogenous thyrotropin 
(cTSH) in distinguishing hypothyroid from euthyroid dogs. See Figure 1 for interpretation.
Thyroxine to Thyrotropin ratios
DPR data for the total T4 to cTSH ratio are illustrated in Figure 10. The ROC curve of the 
total T4 to cTSH ratio results is illustrated in Figure 11.
Median total T4 to cTSH ratio was significantly (p<0.0001) greater in the euthyroid 
compared with the hypothyroid dogs. DPR analysis indicated an optimal cut-off value of
13.1 for the confirmation of hypothyroidism resulting in a sensitivity, specificity and DPR 
of 0.75, 0.97 and 0.72, respectively. The area under the ROC curve was 0.893.
The use of a ratio, and the consequent mathematical nature of the results obtained 
in cases (i.e. a multiplication occurs when dividing by a denominator less than one) was 
responsible for most of the discordant total T4 to cTSH results in hypothyroid dogs in this 
study. Thirteen hypothyroid dogs had unexpectedly increased total T4 to cTSH ratios and 
circulating cTSH concentration was less than 1 ng/ml in all these cases, and less than the 
cut-off for hypothyroidism in 11. Mean (± s.d.) cTSH concentration in the discordant dogs 
was (0.29 ± 0.32 ng/ml) compared with 2.62 (± 2.39 ng/ml) in remaining hypothyroid 
cases.
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Figure 10. Differential positive rate (DPR) curve demonstrating the change in diagnostic 
sensitivity, specificity and DPR of the total T4 to endogenous thyrotropin (cTSH) ratio for 
hypothyroidism across a range of possible diagnostic cut-off values.
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Figure 11. Receiver operating characteristic (ROC) curve for total T4 to endogenous 
thyrotropin (cTSH) ratio in distinguishing hypothyroid from euthyroid dogs. See Figure 1. 
for interpretation.
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DPR data for free T4 to cTSH ratios are illustrated in Figure 12. The ROC curve of free T4 
to cTSH ratio results is illustrated in Figure 13.
Median free T4 to cTSH ratio was significantly (p<0.0001) greater in the euthyroid 
compared with the hypothyroid dogs. DPR analysis indicated an optimal cut-off value of
13.2 for the confirmation of hypothyroidism resulting in a sensitivity, specificity and DPR 
of 0.84, 0.90 and 0.74, respectively. The area under the ROC curve was 0.912.
Seven hypothyroid dogs had unexpectedly increased free T4 to cTSH ratios. As 
occurred with the total T4 to cTSH ratios, this was generally due to unusually decreased 
cTSH values. This mathematical complicating effect occurred despite undetectable free T4 
concentrations in five of the seven cases.
Eight euthyroid dogs had unexpectedly decreased free T4 to cTSH ratios. Again, 
these typically resulted from discordant cTSH values, since six of the eight cases had cTSH 
concentrations within the hypothyroid range.
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Figure 12. Differential positive rate (DPR) curve demonstrating the change in diagnostic 
sensitivity, specificity and DPR of the free T4 to endogenous thyrotropin (cTSH) ratio for 
hypothyroidism across a range of possible diagnostic cut-off values.
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Figure 13. Receiver operating characteristic (ROC) curve for free T4 to endogenous 
thyrotropin (cTSH) ratio in distinguishing hypothyroid from euthyroid dogs. See Figure 1 
for interpretation.
The diagnostic performance o f total T4, total T3, free T4 and cTSH estimation, when used 
alone and in combination for the diagnosis o f hypothyroidism are summarised in Table 4.
Total T4 Total T3 Free T4 cTSH Total T4 to Free T4 to
(nmol/L) (nmol/L) (pmol/L) (ng/ml) cTSH ratio cTSH ratio
Cut-off 14.8 1.77 6.66 0.69 13.1 13.2
Sensitivity 0.96 0.76 0.81 0.79 0.75 0.84
Specificity 0.70 0.80 0.93 0.82 0.97 0.90
DPR 0.67 0.56 0.74 0.61 0.72 0.74
Area under 
ROC curve 0.919 0.805 0.933 0.816 0.893 0.912
Table 4. Diagnostic cut-off, sensitivity, specificity, differential positive rate (DPR) and area 
under the receiver operating characteristic (ROC) curve for serum total T4, total T3, free T4 
and cTSH concentrations, and total and free T4 to cTSH ratios.
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4.5 DISCUSSION
Ideally a diagnostic test would have a sensitivity and specificity both equal to one, i.e. no 
false positive or false negative results. However, in practice this is rarely the case and the 
actual values depend largely on the diagnostic cut-off chosen for confirmation or exclusion 
of disease. Altering the cut off in one direction will change the sensitivity and specificity 
whilst moving it in the other direction will have the opposite effect. For example decreasing 
the diagnostic cut-off point of a test in which high results are considered abnormal will 
increase the diagnostic sensitivity but decrease the specificity. However increasing the cut­
off for the same test or decreasing the cut-off for a test in which low results are abnormal 
will decrease the test sensitivity but increase the specificity. In practice the chosen cut-off 
point depends largely on the relative requirements for either a sensitive or a specific test.
As is evident from the reviewed literature, most cut-off values are selected either by 
use of laboratory reference limits or by generation of a “normal range” from apparently 
healthy dogs. However, as discussed in Chapter 5, such values are rarely the most 
appropriate cut-offs to use. A simple mathematical method for calculation o f the most 
accurate cut-off is achieved by use of DPR analysis. The DPR equals the sensitivity minus 
(1-specificity) and can be calculated at each possible cut-off value for a given test. The cut­
off with the highest DPR gives the best overall test performance. Alternatively, the DPR 
can be used to identify a cut-off which will give a test with the desired values for either 
diagnostic sensitivity or specificity. For example if the test is to be used primarily as a 
screening test then diagnostic sensitivity is of most importance and an appropriate value 
can be selected. Alternatively if confident confirmation of disease is more important, then 
DPR analysis can be used to identify a cut-off value with a suitably high diagnostic 
specificity. It should be clear that the DPR is essentially another method o f representing the 
data used for ROC curve generation. The greatest DPR value corresponds to the point on 
the ROC curve nearest to the top left hand comer of the graph. DPR analysis is o f most use 
in the selection of optimal cut-off values whereas comparison of several diagnostic tests is 
best achieved by ROC curve generation.
This study has confirmed the applicability o f DPR and ROC curve analysis to the 
study of thyroid disease in the dog. DPR analysis proved to be a valuable and flexible 
statistical tool in the categorisation of cases and optimisation of the diagnostic performance 
of the thyroid tests studied. The techniques assisted in the identification of appropriate cut­
off values for confirmation of hypothyroidism and assisted in the comparison of the 
performance of the various tests investigated. The clinical utility of DPR analysis in
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particular, was exemplified by its identification of a suitable cut-off value for total T4 
concentration, following selection of the desired diagnostic performance criteria. A 
technical limitation of the methods currently available for DPR analysis, is that only cut-off 
values actually obtained from at least one individual in the study are available for selection 
as the ‘optimal’ cut-off. Currently there is no software designed to allow interpolation of 
the DPR at values in between those seen in study cases. The production of such a 
computerised model would enhance this already valuable technique.
This study has confirmed that circulating concentrations of total T4, free T4 
measured by equilibrium dialysis and total T3 are usually decreased, and cTSH usually 
increased, in spontaneous canine hypothyroidism. A high diagnostic sensitivity of total T4 
estimation for hypothyroidism was confirmed, supporting the results of previous studies 
(Belshaw & Rijnberk, 1979; Kaelin, Watson & Church, 1986; Peterson et al, 1997). 
However, as exemplified by the similar DPR values across a range of possible cut-off 
values, this could be manipulated at the expense of specificity depending on the required 
test characteristics without significant loss of over-all performance. This feature o f total T4 
measurement in the diagnosis of hypothyroidism has not been reported previously. 
Approximately one third of the euthyroid dogs with NTI had a depressed total T4 
concentration confirming the poor specificity of this analyte for hypothyroidism. This 
supports the results o f previous studies (Lorenz & Stiff, 1980; Larsson, 1988; Peterson et 
al, 1997).
Previous studies have reported poor discriminatory ability of total T3 in the 
differentiation of hypothyroidism from NTI and consequently total T3 estimation is now 
uncommonly performed in dogs (Nelson et al, 1991; Miller et al, 1992). The results of 
this study confirm the poor overall performance of total T3 compared to the other analytes 
as demonstrated by the low corresponding DPR and area under the ROC curve. However, 
the results demonstrate that in contrast to humans, total T3 is less frequently depressed in 
dogs with NTI than is total T4. This is similar to previous reports including the recent study 
by Peterson et al, (1997) who used the same diagnostic criteria for case allocation as the 
present study. Of the 15 euthyroid dogs with depressed circulating total T3 values in the 
present study, serum total T4 was normal in nine suggesting that hypothyroidism was highly 
unlikely. In addition, only one each o f the remaining six dogs had abnormal free T4 or 
cTSH concentrations. Consequently an erroneous diagnosis of hypothyroidism could 
generally be avoided by concurrent examination of additional indices of thyroid function. In
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contrast, the hypothyroid dogs with total T3 values greater than 1.77 nmol/L generally had 
abnormal total T4 , free T4 and cTSH results.
Free T4 measured by equilibrium dialysis was the single most accurate test 
investigated supporting the findings of Peterson et al., (1997). This was exemplified by the 
greater area under the ROC curve, and particularly by the higher optimal DPR for free T4 
compared to total T4, total T3 or cTSH measurement. Normal free T4 results were obtained 
from eight hypothyroid dogs. Interestingly these included the five individuals with the 
highest post-TSH total T4 concentrations. The post-TSH total T4 concentration is an 
indicator of maximal thyroid functional reserve and therefore reflects the extent of thyroidal 
destruction. The normal circulating free T4 concentration in these five dogs may be 
consistent with an attempt to maintain thyroid function in the face of impending failure. 
Subnormal free T4 was an uncommon occurrence in the euthyroid dogs, confirming the 
high diagnostic specificity of this analyte for hypothyroidism. Drug preparations including 
glucocorticoids, phenobarbitone and non-steroidal anti-inflammatory therapies were being 
administered to some of these cases and may have been responsible for the decreased free 
T4 results. Interestingly, two of the six euthyroid dogs with subnormal free T4 values had 
testicular tumours. The role of these in the free T4 results obtained is unclear. Although 
oestrogen concentration was not measured in these cases, hyperoestrogenism has been 
previously shown to have only minimal effect on thyroid function (Gosselin et al., 1980). 
This study has confirmed the considerably greater clinical value of estimation of free T4 
using a dialysis method rather than the commonly used “analogue” immunoassays (Nelson 
et al, 1991). This is similar to the conclusions of previous reports comparing available free 
T4 methodologies in human samples (Ekins, 1993).
This study clearly demonstrated the ability of circulating cTSH estimation to assist 
in the differentiation of hypothyroidism from NTI. Whilst the test is therefore a very useful 
tool in the investigation of canine hypothyroidism, inappropriately elevated or depressed 
cTSH results did occur in 18 and 21 % of euthyroid and hypothyroid cases, respectively. 
The specificity of cTSH estimation for hypothyroidism reported in this study may have 
been artefactually reduced slightly since a few o f the dogs were referred following 
identification of abnormal circulating cTSH concentrations. This inherent bias will tend to 
increase the percentage of false-positive cTSH results obtained.
The most common apparent causes o f discordant cTSH results in euthyroid dogs in 
this study included recovery from a known NTI and the recent use of sulphonamide- 
containing medication supporting the results o f previous studies (Spencer, Eigen, Shen,
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Duda, Qualls, Weiss & Nicoloff, 1987; Campbell et al, 1996). This results of this study 
therefore indicate that a thorough history taking, and as far as possible the exclusion of NTI 
form a crucial part of the investigation of suspect hypothyroidism. It is recommended that 
these are performed prior to diagnostic testing. O f the remaining discordant euthyroid 
cases, cTSH returned to normal in three of the dogs from which further samples were 
obtained and therefore follow-up cTSH estimations may be useful in some cases when the 
diagnosis in an individual remains in doubt.
In humans, “subclinical” or “compensating” hypothyroidism, whereby TSH 
concentration increases in the early stages of thyroid dysfunction to maintain normal 
circulating total thyroid hormone concentration, is recognised. In these individuals, 
circulating TSH concentrations are “inappropriately” increased but are a good predictor of 
the future development of hypothyroidism. Such a phenomenon has also been proposed in 
dogs (Graham et al, 1998). In theory, this may have been a cause of some of the 
discordant cTSH values which occurred in euthyroid dogs in the present study. 
Investigation of this would require long-term follow up o f suspect cases and was not 
performed. However, many humans with “compensating hypothyroidism” are identified 
during routine screening tests and are not necessarily clinically unwell. This is in contrast to 
the dogs in this study, all o f which had clinical abnormalities consistent with 
hypothyroidism. At present, health screening tests are rarely performed in dogs. 
Consequently, if dogs do undergo a period of “subclinical” hypothyroidism prior to the 
development of clinical hypothyroidism, there is no reason to expect those cases to be 
blood sampled until the subclinical phase has ended, and the clinical abnormalities 
developed. Alternative diagnoses were reached in all euthyroid cases in the present study 
suggesting that “compensating hypothyroidism” was not responsible. Furthermore it is 
unclear why dogs with compensating hypothyroidism, and therefore by definition “normal” 
circulating thyroid hormone concentrations would develop clinical signs of thyroid 
dysfunction. Nevertheless this may be an area worthy of future study as health screening 
and preventative medicine become more routinely performed in veterinary medicine.
Possible causes of discordant cTSH results in hypothyroid dogs have been proposed 
including undetectable isoforms of cTSH and central hypothyroidism (Jensen et al., 1996; 
Peterson et al., 1997; Ramsey et al, 1997; Scott-Moncrieff et al, 1998). The results of 
this study suggest that spontaneous central hypothyroidism is uncommon since cTSH 
concentrations at or near the assay LoD were uncommon in the hypothyroid dogs. Central 
hypothyroidism therefore does not appear to be a frequent cause of discordant cTSH
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concentrations. The possibility of undetectable cTSH isoforms was not investigated in this 
study. The presence of concurrent NTI in dogs with hypothyroidism may have contributed 
to the finding of reference range cTSH results in a number of the dogs in the present study. 
However, it remains unclear why other dogs with hypothyroidism and concurrent NTI had 
the expected elevations in circulating cTSH. The severity and duration of illness may be of 
importance and is worthy of further study.
Based on the results o f this study the measurement of cTSH in isolation cannot be 
recommended. However, of the cases with discordant cTSH results, only one of the 
hypothyroid dogs had a normal circulating total or free T4 concentration whereas most 
euthyroid dogs had normal total T4 and free T4 concentrations. The combined estimation of 
either total or free T4 in association with cTSH is therefore useful irrespective of disease 
status. It is clear from these results that concurrent estimation of additional thyroid 
parameters reduces the misinterpretation o f discordant cTSH concentrations in the vast 
majority of cases. In the case of free T4 in particular it is clear that very few animals are 
misdiagnosed as hypothyroid, when this is measured alongside cTSH supporting the results 
of similar studies (Peterson et al., 1997). The diagnostic accuracy of cTSH was also 
dramatically improved when evaluated as part of a ratio with either total or free T 4 .  
Overall, the calculation of the circulating free T4 to cTSH ratio, was a better performing 
test as assessed by the area under the ROC curve, than the total T4 to cTSH ratio. 
However, when used at their optimal cut-off values, the diagnostic performance of each 
method was similar. The use of total T4 as a ratio was less sensitive and more specific than 
the free T4 to cTSH ratio. This is in contrast to the performance of the analytes when 
evaluated alone. However, this was simply a consequence of the selected cut-off value, and 
it is clear from Figure 10 that the total T4 to cTSH ratio DPR plateau is, as was the case 
with total T4 alone, relatively flat across a range o f cut-off values. The selection of a higher 
cut-off could therefore be adopted for the total T4 to cTSH ratio if it was intended to be 
used primarily as a screening test.
The use of the bovine TSH response tests has been criticised because of the 
potential for anaphylactic reaction and the expense o f the test (Nachreiner, 1991; Hasler & 
Rohner, 1992). In this study no adverse clinical signs were recognised in any of the dogs 
following the administration o f TSH. The criteria used for performing and interpreting the 
test were similar to those most recently published (Frank, 1996; Peterson et al., 1997; 
Scott-Moncrieff & Nelson, 1998). This protocol was practical for use in a clinical research 
setting and was not prohibitively expensive even in the largest dogs. Indeed the reliable
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diagnosis of hypothyroidism with the TSH response test is more economically justifiable 
compared to the costs of inappropriate lifelong replacement therapy (Ferguson, 1991). It 
should be clear that whilst the bovine TSH response test is undoubtedly the most reliable 
means currently available for confirming canine hypothyroidism, it is not a perfect test and 
difficulties in case categorisation can still occur (Panciera, 1990b). Equivocal TSH 
response test results therefore remain a problem. However, the use of the equivocal 
category o f TSH response test results, in association with case follow-up information and 
additional test results did allow confident classification of the dogs used in this study. This 
allows confidence in the conclusions reached in this study regarding the single-test analytes 
compared to some previous studies using less reliable methods for case categorisation 
(Ramsey et al., 1997). The use of an equivocal category for the TSH response test was 
useful, and demonstrated that the majority of cases with borderline TSH response test 
results are ultimately confirmed as euthyroid.
In conclusion, the results of this study have identified a number of the limitations of 
the currently available tests o f canine thyroid function and provide guidance on the most 
reliable approach to confirm hypothyroidism. Firstly, it is clear that numerous factors, but 
particularly recovery from NTI and sulphonamide therapy may influence test results. 
Therefore as far as is practical, the presence of NTI should be excluded and drug therapy 
be taken into account prior to performing thyroid function tests. If NTI cannot be 
completely excluded, dogs should be clinically stable when thyroid function tests are 
performed. Secondly, as an individual parameter, free T4 estimation is the most reliable test 
for canine hypothyroidism followed by total T4 measurement. However, given the higher 
cost o f free versus total T4 estimation, total T4 is an economically justifiable solitary first 
test particularly if used primarily as a screening test. Thirdly, the use of circulating cTSH or 
total T3 estimation alone cannot be recommended. However, it is clear that the use o f two 
or more tests simultaneously, dramatically improves the accuracy for diagnosing 
hypothyroidism compared with single test analysis. In particular, the measurement of either 
total T4 or free T4 with cTSH provides a much more sensitive and specific assessment of 
thyroid status than any of the analytes individually. The use of total and free T4 to cTSH 
ratios is also preferable to the individual analytes. However, because of the mathematical 
effects that use of a ratio can introduce, overall consideration o f the multiple individual 
tests results remains of principal importance.
If only one tests is to be performed, free T4 measurement is the most reliable 
method. If  two tests are performed, either free or total T4 should be measured with cTSH.
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In cases with a discordant pair of results, an additional test usually clarifies the situation 
irrespective of thyroid status and rarely results in an erroneous diagnosis. The use of TgAb 
measurement is discussed in detail in Chapter 7 and although not specifically reported in 
this chapter, may be particularly beneficial in this regard. The greatest diagnostic dilemma 
probably arises in the dog investigated using the diagnostic protocol outlined above and in 
which decreased total T4 and normal cTSH results are subsequently obtained. Measurement 
of any other analyte but particularly free T4 concentration is advised in such a case. If after 
further testing, the diagnosis remain unclear, TSH response testing is the preferred option.
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CHAPTER 5
EPIDEMIOLOGICAL, CLINICAL AND ROUTINE CLINICOPATHOLOGICAL 
FEATURES OF CANINE HYPOTHYROIDISM
5.1 LITERATURE REVIEW 
Epidemiological Features of Hypothyroidism
Hypothyroidism is considered to be one of the most common endocrine disorders of dogs 
and several studies have previously evaluated some of the epidemiological features of the 
disease (Nesbitt, Izzo, Peterson & Wilkins, 1980; Milne & Hayes, 1981; Kaelin et al, 
1986; Panciera, 1994; Feldman & Nelson, 1996; Peterson et al, 1997). However, these 
reports have been complicated by inconsistency in the diagnostic criteria applied for 
confirming hypothyroidism, particularly the use of what are now often considered 
unreliable diagnostic tests. Consequently, estimation of the prevalence of hypothyroidism 
varies between studies. Panciera, (1994) reported the prevalence to be 0.2 % using rigid 
criteria for confirmation of hypothyroidism, whereas Milne & Hayes, (1981) reported a 
prevalence of 0.64 % using much looser diagnostic criteria. Most large surveys of 
hypothyroidism have examined the canine population in the United States which is not 
necessarily representative of the UK dog population. This, in addition to the variable 
quality of diagnostic criteria used has resulted in a surprising lack of reliable 
epidemiological data regarding this disease worldwide, and in the UK in particular.
Age
Nesbitt et al, (1980) evaluated 108 dogs tentatively diagnosed with hypothyroidism based 
on the demonstration of depressed circulating concentrations of total T4 and/or total T3. 
Clearly, these criteria are poorly specific for hypothyroidism and the results must be 
interpreted accordingly. The age of onset of clinical signs was recorded in 96 of the cases 
and was less than one year in 11 (11.5 %), between one and three years in 44 (45.8 %), 
between four and sue years in 28 (29.2 %) and over seven years o f age in 13 (13.5 %) dogs. 
Large breed dogs reportedly had an earlier age of onset compared to small breeds. 
However, these data were not provided.
Milne & Hayes, (1981) diagnosed hypothyroidism in 3184 cases out of 1.1 million 
dogs seen at multiple veterinary teaching hospitals. The diagnosis of hypothyroidism was 
confirmed using a variety o f methods including the presence o f appropriate clinical signs,
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historical details, clinicopathological analysis and thyroid gland histopathological 
examination. One hundred and six (3.3 %) dogs were less than one year of age, 227 (7.1 
%) were one to two years old, 741 (23.3 %) were between two and three years, 1058 (33.2 
%) were between four and six years, 674 (21.2 %) were between seven and nine years and 
378 (11.9 %) were greater than 10 years of age. The relative risk of age for the 
development of hypothyroidism was stratified by breed, using “high risk” and “low risk” 
breed categories. High risk breeds were reported to be more likely to develop 
hypothyroidism at an earlier age (up to three years of age) after which the risk slowly 
declined. This was interpreted by the authors as suggesting a genetic component in the 
aetiology of the disease. Conversely, low risk breeds tended to have a lower risk of 
hypothyroidism in the younger age categories, but this steadily increased until nine years of 
age.
Kaelin et al, (1986) confirmed hypothyroidism with TSH response tests in 16 dogs. 
The protocol used for the test was based on the collection of blood samples immediately 
prior to and 12 hours following the subcutaneous or intramuscular administration of 5 i.u. 
or 10 i.u. bovine TSH to dogs less than or greater than 10 kg, respectively. The age of 
affected dogs was unknown in one case, and ranged from 0.3 to 11 years (median six 
years) in the remaining 15 animals. Thirteen of the dogs were at least four years of age and 
the authors reported that the two animals under this age (aged 0.3 and 0.8 years) were 
likely to have had congenital hypothyroidism.
Panciera, (1994) confirmed hypothyroidism in 6 6  dogs based on the results of TSH 
response tests. Mean age at the time of diagnosis was 7.2 years (range 0.5 to 15 years).
Median age in the 54 dogs with confirmed hypothyroidism reported by Peterson et 
al., (1997), who also used bovine TSH response tests to classify cases, was six years (range 
2 to 13; interquartile range 4 to 7 years) compared to a median of 10 years (range 2 to 17; 
interquartile range 6  to 13 years) in 54 euthyroid dogs. No statistical analyses of these 
results were reported or performed.
Breed
Nesbitt et al, (1980) reported the breed distribution of 108 hypothyroid dogs which 
included 13 (12 %) doberman pinschers, eight (7.5 %) great Danes, seven (6.5 %) each of 
poodles, dachshunds, and schnauzers, and six (5.5 %) each of Irish setters and boxers. The 
remaining 54 (50 %) dogs were composed of 27 different breeds. Large and giant breeds 
accounted for approximately one third of the cases in the study. However, no information
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was provided regarding the distribution of these and other breeds within the non­
hypothyroid population examined.
Milne & Hayes, (1981) determined the effect of breed on the risk of developing 
hypothyroidism by calculating the relative risk with the associated 95 % confidence 
intervals for each breed. Airedale terriers, miniature and standard dachshunds, doberman 
pinschers, golden retrievers, miniature schnauzers, Irish setters, Shetland sheepdogs, 
cocker spaniels and pomeranian dogs were found to be at significantly increased risk of 
hypothyroidism. German shepherds and mixed breed dogs were significantly less likely to 
develop hypothyroidism than other breeds. The assessment of relative risk was made by 
comparison of the relative number of each breed in which a diagnosis o f hypothyroidism 
was made, compared to the number of that breed with diseases other than hypothyroidism. 
The population studied consisted of animals seen at 15 veterinary teaching hospitals and it 
is therefore likely that these data represented mainly second-opinion cases.
Statistical analysis of the breeds of hypothyroid dogs reported by Kaelin et al., 
(1986) was not possible due to the small number of cases. The 16 cases included two 
doberman pinschers, one cocker spaniel, one schnauzer, nine dogs of various other breeds 
and three crossbreed dogs.
Panciera, (1994) determined the effect of breed on the likelihood o f developing 
hypothyroidism using chi squared analysis and calculated odds ratios (o.r.) for each 
category. The reference population was considered to be all dogs examined at the same 
hospital during the study period in which a diagnosis of hypothyroidism was not made. Of 
the 6 6  hypothyroid dogs, doberman pinschers (n=1 0 , o.r.=6.06) and golden retrievers 
(n= ll, o.r.=2 .8 6 ) were significantly at risk of developing hypothyroidism compared with 
other breeds. Crossbreed dogs accounted for nine cases, and no other breed was 
represented by more than three individuals.
Feldman & Nelson, (1996) diagnosed hypothyroidism in 130 cases using 
unspecified criteria and reported the breeds most commonly affected to be golden retrievers 
(n=24, 18 %), doberman pinschers (n=22, 17 %), Labrador retrievers (n=8 , 6  %), cocker 
spaniels (n=7, 5 %), German shepherds (n=7, 5 %) and crossbreed (n=7, 5 %) dogs.
Peterson et al., (1997) reported the most commonly affected breeds to be golden 
retrievers (n=8 , 15 %), cocker spaniels (n=6 , 11 %), doberman pinschers (n=5, 9 %), 
dalmations (n=4, 7 %), and two each o f boxers, German shepherds, Labrador retrievers, 
poodles and Shetland sheepdogs. Six (11 %) dogs were crossbreeds and the remaining 15 
dogs represented 15 other breeds. However, the same study reported a similar distribution
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of breeds within the euthyroid group suggesting that either certain breeds were more 
prevalent in the referral population studied, or were more frequently tested for 
hypothyroidism.
Clearly, several breeds including the doberman pinscher, golden retriever and 
cocker spaniel have been reported to be particularly prone to hypothyroidism. The view is 
also widely held that purebred dogs are more frequently affected than crossbreeds. This has 
been presumed to indicate a genetic predisposition to the development o f hypothyroidism 
(Milne & Hayes, 1981). The increased incidence o f thyroiditis and thyroglobulin 
autoantibodies within particular breeds and families of dog has supported this contention 
(Conaway et al, 1985; Benjamin, Stephens, Hamilton, Saunders, Lee, Angleton & 
Mallinckrodt, 1996) and is discussed in detail in Chapter 7. However, much o f the 
published data concerning the prevalence of thyroiditis has been performed with 
experimental animals, particularly beagles, a breed known to be prone to the development 
of thyroiditis (Benjamin et al, 1996). The role that pedigree status and breed have on the 
incidence o f clinical hypothyroidism cannot necessarily be inferred from these experimental 
studies.
Gender
Nesbitt et al, (1980) reported a roughly equal number o f hypothyroid males (n=55) and 
females (n=53). However, no data were provided regarding the neutering status of these 
animals.
Of the 3184 hypothyroid dogs reported by Milne & Hayes, (1981), 1811 (56.9 %) 
were female (733 neutered) and 1373 (43.1 %) were male (89 neutered). After controlling 
for the effect of age and breed, there was no difference in the risk o f developing 
hypothyroidism between sexually intact males and females. Male castrated dogs were at 30 
% increased risk compared to intact males but this was not statistically significant. 
However, neutered female dogs were significantly at risk compared to intact females. This 
effect was particularly marked in the high risk breeds.
Kaelin et al, (1986) reported hypothyroidism in 16 dogs of which six were female 
(four neutered) and 10 male (one neutered). No statistical analysis of these data were 
performed.
Panciera, (1994) reported that 30 o f 6 6  (45 %) hypothyroid dogs were male (18 
neutered) compared to 36 (55 %) females (30 neutered). Neutered males (o.r.=4.18) and 
neutered females (o.r.=3.46) were significantly at risk of developing hypothyroidism
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compared with intact females. Neutered dogs regardless of sex were reported to be 
significantly at risk of developing hypothyroidism compared to intact animals. The 
influence of neutering was apparent both before and after stratification o f the data by age.
Thirty one of 54 (57 %) hypothyroid dogs reported by Peterson et al, (1997) were 
female (22 neutered) compared to 23 male (12 neutered). The euthyroid group in the same 
study consisted of 26 (48 %) female (20 neutered) and 28 (52 %) male (15 neutered) dogs. 
Although not specifically reported, chi squared analysis of these data revealed no significant 
difference in the sex or neutering status between the hypothyroid and euthyroid groups.
It is known that sex hormones have a mild effect on thyroid function in the dog and 
the relevant studies have been reviewed in Chapter 4. It has been suggested that the 
association between neutering and hypothyroidism may in fact be related to the influence of 
sex hormones on the immune system. In experimental mice, castration increases the 
severity of autoimmune thyroiditis (Okayasu, Kong & Rose, 1981). However, 
administration of oestrogens to ovariectomised female and castrated male rats ameliorates 
pre-existing thyroiditis. By contrast, progesterone administration to these individuals 
worsens the condition (Ahmed, Young & Penhale, 1983). The influence of sex and 
neutering status on the presence of TgAb in dogs is discussed in Chapter 7.
In humans, a number of variables including iodine consumption, gender and 
pregnancy play a role in the susceptibility to thyroiditis (Weetman, 1996). There is also an 
inverse correlation between birth weight and the prevalence of TgAb in women (Phillips, 
Cooper, Fall, Prentice, Osmond, Barker & Rees Smith, 1993). Clearly several mechanisms 
are likely to play a role in the development of this disease in all species, and further studies 
will be required to clarify these in dogs.
Clinical Features of Hypothyroidism
Thyroid hormones play a role in numerous cellular metabolic processes, discussed in detail 
in Chapter 4. Therefore deficiency of thyroid hormones can have diverse biological effects. 
There is widespread agreement that the clinical features of canine hypothyroidism are 
variable and non-specific (Feldman & Nelson, 1996). In addition the insidious nature of 
hypothyroidism makes appreciation of the clinical changes more difficult.
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Dermatological Features
Thyroid hormones play several important roles in the maintenance of dermal health and 
hypothyroidism is the most common endocrine disease affecting the skin (Scott, 1982; 
Feldman & Nelson, 1996). Dermatological abnormalities in hypothyroidism can be 
extensive and are reported in the majority o f affected dogs (Panciera, 1994). Thyroid 
hormones are necessary for the initiation of the anagen phase of the hair follicle cycle. 
Absence of thyroid hormones results in persistence of the telogen growth phase, hairs 
become easily epilated and eventually alopecia results. This commonly starts in areas 
undergoing friction such as the neck in dogs that wear collars and on the tail resulting in 
the “rat tail” typical of hypothyroidism. The alopecia is usually bilaterally symmetric in 
appearance but focal, mulitfocal and asymmetric alopecia can occur. Hair loss slowly 
progresses and will ultimately affect the flanks and trunk. The extremities are usually 
spared although giant breeds may suffer from alopecia of the extremities whilst the trunk 
remains relatively unaffected (Panciera, 1997b). The hair that remains is usually dry and 
brittle and may become lighter in colour presumably due to environmental bleaching. Some 
variation in lesion type and distribution may be breed related with Artie breeds often losing 
primary hairs giving a woolly coat appearance, daschunds developing pinnal alopecia, nasal 
alopecia occurring particularly in retrievers, and hypertrichosis being reported in boxers 
and Irish setters (Rosychuk, 1997). Hyperkeratosis occurs causing scaling and scurfing of 
the skin (Panciera, 1990a). Accumulation of dermal mucopolysaccharides and hyaluronic 
acid occurs due to an imbalance in the normal thyroid hormone-controlled production and 
degradation of these molecules, and results in myxoedematous skin thickening which is a 
common complaint in affected humans (Bernhard, Freedberg & Vogel, 1996). Dog owners 
rarely notice such a change in their pets, although the skin thickening can give rise to the 
so-called “tragic facial expression” due to thickening o f the lips, over the forehead and 
drooping of the eyelids. Thyroid hormones assist the humoral and cellular immune 
responses, and consequently hypothyroidism reduces resistance to infection. Secondary 
recurrent and persistent superficial and deep pyodermas are therefore commonly reported 
in hypothyroidism (Peterson & Ferguson, 1989; Panciera, 1990a; Rosychuk, 1997). These 
infections may be poorly responsive to appropriate antibiotic therapy until the 
hypothyroidism is controlled, inflammatory lesions often include accumulation of 
lymphocytes, neutrophils, macrophages and plasma cells and are presumably related to 
either mild secondary pyoderma and/or the irritation associated with seborrhoeic changes. 
Such abnormalities may result in pruritis with secondary self-induced excoriation and
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trauma which can complicate the clinical and histopathological analysis. Other 
dermatohistopathological changes supportive o f hypothyroidism include dermal thickening 
reported in 41 %, myxoedema reported in approximately 30 % and vacuolation of the 
arrector pili muscles reported in as many as 75 % of cases (Scott, 1982; Yeager & 
Wilcock, 1994).
In a study of 108 hypothyroid dogs, Nesbitt et al, (1980) reported alopecia in 92 
(85 %), loss o f coat condition including dryness, dullness, dandruff, scaling and hair 
coarseness in 51 (47 %), hyperpigmentation in 34 (31 %) and pyoderma in 30 (28 %). 
Kaelin et al, (1986) documented alopecia in 12 of 16 (75 %) hypothyroid dogs. Skin 
biopsies in five of these cases revealed hyperkeratosis and follicular plugging, and in four of 
them there was hyperpigmentation. In two dogs the dermis was thickened. In two cases, 
the arrector pili muscles were hypertrophic and vacuolation was also evident in one. These 
latter changes are considered to be particularly characteristic of hypothyroidism (Scott, 
1982). Panciera, (1994) reported dermatological abnormalities in 39 of 66 (59 %) 
hypothyroid dogs, most commonly seborrhoea (n=26, 39 %), alopecia (n=17, 26 %) and 
pyoderma (n=7, 11 %). The alopecia was frequently bilaterally symmetric although hair 
loss in areas undergoing friction was also common.
Metabolic Features
A range o f clinical signs associated with hypothyroidism including weight gain, lethargy, 
exercise intolerance and weakness are collectively described as “metabolic” abnormalities. 
These signs are considered to be manifestations of the reduced metabolic rate which occurs 
in these individuals (Panciera, 1997b). In hypothyroid humans, basal metabolic rate reduces 
by up to 40 % and the rate of heat production falls, reflecting the reduction in a wide 
variety of energy-generating reactions. This is often associated with cold intolerance and 
some degree of weight gain despite a decrease in appetite. The onset o f metabolic signs is 
typically insidious often making their appreciation by owners particularly difficult. 
However, the clinical response following appropriate therapy can be dramatic, 
retrospectively confirming the extent of the problem. Anecdotal comments in the literature 
suggest that the metabolic signs associated with central hypothyroidism are less severe than 
primary hypothyroidism (Panciera, 1990a; Rijnberk, 1996). However, no evidence for this 
assertion has been published.
Nesbitt et al, (1980) reported lethargy and obesity in 12 (11 %) and nine (8 %) of 
108 hypothyroid dogs, respectively. Eleven of 16 (69 %) hypothyroid dogs reported by
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Kaelin et al, (1986) were obese and the same number were lethargic. Two cases (12 %) 
were reported to be hypothermic. Panciera, (1994) reported obesity to be common but 
generally mild although several individuals were grossly obese, weighing over 75 % more 
than the ideal breed weight. Lethargy was recorded in 13 (20 %) of the 66 cases. Feldman 
& Nelson, (1996) reported weight gain (n=48, 48 %), lethargy and mental dullness (n=35, 
35 %) to be the most prevalent clinical abnormalities in a study o f 100 dogs with 
hypothyroidism. That study suggested that the severity of metabolic signs are related to the 
stage of the thyroid disease which may account for the differences reported between 
studies.
Neuromuscular Features
Neuromuscular abnormalities including generalised lower motor neurone (LMN) paresis, 
peripheral vestibular disease, megaoesophagus, laryngeal paralysis, primary 
encephalopathy, cranial nerve disorders, mononeuropathies, neuromuscular junction 
disorders, myopathies and seizures have been variously reported in hypothyroid dogs 
(Braund, Dillon, August & Ganjam, 1981; Chastain, Graham & Riley, 1982; Dewey, 
Shelton, Bailey, Willard, Podell & Collins, 1995; Coates, 1997). Neurological signs were 
recorded in 19 of 66 (29 %) hypothyroid dogs reported by Panciera, (1994) although some 
of these individuals had more than one neurological complaint. Four dogs had unilateral 
and one had bilateral facial nerve paralysis. Four dogs had unilateral peripheral vestibular 
nerve disease of which three dogs had additional neurological deficits. Three dogs had 
generalised neuromuscular disease. She dogs (all of which were doberman pinschers) had 
cervical spondylomyelopathy, five had laryngeal paralysis and five had megaoesophagus. 
Jaggy, Oliver, Ferguson, Mahaffey and Glaus Jun, (1994) reported lower motor neuron 
signs in 11 (38 %), peripheral vestibular deficits in nine (31 %), laryngeal paralysis in five 
(17 %) and megaoesophagus in four (14 %) of 29 hypothyroid dogs with neurological 
signs. In each case the diagnosis had been based on TSH response tests and a positive 
response to thyroid hormone medication with a follow up period of at least six months. 
Many o f the dogs with other neurological signs had concurrent generalised LMN signs 
which was considered the most common clinical manifestation. However, some studies of 
canine hypothyroidism including 16 dogs reported by Kaelin et al, (1986) and 108 dogs 
reported by Nesbitt et al, (1980) make no reference to neuromuscular abnormalities.
The pathological basis for hypothyroid neuropathies is most likely due to axonal 
degeneration and demyelination (Pollard, 1993). However, confirmation of a genuine
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cause-effect relationship of certain neuromuscular abnormalities, particularly 
megaoesophagus and laryngeal paralysis is complicated by the variable response of these 
conditions to thyroid hormone supplementation and their regular occurrence in euthyroid 
dogs (Jones, Jergens & Guilford, 1989; Jaggy & Oliver, 1994; Jaggy et al, 1994). The true 
role of thyroid dysfunction in their development therefore remains to be clarified. Variation 
in the quality of case detail recording and classification of cases may also partly account for 
the differences reported between studies.
Neuromuscular signs are relatively common in human patients with hypothyroidism. 
These include peripheral neuropathies in up to 75 % of patients, and less frequently central 
nervous system abnormalities (DeLong, 1996). The pathological basis for these changes 
appears to vary but may include axonal degeneration, slowed conduction velocities or 
subcellular cerebellar deficits. Appropriate thyroid hormone replacement therapy in affected 
human patients is usually curative although recovery can take up to two years in severely 
affected individuals. It is currently unclear if the higher incidence of neurological symptoms 
reported in humans compared to hypothyroid dogs is related to a genuine species difference 
or a reduced detection of the more subtle neurological signs in dogs.
Cardiovascular Features
Thyroid hormones act on the myocardium by stimulating myocardial hypertrophy, exerting 
a positive inotropic effect and increasing responsiveness to adrenergic stimulation (Kienle, 
1997). In humans, thyroid hormones regulate these mechanisms by varying the expression 
of a number of myocyte contractile proteins and altering both myocyte sodium and calcium 
transport and mitochondrial function. Consequently, thyroid hormones can rapidly increase 
cardiac contractility and lower systemic vascular resistance. Correspondingly, in human 
hypothyroid patients, all measurements of left ventricular performance including cardiac 
output, stroke volume and heart rate are significantly decreased. In addition the rate of 
diastolic ventricular relaxation reduces, and wall compliance diminishes further impairing 
cardiac performance (Klein & Ojamaa, 1996).
In dogs the effect of thyroid hormones on cardiac function is much less clearly 
defined. The most frequently recognised electrocardiographic abnormalities in hypothyroid 
dogs are small QRS complexes, inverted T waves and sinus bradycardia (Nijhuis, Stokhuff, 
Huisman & Rijnberk, 1978). There appears to be a direct correlation of the severity of the 
electrocardiographic (ECG) abnormalities with the degree of hypothyroidism (Nijhuis et 
al, 1978). These changes typically reverse with appropriate hormone replacement therapy.
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Experimentally induced hypothyroidism has also been demonstrated to reduce myocardial 
function in dogs (Santos, Miller & Mathew, 1980). However, spontaneous congestive 
cardiac failure appears a rare complication of hypothyroidism unless in the presence of 
concurrent cardiac disease.
The possibility of a relationship between hypothyroidism and cardiac disease, 
specifically dilated cardiomyopathy (DCM) has been frequently suggested in the literature. 
However, there is surprisingly little solid evidence for a genuine cause and effect 
relationship between the two conditions. Calvert, Chapman & Toal, (1982) evaluated 
thyroid status in 13 dogs with spontaneous DCM. Only one of these dogs had an abnormal 
response to exogenous TSH administration consistent with hypothyroidism. Panciera & 
Refsal, (1994) evaluated the effect of spontaneous cardiac failure on thyroid function and 
reported no significant difference between those animals with clinical heart disease, and 
healthy control animals. More recently Calvert, Jacobs, Medleau, Pickus, Brown & 
McDermott, (1998) evaluated the results o f bovine TSH response tests in 152 doberman 
pinschers with various diseases. Cardiomyopathy was confirmed in 79 (52 %) cases of 
which 23 (29 %) were classified as hypothyroid. However, 29 of the 73 (40 %) non-DCM 
cases were also reported to be hypothyroid and there was no significant difference in the 
prevalence o f cardiac disease between the hypothyroid and euthyroid dogs. Furthermore, of 
those dogs with DCM, the thyroid status was not significantly different between the sub­
groups with or without congestive cardiac failure. This large and well controlled study 
supports the comments by Kienle (1997) that a relationship between hypothyroidism and 
clinical cardiac failure remains to be proven.
Reproductive Features
Clinical reproductive abnormalities including persistent anoestrus, galactorrhoea, infertility 
and prolonged inter-oestrus interval in the bitch, and decreased fertility and libido in the 
male dog have all been attributed to hypothyroidism (Chastain & Schmidt, 1980; Johnson, 
Larsen & Olsen, 1982; Feldman & Nelson, 1996). However, the mechanism o f the 
interrelationship between thyroid hormones and reproductive function remains unclear and 
whilst there is evidence of an association between lymphocytic thyroiditis and lymphocytic 
orchitis in genetically susceptible beagles (Fritz, Lombard, Tyler & Norris, 1976) the data 
confirming spontaneous hypothyroidism as the cause of clinical reproductive abnormalities 
is in fact sparse. Nesbitt et al., (1980) documented abnormal oestrus in five of 108 (5 %) 
dogs with spontaneous hypothyroidism. However, more specific details of the reproductive
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problems were not provided. Panciera, (1994) reported reproductive abnormalities (one 
each of decreased libido and a history of abortion) in two of 66 (3 %) hypothyroid dogs 
classified by bovine TSH response tests. Johnson, Olivier, Nachreiner & Mullaney, (1999) 
reported no decrease in male reproductive performance as assessed by daily sperm 
production, ability to ejaculate and total scrotal width in six beagles two years following 
radiothyroidectomy. Clinical reproductive disease as a result of hypothyroidism therefore 
appears to be a relatively uncommon feature.
Other Features
A variety o f other clinical signs have been less frequently associated with canine 
hypothyroidism. Corneal lipidosis associated with hypothyroidism and hyperlipidaemia has 
previously only been described in German shepherd dogs (Crispin & Barnett, 1978). 
Gastrointestinal disease, particularly constipation related to impaired motility, has been 
reported in humans and if left untreated this can progress to a state of pseudo-obstruction. 
There is similar data relating to affected dogs (Feldman & Nelson, 1996). More recently 
diarrhoea resulting from small intestinal bacterial overgrowth (SIBO) has also been 
reported as a gastrointestinal feature of canine hypothyroidism (Jackson, Jackson, Wotton 
& Hall, 1998). The authors had no evidence for an underlying mechanism to link the two 
conditions, but considered the possibility of reduced intestinal motility, predisposing to 
bacterial overgrowth.
Clinicopathological Features of Hypothyroidism
There are well described biochemical and haematological abnormalities associated with 
hypothyroidism in both humans and dogs. However, these changes are usually compared 
with laboratory reference ranges, and are widely accepted as being neither sensitive nor 
specific for the condition. Consequently routine clinicopathological changes are considered 
merely supportive of a clinical diagnosis and the results of additional endocrine testing. The 
most common abnormalities reported in the literature include anaemia, hyperlipidaemia, 
and elevated circulating creatine kinase (CK) concentration.
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Anaemia
Haematological changes associated with hypothyroidism have been recognised in humans 
since the late 1800s. Similar changes are now also reported in affected dogs. The anaemia, 
often termed a “physiological” anaemia is most commonly normocytic normochromic, and 
is presumed to be related to the reduction in metabolic and therefore oxygen requirements 
in affected patients. Various other types of anaemia have also been reported in human 
hypothyroid patients including macrocytic, and hypochromic microcytic anaemias. These 
abnormalities result from a variety o f mechanisms including decreased erythropoietin 
production associated with reduced oxygen demand, reduced bone marrow activity, 
haemolysis, iron deficiency and idiopathic forms (Green & Ng, 1986). A reduction in 
peripheral tissue oxygen utilisation and impaired gastrointestinal iron absorption are also 
likely to be partly responsible for the red blood cell changes found in thyroid deficient 
states. The severity and chronicity o f hypothyroidism is generally reflected by the degree of 
anaemia. However, this is not always the case and the changes are not specific for 
hypothyroidism.
Kaelin et al., (1986) reported a normocytic normochromic anaemia in five of 12 (42 
%) hypothyroid dogs classified based on inadequate response to TSH administration. 
Panciera, (1994) reported the same abnormality in 18 of 57 (32 %) hypothyroid dogs which 
were also confidently diagnosed. Feldman & Nelson, (1996) reported anaemia in under 50 
percent of their dogs but more detailed data were not provided.
Hyperlipidaemia
Alterations in lipid metabolism are associated with hypothyroidism and result from changes 
in a number metabolic processes. Abnormalities of the triglyceride rich lipoproteins 
(chylomicrons and very low density lipoproteins (VLDL)), and cholesterol-rich lipoproteins 
(low density lipoproteins (LDL) and high density liporpoteins (HDL)) may all play a role in 
the alteration of the lipid profile in affected animals. In dogs as well as humans, this 
“hypothyroid hyperlipidaemia” is primarily caused by a reduction in the rate of lipid 
degradation (Peterson & Ferguson, 1989). Thyroid hormones enhance the degradation of 
cholesterol to bile acids and may increase the sensitivity of adipose tissue to the lipolytic 
effects of several hormones. In addition, the activity of lipoprotein lipase is diminished in 
thyroid hormone deficient states (Zerbe, 1986). Whilst there is a concomitant reduction in 
lipid synthesis in hypothyroidism the degradation is affected to a greater extent and the net 
effect is therefore an accumulation within the circulation (Feldman & Nelson, 1996).
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Kaelin et al, (1986) reported an increased blood cholesterol in 10 of 14 (71 %) 
hypothyroid dogs which is similar to 40 of 55 (73 %) hypothyroid cases reported by 
Panciera, (1994). Peterson & Ferguson, (1989) reviewed the literature of hypothyroid dogs 
categorised by TSH response tests and reported hypercholesterolaemia in 45 of 56 (80 %) 
cases. Feldman & Nelson, (1996) report hypercholesterolaemia in over 75 % of their 
hypothyroid dogs. However, more detailed data were not provided. The magnitude of 
hypercholesterolaemia tends to be greater in hypothyroidism than in other illnesses 
including other endocrine diseases (Barrie, Watson, Stear & Nash, 1993). Therefore whilst 
hypercholesterolaemia is not specific for hypothyroidism, an unusually exaggerated increase 
in cholesterol concentration should prompt consideration of hypothyroidism in particular.
Data on the severity and frequency of abnormalities in triglyceride concentrations in 
hypothyroidism are sparse. However, anecdotally, the changes in circulating triglyceride 
concentrations are less consistent than for cholesterol (Peterson & Ferguson, 1989; Zerbe, 
1986). Rogers, Donovan & Kociba, (1975) diagnosed hypothyroidism in 26 dogs and 
reported increased concentrations of serum triglycerides, cholesterol and occasionally free 
glycerol. In cases with less severe hyperlipidaemia, only hypercholesterolaemia occurred. 
However, the diagnostic criteria used for confirming hypothyroidism in this study were 
unreliable with a number not even having circulating total T4 estimations performed.
Creatine Kinase
Elevations in CK have been previously reported in hypothyroidism. However, the aetiology 
of this abnormality is unclear and whilst it is commonly assumed to resujt from a 
hypothyroid myopathy, hypothyroid dogs with histologically confirmed myopathy can have 
normal CK results whilst others without abnormal muscle biopsy findings may have 
elevated CK concentrations (Braund et al, 1981). Karlsberg & Roberts, (1978) 
investigated the pharmacokinetics of circulating CK in four healthy dogs prior to and 
following the induction of hypothyroidism by 131I radiothyroidectomy. That study 
suggested that the increased CK concentration may in fact be related to a decreased rate of 
plasma clearance.
Panciera, (1994) reported elevated CK in nine o f 51 (18 %) hypothyroid dogs 
although the increase tended to be marginal. Jaggy et al., (1994) reported a similar finding 
in three of 29 (10 %) hypothyroid dogs with neurological signs.
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Other clinicopathological abnormalities
Several additional clinicopathological abnormalities have been reported in hypothyroidism 
including mild hypercalcaemia, increased alkaline phosphatase activity, thrombocytosis and 
decreased mean platelet volume (Kaneko, 1989; Sullivan, Gompf, Schmeitzel, Clift, 
Cottrell & McDonald, 1993; Panciera, 1994). However, none of these abnormalities have 
been considered to be of diagnostic utility due to their insensitive and non-specific pattern 
of change in hypothyroid dogs and those with NTI.
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5.2. INTRODUCTION
There are widely held preconceptions regarding the typical epidemiological, clinical and 
clinicopathological features of hypothyroidism in the dog. However, surprisingly few 
published reports of these characteristics have been based on cases in which 
hypothyroidism has been confirmed using appropriate and accurate diagnostic criteria. In 
addition, most of the studies reported elsewhere have examined dogs from the United 
States or Australia (Nesbitt et al, 1980; Milne & Hayes, 1981; Kaelin et al, 1986; 
Panciera, 1994). These data may not therefore be truly representative o f the UK dog 
population. The clinical and clinicopathological features of hypothyroidism have been 
previously reported (Panciera, 1994). However, like most other similar studies, the 
clinicopathological abnormalities in affected dogs were compared with laboratory reference 
ranges. Consequently the specificity of these features for hypothyroidism remains unclear 
since the incidence of similar abnormalities in dogs in which hypothyroidism is suspected 
but excluded, has not been reported.
This study was designed to evaluate the epidemiological, clinical and 
clinicopathological features of confidently diagnosed hypothyroidism in a population of 
dogs from the UK. A novel approach was to determine the diagnostic value of routine 
biochemical and haematological parameters by identification of those analytes which most 
reliably distinguished hypothyroid dogs from those with clinically similar illness but in 
which a diagnosis of hypothyroidism was ultimately excluded.
5.3 MATERIALS AND METHODS 
Case Material and Classification
The case material comprised a series of 140 dogs referred to the University of Glasgow 
Veterinary School and subsequently investigated for suspected hypothyroidism as outlined 
in Chapter 2. Based on the total T4 response to exogenous stimulation with bovine TSH, 
the dogs were classified as either hypothyroid (n=52) or euthyroid (n=88) using the criteria 
detailed in Chapter 4. Results of hormone analyses from these cases are detailed in Chapter 
4.
Routine Clinicopathological Analysis
Routine biochemical and haematological analyses were performed as described in Chapter 
2 .
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Clinical Control Groups
Three groups of cases categorised as the euthyroid, hospital and external groups were used 
as the clinical control groups as outlined in Chapter 2. To assess if the distribution of 
breeds within the referral group were likely to be influenced by particular specialities or 
disciplines within DVCS, the hospital system was interrogated as outlined in Chapter 2. 
The referral group was subdivided according to the speciality to which the cases were 
referred, for example, orthopaedics, ophthalmology, neurology, general medicine etc. The 
cases within each discipline were then subdivided by breed. The intention of this was to 
allow comparison of breed distribution between disciplines and identify any specialities in 
which there was marked over-referral of a particular breed. It was conceded that this 
approach would not allow the identification of disciplines in which breeds were significantly 
underrepresented. Only disciplines with greater than 10 cases of a single breed constituting 
at least 10 percent of the total number of referrals of that breed were analysed. These 
values were chosen arbitrarily but it was considered that any biases within a discipline 
which involved under 10 percent o f the total referrals of that breed would be unlikely to 
have a marked effect on the general control population. It was intended that any subsets 
with a confirmed bias would be removed prior to statistical analyses.
Clinicopathological Control Groups
Results of biochemical and haematological analyses from the hypothyroid dogs were 
compared with clinicopathological controls as outlined in Chapter 2.
Data Manipulation
Clinicopathological results were recorded, stored and analysed as outlined in Chapter 2. All 
results are reported as median (semi-interquartile range (SIR)). The association of sex, 
neutering status and pedigree status with the development of hypothyroidism was 
determined by calculating o.r.’s with the associated 95 % confidence intervals using each of 
the two clinical control groups. The ages of the hypothyroid, euthyroid and hospital groups 
were compared using analysis of variance techniques with post hoc pairwise comparison of 
means using Newman-Keuls multiple range tests. The association o f breed with 
hypothyroidism was determined by chi-squared analysis using each o f the clinical control 
groups and breeds represented by at least five cases in each group. A Mann-Whitney U test 
was used to compare routine haematological and biochemical results between the 
hypothyroid and euthyroid dogs. Diagnostic sensitivity and specificity were defined as
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described in Chapter 2. Diagnostic efficiency of individual analytes was defined as the 
percentage of results which correctly classified cases irrespective of their disease status.
5.4 RESULTS 
Signalment
The hypothyroid group consisted of 23 male (5 neutered) and 29 female (15 neutered) 
animals ranging in age from three to 13 years (mean ± s.d., 7.6 ± 2.6 years). Of these 
animals 46 were classified as pedigree and the remaining six as crossbreeds. The breed 
types and breeds most commonly affected are detailed in Table 5 and displayed in Figure 
14. The euthyroid group consisted o f 49 male (10 neutered) and 39 female (22 neutered) 
animals ranging in age from one to 14.5 years (mean ± s.d., 7.3 ± 3 .3  years). Of these 
animals 83 were classified as pedigree and the remaining five as crossbreeds. The breed 
types and breeds are detailed in Table 5 and displayed in Figure 15. The relevant hospital 
group during the study period consisted of 3040 male (588 neutered) and 2722 female 
(1371 neutered) dogs ranging in age from 0.02 to 22.8 years (mean ± s.d., 5.9 ± 3.8 years). 
Of these animals 5315 were classified as pedigree and the remaining 447 as crossbreeds. 
The breed types and breeds most commonly referred are detailed in Table 5 and displayed 
in Figure 16. The distribution o f breeds within each referral discipline, and the attempted 
analysis of these data are detailed in Appendix 31. The external group consisted of a total 
of 1,052629 dogs distributed between 192 breeds. These cases are detailed in Table 5.
The most common breeds and breed types in the study are displayed in Figure 17. 
There was no significant difference in breed distribution between the hypothyroid and either 
the euthyroid, hospital or external control groups. However, there were significant 
differences between the euthyroid and external (p<0.001) groups with collies being 
markedly over-represented in the euthyroid group. There was also a significant (p<0.001) 
difference between the hospital and external group breeds, with collies, terriers, rottweilers 
and doberman pinschers being most over-represented in the hospital group. Despite this, 
eight of the 10 numerically largest breeds in the external group were amongst the 10 most 
frequently represented breeds in the hospital group.
The pedigree distribution o f each group is shown in Figure 18. There was no 
significant difference in pedigree status between the hypothyroid and both the euthyroid 
and hospital groups. No comparison with the external group could be made.
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Breed Hypothyroid Euthyroid Hospital External
Retrievers 10 22 1015 199098
Spaniels 7 6 632 114927
Terriers 6 12 941 151992
Crossbreeds 6 5 447 0
Doberman 3 4 96 10014
Japanese Akita 2 0 21 4302
Collies 2 8 489 20971
Schnauzer 2 1 37 10594
Sheltie 2 2 49 11866
Rottweiler 2 3 143 15376
Boxer 1 3 178 38586
German shepherd 1 1 484 96485
Griffon 1 0 4 500
Hovawart 1 0 0 78
Pointers 1 0 37 9251
Poodle 1 0 99 19456
Pug 1 0 5 2144
St Bernard 1 0 32 3296
Setters 1 4 79 12268
Viszla 1 0 16 1800
Beagle 0 0 27 3809
Belgian Shepherd 0 1 3 1950
Bernese Mountain Dog 0 1 40 3133
Bichon Friese 0 1 18 10778
Borzoi 0 1 1 745
Bullmastiff 0 1 56 7847
Chow chow 0 2 28 2830
Dachshund 0 2 50 18424
Dalmation 0 1 28 13610
Lhasa Apso 0 2 31 12742
Newfoundland 0 1 43 3758
Pekinese 0 1 27 6264
Pyrenean Mountain Dog 0 1 12 1221
Samoyed 0 1 31 4849
Shih Tzu 0 1 31 17973
Others 0 0 532 219692
Totals 52 88 5762 1052629
Table 5. Distribution of the breed-types of the hypothyroid, euthyroid, hospital and 
external groups of dogs.
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Figure 14. Distribution o f breed-type o f 52 dogs with confirmed hypothyroidism.
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Figure 15. Distribution o f breed-type of 88 euthyroid dogs investigated for hypothyroidism 
but in which alternative diagnoses were made.
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Figure 16. Distribution o f breed-type of all referred dogs which were not investigated for 
hypothyroidism.
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Figure 18. Relative numbers of the hypothyroid, euthyroid and referral groups o f dogs 
which classified as either pedigree or non-pedigree,
Details o f the sex and neutering distribution o f dogs in the hypothyroid, euthyroid 
and hospital groups are shown in Table 6. There was no significant difference in sex or 
neutering status between the hypothyroid and either the euthyroid or hospital control 
groups. No comparison with the external group could be made.
Group Hypothyroid Euthyroid Hospital
Male Entire 18 39 2452
Male Neutered 5 10 588
Female Entire 14 17 1351
Female Neutered 15 22 1371
Total Male 23 49 3040
Total Female 29 39 2722
Total Entire 32 56 3803
Total Neutered 20 32 1959
Total 52 88 5762
Table 6. Details o f the gender and neutering status o f the hypothyroid, euthyroid and 
hospital groups of dogs.
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The age distribution for the hypothyroid, euthyroid and hospital groups is displayed 
in Figure 19. The hypothyroid and euthyroid dogs were significantly (p < 0.001) older than 
the hospital group but were not significantly different to each other. However, as can be 
seen from Figure 19, there were a large number of young animals referred to the hospital 
for investigation of juvenile diseases. The exclusion of this biologically distinct group of 
dogs less than two years of age removed the statistically significant effect.
To identify the cause of the skewed age distribution data in the hospital group, the 
number of dogs less than two years o f age was compared to the corresponding number 
above this age in each discipline. These data are displayed in Figure 20. There were highly 
significant (p<0.001) differences in the number o f juvenile dogs referred to various 
disciplines. Orthopaedics had a significantly increased, whereas oncology, soft tissue 
surgery, endocrinology, and neurology, had a significantly decreased number of animals 
referred who were less than two years o f age.
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Clinical Findings
The most commonly reported clinical abnormalities in the hypothyroid dogs are displayed 
in Figure 21. The most common group of clinical features were metabolic signs, at least 
one of which was recorded in 44 (85 %) cases. These included lethargy (n=40, 77 %), 
obesity or weight gain (n=22, 42 %), exercise intolerance (n=14, 27 %), cold intolerance 
(n=5, 10 %), generalised weakness (n=6, 11 %) and shivering (n=3, 6 %). Dermatological 
abnormalities were recorded in 41 (79 %) cases and included hair thinning (n=29, 56 %) 
particularly affecting the flanks, tail and thighs, dry or poor quality coat (n=15, 29 %), skin 
hyperpigmentation (n=10, 19 %) and superficial pyoderma (n=8, 15 %). A typical example 
is illustrated in Figure 22. Otitis, seborrhoea, skin thickening, skin odour, nasal 
hypopigmentation and comedones were each recorded in fewer than 10 % of cases. 
Metabolic and dermatological signs were observed concurrently in 35 (67 %) dogs. Less 
common clinical signs included diarrhoea (n=2), neurological signs (n=3), and irregular 
interoestrus intervals (n=l). The neurological signs included facial nerve paralysis in two 
dogs and ataxia, vertical nystagmus and proprioceptive deficits in one further dog 
presumably related to a concurrent encephalitis of unknown aetiology confirmed at post 
mortem examination. Histological examination o f the thyroid gland in the latter case was 
confirmatory of idiopathic atrophy.
Other concurrent diseases were present in 20 of the hypothyroid dogs. These 
included musculoskeletal disease (n=4), consisting of one case each of osteoarthritis, 
unilateral cranial cruciate rupture, cervical spondylopathy, patellar luxation with tarsal 
ligament collapse; dilated cardiomyopathy (n=3), adult onset demodecosis (n=2), ocular 
abnormalities (n=2), mammary neoplasia (n=2), eosinophilic bronchitis (n=l), 
hyperadrenocorticism (n=l) and interdigital cysts (n=l). Five (10 %) hypothyroid dogs had 
concurrent diabetes mellitus including one of the dogs with mammary neoplasia.
Further details o f the case with concurrent hyperadrenocorticism are provided in 
Appendix 32.
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Figure 22. Example of dermatological abnormalities in a dog with confirmed spontaneous 
hypothyroidism.
Clinicopathological Findings
The reference limits obtained by analysis of the clinicopathological data from the euthyroid 
group are detailed alongside the corresponding laboratory reference limits in Table 7
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Reference limits
generated from the Laboratory
euthyroid group reference limits
Lower Upper Lower Upper
Analyte Observations reference reference reference reference
limit limit limit limit
Urea 87 2.32 13.50 2.5 8.5
Sodium 87 135.45 151.85 136 159
Potassium 87 3.60 5.69 3.4 5.8
Chloride 87 99.15 124.70 95 115
Calcium 85 2.22 2.91 2.34 3
Magnesium 85 0.61 0.94 0.6 0.87
Phosphate 85 0.58 2.23 0.9 2.9
Glucose 72 4.33 13.72 3.3 6.5
Cholesterol 87 3.02 15.47 2 7
Creatinine 87 56.60 182.95 45 155
Bilirubin 85 0.00 4.00 0 10
ALKP 87 33.30 1646.80 0 230
AST 86 11.13 54.63 0 40
ALT 86 8.50 223.25 0 90
Total Protein 86 54.13 79.00 50 78
Albumin 86 27.13 43.88 29 36
Globulin 86 22.00 47.00 28 42
Creatine
Kinase 60 61.18 452.40 0 150
Triglyceride 54 0.50 6.19 0.1 0.6
y-glutamyl
transferase
54 2.00 10.00 0 20
Fructosamine 82 168.25 427.70 162 310
RBC 57 5.18 7.77 5.5 8.5
Hb 57 11.94 17.50 12 18
MCV 57 61.00 73.60 60 77
MCH 57 20.80 25.96 19.5 24.5
MCHC 57 32.84 37.74 32 36
PLT 56 166.50 550.38 200 500
MPV 56 6.60 10.53 none none
WBC 57 5.48 28.26 6 12
Neutrophil 57 3.78 22.63 3 11.8
Lymphocyte 57 0.53 3.32 1 4.8
Monocyte 57 0.08 1.69 0.15 1.35
Eosinophil 57 0.00 1.07 0.1 1.25
Table 7. Biochemical and haematological reference limits generated from the euthyroid 
group of dogs. Laboratory reference limits are also shown for comparison. See Appendices 
2 and 4 for key and units.
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The most common clinicopathological abnormalities in the hypothyroid and 
euthyroid groups when compared with the laboratory reference limits are summarised in 
Table 8. Examination of these results reveals a similar pattern of clinicopathological 
changes in both these groups. Elevated concentrations of triglycerides and cholesterol were 
the most diagnostically sensitive routine tests occurring in 30 of 34 (88 %) and 40 of 51 
(78 %) hypothyroid and 45 of 54 (83 %) and 40 of 87 (46 %) euthyroid dogs, respectively. 
However, these parameters were associated with poor diagnostic specificity (0.17 and 0.54, 
respectively). The most diagnostically efficient abnormalities were reduced RBC count 
(0.69) and elevated fructosamine concentration (0.68) which occurred in 19 of 47 (40%) 
and 19 of 44 (43 %) hypothyroid, and 13 of 84 (15 %) and 15 of 82 (18 %) euthyroid 
dogs, respectively.
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Results of comparison of the routine hypothyroid clinicopathological results with 
the reference limits generated from the euthyroid group are displayed in Table 9. Using this 
approach, the most frequent abnormalities in the hypothyroid group were elevated serum 
cholesterol in 10 (20 %), and y-GT concentration in six (18 %), and decreased RBC in 14 
(30 %), haemoglobin in 13 (30 %) and neutrophil count in eight (17 %) o f the cases tested.
Statistically significant differences in sodium, chloride, calcium, cholesterol, 
creatinine, AST, globulin, fructosamine, RBC count, Hb concentration, MCH, MCHC and 
eosinophils were found in the hypothyroid dogs compared with the euthyroid group (Table 
10).
Analyte Number
tested
Median
(SIR)
No. (%) outwith 
reference limits 
Above Below
Reference
limits
Cholesterol 51 10.3 (7.0) 10 (20 %) 1 (2 %) 3.0-15.5
y-GT 34 5.0 (3.0) 6(18% ) 2 (6 %) 2.0- 10.0
RBC 47 5.6 (1.2) 1 (2 %) 14 (30%) 5.2 - 7.8
Haemoglobin 43 12.9 (2.3) 0 13 (30%) 11.9-17.5
Neutrophils 47 7.4 (5.4) 2 (4 %) 8(17% ) 3.8 - 22.6
SIR semi-interquartile range
Table 9. Abnormal biochemical and haematological results in hypothyroid dogs compared 
to the reference limits derived from the euthyroid group of dogs in which hypothyroidism 
had been suspected but excluded. See Appendices 2 and 4 for key and units.
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Analyte Hypothyroid 
(median (SIR))
Euthyroid 
(median (SIR))
p-value
Sodium 144 (4) 146 (4) 0.0004
Chloride 110(7) 112(6) 0.0038
Calcium 2.7 (0.3) 2.6 (0.3) 0.01
Cholesterol 10.3 (7.0) 6.9 (4.0) <0.0001
Creatinine 105 (37) 90 (27) 0.0013
AST 26 (15) 23 (12) 0.0382
Globulin 33.0 (6.7) 29 (7.2) 0.0033
Fructosamine 299 (84) 249 (55) 0.0025
RBC 5.6 (1.2) 6.5 (1.2) <0.0001
Hb 12.9 (2.3) 15.4 (2.0) <0.0001
MCH 23.0(1.8) 23.8(1.9) 0.02
MCHC 34.5(1.9) 35.3(1.6) 0.0016
Eosinophils 0.19(0.32) 0.33 (0.34) 0.0279
SIR semi-interquartile range
Table 10. Statistically significant differences in the routine biochemical and haematological 
results between hypothyroid and euthyroid groups of dogs. See Appendices 2 and 4 for key 
and units.
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5.5 DISCUSSION
A fundamental objective in the epidemiological study of any disease is the identification of 
biological and environmental associations with the disease. In some cases a solitary “cause” 
of the disease may be identified. Alternatively, a variety o f factors, all o f which increase the 
likelihood of the occurrence of the disease may be identified. The identification of a 
biological characteristic or trait associated with a particular condition requires 
demonstration that the trait is significantly over or under-represented in the diseased 
compared to the non-diseased “control” population. Clearly, with the exception of the 
disease being studied, the control group should be similar in all other respects to the 
diseased group. Given an adequate quantity of data, this “matching” o f groups is achievable 
for certain biological characteristics such as age, breed and sex. However, in practice 
matching certain other variables such as nutrition, local environmental conditions, previous 
diseases or therapies is unrealistic due to inadequate data. It should be clear that by 
matching diseased and control groups for a particular variable, the association of that 
variable with the presence of disease can no longer be evaluated.
A particular problem which exists in nearly all clinical research studies, results from 
biases within the population which is investigated for disease, compared to the population 
at risk from disease. For example, it would be naive to assume that the signalment data for 
cases presenting to veterinary surgeons reflected the true distribution in the general canine 
population. Social, economic and disease factors all play a role in determining if an animal 
is submitted by its owner for veterinary investigation. Therefore, the frequent presentation 
of one particular breed of dog with any specific disease does not necessarily imply that the 
breed is prone to that disease in the general canine population. Such a pattern may result 
from disproportionate submission of that breed to veterinary surgeons for investigation. 
This biasing effect of dogs at risk of disease compared to dogs with the opportunity for 
veterinary investigation is particularly marked in the case of a referral population since only 
a specific subset of diseased cases are referred to a second opinion clinic. This complicating 
feature of epidemiological analysis is important to appreciate if the results o f clinical study 
are not to be misinterpreted.
The use of referral data is further complicated by the influence that specialties 
within the referral centre exert on the make-up o f the control category. Heavy biases with 
respect to age and breeds of dogs are particularly common within certain disciplines and 
may affect the eventual analysis. This will affect the apparent association of age, sex, breed 
etc. amongst the group of dogs under study (Graham, 1995). This feature was clearly
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demonstrated in the present study, with a high percentage of referred cases being juvenile 
animals. The distribution of cases within a referral control population should be examined 
and if necessary any such biases removed during the selection of the control group. This 
was performed in the present study and highlighted that the statistically significant effect of 
age between both the hypothyroid and euthyroid groups, compared with the hospital group 
was simply a consequence of this type of error. However, as evidenced by the results 
detailed in Appendix 31, the practical difficulties associated with completely resolving this 
issue can become truly prohibitive. A comprehensive study of this aspect of referral 
epidemiology alone would be worthy of a dedicated study.
Despite these problems, in clinical research a pragmatic approach to the selection of 
control groups is usually necessary. In practice, most studies use those cases which were 
confirmed with diseases other than the one o f interest during the equivalent time period as 
the control group (Milne & Hayes, 1981; Panciera, 1994). To an extent this allows 
comparison of “like with like” and assists in identifying biological associations with disease. 
This approach was adopted in the present study and was found to be practical and 
achievable. The results are therefore directly comparable with other equivalent studies. 
However, without a knowledge of the biological phenotype of the general canine 
population in comparison to the referral population, extrapolation of the results must be 
performed cautiously. The study by Nesbit et al, (1980) is an example of these problems as 
they relate to canine hypothyroidism in particular. In that study hypothyroidism was 
reported to be most common in doberman pinschers, great Danes, poodles, and schnauzers. 
However, no information was provided regarding the distribution of these and other breeds 
within the non-hypothyroid population examined. Consequently the conclusions on breed 
predisposition to hypothyroidism are questionable since the apparently high prevalence of 
these breeds may simply have been the result o f a high prevalence within the referral 
population itself. There is a surprising absence of even basic demographic data on the 
number and signalment of dogs within the UK and this further hinders the epidemiological 
analysis of diseased populations.
The external group was selected and included in the present study for two reasons. 
Firstly it was used for directly comparing to the breed data obtained from the hypothyroid 
dogs. Secondly, comparison of the hospital group with the external group was desirable to 
provide some indication of the “trueness” of the distribution of referred dogs in relation to 
the relative number of those breeds in the general population. No information of the 
relative numbers of males and females was available from the KC. It was accepted that the
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external control group data were subject to potential error from a variety o f causes. These 
included
• changing trends in breed popularity influencing the number of new KC registrations 
relative to the total number of that breed in the general population
• any demographic variation specific to central and western Scotland from where the 
majority of the hospital group was referred
• the inability to assess any effect of crossbreeds as a specific “breed type”
It was considered that in reality the first two criteria were unlikely to have an undue effect 
on the results. These assumptions were supported by the “first twenty tables” published by 
the KC. These list the 20 most commonly registered breeds each year, and during the 
period of study showed very little annual variation suggesting relatively stable breed 
popularities. Also, the fairly similar breed rankings of the external and hospital groups of 
dogs, suggests that the local geographical breed demographic composition is similar to that 
of the UK as a whole. The third criteria was recognised as a genuine limitation but 
accurately addressing it was considered to be outwith the scope of this study. Nevertheless 
some estimation of this factor was desirable to allow evaluation of any influence that 
pedigree versus non-pedigree status may have on the development of hypothyroidism. The 
most recent data published by the Pet Food Manufacturers’ Association (PFMA) (PFMA 
Profile, 1998), estimated that approximately 60 % of dogs within the UK are pedigree 
whilst the remainder are crossbreeds. Consequently this estimate was used as a basis from 
which the distribution of pedigree and non-pedigree dogs within the hypothyroid and 
control groups could be evaluated.
The data initially obtained from the KC was grouped according to the breeds used 
in the KC classification scheme. However, in practice, when first referred to the DVCS 
many of the hypothyroid or various control dogs were only broadly classified with regard 
to their breed. For example a referred German spitz may have only been classified as 
“German spitz” with no reference to, in this case, either Klein or Mittel. Consequently the 
breed classification of the hypothyroid and control animals was not consistent with that of 
the KC for all types. Where appropriate, the KC data were combined to generate groupings 
which corresponded to that of the other groups of dogs in the study. For example all 
spaniels, whether cavalier, cocker or springer varieties, were combined and considered as a 
single breed type for statistical analysis. This grouping risked masking predispositions
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present within one variety of a particular breed type which may not be present in the others. 
However, the grouping was considered necessary to allow any valid comparisons with the 
other dogs in the study. In addition, the grouping o f breeds into “types” allowed the broad 
genetic makeup of groups to be maintained, whilst increasing the size of the groups 
therefore making them more suitable for useful statistical analysis. This was particularly 
relevant in the hypothyroid group where the number of animals of each breed type was 
relatively small. Whilst not a perfect solution, this approach was considered a practical and 
reasonable one.
A second problem associated with the quality of data collection in all cases referred 
to the DVCS resulted from poor recording of cases as pedigree or non-pedigree types. In 
some cases, dogs were categorised as being non-pedigree but of predominantly one type 
for example “rottweiler-cross”. However, for many cases, only the predominant breed type 
would be recorded potentially misclassifying a substantial number of non-pedigree dogs as 
pedigree. This was recognised as a genuine limitation of the present study when evaluating 
the effect of pedigree on the development of hypothyroidism, since accurate classification 
of pedigree status could not always be relied upon. The approach adopted for the purposes 
of this study, was to classify all those cases recorded as crossbreeds as “non-pedigree” and 
in the remaining animals, in which a single breed was recorded, as “pedigree”. This 
approach immediately introduces a degree of error into subsequent statistical analyses and 
artificially increased the apparent referral o f pedigree animals. However, the advantage of 
this approach was twofold. Firstly it increased the numbers of cases within each breed or 
breed-type category as discussed above, making the data more amenable to statistical 
analysis. Secondly, the use of categories in which a single breed was identified as the 
predominant, if not the sole breed, maintained the broad genetic makeup of the categories 
as pedigree-type or non-pedigree. Given the unavoidable limitations inherent within the 
hospital data recording system, as with breed type classification it was felt that the 
advantages associated with this solution outweighed the disadvantages.
In the present study there was no apparent effect of either sex or neutering status 
on the likelihood of being hypothyroid. This is similar to the results o f Peterson et al., 
(1997) but is in contrast to the findings o f Milne & Hayes, (1981); and Panciera, (1994). 
The loose diagnostic criteria employed by Milne & Hayes, (1981) for the confirmation of 
hypothyroidism casts doubt on their conclusions. However, like the present study, 
Panciera, (1994) also used TSH response testing to confirm hypothyroidism and the 
reasons for the discrepancy with that study is unclear. This variation may reflect a
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difference in the populations under study although both Panciera, (1994) and Peterson et 
al, (1997) investigated dogs in the United States of America (USA) with differing results. 
Irrespective of any influence that gender and neutering status may have on the development 
of hypothyroidism, it is clear that in the dog at least, both males and females whether 
sexually entire or neutered are frequently affected by hypothyroidism.
The results of this study confirmed that hypothyroid dogs are significantly older 
than the general hospital referral population. However, a more detailed analysis o f the 
distribution of dog ages within the referral population revealed a strongly bimodal pattern 
with a large number of young cases. This peak o f juvenile referrals is not surprising since 
many cases are referred for investigation or treatment of congenital or juvenile 
developmental conditions. This was confirmed by demonstrating a statistically significant 
variation in the age distribution o f dogs referred to the varying disciplines and is consistent 
with the nature of many of the diseases seen within each of these groups. This problem 
highlights one potential bias introduced by use o f a referral population as a control group. 
However, as already discussed, it is rare for published studies to take these effects into 
account (Milne & Hayes, 1981; Kaelin et al, 1986; Panciera, 1994). It is clear from the 
results of the present study that if not identified and eliminated, this type of influence may 
artificially create or inadvertently mask genuine biological phenomena.
The exclusion of this biologically distinct group of juvenile individuals from the 
referral controls confirmed that there was in fact no difference in age between hypothyroid 
dogs and those referred for other conditions. Similarly there was no difference in the age 
distribution of the hypothyroid and euthyroid dogs. Based on these results the age o f a dog 
is therefore not particularly useful in the investigation of hypothyroidism. However, the 
results do indicate that juvenile animals (less than two years of age) are rarely affected, and 
the diagnosis is equally likely any time between approximately four and 1 1  years o f age. 
Since no breeds or breed types were identified as being predisposed to hypothyroidism, 
stratification of either high-risk or low-risk breeds to compare the relative risk in varying 
age groups was not considered appropriate. Comparison of this feature with the report by 
Milne & Hayes, (1981) was therefore not possible.
The most commonly affected breed types in the present study were retrievers, 
spaniels, terriers, crossbreeds and dobermans. This is broadly similar to the most recent 
reports of the breed distribution of hypothyroid dogs, most o f whom confirmed 
hypothyroidism using reliable criteria (Panciera, 1994; Feldman & Nelson, 1996; Peterson 
et al, 1997). The results vary from those reported in earlier studies most o f which used
Chapter 5 150
more dubious criteria for case classification (Nesbitt et al, 1980; Milne & Hayes, 1981). 
However, there was no significant difference between the breed distribution of the 
hypothyroid cases with either the euthyroid or hospital control groups. The apparent over­
representation of breed types such as retrievers and spaniels may therefore simply reflect 
their popularity within the referral population.
There was a marked bias in the distribution of certain breeds in the referred 
population compared to their number in the external group, with collies, terriers, 
rottweilers and doberman pinschers being significantly over-represented in the hospital 
group. Again this is partly due to the nature of the referral population since a number of 
disciplines include diseases with marked apparent breed-predispositions which bias the 
control data. This further exemplifies the potential difficulties associated with using a 
referral population as a control group.
Whilst a true estimation o f the relative distribution of pedigree and non-pedigree 
dogs within the general population is difficult to establish with any degree o f accuracy, it 
certainly seems unlikely to be reflected by the individuals in this study. The number of 
pedigree dogs referred approached 90 % of all cases seen and this was responsible for the 
difficulties in further statistical analysis. However, even the PFMA estimated prevalence of 
60 % pedigree dogs in the general canine population may well be higher than the true 
figure. The results of this study suggest that pedigree dogs are genuinely more frequently 
referred than are non-pedigree dogs. However, the present study has certain fundamental 
limitations discussed above, and no well controlled studies have previously accurately 
investigated this subject. Nevertheless the present study has identified this as an area 
worthy of additional investigation.
There was no significant difference in the pedigree status of dogs in the 
hypothyroid, euthyroid and referral groups. However, the relatively large number of 
pedigree compared to crossbreed dogs in the control groups makes analysis o f this variable 
prone to statistical interference. In addition due to the variability in the quality o f data 
recording regarding the true pedigree status of the dogs in this study, the definition of 
pedigree used for this study is fairly loose as discussed previously. Consequently, these 
dogs may in fact be more accurately considered as “purebred-type” animals. The 
consequence of both the classification protocol used, and the marked asymmetry in 
numbers of “pedigree” and “non-pedigree” dogs ultimately made the evaluation of this 
factor on the development of hypothyroidism difficult to assess. The absence of any 
apparent breed predisposition may suggest that there is no strong pedigree effect on the
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development o f the disease but further studies are required. The subject of pedigree status 
on development of hypothyroidism is discussed in Chapter 7.
Metabolic signs were the most common clinical signs observed being reported in 85 
% o f cases. These included lethargy, obesity or weight gain, and exercise intolerance. 
These figures are similar to those reported by Kaelin et al, (1986) but suggest that 
metabolic abnormalities are in fact more prevalent than reported in most previous studies 
(Nesbitt et al, 1980; Panciera, 1994; Feldman & Nelson, 1996). Whilst the differences may 
reflect the varying populations studied, other explanations include the severity of disease 
which may influence the signs observed (Feldman & Nelson, 1996).
Dermatological abnormalities were also particularly common occurring in 79 % of 
cases. The most common of these were alopecia, poor coat quality, hyperpigmentation, and 
superficial pyoderma. These are similar to the findings of previous studies (Nesbitt et al, 
1980; Kaelin et al, 1986; Panciera, 1994). Of particular interest amongst the hypothyroid 
group was the high percentage with both metabolic and dermatological abnormalities (67 
%). This combination therefore proved to be a useful marker for the presence of the disease 
and based on these results their combined presence should certainly prompt further 
investigation of hypothyroidism.
Other clinical signs were considerably less common than either metabolic or 
dermatological abnormalities. Neurological signs occurred in three dogs but in two of them 
the relationship o f these signs to hypothyroidism was made more difficult to interpret by 
concurrent disease. In the third case, with facial nerve paralysis, a good clinical response 
occurred following appropriate thyroid hormone replacement therapy. A number of 
hypothyroid dogs had concurrent diseases which were not considered likely to be related to 
the thyroid disease. Musculoskeletal disease and neoplasia occasionally occurred but were 
considered coincidental.
The role of hypothyroidism in the three cases with dilated cardiomyopathy is 
interesting even if not entirely clear. From the study reported by Calvert et al, (1998) it 
seems clear that hypothyroid dogs are not more likely to develop dilated cardiomyopathy 
than euthyroid dogs. However, finding this abnormality in three of 52 affected cases was 
higher than expected. One explanation may be that the study of Calvert et al, (1998) 
evaluated only doberman pinschers, a breed known to be predisposed to cardiomyopathy. 
This population bias will potentially decrease any effect of thyroid disease as a causative 
factor. Additionally, the three affected dogs in the present study consisted o f a Labrador
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retriever, English springer spaniel and a Hungarian viszla and studies with a larger number 
of various breeds of dog would undoubtedly be of considerable value.
The presence of concurrent diabetes mellitus in 10 % of hypothyroid cases was of 
particular interest and suggestive of autoimmune polyglandular disease in these individuals 
(Graham, 1995; Feldman & Nelson, 1996; Dixon, 1998). The investigation of these cases 
in more detail is outlined in Chapter 7.
Much of the discussion relating to the selection of appropriate cases to use as 
control animals in the investigation of the epidemiological features o f disease, applies 
equally to the study of clinicopathological abnormalities. Traditionally the routine 
biochemical or haematological evaluation of diseased animals has assisted with the 
confirmation or exclusion of disease by comparison of the observed values with the 
reference distribution. This is the distribution of reference values obtained from a range of 
putatively “healthy” individuals, the reference sample group, who are considered to be 
representative of the entire reference population. However, the use o f clinicopathological 
tests in this way is complicated for a number of reasons.
“Normal” biological variation exists within the state of “normality” and this should 
be considered during selection of a reference sample group. Factors such as the breed, age, 
sex, reproductive state, dietary variation, state of nutrition, housing, season etc. may all 
potentially influence certain test results and should theoretically be taken into account. 
However, the practicalities o f accounting for all potentially influential variables can rapidly 
become prohibitive, with the financial and labour requirements often being the most 
constraining factors. Consequently as with clinical control groupings, a pragmatic approach 
to the selection of the reference sample group is generally employed. In fact, the reality is 
that many reference sample groups are composed of small numbers of animals, frequently 
o f a single breed housed in similar environmental conditions. Consequently the range of 
samples used for calculation of the reference limits is frequently very limited. An obvious 
example of this is the widespread use of beagles in veterinary research which are often the 
source of “normal” blood samples.
A second and more fundamental problem exists in relation to the use of 
conventional clinicopathological control groups. It is traditional to compare observed 
values with the reference limits derived from a supposedly normal reference sample group. 
Therefore by definition the identification of an “abnormal” value only in fact serves to 
distinguish diseased animals from healthy animals. However, the purpose of 
clinicopathological analysis is generally to support or refute a clinical suspicion or diagnosis
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and it is certainly rare that samples are analysed to differentiate “health” from “disease” 
per-se. This misuse of reference limits is either widely ignored or misunderstood. When 
trying to differentiate between particular diseases as is most often the case in practice, the 
most appropriate reference sample group is in fact those cases in which a particular disease 
is suspected but proven not to be present. These animals represent the cases which in 
practice must be segregated from patients with the disease in question.
Most practical problems arise when examining analytes which can be affected by 
multiple types of disease or pathological processes. For example increased circulating 
cholesterol concentrations are associated with a variety of disease states including diabetes 
mellitus, hypothyroidism, hyperadrenocorticism, hepatic disease, and hypoalbuminaemia. 
The specificity of hypercholesterolaemia for any one of these diseases, some of which are 
clinically very similar, is correspondingly poor.
When compared with the laboratory reference ranges, the abnormalities obtained 
from the hypothyroid dogs gave results broadly in keeping with previous studies. 
Cholesterol was elevated in 78 % of the hypothyroid dogs tested which is similar to the 
studies by Kaelin et al., (1986); Peterson & Ferguson, (1989); and Panciera, (1994). 
Circulating fructosamine concentration was increased in 43 % of the hypothyroid group 
which is a previously unreported finding in dogs. This abnormality is recognised in human 
hypothyroid patients whilst hyperthyroid humans typically have subnormal fructosamine 
concentrations (Ford, Lim & Crooke, 1987; Waterson & Mills, 1988; Sako, Umeda, 
Hashimoto, Haji & Nawata, 1989). The abnormalities in both situations are attributed to a 
change in rate of protein turnover rather than any effect on glycaemic control itself. The 
diagnostic specificity o f fructosamine for hypothyroidism (0.82), following the exclusion of 
dogs with known diabetes mellitus, was surpassed only by the RBC count (0.85). Based on 
the results o f this study, and given the relative ease with which diabetes mellitus can usually 
be excluded, the addition of fructosamine estimation as a screening test when investigating 
suspect hypothyroidism is likely to be of at least as much value as the other routine 
biochemical and haematological analytes currently available. Creatine kinase was increased 
in 35 % of affected dogs which is slightly more than 10 % reported by Jaggy et al, (1994) 
and 18 % reported by Panciera, (1994). However, in the present study, the same 
percentage o f euthyroid dogs had increased CK concentrations and the analyte was 
therefore o f no predictive value. Forty percent of the hypothyroid dogs were anaemic 
which is similar to previous reports (Kaelin et al., 1986; Panciera, 1994; Feldman & 
Nelson, 1996). Although the RBC count was also depressed in 15 % o f the euthyroid
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group, this analyte followed closely by fructosamine and cholesterol was overall the most 
efficient routine parameter at separating hypothyroidism from clinically similar non- 
thyroidal illness.
It is clear from the results presented that a substantial number o f euthyroid dogs 
with various non-thyroida! illnesses had routine biochemical and haematological parameters 
well outwith typical laboratory reference limits. This included many of the analytes 
traditionally associated with abnormal values in hypothyroidism including cholesterol, CK, 
and RBC count. The effect o f this was that the specificity of some of these measurements 
for predicting the presence o f hypothyroidism was particularly poor. The reference 
distribution generated from the euthyroid group results was correspondingly wide. 
Comparison o f the hypotfiiyroid results with the reference limits derived from these data 
served to clearly illustrate the very poor specificity of most routine parameters for 
hypothyroidism. This feature of the present study emphasises the errors that are widely 
ignored in the compariso n of results with so-called “normal” populations in which the 
control samples are collected from healthy patients. It is clear from the present study that 
such comparisons do no t produce a true reflection of the predictive value of these 
parameters for hypothyroidism and the same is likely to be true for most diseases.
The use o f the euthyroid group reference limits, allowed the identification of routine 
parameters which were significantly different between those dogs with hypothyroidism, and 
those cases with clinically similar illnesses. Although the results presented confirm a large 
number o f variables are statistically different between the groups, only those analytes with 
values outwith the reference limits are likely to be o f diagnostic use in practice. Using this 
novel approach, elevatioms in cholesterol and y-GT, and decreases in RBC count, 
haemoglobin and neutropM count were the most common abnormalities associated with 
hypothyroidism. Although the control data needed to generate these results is clearly 
demanding in terms of clinical material, accurate case classification, and time requirements 
including statistical analysis, their improved diagnostic specificity is highly desirable. The 
future use o f this type o f control data should be encouraged from both academic 
institutions and commerciail diagnostic laboratories.
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CHAPTER 6
TREATMENT AND THERAPEUTIC MONITORING OF HYPOTHYROIDISM
6.1 LITERATURE REVIEW 
Treatment of Hypothyroidism
Indications and Contraindications
The principal indication for THRT in dogs is the treatment of spontaneous hypothyroidism. 
There are few indications for bilateral thyroidectomy in the dog and therefore little is 
known about the requirement for THRT after such a procedure. It may be that as in the cat, 
where bilateral thyroidectomies are frequently indicated for the treatment of 
hyperthyroidism, accessory thyroid tissue may be activated, thereby obviating the need for 
THRT (Swalec & Birchard, 1990). However, cTSH may have growth stimulatory 
properties on thyroid tumours and therefore could play a role in subsequent recurrence 
(Verschueren, Rutteman, Vos, van Dijk & de Bruin, 1992). Therefore, THRT has been 
recommended following surgical removal of thyroid carcinomas in dogs, even when 
unilateral, on the basis that such therapy inhibits production of cTSH. THRT has also been 
recommended following transphenoidal hypophysectomy, a technique investigated for the 
treatment of pituitary dependent hyperadrenocorticism in dogs (Meij, Mol, van den Ingh, 
Bevers, Hazewinkel & Rijnberk, 1997).
The role of THRT in NTI has been studied in dogs as well as humans. Brent & 
Hershman, (1986) evaluated the effect of intravenous T4 replacement therapy on mortality 
in 11 of 23 hospitalised human patients with severe NTI and subnormal circulating total T4 
concentration. Prognosis was not altered by therapy, and mortality was similar in both the 
treated (73 %) and untreated (75 %) patients. DAlecy, (1997) evaluated the effect of 
intensive THRT immediately following controlled experimental cardiac arrest in dogs. A 
neural protective effect was demonstrated in those dogs receiving the THRT compared to 
control cases. The author concluded that thyroid hormone-mediated improvement in 
systemic oxygen consumption and tissue delivery may have contributed to the protective 
effect. However, whilst intensive THRT regimes such as these have been shown to be 
beneficial in experimental situations, there remains little evidence to support the use of 
THRT to “treat” the subnormal thyroid hormones encountered in the more typical NTI 
encountered in veterinary practice (Panciera, 1997a). The reduced peripheral conversion of 
T4 to T3, and the reduced secretion of TSH documented in NTI likely serve to reduce
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metabolic demand, particularly catabolic activity. Over-riding this protective mechanism is 
probably unwise.
Physiological Considerations
A review of normal thyroid gland and thyroid hormone physiology and metabolism is 
provided in Chapter 4 and those comments remain relevant to a discussion on therapy for 
hypothyroidism.
Ideally, the goal of treatment in the hypothyroid patient is to mimic the secretory 
pattern of the healthy thyroid gland thereby restoring the patient to a state of physiological 
normality. However, the only practical method for implementing chronic THRT in dogs is 
by oral administration of thyroid hormone preparations. Such “bolus” type dosing is thus a 
relatively crude alternative when compared with the normal pulsatile secretion of the 
thyroid hormones (Kemppainen & Sartin, 1984). Therefore, achieving a state of 
physiological normality is an impractical objective. A more reasonable goal is the 
elimination o f routine clinicopathological and clinical abnormalities associated with the 
disease, thereby restoring the animal back to “clinical” health.
As discussed in Chapter 4, thyroid hormones circulate largely bound to plasma 
proteins. However it is the free hormone which is the metabolically active fraction available 
for entry into cells. The protein bound moiety serves to distribute the hormone throughout 
the circulation and being in dynamic equilibrium with the free moiety, acts as a reservoir of 
hormone. This applies in both healthy dogs and those receiving THRT, and provides a 
buffering mechanism which protects against rapid increases or decreases in free thyroid 
hormone concentrations. Certain organs, especially the liver and the kidneys can also store 
and rapidly exchange large quantities o f thyroid hormones with the circulation. This 
provides additional buffering capacity (Ferguson, 1986). These normal physiological 
mechanisms fortuitously assist in delivering a relatively even supply o f free thyroid 
hormones and therefore help reduce the “peak and trough” characteristics of THRT.
As previously discussed, circulating free T4 constitutes approximately 0.1 % of the 
total T4 concentration in dogs, whereas approximately 1 % of total T3 circulates unbound. 
Free T3 therefore has an increased volume of distribution compared to T4 which is more 
tightly contained within the circulation. This promotes a faster exit of T3 from the vascular 
compartment into the peripheral tissues and as a consequence T3 is metabolised more 
rapidly. The half life of T3 in dogs (five to six hours) is correspondingly shorter than T4 (10
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to 16 hours). The biological activity o f T3 is considerably greater on a per-molar basis than 
that of T 4 .  Whilst this may imply that therapy for hypothyroidism would be more efficiently 
achieved by the administration of T3, the shorter half life requires that this form o f therapy 
be administered more frequently. In addition, the potential for thyrotoxicosis due to 
overdosage is greater with T3 -containing products (Panciera, 1997a). Also, most 
circulating T3 in dogs normally originates from peripheral deiodination of T4. This step 
allows maintenance of both normal total and free T4 and T3 concentrations in the healthy 
individual assuming an adequate supply of T4. However, administration of exogenous T3 
circumvents this enzymatic step which usually functions normally in hypothyroid dogs. The 
use of T4-containing preparations is therefore preferable to those containing only T3 when 
instituting THRT (Refsal & Nachreiner, 1997b; Panciera, 1990b).
The modes of action of the thyroid hormones has been reviewed in Chapter 4. 
Broadly speaking, the metabolic activity of free T3 and free T4 results from combination of 
hormone with cell membrane and nuclear receptors. The molecular effect usually results 
from gene transformation or protein synthesis and therefore the overt clinical responses to 
thyroid hormone supplementation are diverse, including tissue growth, maturation and 
repair. Consequently, there is a lag phase between thyroid hormone induced molecular 
changes which effectively occur instantaneously, and the occurrence of clinical changes 
which may take place over weeks or months.
Determinants of Clinical Efficacy of Therapy for Hypothyroidism
The ultimate determinants of the efficacy o f THRT depend upon drug administration and 
absorption characteristics, and peripheral and cellular hormone metabolism. It is estimated 
that the total daily secretion o f T4 in the dog is approximately 0.0194 nmol/kg (Ferguson, 
1986). However when Hulter, Gustafson, Bonner, Toto & Mackie, (1984) administered 
this dose of hormone intravenously or subcutaneously to thyroparathyroidectomised dogs, 
the circulating hormone concentrations remained severely depressed. In fact it was not until 
doses four times greater were administered that normal blood concentrations were 
achieved. No definitive explanation for this finding was provided by the authors but 
possible causes include an effect o f hypothyroidism or hypoparathyroidism on serum 
binding capacity for thyroid hormones, local hormone degradation at the site of 
administration or erroneous estimation of the true thyroid hormone production rate in 
healthy dogs. Irrespective o f the mechanism, if normalisation of circulating thyroid 
hormone concentrations is a requirement when treating canine hypothyroidism, greater
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doses of hormone supplement are required than suggested by the daily production rates in 
healthy dogs.
An additional variable to be considered after oral administration of hormone, is the 
effect of gastrointestinal absorption. In humans, approximately 50-80 % of T4 and nearly 
100 % of T3 is absorbed following oral administration. However, variation occurs as a 
result of variable intraluminal contents such as plasma proteins, intestinal bacterial load and 
other dietary components. These may bind free hormones and therefore inhibit their 
absorption. In the dog, it is estimated that only between 10 % and 50 % of orally 
administered T4 is absorbed from the intestinal tract therefore increasing the required 
therapeutic dose when given by this route (Ferguson, 1986). Further increases are likely to 
be required in dogs with concurrent small intestinal malabsorption diseases (Panciera, 
1997c).
As previously discussed, peripheral conversion of T4 to T3 is responsible for 
production of most of the circulating T3 in dogs. This process is equally important in 
hypothyroid dogs being supplemented with exogenous T4. In humans, the conversion 
process is impaired in most chronic disease states, including starvation, diabetes, hepatic 
and renal diseases. A number of dogs in which inhibition of peripheral deiodination of T4 to 
T3 is suspected have been reported. However, although rarely recognised in humans 
(Kleinhaus, Faber, Kahana, Schneer & Scheinfeld, 1988), this is yet to be documented as a 
spontaneous abnormality in dogs, and is usually due to the presence of concurrent illness or 
drug therapy (Ferguson, 1986; Panciera, 1990b). It has been suggested that hypothyroid 
dogs with concurrent illnesses or those receiving certain medications may therefore require 
greater doses of T4 supplementation to achieve an optimal clinical response (Ferguson, 
1986) but this remains to be proven. Given the “protective” reduction in thyroid hormone 
concentrations associated with NTI in dogs, it seems unlikely that any change in dosing 
strategy to maintain the relative concentrations o f T3 and T4 is required in these cases. The 
mechanisms by which NTI and drug therapy can interfere with thyroid metabolism are 
reviewed in Chapter 8 .
Ultimately, the pivotal determinant o f the clinical effect of THRT is the molecular 
and cellular action of the hormones. As indicated above, the production of proteins, and 
maturation and growth o f body tissues has clinical utility long after the thyroid hormones 
integral to their development have been metabolised and eliminated. The biological half 
lives of the hormones are therefore considerably longer than the corresponding circulating 
half lives.
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Therapeutic Regimes 
Choice o f Product
Worldwide, a number of products for THRT are available. These can be divided into crude 
thyroid products, and synthetic preparations. The crude products are derived from 
desiccated porcine, ovine, or bovine thyroid glands. The thyroid hormone content in these 
products is more variable between preparations and between batches compared with 
synthetic hormone products (Rosychuk, 1982). Bioavailability is therefore not only greater 
but also more consistent for synthetic compared to crude preparations. The crude product 
shelf life is also shorter than that o f the synthetic drugs. Within the UK, there are no 
licensed crude thyroid hormone products currently available for THRT in dogs and 
synthetic T4 is the product of choice for almost all cases of canine hypothyroidism 
(Ferguson, 1986). The remainder of this review will therefore deal only with synthetic 
products which offer greater stability and standardisation o f potency (Rosychuk, 1982). 
Various synthetic THRT preparations exist, consisting of T4, T3, or in some cases a 
combination o f both hormones.
A number of synthetic T3 products for THRT are available outside the UK. 
However, there are few indications for these products. As already stated, T3 administration 
circumvents the normal physiologic process of T4 deiodination to T3. Consequently whilst 
circulating total and free T3 concentrations may be within the therapeutic range after T3 
administration, total and free T4 concentrations remain subnormal. The variable T3 and T4 
requirement o f various tissues also makes T3 administration less desirable. Administration 
of purely T3-containing products may result in adequate concentrations in organs such as 
the liver, kidneys and heart which derive their T3 from the circulation. However, the 
principal source of intra-pituitary free T3 is deiodination o f free T4 within the pituitary gland 
by type II 5'-D. Therefore, the brain and pituitary gland may be deficient in free T3 if 
circulating concentrations of free T4 are subnormal. Conversely, it has been suggested that 
administration of sufficient T3 to provide adequate brain and pituitary concentrations may 
result in excessive concentrations in other organs (Ferguson, 1986). In addition, since the 
half life of T3 is much shorter than that of T4 more frequent dosing is required if circulating 
concentrations are to be maintained. One of the uncommon situations in which T3 THRT 
may be of use, is in cases with small intestinal malabsorptive diseases. In these cases, the 
improved absorption characteristics of T3 compared to T4 has been suggested to be 
beneficial (Panciera, 1990b) but this remains to be proven.
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Various commercial products containing a combination of T4 and T3 are available 
for use in THRT. The objective of the combined products is to mimic normal thyroidal 
secretion. However, most preparations contain a lower T4 to T3 ratio that that which is 
normally secreted in dogs (Laurberg, 1977). Administration of these products at the 
standard dose tends to result in low or low-normal circulating total T4 concentrations in 
dogs. However, using an increased dose to normalise total T4 usually results in excessive 
total T3 concentrations, potentially capable of producing thyrotoxicosis (Ferguson, 1986).
The only licensed product in the UK for THRT in dogs is Levothyroxine Sodium, 
(Soloxine, Daniels Pharmaceuticals). This is a chemically derived compound which is 
identical to naturally occurring L-T4. This product is the treatment of choice for several 
reasons. First, L-thyroxine is the principal secretory product of the thyroid gland and is the 
physiologic “pro-hormone” for the more potent T3. Since re-establishment of normal 
circulating T4 and T3 concentrations is desirable, this is best achieved by administration of 
T4. Pituitary synthesis and secretion of TSH is most effectively regulated by free T4 
concentrations. The improved standardisation and potency o f the synthetic T4 product 
compared with crude products is also preferable and reduces the risk of between-batch 
variability.
Choice o f Dosing Regime
Whilst it is widely accepted to be the product of choice for treating hypothyroidism in dogs 
and humans, the dosing schedule for synthetic T4 in dogs remains controversial. Since 
therapy is invariably lifelong, the identification o f the optimal therapeutic and economic 
regime for an individual is important. In addition, a regime must be practical to implement 
chronically to ensure optimal owner compliance.
Kemppainen & Sartin, (1984) evaluated circulating total T4 concentration every 20 
minutes for 25 hours in nine normal beagle dogs exposed to continuous 12 hour light/dark 
cycles. The study confirmed episodic but not circadian release of T4. Mean (± s.d.) total T4 
concentration was 17.8 (± 4.4) nmol/L with 3.3 (± 2.9) peaks per day. Consequently, there 
are no recommendations on the time o f day most suitable for THRT which is likely to be of 
no importance as long as it remains reasonably consistent between days.
Most T4 product supplementation protocols reported in the literature suggest using 
a total daily dose ranging from 0.02-0.04 mg/kg body weight. However recommendations 
have included giving this total dose either once, or divided twice or three times daily 
(Halliwell, 1979; Martin & Capen, 1979; Rosychuk, 1982). Alternative dosing schedules
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have recommended dosing based on body surface area (0.5 mg/m2 per day) (Chastain, 
1982). The use of divided dose BID therapy results in less fluctuation of circulating T4 
concentrations compared to administration of the same total dose as a single daily bolus 
(Nachreiner & Refsal, 1992; Nachreiner et al., 1993). However, as discussed above, the 
biologic action of the thyroid hormones exceeds that o f the plasma half life making once 
daily therapy successful in most cases (Rosychuk, 1982; Ferguson, 1986; Panciera, 1997c). 
Whilst acknowledging this fact several authors do nevertheless recommend twice daily 
dosing schedules to maximise the therapeutic response, with some subsequently reducing 
the dose to once daily if the response is favourable (Stogdale, 1980; Panciera 1990b; 
1997c).
Nachriner & Refsal, (1992) evaluated thyroid hormone results from 2674 dogs 
receiving THRT. In that study an increase in dose of greater than two fold caused a mean 
increase in peak total T4 concentration of 59 %. The authors suggested that this may have 
resulted from less efficient absorption at the higher doses, saturation of binding proteins or 
dose dependent kinetics.
The dose requirement to achieve “therapeutic” blood hormone concentrations was 
investigated by Nachreiner et al., (1993) who determined the pharmacokinetics of T4 
administered to thyroidectomised dogs. Doses varying from 0.011-0.044 mg/kg given once 
or twice daily were examined. Not surprisingly, peak circulating total T4 concentrations 
were greater at the larger doses. In addition, the larger daily doses were also associated 
with a decrease in biologic half life of the hormone, supporting the concept of dose- 
dependent kinetics. Broadly speaking doubling the dose of T4 administered tended to 
increase the peak circulating total T4 concentration by approximately 60 %, supporting the 
results of the earlier study by Nachreiner & Refsal, (1992). Marked inter-individual 
variation in hormone pharmacokinetics was reported, which was generally consistent within 
dogs at each of the dosing regimens. Thus some individuals required higher doses or 
frequency o f therapy to achieve similar blood total T4 concentrations than did others. 
Therapy may therefore have to be highly individualised and tailored to the requirements of 
the individual dog.
Complications o f Treatment
Most complications following the institution of THRT in hypothyroid dogs result from 
either inadequate or excessive dosage. Suboptimal dosing will simply result in either an
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inadequate improvement, or no improvement at all. Biochemical confirmation of this can be 
easily achieved using the normal monitoring strategy described below. Although excessive 
THRT may result in signs of hyperthyroidism, dogs, unlike humans, are largely resistant to 
the effects of over-supplementation and only occasionally develop clinical signs of 
thyrotoxicosis (Kaptein et ah, 1994). This is probably due to the rapid metabolism of 
thyroid hormones in dogs, particularly biliary and faecal excretion. In addition, the 
considerable reserve binding capacity o f the thyroid hormone binding proteins, is capable of 
compensating for marked increases in total thyroid hormone concentration without serious 
alterations in free hormone values (Larsson et al., 1985). Since it is the free hormone that is 
most metabolically relevant, this further improves the dog’s resistance to iatrogenic 
hyperthyroidism. Iatrogenic thyrotoxicosis is more likely when T3 products are employed 
(Rosychuk, 1982; Panciera, 1997a) since the active hormone is faster acting and more 
metabolically potent than T4.
Whilst some studies have required the use of up to 20 times the standard dose of 
THRT to induce clinical thyrotoxicosis in dogs (Piatnek & Olson, 1961), it is apparent that 
there is considerable inter-individual variation in susceptibility to thyrotoxicosis (Belshaw & 
Rijnberk, 1979; Panciera, 1990b). However, the reason for this remains unclear. The 
clinical signs o f exogenous thyrotoxicosis include polydipsia, polyuria, polyphagia, panting, 
weight loss, tachycardia and pyrexia. A diagnosis can be confirmed by demonstration of 
grossly elevated circulating thyroid hormone concentrations, and signs should resolve 
within several days of stopping therapy (Jeffers, 1990).
Gradual introduction of THRT has been recommended in dogs with decreased 
ability to metabolise T4 and increased risk of thyrotoxicosis such as hypoadrenocorticoid, 
aged, cardiac and diabetic patients. A divided dose protocol, starting with 25 % of the 
normal dose, increasing by 25 % increments every fortnight until optimal stabilisation is 
achieved is widely cited within the literature (Ferguson, 1986; Jeffers, 1990; Panciera, 
1990b). However, these guidelines are largely empirical and whilst there is general 
agreement that care is needed in treating cases with concurrent hypothyroidism and 
hypoadrenocorticism (Rosychuk, 1982; Bowen, Schaer & Riley, 1986; Ferguson, 1986) 
there is relatively little evidence of problems associated with THRT in the presence of most 
other concurrent diseases in dogs (Rosychuk, 1982).
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Therapeutic Monitoring
The evaluation of the success or failure of therapy in patients receiving THRT should be 
primarily a clinical judgment. Resolution of certain clinical signs such as mental dullness 
and lethargy may occur within as little as seven days after commencing therapy (Panciera, 
1994), although others such as dermatological abnormalities may take up to five months to 
improve (Rosychuk, 1982; Ferguson, 1986). As normal follicle turnover is re-established 
after commencing THRT, there is frequently an increased shedding of hair prior to obvious 
regrowth. Consequently, worsening of the alopecia is not an uncommon finding in the 
initial stages of therapy (Rosychuk, 1982). There is also variation in the extent of clinical 
improvement reported with THRT depending on the system involved. Whilst metabolic and 
dermatological abnormalities improve very markedly, others including neurological 
abnormalities, megaoesophagus and laryngeal paralysis show a much poorer response to 
therapy (Panciera, 1994). This may be partly related to the dubious relationship of 
hypothyroidism in the aetiology o f these abnormalities as discussed in Chapter 5, as well as 
a genuine differences in response between the various body systems. Rosychuk, (1982) 
suggested that weight loss occurs within the first four to six weeks, but is not completed 
for several months after starting THRT. Panciera, (1994) reported weight loss in the 
majority of 34 treated hypothyroid dogs with follow up information within eight weeks of 
starting THRT.
Clearly a valid evaluation of the response to THRT, particularly in a case with a 
suboptimal clinical response, can only be made if therapeutic circulating hormone 
concentrations are known, and therefore post-pill monitoring samples should be part of the 
monitoring process. It has been suggested that a “steady-state” condition is not achieved 
and therefore this initial monitoring should not be performed until approximately four to 
eight weeks after starting THRT, or after changing the dosing regime, in both humans and 
dogs (Rosychuk, 1982; Ferguson, 1986; Panciera, 1990b; Brent & Larsen, 1996; Refsal & 
Nachreiner, 1997b).
Nachreiner & Refsal, (1992) evaluated total and free iodothyronine concentrations 
in 2674 blood samples from dogs receiving THRT following removal of those cases with 
T3Ab or T4Ab. Whilst the study was laboratory based and evaluation of clinical response 
was not performed, the high number o f samples analysed helped to compensate for this. 
Peak circulating concentrations of each of the four iodothyronine fractions occurred 4.1 to 
six hours after oral hormone administration irrespective of once versus twice daily 
therapeutic schedules. The peak concentrations were generally higher in dogs which
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received once daily therapy compared to those in which the total daily dose was split. Dogs 
receiving a veterinary synthetic L-T4 preparation had significantly greater circulating total 
and free T4 concentrations compared with a commonly used human L-T4 preparation, and 
various other generic preparations as a group. The authors suggested that the most likely 
explanation for this was variation in the thyroxine content between preparations. For 
equivalent doses, generic products typically resulted in peak thyroid hormone 
concentrations approximately 10 to 15 % lower than the proprietary products. Larger dogs 
tended to have lower therapeutic hormone concentrations for a given dose compared to 
smaller dogs. No definite explanation was provided for this finding, although Reimers et 
al., (1990) demonstrated decreased naturally occurring thyroid hormone concentrations in 
large breed dogs compared with smaller breeds, and a normal physiological difference 
between breeds may therefore also be important in treated cases. There was marked inter­
dog variation in the dose of thyroid hormone supplement required to achieve therapeutic 
hormone concentrations. Therefore failure to adequately respond to THRT may be the 
result o f inadequate dosing for that individual, and confirmation of this requires appropriate 
blood hormone measurements.
In humans receiving THRT, objective therapeutic monitoring is principally achieved 
by circulating TSH estimation. Return of circulating TSH concentration to the reference 
range is generally associated with good clinical control. Human TSH assays are capable of 
differentiating “normal” results from the subnormal values typical of over supplementation 
(Brent & Larsen, 1996). However, the currently available commercial cTSH assays are 
unable to differentiate normal from subnormal values, therefore reducing the utility o f this 
measurement for therapeutic monitoring in dogs (Refsal & Nachreiner, 1997b). The precise 
serum thyroid hormone profile associated with good clinical response has not been 
identified in dogs with spontaneous hypothyroidism (Refsal & Nachreiner, 1997b). 
However, in one report, treatment o f experimentally induced hypothyroidism in beagles 
was accomplished with a mean dose o f 0.034 mg/kg/day (Hesch and Koehrle, 1986). It has 
been suggested that peak concentrations in the normal to high-normal range, are a 
reasonable objective (Ferguson, 1986; Panciera, 1990b). Refsal & Nachreiner, (1997b) 
suggested that elevated peak circulating concentrations may be a desirable objective end­
point of therapy. No “maximum” hormone concentration whereby thyrotoxicosis is 
probable in dogs has been identified in clinical studies, although experimental studies using 
massive doses have certainly achieved this (Piatnek & Olson, 1961). The absence of this 
clinical data may partly reflect the capacity of dogs to compensate for over-
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supplementation of THRT at most commonly used dosing regimes. In dogs with increased 
peak total T4 concentrations, total T3 results tend to be within the reference range 
indicating physiological adaptation to avoid thyrotoxicosis (Nachreiner & Refsal, 1992). 
Pre-pill “trough” concentration measurement has also been advocated as a possible 
monitoring tool (Feldman & Nelson, 1996), and Ferguson, (1986) suggested that given the 
dog’s resistance to the development of thyrotoxicosis, nadir thyroid hormone 
concentrations in the “normal” range may be desirable.
The return of routine clinicopathological parameters to within the appropriate 
reference limits can be used to support the interpretation of an individual’s clinical response 
and circulating thyroid hormone concentrations during therapeutic monitoring (Feldman & 
Nelson, 1996). However whilst Feldman & Nelson, (1996) suggested that improvements in 
routine clinical pathology occur within two to four weeks of starting THRT in dogs, very 
little data have been published.
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6.2 INTRODUCTION
Many protocols for the treatment and therapeutic monitoring of canine hypothyroidism 
have been advocated. However, whilst general guidelines are provided in the veterinary 
literature, there is very little objective information with which to correlate the clinical and 
clinicopathological response to therapy in dogs. In particular, being a fairly novel test, there 
is limited information with which to evaluate the role of cTSH estimation in therapeutic 
monitoring. In addition, the most appropriate time after starting THRT before monitoring 
should be performed is unclear. Similarly there is a dearth o f data concerning the detail of 
clinicopathological changes in hypothyroid dogs following the start of THRT. The 
objectives of this study were to evaluate the clinical response to therapy using a commonly 
used dosing schedule, and investigate in detail the endocrine and routine clinicopathological 
changes which occur during THRT in a group of dogs with reliably confirmed 
hypothyroidism.
6.3 MATERIALS AND METHODS 
Case Material and Data Manipulation
Data from the 52 hypothyroid dogs discussed in previous chapters were initially considered 
for inclusion in the study. The clinical and clinicopathological parameters detailed in 
Chapter 2 were recorded for each case at each monitoring check. The data were grouped 
primarily according to case number and secondarily according to length of time on THRT. 
Duration of THRT was divided into four time frames, or ‘Visits”. This was performed to 
allow analysis of any change in clinical and clinicopathological parameters with increasing 
duration of THRT. The temporal criteria used to determine visits were chosen to provide a 
reasonable spread o f times applicable in practice, with similar numbers of cases in each 
category. These data are summarised in Table 11.
In individual dogs that were seen on multiple occasions within an individual “visit” 
time period, the monitoring check with most recorded data was used and the other was 
excluded from the analyses. This prevented data from individuals biasing the mean results 
of that “visit” as a whole. The data recorded for each dog-visit are detailed in Appendix 4. 
Only cases with complete pre-treatment data and data from at least one follow up 
examination were included. To be included, data must have been recorded for duration of 
THRT, comments on clinical response, and circulating total T4 and cTSH concentrations 
(collected six hours after tablet administration in those dogs receiving therapy). If any of
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these data were missing, the dog-visit was automatically excluded. The great majority of 
dog-visits which were included also had results of body weight measurement, routine 
biochemistry and haematology analyses.
Visit Duration of THRT (days)
1 Pre-treatment
2 9-28
3 29-70
4 71-112
Table 11. Temporal criteria used to define each of the “visit” periods into four distinct 
groups based on the length of time on thyroid hormone replacement therapy (THRT).
As a result o f the strict criteria used for inclusion, 21 cases were excluded because 
there were insufficient repeated analyses with adequate data following the start of THRT. 
These typically occurred due to owners’ financial restraints or more commonly failure to 
regularly return for follow up examinations. The approximate follow up times requested of 
owners at the outset of the study were two, six and 12 weeks after the start o f THRT. 
These periods were subsequently modified in individual cases as appropriate depending on 
factors such as response to therapy or the development of concurrent problems. Body 
weight data were calculated and analysed as percentages of the animals pre-treatment 
weight. This was performed to eliminate the biasing effect that would be exerted by 
particularly large or small dogs in subsequent analyses, since not all dogs had body weight 
data for every visit.
Treatment Protocol
All dogs were started on synthetic T4 replacement therapy as described in Chapter 2. 
Thyroid hormone doses approximating 0.02 mg/kg given once daily were used initially and 
subsequently modified as clinically required.
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Therapeutic Monitoring
Samples were collected for total T4 , cTSH and routine biochemical and haematological 
profiles six hours after T4 administration. Sample handing and analyses were performed as 
described in Chapter 2. A full clinical examination was performed at each visit and changes 
in clinical signs including body weight were recorded as described in Chapter 2.
Statistical Analysis
Data were sorted and stored as described in Chapter 2. The effect o f time period on 
clinicopathological parameters was evaluated using a general linear model analysis of 
variance with post hoc pairwise comparison of means performed by Newman-Keuls 
multiple range testing. All statistical computations were performed using MINITAB 9.2 for 
Windows (Minitab Inc.). Clinicopathological results were categorised into those from cases 
who needed an increase in THRT dosage at any point during the study and those in which 
the dosage was not changed. Comparison of the clinicopathological parameters at visit two 
between these two groups was performed using a Mann-Whitney U test.
6.4 RESULTS
The number of dog-visits included in each visit group, and the associated temporal data are 
detailed in Table 12. The mean results of all endocrine analyses categorised by visit are 
detailed in Table 13. Median total T4 concentrations were 4.7, 52.0, 46.7 and 52.3 nmol/L 
at visits one to four, respectively. The total T4 results had a relatively gaussian distribution 
when plotted and manually inspected. This was supported by similar mean and median 
results. However, examination of the cTSH results revealed a considerable bias in 
distribution with median results o f 0.03, 0.03 and 0.02 ng/ml at visits two, three and four, 
respectively. A small number o f cases with particularly increased results were responsible 
for this effect. Circulating cTSH results were above the reference range in 26 o f 31 (83.9 
%), two of 26 (7.7 %), one of 25 (4 %) and one of 22 (4.5 %) cases at visits one, two, 
three and four, respectively. Clinical and endocrine results from each dog at each visit are 
detailed in Appendix 33.
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Dogs with 
complete data mean
Days on treatment 
s.d. min max
Visit 1 31 NA NA NA NA
Visit 2 26 17.77 4.85 9 28
Visit 3 25 49.36 10.89 29 69
Visit 4 2 2 95.91 11.25 77 1 1 2
Table 12. Summary figures of the number of dogs included in each visit period, and the 
corresponding group temporal data for duration of thyroid hormone replacement therapy. 
NA Not Applicable
Mean ± s.d. (range) Mean ± s.d. (range)
total T4 (nmol/L) cTSH (ng/ml)
Visit 1 (pre treatment) 7.0 ±3.9 (4.7-17.8)2,3,4 2.51 ±2.68 (0.01-12.3)2,3,4
Visit 2 54.7 ±24.8 (8.3-100.5)1 0.17 ±0.35 (0.01-1.65)'
Visit 3 51.8 ± 18.2 (26.8-103.5)' 0.16 ±0.33 (0.01-1.62)'
Visit 4 56.5 ±22.9 (12.6-116.5)' 0.12 ±0.23 (0.01-1.00)'
Table 13. Total T4 and cTSH concentrations obtained from dogs receiving thyroid 
hormone replacement therapy categorised by visit. All samples from were collected six 
hours after T4 administration.
1 significantly different from visit one 2 significantly different from visit two
3 significantly different from visit three 4 significantly different from visit four
The dosing adjustments and mean dose concentrations (per kg body weight) 
grouped by visit period are summarised in Table 14. Of the 31 dogs on treatment, dose
adjustments were required in 15 o f them at some point during the course of therapy. The
dose of THRT was increased in 11 dogs (five dogs at visit two, four dogs at visit three and 
two dogs at visit four) and decreased in four dogs (three dogs at visit three and one dog at 
visit four) as outlined in Table 14. The mean dose of T4 administered to all dogs was 
0.0200, 0.0210, 0.0248 and 0.0284 mg/kg body weight at visits one, two, three and four, 
respectively. The cases in which a dose change was required are detailed in Table 15. The 
mean dose of T4 administered to the dogs which did not require a change in dose at any
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time during the study was 0.0201, 0.0213, 0.0211 and 0.0227 mg/kg body weight at visits 
one, two, three and four, respectively. In one dog with chronic diarrhoea, an unusually 
large dose of T4 replacement therapy was required (0.076 mg/kg) to obtain an adequate 
clinical response and adequate six hour post-pill total T4 concentration. Twice daily therapy 
was not considered necessary in any o f the 31 dogs.
Visit 1 Visit 2 Visit 3 Visit 4
Mean dose of therapy (mg/kg) 0 . 0 2 0 0 0 . 0 2 1 0 0.0248 0.0284
Dogs needing increased dose NA 5 4 2
Dogs needing decreases dose NA 0 3 1
Table 14. Dosing schedules and number of cases requiring a change in dose of therapy at 
each visit out o f 31 hypothyroid dogs receiving thyroid hormone replacement therapy.
Dog
Number
Hospital
Number
Visit Total T4 
(nmol/L)
cTSH
(ng/ml)
Direction of 
adjustment
Dose change
(mg)
2 131136 3 38.4 0.03 Increase 0.5 to 0.8
3 131132 2 13.3 1.65 Increase 0.2 to 0.3
4 131486 3 26.8 0.54 Increase 0.15 to 0.3
5 129827 3 43.5 0 . 0 1 Decrease 0.5 to 0.3
6 133137 4 23.0 4.00 Increase 0.5 to 0.7
1 0 132396 3 103.5 0 . 0 1 Decrease 0.6 to 0.5
1 1 122647 2 42.3 0.14 Increase 0 . 6  to 0 . 8
13 130375 3 49.2 0.39 Decrease 0.3 to 0.15
14 134156 4 31.4 0.15 Increase 0.5 to 0.8
2 1 127111 4 95.9 0.19 Decrease 0.7 to 0.5
2 2 133778 3 39.8 0 . 0 1 Increase 0.5 to 0.6
23 133641 2 29.3 0.75 Increase 0.5 to 0.8
24 132391 2 8.3 0 . 0 2 Increase 0 . 6  to 2 . 0
25 127627 2 29.1 0 . 0 1 Increase 0.3 to 0.4
30 129757 3 31.4 0 . 2 2 Increase 0 . 8  to 1 . 0
Table 15. Summary of cases requiring alteration in thyroid hormone replacement therapy.
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Two dogs with subnormal peak total T4 concentrations required an increase in 
dosage at visit two based on an inadequate clinical response to therapy. One (dog 24) had a 
peak total T4 concentration of 8.3 nmol/L. There was persistent diarrhoea in this case and 
poor gastrointestinal absorption was suspected as the reason for initial therapeutic failure. 
Following an increase in dose subsequent peak total T4 results (41.9 and 40.9 nmol/L) were 
consistent with adequate absorption and this was matched by resolution of clinical signs. In 
the remaining dog (dog 3), the peak total T4 result was subnormal (13.3 nmol/L). In the 
other cases that required an increased dose, peak total T4 values were within the reference 
range but the clinical response was considered suboptimal. In one of these cases (dog 6 ), 
the dosage change was made between visits three and four and therefore these data are not 
shown in Appendix 33. The relevant monitoring total T4 and cTSH values in this case when 
the dosage adjustment was made were 23.0 nmol/L and 4.0 ng/ml, respectively. For 
statistical purposes, these data were assigned to visit four. Although many of the dogs 
which needed an increase in therapy had reference range peak total T4 concentrations, the 
results were generally lower than those in which an increase in dose was not required. Eight 
o f the 11 dogs requiring an increase in dosage had peak total T4 values < 35nmol/L. In 
contrast, the minimum peak total T4 concentration obtained at any visit from all the dogs in 
which no dosage increase was required was <35 nmol/L on only one occasion.
Four o f the 31 dogs required a decrease in therapy. In two of these dogs (dogs 10 
and 21) peak total T4 results were approximately 100 nmol/L although only mild clinical 
signs of hyperthyroidism (polydipsia and hyperactivity) was present in just one of them. 
Two additional cases (dogs 6  and 9) had peak total T4 concentrations approximately 100 
nmol/L but neither of these cases required a reduction in therapy. Following the reduction 
in dose in dog 10, a subnormal peak total T4 concentration (12.6 nmol/L) was obtained 
from a subsequent monitoring sample. However, this was attributed to failure of 
appropriate therapy on the day o f testing since the dog was clinically well controlled and 
the corresponding cTSH result (0.01 ng/ml) was at the assay LoD. The dose of therapy did 
not subsequently need to be adjusted in this case. In the other two cases requiring a 
reduction in dosage (dogs 5 and 13), peak total T4 results were not excessive (43.5 and
49.2 nmol/L) but clinical signs of hyperthyroidism were apparently present (marked 
hyperactivity in both cases). The reduction in dose in these two dogs was associated with 
an improvement in the unwanted signs. However, it was difficult to ascertain if the dogs 
were genuinely clinically hyperthyroid or if the behavioural changes considered undesirable
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by the owners were only a relative change compared to the pre-treatment demeanour. In 
two of the four dogs requiring a dose reduction, cTSH was equal to the assay LoD.
At each treatment visit, most dogs had circulating cTSH concentrations near the 
assay LoD. Seven o f the dogs which needed an increase in dosage had cTSH values greater 
than the median value for all dogs at the corresponding visit. In the remaining four cases, 
the cTSH result was approximately the median group value for the visit but an increase in 
dose was clinically required. Circulating cTSH values were similar to the visit median in 
two of the four dogs (dogs 5 and 10) in which a decrease in therapy was required, but 
greater than the median result in the remaining two cases (dogs 13 and 2 1 ).
The relative changes in body weight categorised by visit are detailed in Table 16.
Percent pre-treatment body weight
Visit 1 1 0 0  2 -3 -4
Visit 2 95.8 ± 3.9 M
Visit 3 93.2 ±4.8 M
Visit 4 91.3 ±5.5 l -2 -3
Table 16. Change in body weight following therapy for hypothyroidism. All values are 
expressed as mean (± s.d.) percentage of the original (pre-treatment) body weight.
1 significantly different from visit one 2 significantly different from visit two
3 significantly different from visit three 4 significantly different from visit four
Broadly speaking all dogs exhibited either a good or excellent clinical response to
THRT. Some clinical improvement was noticed in almost all cases by visit two. Metabolic 
signs such as mental demeanour and willingness to exercise were usually the first signs to 
improve and were typically reported to start within three or four days of therapy. 
Approximately half of all owners spontaneously commented that the dog was behaving 
“more like a puppy”. Hair coat improvements were normally reported by visit three. 
Commonly there was a period o f initial hair loss prior to re-growth. In a number of cases, 
the hair coat was considered normal by visit three, although whilst improved, many dogs 
still had some hair coat abnormalities by visit four. The most obvious dermatological
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improvements were regrowth of hair, and resolution of pyoderma. In several cases there 
was darkening of the hair coat. In one case, the owner commented that the dog had started 
barking again, although the loss o f vocation had not been identified as a problem prior to 
starting therapy. There was nearly universal improvement in the level of activity which was 
exhibited by the treated dogs, including those cases in whom this was not recognised as a 
problem before starting therapy. In one dog with comeal lipidosis, the ocular abnormalities 
did not resolve with therapy and in fact continued to deteriorate despite normalisation of 
the dog’s lipid profile. In other respects this dog clinically improved. One dog developed an 
acute temporary lameness during THRT but this was not considered related to the 
treatment and responded to alternative therapy. Two dogs with concurrent diabetes 
mellitus, and one dog with concurrent dilated cardiomyopathy were treated with the same 
dosing protocol o f THRT as the other cases. None of these three cases needed a change in 
dose strategy, and no worsening o f the concurrent problems were identified as a result of 
instituting THRT.
The biochemical and haematological results from each dog at each visit are detailed 
in Appendices 34 and 35. The results o f routine biochemical analyses categorised by time 
period are detailed in Table 17. The results o f routine haematological analyses categorised 
by time period are detailed in Table 18. Significant changes in results of sodium, calcium, 
phosphate, glucose, cholesterol, creatinine, ALKP, AST, total protein, albumin, globulin, 
triglycerides, fructosamine, RBC count, haemoglobin, MCV and MCH occurred at various 
times after the start o f THRT. These changes are detailed in the relevant Tables. Mean (± 
s.d.) circulating creatinine concentration was significantly (p<0 .0 1 ) greater at visit two in 
those dogs which needed an increase in THRT dosage at some point during the study (107 
± 24.1 jumol/L) compared to those in which no adjustment was necessary (77.1 ± 16.7 
pmol/L). No other routine parameters were significantly different between these two 
groups.
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6.5 DISCUSSION
In this study, 16 of the 31 dogs did not need any adjustment in the dose of THRT following 
the start of treatment. An increase in dose was required in 11 of the dogs, whilst four dogs 
needed a dose reduction. This supports the presence of individual variation in the 
requirement for THRT previously reported in experimental cases by Nachreiner et ah, 
(1993). Broadly speaking, a peak total T4 concentration of less than 35 nmol/L was 
common in dogs which needed an increase in dosage, but was rare in dogs who were 
clinically adequately treated. This value may therefore be used as a guide to the likelihood 
of clinical response to therapy. No dogs needed more than one dose adjustment. The time 
required after starting therapy until a dose adjustment was required was variable. However, 
most dose alterations were typically required at one of the first two checks. Only three of 
31 (9.7 %) dogs required a dosage change at visit four. Overall, there was a slow increase 
in the mean (per kg) dose of T4 required to maintain good clinical control from a starting 
dose of 0.0200 mg/kg/day to a final mean dose of 0.0284 mg/kg/day. This may partly 
reflect the reduction in mean body weight of the dogs after starting treatment, artificially 
increasing the mean daily dose. However, this was not solely responsible, since the mean 
body weight o f all the dogs as a group decreased by less than 10 % during the study period, 
whereas the mean dose of THRT increased by over 40 % during this time. Of those dogs 
which did not require a change in dose, the mean dose of therapy per kg body weight 
increased broadly in line with the mean reduction in body weight. This supports the finding 
that in certain individuals, a genuine requirement for an increase in therapy to achieve 
optimal clinical control exists. However, clearly this is not the case in all dogs, again 
demonstrating the variation in response of dogs to THRT.
The measurement of cTSH in dogs receiving THRT demonstrated that there is a 
rapid and profound decrease in circulating cTSH in most dogs within approximately two 
weeks of commencing therapy. No assessment of cTSH was made prior to this time, and 
therefore the exact time taken for the suppressive effect of therapy to alter cTSH values, 
remains unclear. The results demonstrated that return of cTSH to the euthyroid range 
occurs in the majority of treated dogs and in most cases, results are usually at or near the 
assay LoD. However, at each visit there were a number of dogs with persistently increased 
cTSH values. In most cases (dogs 3, 6, 23) as detailed in Table 15 and Appendix 33, these 
corresponded to dogs with a clinical requirement for increased therapy. The monitoring 
cTSH concentration was increased in only one dog (dog 11, visit 3) in which no increase in 
therapy was clinically required at that time. This dog had developed a temporary unrelated
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musculoskeletal condition when the inappropriately increased cTSH result was identified. 
No change in THRT was made at that time and none was subsequently required. It is 
possible that the dog was recovering from the concurrent illness at the time of testing. With 
this exception, the results indicate that cTSH within the hypothyroid range is usually 
indicative of a clinical requirement for an increase in THRT dosage. However, in many of 
the dogs (dogs 2, 4, 11, 14, 22, 24, 25 and 30) requiring an increase in therapy, the cTSH 
value was within the euthyroid range. Therefore, the cTSH result was of little use in 
confirming the adequacy of therapy. Using near complete suppression of cTSH as an 
indicator of the adequacy o f therapy was not particularly useful either since four of 11 dogs 
with a clinical requirement for an increased dose had cTSH results at or near the assay 
LoD. Similarly, over-supplementation could not be reliably identified by demonstration of 
markedly suppressed cTSH values since two o f four dogs in which the dosage was 
decreased had typical euthyroid range concentrations. The reason for the poor reliability of 
cTSH to identify dogs with a requirement for alterations in dose is unclear but may be 
related to the duration of therapy, owner compliance or individual case variation. This is 
certainly an area worthy of further study.
One limitation of the study is that the decision to make dose adjustments was based 
on consideration of clinical and clinicopathological results, including hormone 
concentrations. Potentially, this may have artificially altered the mean peak total T4 
concentration and mean dose o f THRT per kg body weight. Nevertheless, the slow 
increase in dose of THRT is likely to be in part at least, due to a genuine physiological 
requirement since the overriding factor used to determine if dose adjustments were 
instituted was the clinical presentation and 11 of the 31 (35.5 %) dogs required an 
increased dose. Ultimately all dogs were well clinically controlled on once daily therapy, 
confirming that this therapeutic approach is appropriate in the vast majority of dogs. Once 
daily dosing is less physiologically normal than twice daily therapy, but the clinical response 
is clearly adequate and the cost of therapy is obviously reduced. In addition, the likelihood 
of improved owner compliance also makes this approach preferable.
There was biochemical or clinical evidence of hyperthyroidism in four of 31 (12.9 
%) of cases. However, both biochemical and clinical evidence o f this complication was only 
present in one dog, and the signs were mild. The resistance of at least some of the dogs to 
clinical hyperthyroidism despite markedly increased total T4 concentrations supports 
previous reports (Kaptein et ah, 1994). However, it is unclear why the presence of 
hyperthyroid signs apparently occurred in two dogs with “high normal” peak total T4
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concentrations. The reduced dose requirement in these dogs was largely owner driven, and 
whilst the dogs may well have been “hyperexcitable”, it is difficult to confirm that this was 
pathological and not simply a nuisance.
Several dogs with concurrent NTI including diabetes mellitus and DCM were 
treated with a standard therapeutic regime. No complications of this approach were 
recognised indicating that the widespread belief that such dogs should have THRT 
gradually introduced may not necessarily be the case (Ferguson, 1986; Jeffers, 1990; 
Panciera, 1990b). Confirmation o f this would require study of a larger number of dogs with 
reliably confirmed hypothyroidism and concurrent NTI. One dog with chronic diarrhoea 
required a markedly higher dose o f THRT to control the clinical signs. Despite eventual 
resolution of the diarrhoea, the peak total T4 concentrations remained within the mid­
normal range and clinical signs o f hyperthyroidism did not develop, and so the dosing 
schedule was not modified. The findings in this dog are interesting. The high dosage 
requirement was initially presumed to be solely the result o f the gastrointestinal disease. 
However, following successful treatment of the intestinal disease, typically “normal” six 
hour post pill total T4 concentrations were obtained from this dog despite the continued use 
o f an unusually high dose o f THRT. The presence o f residual intestinal pathology, capable 
of interfering with drug absorption, but not sufficiently severe to cause continued diarrhoea 
is an one possible explanation. Alternatively, the high dosage may reflect the marked inter­
individual variation in requirement for THRT. However, perhaps the most likely 
explanation for the findings in this dog simply relate to the ability of this species to 
efficiently eliminate excess T4 as discussed previously. An alternative initial approach to this 
case, when reduced intestinal absorption was suspected, would have been administration of 
a T3 containing product (Panciera, 1990b). However, this was not deemed necessary.
The change in body weight of hypothyroid dogs following THRT was dramatic 
with significant reduction occurring by the first visit (mean duration 17.8 days) after 
commencing THRT. These results indicate that a standard dose of T4 replacement therapy 
has a more rapid influence on body weight than was previously realised (Rosychuk, 1982; 
Panciera, 1997c). Interestingly, this pattern of weight loss continued throughout the period 
o f study such that although no dogs suffered excessive weight loss, the mean body weight 
was significantly decreased at visit four compared with visit three. This confirms that the 
metabolic normalisation which results from THRT continues up until and possibly even 
beyond the mean visit-four period o f 96 days after starting THRT.
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Broadly speaking the changes in clinical signs which occurred following the start of 
THRT were similar to previous reports (Rosychuk, 1982; Jeffers, 1990; Panciera, 1997c). 
The changes in clinical parameters which could be objectively measured such as body 
weight have already been discussed. However the mean time required for most types of 
clinical abnormality to improve was difficult to accurately categorise. This is a common 
problem encountered in performing a clinical study such as this, since clinical improvements 
are usually progressive in nature. Furthermore variation between cases, such as in this study 
the need for a dose change, unavoidably occurs, complicating categorisation. Nevertheless, 
general conclusions can be drawn and whilst the time taken for improvement of clinical 
signs varied, it did undoubtedly depend on the body system affected. Lethargy was almost 
without exception improved by visit two and as can be seen from Table 15, weight 
reduction occurred quickly after starting therapy. Exercise tolerance appeared to improve 
continuously throughout the study as dogs became stronger and apparently more athletic. 
The reduction in body weight probably also contributed to this finding. Few dogs exhibited 
any change in hair coat by visit two, although this was usually improved by visit three. The 
deterioration and subsequent improvement in alopecia tended to occur during this interval. 
Although not specifically detailed, a number of the cases were intermittently checked for 
over a year beyond the initial study. Of these cases, no substantial clinical problems or 
complications were noted, although intermittent pyodermas were occasionally reported.
Circulating cTSH concentrations were significantly decreased at all visits compared 
to pre-treatment values, but were not significantly different between the treatment visits. 
Circulating cTSH concentration was within the reference range in 92.3 % cases by visit two 
compared with 16.1 % cases before treatment. It is clear from this that the negative 
feedback effect of THRT on pituitary cTSH release generally occurs rapidly after starting 
therapy. There was no significant change in mean six-hour post pill total T4 concentration 
in monitoring samples between visits two, three or four. Whilst this is broadly consistent 
with the rapid stabilisation of thyroid hormone concentrations in most dogs, these data are 
influenced by the fact that dose alterations were made partly based on peak total T4 results. 
As discussed previously, this will have contributed to maintaining similar mean peak total 
T4 values between visits. Nevertheless, the recognition that cTSH and peak total T4 are 
usually within the reference ranges within approximately two weeks after the start of 
therapy suggests that THRT can be adequately monitored much sooner than previously 
realised (Rosychuk, 1982; Ferguson, 1986; Panciera, 1990b; Brent & Larsen, 1996; Refsal 
& Nachreiner, 1997b). This has obvious beneficial effects for the welfare o f treated dogs,
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particularly those who require dosage changes to achieve an optimal clinical response. 
Based on the results of this study, approximately 20 % of cases may need a dosage 
adjustment at the first check after starting treatment, and approximately 30 % of dogs may 
need dosage adjustments at a subsequent visit. It is apparently rare for an individual to 
require more than one dose adjustment during the first three months of therapy.
The circulating total T4 concentrations obtained at visits two, three and four are 
similar to or slightly higher than previous recommendations for therapeutic hormone 
concentrations (Rosychuk, 1982; Panciera, 1994; Refsal & Nachreiner, 1997b). These 
values, and the confirmation of minimal subsequent changes in either mean total T4 or 
cTSH values after the initial visit, provides a guideline for objective clinicopathological 
monitoring results which may be used in fiiture studies.
The effect o f THRT on routine biochemical and haematological parameters 
produced a large amount of data to support previous anecdotal evidence in the veterinary 
literature. In addition it revealed a number of previously unreported features.
Circulating cholesterol and triglycerides were highly significantly decreased at visits 
two, three and four compared to the pre-treatment visit. There was no significant change in 
either cholesterol or triglyceride concentrations between the three treatment visits. This 
indicates that lipid metabolism is rapidly restored following the start of THRT, and treated 
cases demonstrate a quick normalisation o f their lipid profile. This feature may be useful 
when monitoring dogs receiving THRT, particularly since these tests are easily performed 
and relatively inexpensive. However, there was no significant difference in the magnitude of 
the decrease in cholesterol or triglyceride concentrations at visit two in those dogs which 
were adequately treated, compared to those in which a subsequent dose adjustment was 
required. Therefore, whilst measurement of these parameters may assist in confirming that 
owner compliance is broadly acceptable, and that the dog is biochemically improving, the 
diagnostic utility of these analytes is of limited value in accurate therapeutic monitoring. 
Further study, with a larger number o f samples from dogs needing dosage adjustments and 
from those not requiring a dose adjustment would be useful, since the relatively small 
sample numbers in this study may have reduced the likelihood of identifying any such 
statistically significant effects in the present study.
Blood glucose concentration was significantly decreased at visit three compared 
with visit one, but not between any other time periods. There is no obvious explanation for 
this finding. However, the median visit two blood glucose concentration was in fact even 
further decreased but was not statistically significant and therefore it is almost certain that
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the statistical effect resulted from the number of samples in each of the groupings. The 
finding was considered to be a purely statistical and not biological effect. The result is 
therefore not considered to have any clinical relevance.
Circulating total protein concentration was significantly decreased at visits three 
and four compared to visit one. Albumin was significantly decreased at visit four compared 
to both visits one and two. The globulin concentration was significantly decreased at visits 
two and four compared to visit one. The most likely explanation for the protein 
concentration and profile changes which occurred is an increase in protein turnover 
associated with normalisation of metabolic rate, including energy consumption, following 
the start of THRT. There was a short lag phase before significant changes in total protein 
results were identified. This is consistent with a progressive metabolic improvement with 
THRT. The half life of albumin in dogs is over eight days in healthy dogs (Kaneko, 1980) 
and likely therefore to be even greater in hypothyroid animals, whose metabolic 
requirements and catabolic activity are reduced.
There was a marked, and highly significant reduction in mean circulating 
fructosamine concentrations following the start o f THRT. This has not been previously 
reported in dogs. In humans with hypothyroidism, increased fructosamine concentration is 
recognised and considered to be due to reduced protein turnover rate rather than any 
abnormality of glycaemic control itself (Waterson & Mills, 1988). A similar mechanism is 
likely to be responsible in dogs, and the changes following instigation of THRT are 
presumably simply a reversal of this process. This conclusion is supported by the change in 
protein concentrations which occurred. The decrease in fructosamine concentration was 
statistically significant between every visit including visits three and four, indicating that 
even by a mean of 96 days o f THRT, fructosamine may not have completely stabilised.
Mean circulating sodium concentration was significantly increased at all visits after 
starting therapy. However, the actual concentrations remained well within acceptable 
reference limits and were of no clinical significance. The cause of the change was likely to 
be a resolution of sample lipaemia, which artefactually decreases measured blood sodium 
concentration (Harrington & Cohen, 1973), after starting THRT.
Blood calcium concentration was significantly decreased at visit four compared to 
visits one, two and three. The concentration remained within acceptable reference limits 
and therefore was also of little clinical utility. The likely explanation for this previously 
unreported finding is an apparent decrease in calcium due to reduced circulating albumin
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concentration which also occurred. Since total as opposed to ionised calcium was 
measured, the effect of protein fluctuations is unavoidable with the methodology used.
There was a highly significant reduction in creatinine concentration following the 
start o f THRT, with values being reduced at each o f visits two, three and four when 
compared to pre-treatment values, but not when compared to each other. This is a 
previously unreported finding and may be the result of improved glomerular filtration rate, 
as systolic blood pressure returns to normal. The creatinine production rate is directly 
proportional to lean muscle mass, and consequently to body weight. However, the 
reduction in body weight in the dogs in the present study is unlikely to have influenced 
creatinine concentration since most of the excess weight associated with hypothyroidism 
results from excess adipose tissue as opposed to muscle. The rapid change in creatinine 
concentration indicates that these metabolic improvements occur quickly following the start 
o f replacement therapy. Mean body weight continually decreased throughout the study 
whereas mean creatinine concentration was not significantly different between visits two, 
three and four. Again, this indicates that the alteration in body weight was of little 
relevance to the changes in creatinine concentration.
Blood ALKP concentration was significantly decreased at visits three and four 
compared to visit one. Again, to the authors knowledge this is a previously unreported 
finding in dogs. Possible explanations include the progressive normalisation of hepatic 
metabolism, including the mobilisation of hepatic lipid deposits once THRT starts and 
weight loss begins. Removal o f excessive fat from the liver is likely to improve the 
cholestasis which is typical of hepatic infiltration irrespective of the cause. This process 
may reasonably be expected to take some time to occur and therefore it is not surprising 
that the visit two ALKP concentration was not significantly different from the pre­
treatment value.
Circulating AST concentrations were significantly decreased at visits three and four 
compared to visit one, and at visit four compared to visit two. However, the numerical 
changes were small and would be difficult to interpret in an individual case. There are 
multiple sources of circulating AST in dogs, including red blood cells and hepatic, cardiac 
and muscular tissue (Willard, 1989). Possible explanations for the decrease in concentration 
with THRT are therefore varied but include resolution of hepatic lipid deposits as discussed 
above, and/or resolution of subclinical myopathic disease (Braund et ah, 1981). The 
absence of any significant change in circulating CK concentration following the start of 
THRT suggests that muscle is less likely to be the source of the AST.
Chapter 6 183
An increase in circulating CK values is traditionally considered to occur in canine 
hypothyroidism but as detailed in Chapter 5, there was no significant difference between 
CK values in hypothyroid compared with euthyroid dogs with various NTI in the present 
study. It is therefore not surprising that there was no statistically significant change in CK 
values in dogs after starting THRT. These findings support the conclusion that circulating 
CK measurement is of little diagnostic utility in either confirming or monitoring therapy for 
canine hypothyroidism.
The RBC count was significantly increased on every visit when compared with the 
median result from the previous visit. This confirms reversal of the physiological anaemia 
which is associated with hypothyroidism in humans and dogs (Green & Ng, 1986). Like the 
change in fructosamine, RBC count decreased between the final two visit periods, 
indicating that it may not have stabilised by the end of the study. Inspection of the data 
revealed that the rate of increase in RBC count was fairly linear throughout the study and 
no plateau was identified. This indicates that the haematological changes would probably 
have continued to improve although a longer follow up period would be necessary to 
confirm this. The fact that RBC count increased within two weeks of commencing THRT is 
useful and indicates that RBC measurement may be of some value in monitoring these cases 
throughout the stabilisation period. However, as discussed for other analytes, analysis of 
samples from a larger group o f dogs, and correlation of these clinicopathological changes 
with clinical response will be needed to confirm statistically useful parameters.
Circulating Hb values were significantly increased at all visits compared with visit 
one, and at visits three and four compared with visit two. The changes and mechanisms 
responsible for these changes are as described for the RBC count. The changes which 
occurred in MCH were likewise considered to be simply a reflection of the alteration in 
haemoglobin concentration. The MCV value was significantly reduced at visit four 
compared to all previous visits. This was not considered to be of any biological 
significance, although the cause of the mild reduction was not apparent.
It is clear that a number o f routine biochemical and haematological parameters 
change significantly following the start o f THRT. There is also variation in the time taken 
for individual parameters to start improving, and the period over which these changes 
occur. The results of this study indicate that in the early stages of therapy, cholesterol, 
creatinine and triglyceride concentrations may be of most value in confirming a 
clinicopathological response to treatment. With more protracted therapy, ALKP, AST, 
albumin and globulin results appear to be good indicators that metabolism is normalising.
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Both RBC count and fructosamine concentration are markers which show rapid and 
continued improvement throughout the course o f treatment, and further study of these 
analytes in particular is warranted.
There was a significant decrease at visit two in circulating creatinine concentration 
in those cases which needed no increase in THRT at any point during the study compared 
with those cases in which an increase was required at some time. This indicates that whilst 
monitoring o f certain parameters as detailed above allows confirmation of biochemical and 
haematological improvements, the estimation o f creatinine in particular provides for a rapid 
and inexpensive method of predicting the adequacy of THRT within as little as two weeks 
after starting therapy. This finding has not been previously reported and because o f the time 
and expense implications, may prove to be an invaluable aid in the routine monitoring of 
canine hypothyroidism. No evaluation was made of potential markers of THRT over­
supplementation due to the small number o f cases in this category.
With the exception of creatinine, none of the routine clinicopathological parameters 
were significantly different at visit two between adequately treated and under-treated cases. 
The similar biochemical and haematological response between these two groups, despite 
the variable clinical response and requirement for dosage adjustments, confirms the need 
for a therapeutic regime tailored to the specific clinical requirements and not 
clinicopathological features o f individual dogs.
In conclusion, good clinical and clinicopathological control of hypothyroid dogs can 
be achieved in the vast majority of cases with once daily THRT. Using a starting dose of 
0 . 0 2  mg/kg, approximately half o f all cases will need a single dosage adjustment within the 
first 1 2  weeks and be adequately stabilised on a mean dose of approximately 0.028 mg/kg 
L-T4. It is rare for more than one dose adjustment to be required in any individual. A mean 
six hour post pill peak total T4 concentration of approximately 55 nmol/L provides good 
clinical control in most cases, and alongside cTSH estimation, can be measured within 
approximately two weeks of starting therapy, or presumably also after making a dosage 
adjustment. A peak total T4 concentration of approximately 35 nmol/L is a reasonably 
reliable cut off which can be used as to indicate that an increase in dose is likely to be 
clinically required in an individual. This provides guidelines which may be adopted in future 
studies. There is a rapid improvement in certain clinical characteristics including weight 
reduction which occurs within approximately two weeks o f commencing THRT. By 
approximately three months after starting THRT, a mean weight reduction o f 10 % can be 
expected. Other clinical improvements are variable but typically lethargy and mental
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demeanour are the first signs to indicate successful treatment, usually improving within two 
weeks of starting THRT. Other clinical improvements have been summarised. Routine 
clinicopathological monitoring is of value in confirming a general metabolic response to 
THRT but is o f limited value in accurately monitoring cases or tailoring therapy. The 
exception is estimation of circulating creatinine which significantly reduces in dogs who are 
adequately treated compared with those who are likely to require subsequent dosage 
adjustments within two weeks o f starting THRT.
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CHAPTER 7
CIRCULATING THYROGLOBULIN AUTO ANTIBODIES 
IN HYPOTHYROID AND EUTHYROID DOGS
7.1. LITERATURE REVIEW 
Thyroid Pathology in Hypothyroidism
In humans, chronic autoimmune thyroiditis is the original paradigm for autoimmune 
diseases in general. This term encompasses a variety of different entities including goitrous 
(Hashimoto’s), atrophic, juvenile, postpartum, silent and focal thyroiditis although the 
interrelationship of some o f these remains unclear. In practice many of these terms are used 
synonymously with autoimmune thyroiditis. The disorder, which is most commonly 
recognised in women, encompasses a range o f clinical and pathological changes from 
asymptomatic pathology detected post mortem, to extensive infiltrative inflammation and 
scarring with complete loss of normal thyroid tissue. The pathology typically consists of 
varying degrees of lymphocytic infiltration, fibrosis and loss of follicular epithelium. It is 
estimated that approximately half of all cases of naturally occurring canine primary 
hypothyroidism result from lymphocytic thyroiditis whereas the remainder result from 
idiopathic thyroidal atrophy (Gosselin, Capen, Martin & Krakowka, 1982).
Gosselin et al., (1981a) evaluated the thyroid glands from 16 dogs with 
spontaneous hypothyroidism using light and electron microscopy. Dogs were confirmed as 
hypothyroid based on the presence of appropriate clinical signs and an inadequate response 
to TSH administration. In seven of the 16 (44 %) cases lymphocytic thyroiditis was 
confirmed which was characterised by difiuse infiltration of the thyroid gland by 
lymphocytes, plasma cells and macrophages. There was formation of lymphoid nodules and 
evidence of follicular destruction progressing to replacement of most of the gland with 
fibrous connective tissue. The basement membrane around the follicles contained electron 
dense deposits and the authors concluded that the pathology observed was immune- 
mediated in origin. In the remaining nine (56 %) dogs, idiopathic follicular atrophy was 
confirmed, characterised by loss of thyroid parenchyma and replacement with adipose 
connective tissue. Follicular cell degeneration with exfoliation into the colloid and 
interfollicular areas was present. Most of these thyroid glands were composed largely of 
adipose tissue interspersed with either small follicles or individual follicular cells. The 
remaining follicular tissue had dilated rough endoplasmic reticulum, large golgi apparatus
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and intracytoplasmic microfollicles. The authors concluded that this pathology was a 
degenerative lesion of the follicular cells although the cause remained unclear. The 
condition was not associated with an inflammatory component.
Lucke et oh, (1983) evaluated the thyroid glands of seven dogs with clinical signs 
consistent with hypothyroidism by light and electron microscopy. No further details 
regarding the diagnostic criteria used to confirm hypothyroidism were provided. The 
pathology observed in six of these cases was similar although varied in severity. Focal to 
diffuse infiltration o f the follicular epithelium, interfollicular tissue and colloid with 
lymphocytes, plasma cells and macrophages, with destruction and replacement of follicles 
was reported. In five of these six animals, there were relatively few normal follicles 
remaining. Most follicles that were left were small and lined by enlarged cuboidal cells 
containing vesicular nuclei and granular eosinophilic cytoplasm. In contrast to Gosselin et 
ah, (1981a), fibrosis was not reported to be a feature of the thyroid glands in any o f the 
cases with inflammatory infiltrate. However, in the sixth case there was minimal 
inflammatory cell infiltrate but striking fibrosis. The authors suggested that this may have 
been the end stage of an inflammatory process although no further evidence for this 
conclusion was provided.
Chastain, Young & Kemppainen, (1989) confirmed hypothyroidism in a dog with 
T3 autoantibodies based on the results of a TSH response test. Histopathological 
examination of the thyroid gland revealed replacement of approximately 50 % of the 
normal gland with adipose tissue. The remaining tissue contained collapsed thyroid follicles 
with low cuboidal epithelium. The follicular cell cytoplasm was pale and vacuolated, and 
scattered aggregates of lymphocytes and plasma cells were observed in the interstitium. 
The histological diagnosis was concurrent lymphocytic thyroiditis and thyroid atrophy. 
Strangely, the authors made no comment regarding the concurrent presence o f both 
idiopathic atrophy and lymphocytic thyroiditis in this case.
Aetiology of Thyroiditis
Broadly speaking, autoimmune diseases occur when there is a failure of T-cell tolerance as 
a result o f both genetic and non-genetic factors. The aetiopathogenesis o f autoimmune 
thyroiditis in humans has been extensively studied and both genetic and non-genetic 
influences play a role. Factors involved in the development and progression of the disease 
may include infectious agents, dietary factors, toxins, hormones, stress and major 
histocompatability complex (MHC) and cytokine regulatory genes (Weetman, 1996). Like
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the human disease, lymphocytic thyroiditis in the dog is also considered to be immune 
mediated (Beale, Halliwell & Chen, 1990). As in humans, a strong genetic predisposition 
has been proposed and is supported by the demonstration of lymphocytic thyroiditis in 
particular breeds and families o f dogs including borzois, great Danes, and beagles (Haines 
et al, 1984b; Conaway et al, 1985; Benjamin et al, 1996). The largest published study 
was conducted by Benjamin et al, (1996) who reported lymphocytic thyroiditis in 26.3 % 
of 276 inter-related control beagles and demonstrated a high degree of heretability for 
hypothyroidism. Nevertheless the underlying defect, or more likely defects, remains 
unclear.
Thyroiditis and Circulating Autoantibodies
The spontaneous development of circulating antibodies to antigenic thyroid tissues as a 
result of AITD was first documented by Roitt, Doniach, Campbell & Hudson, (1956) who 
reported the presence of TgAb in human patients with Hashimoto’s thyroiditis. Since then 
numerous antibodies directed against various thyroidal components have been identified in 
association with human AITD, including thyroid peroxidase (TPO) autoantibodies 
(TPOAb), TSH receptor antibodies (TRAb), T4Ab, and T3Ab (McKenzie & Zakarija, 
1996). Of most clinical impact was the identification of TPOAb by Trotter, Belyavin & 
Waddams, (1957) which have subsequently been shown to be more prevalent and present 
in higher titres than TgAb. TPOAb estimation is currently considered to be the most cost 
effective means of confirming the presence of AITD in humans (McKenzie & Zakarija, 
1996).
The diagnostic utility of TPOAb estimation in the dog has been investigated 
previously. Haines, Lording & Penhale, (1984a) documented TPOAb in 10 of 34 (29 %) 
clinically hypothyroid dogs using an ELISA method. However, although the authors 
concluded that the technique may be useful as a screening aid, antibody titres were low and 
the method was not considered to be sufficiently sensitive or reliable to justify routine 
diagnostic use. More recently, Thacker, Davis, Refsal & Bull, (1995) examined sera from 
50 dogs with autoantibodies to thyroglobulin, T4 or T3. All samples were negative for 
TPOAb. In addition no cross reactivity with human and porcine TPO was identified using 
this method, which was developed using purified canine TPO. Given the widespread 
clinical application of TPOAb estimation in human AITD, the authors concluded that the 
pathogenesis o f lymphocytic thyroiditis was different between humans and dogs.
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Experimental studies in dogs have confirmed that the intrathyroidal injection of 
TgAb is swiftly followed by the development of lesions within the gland similar to naturally 
occurring lymphocytic thyroiditis (Gosselin, Capen, Martin & Krakowka, 1981b). There is 
little doubt that TgAb is involved in the pathogenesis of canine thyroiditis but its exact role 
in the promotion of the disease remains unclear. The measurement of circulating canine 
TgAb is discussed in more detail below.
Currently the only other autoantibodies recognised in association with canine 
thyroiditis are T4Ab and T3Ab. Young, Sartin & Kemppainen, (1985) reported an abnormal 
“T3 binding factor” which interfered with laboratory measurement of total T3 in 18 (< 0.3 
%) of over 6000 samples submitted to a commercial veterinary laboratory for evaluation of 
thyroid function. The presence of a T3-binding factor was suspected in those samples with 
markedly increased apparent total T3 concentrations. Binding of T3 by the unknown factor 
was diminished by the addition o f exogenous T3 and could be precipitated by the addition 
of goat anti-dog IgG. Scatchard analysis demonstrated that the characteristics of the 
binding factor were similar to that of human T3 autoantibodies and the authors concluded 
that canine T3 autoantibodies were responsible for the anomalous increase in apparent total 
T3 concentrations.
Subsequently, Thacker, Refsal & Bull, (1992) developed assays for TgAb, T4Ab 
and T3Ab. The TgAb assay developed was an ELISA method utilising purified canine 
thyroglobulin coated to the plate wells, and goat anti-dog IgG conjugated with alkaline 
phosphatase. Negative reference sera were obtained from 13 healthy dogs with reference 
range circulating thyroid hormone concentrations and normal thyroid gland histological 
findings. Two further dogs were repeatedly immunised with purified canine thyroglobulin in 
adjuvant and serum samples from these dogs were designated as the positive controls. An 
agarose gel electrophoresis assay was used to detect T3Ab and T4Ab. Positive control 
samples were obtained from one dog with increased total T4 and decreased total T3 
concentrations on RLA, consistent with autoantibodies to T3 and T4. The authors examined 
serum from 119 dogs with clinical signs consistent with hypothyroidism and reported the 
presence o f TgAb, T3Ab and T4Ab in 50 (42 %), 39 (33 %) and 31 (26 %) samples 
respectively. Autoantibodies to at least one of the three antigens were present in 58 (49 %) 
of the cases. The prevalence of T3Ab and T4Ab in the samples in this study is considerably 
greater than in subsequent studies but the reason for this is unclear.
Gaschen et al, (1993) progressed this work and revealed that as well as being 
associated with apparent elevations in serum total T3 concentration, the presence of T3Ab
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was significantly associated with the presence of TgAb. Circulating T3Ab were measured 
by incubation of sample with radiolabelled T3 followed by the addition of dextran-coated 
charcoal. After centrifugation, the radioactivity remaining in the supernatant was 
determined and compared to standards prepared from mouse monoclonal T3Ab (Chrystal 
chemicals). Circulating T3Ab was measured in serum samples from 45 dogs with increased 
TgAb concentrations and two distinct groups were identified. Low T3Ab concentration 
occurred in 28 of the samples, whereas the remaining 17 had markedly increased T3Ab 
concentrations. There was a direct linear correlation between apparent total T3 and T3Ab 
concentration. Furthermore, the addition of T3 to TgAb containing sera, caused a 
significant reduction in the measurable TgAb concentration. The authors concluded that 
T3Ab were most likely generated against specific epitopes present within the thyroglobulin 
molecule and that like TgAb, T3Ab are a valid marker for canine thyroiditis.
Rajatanavin, Fang, Pino, Laurberg, Braverman, Smith & Bullock, (1989) measured 
circulating TgAb in 19 hypothyroid and 20 euthyroid dogs with a sensitive 
radioimmunoprecipitation assay, and T3Ab and T4Ab by polyacrylamide gel 
electrophoresis. Dogs were categorised based on clinical signs and total iodothyronine 
concentrations. A marked association between the presence o f TgAb with both T3Ab and 
T4Ab in canine sera was reported.
Refsal & Nachreiner, (1997a) reported the prevalence of T3Ab only, T4Ab only and 
both autoantibodies in 4.4, 0.2 and 0.7 %, respectively, from approximately 240,000 
samples submitted for thyroid hormone analysis to a veterinary laboratory. The presence of 
autoantibodies was highly associated with samples with increased cTSH or decreased 
thyroid hormone concentrations. Autoantibodies were most common in dogs between two 
and four years of age and in those > 10kg body weight. Certain breeds were more 
commonly affected, particularly the English setter, old English sheepdog, boxer, Brittany 
spaniel and dalmatian.
It is now apparent that both T4 and T3 autoantibodies are rarely present in samples 
without concurrent TgAb and that T3Ab is more frequently identified than is T4Ab. The 
prevalence o f these iodothyronine autoantibodies in only a subset of dogs with TgAb has 
caused most of the recent research to be directed at the identification of TgAb. However, 
the practical importance o f T4Ab and T3Ab lies in their potential to interfere with most 
widely used immunoassays for total T4 and total T3. If  the autoantibody titre is sufficiently 
high, it can bind a significant proportion of the radiolabelled hormone used in the RIA 
procedure. I f  the labelled hormone-autoantibody complex appears in the free fraction of the
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RIA, as occurs with most solid phase techniques, the apparent endogenous hormone 
concentration will be spuriously increased. This occurs with most of the widely used 
thyroid hormone assays (Chastain et al., 1989; Thacker et al, 1992; Kemppainen, Young, 
Behrend, Clark & Smiley, 1996). However, if the labelled hormone-autoantibody complex 
appears in the bound fraction of the RIA, such as with charcoal methods or double 
antibody assays in which the second antibody precipitates the complex, the value will be 
spuriously decreased.
Canine Thyroglobulin Autoantibody Estimation
Since it has become clear that TPOAb estimation is of minimal utility in the investigation of 
canine thyroid disease veterinary interest has centred principally on the estimation of 
circulating TgAb, first identified in dogs by Beierwaltes & Nishiyama, (1968). 
Subsequently, various methods, mostly modifications o f human assays have been used for 
TgAb identification. However, the difference in methodologies has been responsible for 
markedly differing results between reports.
Gosselin et ah, (1980) reported TgAb in 12 o f 25 (48 %) hypothyroid dogs using a 
chromic chloride passive haemagglutination (CCH) method but only 6  (24 %) o f these 25 
animals were positive by tanned cell haemagglutination (TCH). Using the CCH method five 
o f 40 (12.5 %) dogs with various NTI were TgAb positive but all were negative using 
TCH. Haines et al, (1984a) reported TgAb in 20 (59 %) and 18 (53 %) of 34 hypothyroid 
dogs using ELISA and CCH methods respectively but there was marked differences in the 
positive results between methodologies with 1 2  of the cases being positive by one method 
but not the other. Using the same ELISA method, Haines et al, (1984b) reported TgAb in 
28 of 65 (43 %) dogs with non-thyroidal endocrine diseases, 140 of 1057 (13 %) 
hospitalised patients with non-endocrine diseases and 30 of 64 (47 %) healthy dogs closely 
related to TgAb positive hospitalised patients. Vollset & Larsen, (1987) reported 
measurable TgAb in only 11 of 45 (24 %) and 15 of 44 (34 %) suspect hypothyroid dogs 
using glutaraldehyde (GCH) and CCH methods respectively, and only three of 42 (7 %) 
dogs with various NTI including endocrine diseases by both methods.
Recently a commercial TgAb ELISA kit has become available (Canine 
thyroglobulin autoantibody immunoassay kit, Oxford Laboratories). Following clinical 
validation results first presented by Graham, Nachreiner & Refsal, (1997) a more 
comprehensive evaluation of this assay was reported by Nachreiner et al, (1998). Serum 
samples containing T3Ab and T4Ab, and therefore with a high potential for the presence of
Chapter 7 192
TgAb, were evaluated for TgAb and compared to those without iodothyronine 
autoantibodies to determine the optimal diagnostic cut-off of the assay for confirming the 
presence of TgAb. An o.d. value equal to or greater than 200 % of the negative control 
sample was associated with an overall test efficiency of 0.984 and was subsequently 
employed. There was good correlation of the TgAb result with thyroid biopsy findings in 
eight dogs with, and 10 dogs without histological evidence of thyroiditis. Some of these 
cases had mild focal thyroiditis whereas others had more severe thyroid pathology. The 
cases with mild lymphocytic infiltrate typically had low cuboidal follicular epithelial cells, 
consistent with normal thyroid function. However, those cases with more severe and 
diffuse infiltrates had tall columnar epithelial cells consistent with reduced thyroid function 
and increased cTSH concentrations. The implication of this finding is that increased 
circulating TgAb can potentially be used as a marker of thyroid disease, prior to the 
development of functional thyroid failure. In the same study, the prevalence of TgAb in 
random source dogs was evaluated by TgAb estimation in 91 apparently healthy dogs. 
Three cases (3.3 %) were positive for TgAb. Additional investigation of two of these three 
cases demonstrated decreased circulating free T4 and increased cTSH concentrations 
consistent with primary hypothyroidism. In one o f these dogs, thyroid gland biopsy was 
confirmatory of lymphocytic thyroiditis. The third dog was not evaluated further. The 
prevalence of TgAb in 131 dogs with hypothyroidism was also evaluated in the same study. 
Cases were confirmed as hypothyroid based on demonstration of increased circulating 
cTSH and decreased iodothyronine concentrations. However, only cases in which 
autoantibodies to both T3 and T4 were absent were included in the study. In total, 50 of the 
131 (38.2 %) hypothyroid cases were TgAb positive. When hypothyroid dogs including 
those with T3 and T4 autoantibodies were also included, TgAb was present in 87 of 171 
(51%) cases. The mean (± s.d.) age of the TgAb positive and -negative hypothyroid dogs 
was 6.1 ± 2.5 years and 7.1 ±3 .0  years, respectively. The authors concluded that this may 
be consistent with a progressive change from TgAb positivity to TgAb negativity as 
thyroiditis progresses. The prevalence of TgAb was also evaluated in 146 dogs with 
various NTI and was positive in eight (5 %). The non-thyroidal disease categories included 
calcium disorders, hyperadrenocorticism, diabetes mellitus, hypoadrenocorticism and 
obesity. Twenty three of 24 (96 %) samples with T3Ab were positive for TgAb, whereas all 
o f 37 samples with otherwise normal indices of thyroid function were negative for the 
autoantibody.
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Using the same assay, Graham, Refsal & Nachreiner, (1998) studied nine laboratory 
beagles, five of which exhibited various states of thyroid pathology. Three distinct 
categories were identified based on TgAb status, cTSH and total T4 concentrations and 
severity of the thyroid lesions. Subclinical thyroiditis was identified in two cases, defined as 
the presence of mild focal thyroiditis and increased TgAb but otherwise unremarkable 
results. Subclinical hypothyroidism was identified in two cases, defined as the presence of 
severe difluse thyroiditis, increased TgAb and circulating cTSH concentration but normal 
total T4 concentration. Clinical hypothyroidism was present in one dog, defined as severe 
lymphocytic thyroiditis, increased TgAb and circulating cTSH concentration and decreased 
total T4 concentration. TSH response tests were performed in each of the dogs and were 
consistent with the extent of the thyroid pathology. Specifically, the total T4 response to 
TSH was significantly decreased compared with the healthy cases but the authors reported 
that the results were not low enough to be considered hypothyroid by conventional criteria. 
However, these data were not provided. Prolonged observation of these beagles has also 
revealed that two have progressed between stages presumably supporting the dynamic 
nature of lymphocytic thyroiditis in the dog. However, the relevant time period during 
which this transition occurred was not specified.
Using the same assay, Nachreiner, Bowman, Graham, Refsal & Bolliger, (1999) 
evaluated TgAb status in 51201 samples submitted for investigation of possible 
hypothyroidism. The overall prevalence of TgAb positive results was 7.9 %. This 
prevalence was highest in dogs from two to six years of age and declined in dogs older than 
six years. There was no association of TgAb result with gender. The hypothyroid dogs 
(categorised based on subnormal circulating total and free iodothyronine and increased 
cTSH concentrations) which were TgAb positive were significantly younger (median age 
approximately five years) than those hypothyroid dogs which were TgAb negative (median 
age approximately eight years). The authors concluded that hypothyroidism resulting from 
idiopathic atrophy may therefore be a sequel to lymphocytic thyroiditis. The study 
identified a strong breed predisposition for the presence o f circulating TgAb, with 
(prevalence of TgAb positive results within brackets) English setter (26 %), dalmation (17 
%), basenji (16 %), Rhodesian ridgeback (16 %), old English sheepdog (15 %), boxer (14 
%), Maltese terrier (14 %), Chesapeake Bay retriever (13 %), beagle (13 %), cocker 
spaniel (13 %) and Shetland sheepdog (13 %) being most significantly over-represented 
when compared to the prevalence of TgAb in mixed breed dogs. The authors concluded 
that the relationship between TgAb prevalence and breed, supports the hypothesis that
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there is a strong genetic component to the development of thyroiditis and consequently 
hypothyroidism.
Siliart & Stambouli, (1997) previously assessed the same ELISA assay but with 
very different conclusions. Whilst the authors acknowledged the diagnostic errors 
associated with the TRH response test for confirming hypothyroidism, they used an unusual 
variation of it, based on intramuscular administration of TRH, to classify 665 dogs as 
hypothyroid. Circulating TgAb was determined in a group of 40 of these cases and four (10 
%) had a positive TgAb result. The misclassification of euthyroid dogs as hypothyroid was 
likely responsible for the conclusions in the study. Misclassification would also explain the 
finding of circulating cTSH concentrations greater than 0.6 ng/ml in only 20 % of the 
“hypothyroid” dogs in that report which is at marked variance with all other contemporary 
reports as outlined in Chapter 4 (Williams et al, 1996; Jensen et al., 1996; Peterson et al, 
1997; Ramsey et al., 1997; Scott-Moncriefif et al., 1998).
Iverson et al, (1998) developed and validated a separate TgAb ELISA assay to 
that reported by Nachreiner et al, (1998). Canine thyroglobulin was harvested and purified 
from the thyroid glands of three healthy dogs for use in the assay. Three calibrator samples 
were included in each assay run. These included a positive sample from a dog with 
hypothyroidism and histologically confirmed lymphocytic thyroiditis, and two negative 
samples from two healthy dogs with no detectable clinical, haematological or biochemical 
abnormalities. In each assay, a K-value (equal to the o.d. of the positive calibrator minus 
the mean values from the negative calibrators) was calculated and used to calibrate the 
assay. All test samples were compared to the K-value and assigned an Ab value which was 
the percentage of the K value. The assay LoD was defined as the NSB plus twice the s.d. 
obtained from analysis of samples in duplicate with an Ab score less than 7.5 % on 13 
occasions. The LoD was 5.5 % corresponding to an o.d. of 0.009. The intra-assay c.v.’s 
obtained with low, moderate and positive Ab score samples over 15 runs were 3.2, 4.9 and
2.0 %, respectively. The inter-assay c.v.’s obtained with low, moderate and high Ab score 
samples over 10 to 15 runs were 4.6, 7.3 and 9.9 %, respectively. The optimal cut-off value 
calculated by DPR analysis for the confirmation of thyroiditis was 57.4 %. A median Ab 
score in 132 healthy dogs was 10 % which was close to the LoD of the assay. The median 
Ab score in dogs with primary hypothyroidism and confirmed lymphocytic thyroiditis 
(n=l 1), skin diseases (n=35) and other NTI (n=63) was 340, 12 and 8  %, respectively. The 
diagnostic sensitivity of the assay for lymphocytic thyroiditis was 0.91 and the diagnostic 
specificity was 0.97. The prevalence o f TgAb in healthy dogs and dogs with NTI was 5 and
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6  %, respectively. The assay developed by Iverson et al, (1998) has not yet become 
commercially available.
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7.2. INTRODUCTION
In conjunction with appropriate clinical signs and clinicopathological abnormalities, 
evidence of thyroiditis as demonstrated by measurable circulating antibodies to 
thyroglobulin (TgAb) has been considered useful in supporting a diagnosis of 
hypothyroidism (Beale, 1991). However many TgAb measurement techniques previously 
available were cumbersome to use and in particular were associated with positive results in 
euthyroid dogs with NTI (Gosselin et al., 1980; Haines et al., 1984a; 1984b; Vollset & 
Larsen, 1987; Beale et al., 1990; Beale, 1991). A commercial ELISA kit has recently 
become available for canine serum TgAb measurement (Canine thyroglobulin autoantibody 
immunoassay kit, Oxford Laboratories). This assay was recently evaluated by Nachreiner et 
al., (1998) in order to determine a diagnostic threshold for the confirmation o f thyroiditis. 
The purposes of this study were to more fully evaluate the potential value of this assay in 
the investigation of canine hypothyroidism by comparing results from clinically healthy 
dogs and those with confirmed hypothyroidism or NTI.
7.3. MATERIALS AND METHODS 
Case Materia]
A series of 119 dogs referred for investigation o f clinical or clinicopathological 
abnormalities consistent with hypothyroidism outlined in Chapter 2, and 70 apparently 
healthy dogs, were used for the study. Pedigree was classified as described in Chapter 2. 
The dogs were divided into either hypothyroid, euthyroid or healthy groups. The 
hypothyroid and euthyroid dogs were classified as described in Chapter 2. The hypothyroid 
group (mean age 7.4; range 3-12 years) contained 24 female (12 neutered) and 18 male (2 
neutered) and the euthyroid group (mean age 7.4; range 1-14 years) contained 36 female 
(20 neutered) and 41 male ( 8  neutered) dogs. The healthy group consisted o f 70 clinically 
healthy dogs. This group was divided into two subsets, group A consisting o f 19 dogs of a 
variety of breeds (mean age 4.9, range 0.5-12 years) and group B consisting o f 51 bearded 
collies (mean age 3.9, range 0.5-11 years) being sampled at the request of their owners as 
part of a breeding programme. Group A contained 10 female ( 6  neutered) and nine male ( 6  
neutered) dogs and group B contained 32 female (5 neutered) and 19 male (2 neutered) 
dogs.
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Hormone and Thyroglobulin Autoantibody Estimation
Blood samples were collected and stored for estimation of TgAb, cTSH, total T4 and free 
T4 as described in Chapter 2.
Statistical Analysis
The effect of thyroid status, sex, neutering and pedigree status on TgAb results was 
determined by chi-squared analysis. Comparison of dog ages and thyroid hormone 
concentrations between groups was performed using a two-sample t-test.
7.4. RESULTS
Hormone concentrations from each group are summarised in Table 19. The distribution of 
the major diseases in the euthyroid group is summarised in Table 20.
*Healthy Hypothyroid NTI
Basal total T4 (nmol/L) 24.3 ± 6.5 7.8 ±4.5 2 2 . 2  ± 1 1 . 0
Post-TSH total T4 (nmol/L) ND 9.5 ± 6 . 8 62.3 ± 33.2
cTSH (ng/ml) 0.29 ± 0.22 2.2 ± 2.5 0.41 ±0.46
free T4 (pmol/L) 19.6 ±5.5 5.4 ± 3.4 16.5 ±9.25
ND Analysis not done
Table 19. Serum hormone results (mean ± s.d.) in healthy dogs and those with confirmed 
hypothyroidism or non-thyroidal illness (NTI).
* Results exclude two dogs subsequently confirmed as hypothyroid.
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Disease Type Number of Dogs
Dermatological 2 0  (26%)
Obesity 16 (2 1 %)
Non-thyroidal 10 (13%)
endocrine diseases
Neurological 8  ( 1 0 %)
Neoplasia 6  (8 %)
Cardiovascular 6  (8 %)
Musculoskeletal 2 (3%)
Gastrointestinal 3 (4%)
Ophthalmological 2 (3%)
Other* 4 (5%)
Table 20. Principal disease categories affecting dogs with non-thyroidal illness (NTI).
*The “other” category includes one case each of idiopathic tracheitis, vaginitis, 
nasopharyngeal foreign body and iatrogenic hyperadrenocorticism.
There was no significant difference in TgAb-positive, -equivocal or -negative results 
between groups A and B and therefore these were combined for analyses. Results of TgAb 
measurement in each of the three groups are summarised in Table 21 and displayed in 
Figures 23, 24 and 25.
Category Number 
of Dogs Negative
TgAb Result 
Equivocal Positive
Hypothyroid 42 19 (45%) 8  (19%) 15 (36%)
NTI 77 72 (94%) 5 ( 6 %) 0 ( 0 %)
Healthy 70 55 (79%) 1 1  (16%) 4 ( 6 %)
Table 21. Distribution of circulating thyroglobulin autoantibody (TgAb) results in 
hypothyroid dogs, euthyroid dogs with non-thyroidal illness (NTI) and clinically healthy 
dogs.
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There were significantly more TgAb-positive results in the hypothyroid group 
compared to the euthyroid and the healthy groups (p<0 . 0 0 1  in each case) and in the healthy 
group compared to the euthyroid group (p=0.02). There were significantly (p=0.01) more 
TgAb-equivocal results in the hypothyroid group compared to both the euthyroid group 
and to the euthyroid and healthy groups combined but there was no significant difference in 
the distribution of results between the euthyroid and the healthy group.
Four dogs in the healthy group were positive for TgAb. Three of these four dogs 
were entire female bearded collies and the remaining one was an entire male rottweiler. 
Basal thyroid hormone analyses from these dogs are presented in Table 22 and supported 
euthyroidism in two and hypothyroidism in two as evidenced by subnormal total T4 and 
free T4 and markedly elevated cTSH concentrations. One o f the biochemically hypothyroid 
dogs had mild dermatological changes (slight scurfing) which resolved after the institution 
of THRT. The owners of the remaining hypothyroid dogs elected not to treat the case since 
no clinical abnormalities were apparent. No clinical abnormalities have subsequently 
developed in this latter case during a follow up period o f 15 months.
Animal
Basal total 
T4 (nmol/L)
free T4 
(pmol/L)
cTSH
(ng/ml)
BC 09 10.9 4.11 11.3
BC 14 30.4 16.96 0.46
BC 15 14.4 4.74 9.31
R W 1 19.0 13.28 0.19
Table 22. Concentrations o f serum basal total and free thyroxine (T4), and thyrotropin 
(cTSH) in apparently healthy but thyroglobulin autoantibody (TgAb) positive dogs.
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□  Positive
□  Equivocal
□  Negative
Figure 23. Distribution of circulating thyroglobulin autoantibody (TgAb) results from 42 
dogs with confirmed hypothyroidism.
□  Equivocal
□  Negative
Figure 24. Distribution of circulating thyroglobulin autoantibody (TgAb) results from 77 
dogs investigate for hypothyroidism but in which an alternative diagnosis was confirmed.
□  Positive
□  Equivocal
□  Negative
Figure 25. Distribution of circulating thyroglobulin autoantibody (TgAb) results from 70 
clinically healthy dogs.
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There was no significant difference in age, sex or neutering status between TgAb- 
positive and -negative animals within each group although the TgAb-positive hypothyroid 
dogs (mean age 6 .6 , range 3.0-10.6 years) tended (p=0.09) to be younger than the TgAb- 
negative hypothyroid individuals (mean age 8.1, range 4.0-12.0 years).
The most commonly represented breeds and breed-types and the distribution of 
TgAb results within each category are summarised in Table 23. There was no statistical 
difference in the distribution of TgAb positive, equivocal or negative results when grouped 
according to breed-type.
Breed Number
Positive
TgAb Result 
Equivocal Negative
Collies 63 4 1 0 49
Retrievers 32 6 4 2 2
Terriers 2 0 1 3 16
Crossbreeds 13 1 2 1 0
Spaniels 1 1 0 1 1 0
Boxer 5 1 0 4
Doberman 5 0 0 5
Setters 5 0 0 5
Table 23. Distribution of thyroglobulin autoantibody (TgAb) results categorised by breed- 
type from hypothyroid dogs, dogs with non-thyroidal illness (NTI), and clinically healthy 
dogs. Only breed-types with at least five cases are presented.
The distribution of pedigree and non-pedigree status in the hypothyroid, euthyroid 
and healthy groups is detailed in Tables 24, 25 and 26, respectively. There was no 
significant difference in the prevalence o f TgAb-positive results between pedigree and non­
pedigree dogs either within each group or between groups, respectively.
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Pedigree Non-Pedigree
TgAb Positive 14 1
TgAb Equivocal 7 1
TgAb Negative 17 2
Total 38 4
Table 24. Thyroglobulin autoantibody (TgAb) results obtained from 42 hypothyroid dogs 
categorised by pedigree status.
Pedigree Non-Pedigree
TgAb Positive 0 0
TgAb Equivocal 5 0
TgAb Negative 67 5
Total 72 5
Table 25. Thyroglobulin autoantibody (TgAb) results obtained from 77 dogs with 
confirmed non-thyroidal illness (NTI) categorised by pedigree status.
Pedigree Non-Pedigree
TgAb Positive 4 0
TgAb Equivocal 1 0 1
TgAb Negative 46 9
Total 60 1 0
Table 26. Thyroglobulin autoantibody (TgAb) results obtained from 70 apparently healthy 
dogs categorised by pedigree status.
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There was no significant difference in basal total T4 , cTSH or free T4 concentrations 
between TgAb-positive, -negative or -equivocal dogs within the hypothyroid or euthyroid 
groups, respectively. There was no significant difference in hormone results between 
TgAb-negative and -equivocal dogs within the healthy group. Statistical analyses were not 
performed in TgAb-positive animals within this group because of subsequent confirmation 
of hypothyroidism in two of the four animals.
Two of the hypothyroid TgAb positive dogs were subsequently euthanatised for 
reasons unrelated to their thyroid disease. In each case, post-mortem examination, 
including thyroid gland histopathological examination was performed. One case was an 11 
year old entire male boxer euthanatised as a result of a pancreatic carcinoma. The thyroid 
glands from this dog were grossly small and pale. Histopathological examination o f the 
thyroids revealed diffuse multifocal lymphocytic thyroiditis consistent with the TgAb result. 
The second dog was an eight year old entire male border terrier euthanatised as a result of 
encephalitis of unknown aetiology. The thyroid glands from this dog were grossly small and 
pale. Histopathological examination o f the thyroids revealed diffuse thyroidal atrophy and 
replacement o f normal tissue with adipose tissue. No inflammatory infiltrate was present. A 
diagnosis of idiopathic atrophy was made in this case.
All three of the euthyroid, and one of the four hypothyroid dogs with diabetes 
mellitus in whom TgAb was measured were negative for the autoantibody. The remaining 
three hypothyroid cases with concurrent diabetes mellitus were TgAb positive.
In seven hypothyroid dogs with reference range cTSH concentrations, TgAb was 
positive in three (43 %), equivocal in one (14 %) and negative in three (43 %) of them. In 
nine euthyroid dogs with elevated cTSH concentrations TgAb was equivocal in one (11 
%), and negative in eight (89 %) of them.
7.5. DISCUSSION
The demonstration of TgAb in over a third of hypothyroid dogs is broadly similar to 
previous reports (Gosselin et al, 1980; Haines et al, 1984a; Vollset & Larsen, 1987). 
However in those studies whilst the overall percentage was similar to the results reported 
here, there was considerable method-dependent variation between individual cases which 
reduced the diagnostic utility of those assays. Using the same assay as the present study, 
Nachreiner et al, (1998) reported TgAb in just over half of 171 hypothyroid dogs. 
However some of those animals were specifically selected for the presence of thyroid
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hormone autoantibodies which would bias the results in favour of TgAb positivity. The true 
prevalence of TgAb in hypothyroid dogs is therefore likely to be nearer that reported in the 
present study.
None o f the dogs with NTI, including those with non-thyroidal endocrine diseases, 
were positive for TgAb although five ( 6  %) were equivocal. These equivocal cases were 
spread between cardiovascular (n=2 ), dermatological (n=l), endocrinological (n=l), and 
neurological (n=l) diseases. In comparison with the non-thyroidal diseases evaluated by 
Nachreiner et al, (1998) no euthyroid dogs in the present study had recognised calcium 
disorders although cases with hyperadrenocorticism (n=4), diabetes mellitus (n=4), obesity 
(n=9) and hypoadrenocorticism (n=2) were present and negative for TgAb. The high 
prevalence of TgAb positive results associated with non-thyroidal diseases previously 
reported does not appear to be a significant problem with the current assay (Haines et al, 
1984a; 1984b). This supports the conclusions of Nachreiner et al, (1998), confirming the 
much improved specificity of this assay for thyroid disease compared with previous 
methods.
TgAb-positive and -equivocal results occurred in four (6 %) and 11 (16%) of 70 
apparently healthy dogs, respectively. Two of these TgAb-positive dogs had additional 
biochemical evidence of hypothyroidism as did two o f three apparently healthy TgAb- 
positive dogs reported by Nachreiner et al, (1998). This suggests that the presence of 
circulating TgAb in apparently healthy animals could be an early indicator of thyroid 
disease as it is in humans (Gordin & Lamberg, 1975). Of particular interest was the 
extreme elevations in cTSH concentrations found in two of the four cases in the present 
study which approximated 6-7 times that commonly encountered in spontaneous primary 
hypothyroidism. It is therefore plausible that very elevated circulating cTSH concentrations 
may occur in the early, possibly pre-clinical stages of thyroiditis, as the functional capacity 
of the thyroid gland begins to fall. However, because biochemical euthyroidism was 
demonstrated in the remaining two dogs, a TgAb-positive result should not be presumed to 
coexist with thyroid dysfunction. Certainly, caution is advised in over-interpretation of such 
results and additional clinical and clinicopathological monitoring for hypothyroidism is 
required to allow a confident diagnosis. In a previous study, two of eleven TgAb-positive 
euthyroid dogs followed for 18 months developed biochemical but not clinical evidence of 
hypothyroidism (Haines et al, 1984b) although other similar cases showed no such 
progression during this time. The possible subsequent development o f hypothyroidism in
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TgAb-positive healthy dogs could not be supported or refuted in the present study because 
of limited follow-up information. Further study is undoubtedly required in this area.
The importance of TgAb-equivocal results was not addressed by either Siliart & 
Stambouli, (1997) or Nachreiner et a l , (1998). The TgAb assay manufacturers recommend 
re-testing equivocal patients at a later date, although there is no data available to suggest 
whether such an individual is likely to become TgAb-positive or -negative with time. In the 
present study, thyroid hormone concentrations were not significantly different in TgAb- 
equivocal, -negative or -positive cases within each group, which is not supportive of a 
progressive change in TgAb status from negative through equivocal to positive as the 
transition from euthyroidism to hypothyroidism occurs. However, such results may be 
influenced by the relatively small number of cases within each category. TgAb-equivocal 
results were significantly more prevalent amongst hypothyroid than euthyroid dogs, 
suggesting that it may be prudent to undertake further investigation of thyroid function in 
TgAb-equivocal dogs. Lengthier longitudinal case studies will help in clarifying the 
association of TgAb with the stage of thyroid disease.
The TgAb-positive hypothyroid dogs tended to be younger than the TgAb-negative 
hypothyroid supporting the results of Nachreiner et al., (1998). This may be related to the 
earlier onset of hypothyroidism in individuals at risk from lymphocytic thyroiditis (Feldman 
& Nelson, 1996). Alternatively the results may be consistent with a progression from TgAb 
positivity to -negativity with increasing age and disease progression. Nachreiner et al., 
(1998) identified a similar trend and suggested it was indicative o f a progression o f cases 
from lymphocytic thyroiditis in the earlier stages of disease, to idiopathic atrophy in the 
latter (Nachreiner et al, 1999). Whilst this is certainly a possibility, the TgAb results 
themselves are not confirmatory of such a progression and appropriate longitudinal studies 
may help to clarify this issue.
There was no evidence of sex or neutering status influencing TgAb which agrees 
with the findings of previous studies (Haines et al., 1984b; Vollset & Larsen, 1987; Beale 
et al, 1990). This also supports the findings in Chapter 5 in which no influence of sex or 
neutering status on the presence of hypothyroidism was identified.
Previous studies have documented thyroiditis within particular breeds and families 
of dogs (Haines et al., 1984b; Conaway et al, 1985). However whilst individual families 
were not evaluated, no such breed effect was identified in the present study. Although 
several breeds were present in sufficient number to allow statistical analysis, the analysis 
was limited by the small number of cases o f each breed within the hypothyroid category
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specifically. This decreased the likelihood of identifying a genuine breed-predisposition 
since the hypothyroid dogs were represented by a large number o f different breeds. Of the 
breed types studied, retrievers had the greatest percentage of TgAb positive results (19 %) 
as a proportion of the total number evaluated. Although this was markedly larger than the 
next highest value ( 6  %) which occurred in collies, the finding was not statistically 
significant. Evaluation of a larger number of affected dogs is likely to clarify the issue 
regarding the influence of breed on the development of thyroiditis and hypothyroidism.
There was no evidence that pedigree status had a significant effect on the 
prevalence of abnormal TgAb results. As was the case for statistical analysis of breed type, 
evaluation of the effect o f pedigree was limited by the small number o f dogs in the non­
pedigree categories. Whilst the distribution of pedigree and non-pedigree cases could not 
have been predicted before commencement of this study, it is likely that considerably larger 
numbers of cases will be required, including the analysis of specific families of dogs to 
further evaluate this subject.
Of particular interest is the confirmation of idiopathic atrophy in a TgAb positive 
dog. This finding is in contrast to the results of Nachreiner et al, (1998) in which TgAb 
was negative in 10 dogs without histopathological evidence of lymphocytic thyroiditis. One 
possible explanation for this finding is that lymphocytic thyroiditis and TgAb production 
precede the development o f idiopathic atrophy in a number o f hypothyroid dogs. This 
would be consistent with the finding o f TgAb positive results in younger hypothyroid dogs 
than those with TgAb negative results. However, this would not necessarily explain the 
discordancy between the results of the present study and that of Nachreiner et al., (1998) 
and the reason for this finding remains unclear. The possible explanations for this finding in 
the present study are undoubtedly worthy of further study.
TgAb was measured from four of the five hypothyroid dogs with concurrent 
diabetes mellitus discussed in Chapter 5. Of these four cases, TgAb was positive in three 
and negative in one of them. In contrast, three dogs in the euthyroid group with diabetes 
mellitus were all negative for TgAb. Whilst the numbers of cases are inadequate to allow 
meaningful statistical analysis, this findings may be consistent with the presence of an 
autoimmune polyglandular syndrome as the cause of the concurrent hypothyroidism and 
diabetes mellitus in the three TgAb positive dogs (Dixon, 1998).
Serum cTSH is now routinely measured alongside total T4 or free T4 to establish a 
diagnosis of hypothyroidism and these data have been presented in Chapter 4. However a 
subset of hypothyroid dogs have reference range cTSH concentrations and euthyroid dogs
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can have cTSH results within the hypothyroid range (Peterson et al, 1997, Scott- 
Moncrieff et al, 1998). TgAb measurement correctly identified thyroid abnormalities in 
43% of hypothyroid dogs with reference range cTSH concentrations. This confirms the 
value of TgAb measurement in these cases because whilst a negative TgAb result cannot 
exclude hypothyroidism a positive result strongly supports it. In addition, the presence of 
TgAb in a similar proportion of hypothyroid dogs with the expected rise in serum cTSH 
concentration to those with unexpectedly “normal” cTSH results is strong evidence that 
central hypothyroidism is not a common cause of such discordant results.
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CHAPTER 8
THE EFFECT OF NON THYROIDAL ILLNESS AND DRUG THERAPY 
ON TESTS OF THYROID FUNCTION
8.1 LITERATURE REVIEW 
Introduction
The confusion surrounding the interpretation of thyroid function tests in veterinary 
medicine has possibly been the most important reason why the diagnosis o f canine 
hypothyroidism remains problematic. Much of the confusion results from the influence that 
NTI and a variety of commonly used drug therapies have on these tests (Panciera, 1990b; 
Feldman & Nelson, 1996). Whilst there is normally a degree of overlap in the results 
obtained from healthy and hypothyroid dogs, this overlap is considerably greater between 
euthyroid dogs with NTI or those dogs receiving certain therapies, and those with 
hypothyroidism. Additionally, in general veterinary practice and particularly in referral 
institutions, it is common for those dogs being investigated for hypothyroidism to already 
have received drug therapy of one type or another. Consequently, a clear understanding of 
the effect that NTI and drug therapy may have on these tests is particularly important when 
interpreting them in dogs being investigated for suspected hypothyroidism.
Effects of Non-thyroidal Illness on Thyroid Hormones
General Concepts
Several mechanism are responsible for the complicated metabolic alterations in thyroidal 
physiology that occur in NTI. These include reduction in transport binding protein 
concentrations and affinity for thyroid hormones, altered peripheral hormone metabolism 
and production rates, and decreases in peripheral thyroid hormone receptor function. In 
humans various clinicopathological changes can develop during and following NTI and 
these have recently been summarised by Beckett & Wilkinson, (1998). The changes include 
a decrease in circulating TSH during acute illness but an increase, often into the 
“hypothyroid range”, during the recovery phase. Total T3 concentrations may decrease due 
to impaired hepatic uptake of T4 and reduced peripheral conversion of T4 to T3. Circulating 
rT3 values increase due to impaired clearance and both the concentration of thyroid 
hormone binding proteins and their affinity for the thyroid hormones may decrease causing
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a reduction in circulating total thyroid hormone concentrations. These mechanisms are 
discussed in more detail below. Some but not all of these features have now also been 
established in dogs with NTI.
The most commonly recognised clinicopathological thyroidal abnormality in human 
patients with NTI is the “low T3 syndrome” in which serum total T3 concentrations are 
suppressed whilst total T4 values remain normal. In more severe, frequently life threatening 
illnesses, suppression of both serum total T4 and total T3 concentrations can occur and is 
termed the “low T4 state o f medical illness” (Nicoloff & LoPresti, 1996). Previous human 
and veterinary reports have used the phrase “euthyroid sick syndrome” synonymously with 
what is strictly the low T3 syndrome (Wartofsky & Burman, 1982; Ferguson, 1988; 
Peterson & Ferguson, 1989). However, recently the term “euthyroid sick syndrome” has 
been more commonly used to describe the general suppressive effect of NTI on the thyroid 
gland (Ferguson, 1994; Feldman & Nelson, 1996; Nicoloff & LoPresti, 1996).
The Low T3 Syndrome in Humans
In humans the “low T3 Syndrome” is the most common thyroidal derangement associated 
with NTI and occurs in between 25 and 50 % of hospitalised patients (Bermudez, Surks & 
Oppenheimer, 1975). Both total and absolute free T3 concentrations are usually depressed 
whilst total and free T4 concentrations remain normal. The principal cause of the low T3 
syndrome is related to reduction in the peripheral activity of the 5-D enzyme. Reduced 5'- 
D activity causes a reduction in peripheral conversion o f T4 to T3 and of rT3 to 3 ,3 '-T2 . 
Consequently there is a decrease in circulating total T3 and an increase in total rT3 
concentrations (Wartofsky & Burman, 1982). It is now clear that the increase in rT3 
concentration which occurs in NTI is not due to increased production from T4, but results 
solely from the reduced disposal rate (LoPresti, Gray & Nicoloff, 1991). Whilst there is a 
reduction in the production rate of T3, the conversion o f T4 to rT3 remains unaffected, 
neither significantly increasing or decreasing. However, since total T4 concentrations do not 
increase in NTI, there is clearly a discrepancy in T4 disposal products. Evaluation of other 
pathways of T4 disposal suggest that NTI may be associated with an increased production 
of T3 sulphates (T3-S) (Chopra, Wu, Teco & Santini, 1992).
An elevation in rT3 has been documented in numerous NTI in humans including 
acute pyrexia, sepsis, advanced human immunodeficiency virus (HIV) infection and chronic 
cirrhosis (Chopra, Chopra, Smith, Reza & Solomon, 1975; Nicoloff & LoPresti, 1996). 
This feature has been used to assist in the differentiation of NTI from hypothyroidism since
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in hypothyroidism total rT3 concentrations are generally subnormal (Chopra et al, 1979a). 
The notable exception is renal disease in which rT3 may remain normal despite markedly 
depressed total T3 concentrations (Kaptein, Feinstein, Nicoloff & Massry, 1983).
The magnitude of depression o f total and free T3, and the associated increase in 
total and free rT3 in the low T3 syndrome has been well correlated with the clinical outcome 
in humans and therefore has prognostic utility. The time taken for recovery as well as the 
likelihood of recovery can both be inferred from the severity of the changes. Similarly, the 
reversal of these abnormalities is typically associated with clinical improvement and a more 
favourable prognosis (DeGroot, Larsen & Hennemann, 1996).
It is seemingly sensible that during times of illness or physiological stress there is a 
reduction in total and free T3 concentrations, the most potent of the thyroid hormones, in 
an attempt to reduce catabolic activity and thereby conserve energy. However, the basic 
question of thyroidal status within the tissues themselves in NTI remains largely 
unanswered. The absence of clinical hypothyroidism in the low T3 syndrome suggests that 
tissue euthyroidism is probably maintained although this is rather speculative. Whilst actual 
tissue thyroid hormone concentrations are reduced, NTI and starvation are also associated 
with a decrease in the number o f nuclear T3 receptors in both humans and experimental 
animal models. Easier saturation o f the total nuclear receptor load despite reduced 
hormone concentrations has been suggested as one possible mechanism whereby “relative” 
euthyroidism is maintained despite reduced thyroid hormone concentrations (DeGroot et 
al, 1996). Nevertheless this issue remains unclear and following extensive studies on 
fasting patients, it is generally accepted that NTI is probably associated with a mild form of 
thyroid deficiency that limits the breakdown of skeletal muscle for gluconeogenesis 
(Nicoloff & LoPresti, 1996). However, such a functional hypothyroid state is unlikely to be 
present in all tissues since circulating TSH concentrations do not increase.
The Low T4 state of Medical Illness in Humans
The low T4 state of medical illness, whereby total T4 and total T3 concentrations are 
depressed is a less frequent finding in humans with NTI than it is in dogs (Ferguson, 1988) 
and is certainly less common than the low T3 syndrome. Classically this condition is 
characterised by subnormal total but normal free thyroid hormone concentrations although 
in very severe illnesses absolute free hormone concentrations may also be affected. 
Typically, humans progress from the low T3 syndrome to the low T4 state of medical illness 
as the severity of their disease increases. This process may take days or weeks if the
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progression is gradual, but can occur within hours after major trauma, shock or sepsis 
(Vitek & Shatney, 1987). Several mechanisms are responsible for the reduction in thyroid 
hormones which occurs in severe NTI and these are discussed below.
Thyroid hormone binding proteins are frequently subnormal in the low T4 state of 
medical illness as a result of impaired synthesis or as a consequence of the acute phase 
response. The severity and chronicity of the illness will influence the extent of these 
changes. In humans with NTI, there is also a switch from the hepatic production of normal 
TBG to a desialated variety of the protein known as “slow TBG” (Beckett & Wilkinson, 
1998). This modified protein has an affinity for the thyroid hormones only approximately 
one tenth that of normal TBG. Since in humans TBG is the major thyroid hormone binding 
protein this can significantly reduce the total thyroid hormone carrying capacity in NTI.
The presence of inhibitors of thyroid hormone protein binding are important 
determinants o f thyroid hormone concentrations in the low T4 state of medical illness. In 
contrast to the low T3 syndrome in which free T4 is relatively unaffected, the circulating 
free T4 fraction is usually increased in the low T4 state of medical illness suggesting altered 
protein binding (Ferguson, 1997). Since the first identification of serum THBI by Chopra et 
al, (1979b) their presence in up to 90 % of patients with NTI has been confirmed (Chopra, 
Huang, Beredo, Solomon. & Chua Teco, 1986). These serum THBI cause displacement of 
hormone from the carrier proteins resulting in an increase in the circulating free hormone 
fraction. This in turn suppresses pituitary synthesis and release o f TSH. The stimulus for 
thyroid hormone production is consequently reduced and total circulating thyroid hormone 
concentrations decrease until the free hormone concentration returns to normal. In patients 
with NTI, free hormone concentrations are therefore usually maintained despite the 
subnormal total hormone concentrations. It is the THBI that are thought to be responsible 
for this physiological effect (Oppenheimer, Schwartz, Mariash & Kaiser, 1982). These 
binding inhibitors may originate from leakage from diseased tissues but an increase in the 
concentration of “normal” serum constituents has also been proposed as a possible 
mechanism (Chopra, Solomon, Teco & Eisenberg, 1982) and the binding inhibitors have 
been shown to have the characteristics o f normally occurring unsaturated fatty acids such 
as oleic acid (Haynes, Lockett, Farmer, Fitch, Bradwell, Sheppard & Ramsden, 1989).
An analytical consequence of elevated THBI concentrations occurs in free hormone 
assays which require any degree o f sample dilution as part of the procedure. Dilution of 
samples containing THBI causes a reduction in the in vitro THBI concentration. This 
reduces the inhibitory effects of THBI on hormone protein binding and consequently the in-
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vitro free hormone concentration falls. The dialysis o f samples can be shown to be 
equivalent to dilution in this regard. Therefore, dialysis methods for free hormone 
estimation require that the semi-permeable membrane does not allow transit of THBI 
between dialysate and dialysand compartments (Ekins, 1985).
In humans, there is a strong correlation between the magnitude of thyroid hormone 
suppression and the severity of illness and therefore the likelihood of survival (Slag, 
Morely, Elson, Crowson, Nuttall & Shafer, 1981). Consequently thyroid hormones are 
used as a non-specific prognostic indicator in patients with NTI and indeed the prognostic 
value of suppressed circulating thyroid hormone concentrations alone is similar to that of 
more complex multifactorial prognostic methods such as the Apache II scoring system 
(Kaufinan, Dlott, Townsend, Mizuno, Weiner & Nicoloff, 1988). Similarly, the increase in 
the free T4 fraction has also been demonstrated to inversely correlate with the likelihood of 
surviving (Kaptein, Weiner, Robinson, Wheeler & Nicoloff, 1982). Similar studies have 
confirmed the correlation of low total T4 with increased mortality in hospitalised cats 
(Mooney, Little & Macrae, 1996) and a similar association is expected in the dog (Feldman 
& Nelson, 1996).
Thyrotropin in Non-thyroidal Illness
Endogenous circulating basal TSH concentration and TSH response to TRH administration 
are both significantly reduced in humans with severe NTI (Nicoloff & LoPresti, 1996). In 
contrast, even in the earliest stages of primary hypothyroidism in humans, TSH 
concentrations increase, as does the TSH response to TRH administration. Since this 
response is the opposite to that of patients with NTI it has been considered as evidence that 
tissue euthyroidism is maintained in NTI. However, this is certainly not conclusive evidence 
since it is known that NTI may suppress the secretion o f TSH in patients with concurrent 
primary hypothyroidism (DeGroot et al, 1996).
Sumita et al., (1994) prospectively evaluated 41 human patients with various 
critical illnesses of whom ultimately 18 survived and 23 died. Mean ± s.e.m. basal 
endogenous TSH (pU/ml) concentration was significantly lower in the non-surviving 
patients (0.23 ± 0.05) compared to the surviving patients (1.35 ± 0.33). Peak TSH 
concentration after TRH administration was also significantly blunted in the non-survivors 
(1.42 ± 0.38) compared to the survivors (7.52 ± 1.53). Only five patients had a normal 
TSH response to TRH, and all o f these individuals survived.
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An elevation in endogenous circulating glucocorticoids may be at least partly 
responsible for the reduction in circulating basal TSH values in NTI. Other mechanisms 
causing suppression may include an elevation in cytokines plus opioidergic, dopaminergic 
and somatostatinergic pathways although these are currently less well characterised 
(Scanlon & Toft, 1996). The fall in serum TSH in these patients contributes to the decrease 
in thyroid hormone concentrations seen during NTI.
Effect of Non-thyroidal Illness on Thyroid Function in Dogs
In dogs, subnormal circulating total T4 concentrations have been reported in 
hyperadrenocorticism, diabetes mellitus, hypoadrenocorticism, chronic renal failure, hepatic 
diseases and a variety of medical illnesses requiring intensive care (Ferguson, 1994). These 
conditions are typically also associated with reduced circulating total T3 concentrations 
(Ferguson, 1988). Despite these studies, the effect o f NTI on thyroid function is less well 
characterised in dogs than it is in humans (Panciera, 1990b). Nevertheless, it appears that 
certainly in comparison with humans, suppression o f both total T4 and T3 is more common 
than is suppression of T3 alone.
Total Thyroid Hormones
Peterson et al., (1984) evaluated total T4 and T3 concentrations in 102 dogs with 
spontaneous hyperadrenocorticism. Subnormal total T4 and T3 concentrations occurred in 
58 (56.9 %) and 53 (52.0 %) of the dogs, respectively. O f the 102 cases, total T4 alone was 
depressed in 16 (15.7 %), total T3 alone was depressed in 11 (10.8 %), and in 42 (41.2 %) 
cases both hormones were subnormal. In 20 cases monitored after therapy for 
hyperadrenocorticism, mean total T4 and T3 concentration increased significantly, and both 
hormones normalised in all but one o f the dogs. In the same study, circulating total T4 
concentration was also determined in another 2 2  dogs with spontaneous 
hyperadrenocorticism before and four hours after TSH administration. Both pre and post 
total T4 results were significantly depressed compared with those from healthy dogs. 
However, there was a significant increase in total T4 after TSH administration, increasing 
by at least 100 % in all cases. Thyroid gland histopathological examination in 33 of the 
hyperadrenocorticoid dogs prior to therapy did not show evidence of primary thyroidal 
disease. The authors therefore concluded that the changes in thyroid hormone 
concentrations were most likely the result o f either glucocorticoid mediated thyrotropin
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suppression, altered serum thyroid hormone binding or alterations in peripheral thyroid 
hormone metabolism.
Ferguson, (1988) reported subnormal total T4 and T3 concentrations in dogs with 
diabetic ketoacidosis and suggested that the severity of the illness and adequacy o f therapy 
were also important factors in this regard. However, the detailed data on these cases were 
not provided.
Nelson et al, (1991) excluded hypothyroidism in 59 dogs in which hypothyroidism 
had been a diagnostic consideration, based on the results of bovine TSH response tests. 
The various NTI reported in these dogs consisted of allergic inhalant dermatitis, flea allergy 
dermatitis, pruritic superficial folliculitis, hyperadrenocorticism, idiopathic seborrhoea, 
peripheral neuropathy, food hypersensitivity and idiopathic generalised megaoesophagus. 
Total T4 concentration was subnormal in 12 (20 %) o f these cases. When categorised based 
on the type o f NTI, circulating total T4 concentrations were not significantly different 
between those dogs with hyperadrenocorticism or peripheral neuropathy compared with 
the hypothyroid dogs but were significantly lower in the hypothyroid group compared with 
each of the other NTI. Total T3 concentrations were not significantly different between any 
of the groups studied.
Paradis et al, (1991) evaluated circulating total T4 concentrations in 51 euthyroid 
dogs with various dermatopathies. Hypothyroidism was excluded based on TSH response 
test results. Subnormal total T4 concentrations were reported in seven (13.7 %) of the 
cases. However, the case material used in that study was pre-selected to exclude dogs with 
serious NTI. Therefore, the incidence o f subnormal total T4 results amongst the original 
study population, would almost certainly have been considerably greater than that reported.
Larsson, (1988) excluded hypothyroidism in 17 dogs with NTI based on failure to 
respond to THRT and in most cases categorisation was supported by TSH response test 
results. Subnormal total T4 and total T3 concentrations were reported in 10 (58.8 %) and 
one (5.9 %) of the cases respectively.
Vail, Panciera & Ogilvie, (1994) evaluated 83 dogs, either with or without 
neoplastic disease, and with or without chronic weight loss. Mean (± s.d.) total T4 and total 
T3 concentrations were 15.1 (± 4.4) nmol/L and 0.68 (± 0.16) nmol/L in cachexic tumour- 
bearing dogs, respectively both o f which were significantly lower than the corresponding 
values of 25.8 (± 4.9) nmol/L and 1.12 (± 0.19) nmol/L in healthy control dogs. Cachexic 
non-tumour-bearing dogs had corresponding values of 16.2 (± 6.2) nmol/L and 0.74 (± 
0.28) nmol/L which were also significantly lower than the results from the healthy dogs.
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The non-cachexic tumour-bearing dogs had total T4 and total T3 concentrations of 23.8 (± 
7.7) nmol/L and 1.02 (± 0.22) nmol/L, respectively which were not significantly different to 
those of the healthy dogs. The authors concluded that the degree of suppression of thyroid 
function was correlated with either nutritional status or more likely the severity of illness in 
dogs.
Elliot, King & Zerbe, (1995) evaluated circulating total T3 and T4 concentrations 
before and after bovine TSH administration in 109 dogs admitted to an intensive care 
facility. Dogs were classified as either hypothyroid or euthyroid based on the TSH response 
test results. Hypothyroidism was excluded in 67 of the cases and these were subsequently 
used for the remainder of the study. Decreased total T4 and total T3 concentrations 
occurred in 61 % and 56 % of all euthyroid cases, respectively. Thyroid hormone 
concentrations were evaluated by comparing results in those dogs which died of their 
illness (n=20), compared with those which did not die (n=47). O f the dogs that died, 75 % 
had subnormal (less than laboratory reference range) total T3 concentration compared to 49 
% o f those that survived. There was a direct correlation between the suppression of total 
T3 and likelihood of mortality. Neither pre nor post TSH total T4 concentration were 
significantly different between the survivors and non-survivors. However, both pre and 
post-TSH total T3 concentrations were significantly decreased in the dogs that died (0.99 ± 
0.26 and 1.48 ± 0.59 nmol/L, respectively) compared to the survivors (1.54 ± 1.24 and 2.2 
±1.01 nmol/L, respectively). The authors concluded that depressed total circulating T4 is 
the most common thyroidal derangement associated with life-threatening critical illness, but 
that the change in circulating T3 was more closely correlated with eventual outcome.
Peterson et al, (1997) investigated 108 dogs for possible hypothyroidism, and 
excluded the diagnosis in 54 of them based on the results o f TSH response tests. Depressed 
serum total T4 concentrations were reported in 10 (18.5 %) of the dogs. Circulating total 
T3 was measured in 38 of these cases and was below the reference range in three (7.9 %) of 
them.
Scott-Moncriefif et al, (1998) evaluated 49 dogs for hypothyroidism and based on 
TSH response tests excluded this diagnosis in 33 o f them. The specificity o f circulating 
total T4 estimation for hypothyroidism was 0.78. However, the individual thyroid hormone 
data were not provided.
Panciera, Helfand & SoergeL, (1995) evaluated the effect of administration of 
interleukin-2, an important mediator of inflammatory disease, to four adult dogs on total T4 
and total T3 concentration. There was a dramatic and rapid decrease in both thyroid
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hormones during administration of interleukin-2, with total T4 decreasing by 50-75 %, and 
total T3 decreasing by 70-80 % in all dogs. This model o f NTI mimicked the low T4 state of 
medical illness encountered in dogs with spontaneous NTI, and demonstrates the 
potentially profound effect that NTI may exert on thyroid hormone metabolism.
Several studies have examined the effect of NTI on serum total rT3 in the dog but 
have produced conflicting results. Larsson, (1987) reported elevated circulating total rT3 
concentrations in dogs with hepatic and renal disease, and diabetes mellitus but not 
hyperadrenocorticism which is similar to the changes which usually occur in humans. 
However, studies of fasted dogs have reported either no change, or even a slight decrease 
in rT3 concentrations (de Bruijne, Altszuler, Hampshire, Visser & Hackeng, 1981; 
Laurberg & Boye, 1984). In the report by Ferguson & Peterson, (1992) reviewed in more 
detail below, rT3 was measured in 42 dogs with hyperadrenocorticism and compared to 
results from 103 clinically healthy dogs. Mean rT3 concentration was significantly lower in 
the dogs with hyperadrenocorticism (0.17 nmol/L) compared to the healthy dogs (0.39 
nmol/L) with 48 % of the hyperadrenocorticoid dogs having subnormal values. The 
variation in rT3 results between studies may reflect differences between the thyroidal effects 
of glucocorticoid excess typical of hyperadrenocorticism and the other metabolic 
abnormalities such as 5-D activity and protein binding inhibition encountered in various 
other NTI.
Free Thyroid Hormones
The various methodologies available for free T4 estimation and their relative limitations 
have already been reviewed in Chapter 4. Only methods considered as genuine free 
hormone methods will be reviewed.
Ferguson, (1988) reported elevation in the free T4 fraction measured by equilibrium 
dialysis in 10 of 45 (22 %) dogs with spontaneous hyperadrenocorticism suggesting 
diminished serum protein binding. However, 13 (29 %) of the cases had subnormal 
absolute circulating free T4 results indicating that either reduced thyroidal hormonal 
secretion, most likely mediated via cTSH suppression, or enhanced thyroid hormone 
metabolism also contributed to the thyroidal changes. In the same report, the effect of 
experimental removal of renal tissue reducing glomerular filtration rate to approximately 2 0  
% of the pre-surgery values with the consequent induction of severe uraemia, on free T4 
concentration was evaluated. The free T4 fraction was reported to approximately double 
after the surgery whilst total T4 values decreased by approximately half. Consequently, the
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absolute free T4 concentrations remained approximately normal although the actual data 
were not provided.
Ferguson & Peterson, (1992) evaluated a free T4 method which was a modification 
of the indirect dialysis technique reported by Sterling & Brenner, (1966) in 42 dogs with 
hyperadrenocorticism and in 103 clinically healthy dogs. Broadly speaking, the results were 
similar to those reported previously by Ferguson, (1988). The mean free T4 fraction was 
significantly greater in the hyperadrenocorticoid dogs (0.15 ± 0.018 %) compared with the 
healthy animals (0.09 ± 0.003 %) indicative of reduced protein binding. An increased free 
T4 fraction, was present in 16 (38 %) of the hyperadrenocorticoid dogs. Despite this, the 
mean free T4 concentration was significantly lower in the dogs with hyperadrenocorticism 
(16.9 ± 2.3 pmol/L) compared with the healthy dogs (23.6 ± 1 .0  pmol/L). Although 
reduced protein binding was present in 16 cases, the total T4 concentration was within the 
reference range in seven of these dogs. Reduced peripheral conversion of T4 to T3 which 
commonly occurs in human patients with hyperadrenocorticism did not appear to occur to 
any great extent since few dogs had subnormal T3 to free T4 ratios. The authors concluded 
that the mechanism responsible for the changes in free T4 concentrations which occur in 
hyperadrenocorticism differed between humans and dogs. Reduced pituitary cTSH 
secretion was suggested as a possible cause of the thyroidal derangements in canine 
hyperadrenocorticism. This was supported by the failure of rT3 to increase as indicated 
previously.
Scott-Moncrieff et al, (1994) determined free T4 using a modified equilibrium 
dialysis kit in 74 dogs. These cases included healthy dogs, hypothyroid dogs and cases with 
a variety of NTI including hyperadrenocorticism, obesity, hypoalbuminaemia and 
megaoesophagus. Cases were classified based on clinical findings, routine diagnostic testing 
including TSH response testing, and the requirement for THRT. Mean (± s.d.) free T4 was 
significantly decreased in the hyperadrenocorticoid (18.02 ± 7.7 pmol/L) and hypothyroid 
dogs (2.6 ± 2.6 pmol/L) compared with the healthy animals (25.7 ± 10.3 pmol/L). Free T4 
was not significantly different between the other groups o f illnesses and the healthy cases. 
The authors provided no explanation to suggest why the free T4 results were affected by 
hyperadrenocorticism but not by the other illnesses and no data regarding the severity or 
duration of the conditions were provided.
Peterson et al., (1997) evaluated 54 euthyroid dogs in which clinical signs 
suggestive of hypothyroidism had been present but in which that diagnosis was excluded 
based on TSH response test results. Circulating free T4  was determined from these and
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from 150 clinically healthy dogs using the same modified equilibrium dialysis kit as used by 
Scott Moncrieff et al., (1994). A free T4 reference range was determined as the 5th to 95th 
percentiles of the healthy dogs’ results. Median free T4 concentration was 20 pmol/L in the 
dogs with NTI compared to 22 pmol/L in the healthy dogs and 2 pmol/L in the hypothyroid 
dogs. Four (7 %) of the dogs with NTI had a subnormal free T4 result compared with 53 of 
the 54 (98 %) hypothyroid dogs.
Thyroglobulin autoantibodies
A detailed review of the estimation of circulating TgAb in canine NTI has already been 
provided in Chapter 7. Those points will not be reiterated here. However, until the recent 
report by Nachreiner et al., (1998) none of the studies o f canine TgAb estimation utilised 
an assay which was considered adequately reliable. Consequently the apparently high 
prevalence of positive TgAb results from dogs with NTI was difficult to interpret. With the 
development o f the assay reported by Nachreiner et al, (1998), that technical difficulty has 
apparently now been largely overcome, and in that study positive TgAb results were 
identified in 3.4 % of 146 dogs with NTI including dogs with calcium disorders, 
hyperadrenocorticism, hypoadrenocorticism, diabetes mellitus and obesity. However, the 
selection of these limited categories of illnesses may not represent cases with other more 
wide ranging diseases. In particular, the selection o f dogs with hypoparathyroidism, 
hypoadrenocorticism and diabetes mellitus may increase the likelihood of including dogs 
with immune mediated endocrine disorders which are therefore prone to autoimmune 
thyroiditis (Dixon, 1998). The true prevalence of TgAb in dogs with truly wide ranging 
NTI therefore remains unclear.
Thyroid Hormone Therapy in the Treatment of Non-thyroidal Illness
Despite, as discussed above, the absence of a definitive answer to the question “is tissue 
euthyroidism maintained in the face of NTI ?”, there is convincing evidence that thyroid 
hormone replacement in patients with NTI is at best of no benefit and in fact may increase 
mortality. As already indicated in Chapter 6 , Brent & Hershman, (1986) studied the effect 
of intravenous T4 replacement therapy on mortality in hospitalised human patients with 
severe NTI and did not identity any effect o f such therapy on eventual outcome. Little, 
(1985) evaluated the effect of T4 therapy in male rats with decreased total and free T4 
concentrations as a consequence of experimental infection with Streptococcus pneumoniae.
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Those cases treated with T4 were significantly more likely to die and had a significantly 
decreased time to death compared to the control animals. The author concluded that the 
decrease in circulating thyroid hormone concentrations in NTI is beneficial and may serve a 
role in maintaining homeostasis by conserving energy. Studies on the effect of THRT in 
dogs with severe NTI and subnormal thyroid hormone concentrations have not been 
reported.
Effects of Drug Therapy on Thyroid Hormones
General Comments
The mechanisms by which pharmacologic agents alter thyroid hormone metabolism are 
varied but include changes in thyroid hormone secretion, protein binding, intracellular 
metabolism and peripheral conversion of T4 to T3 and rT3 (Meier & Burger, 1996). 
Numerous categories of drugs used in veterinary practice potentially interfere with thyroid 
hormone metabolism. These include glucocorticoids, anticonvulsants, quinidine, non­
steroidal antiinflammatory drugs, sulpha-containing antimicrobials and iodine-containing 
radiocontrast agents (Ferguson, 1994). However, in practice the most important of these 
are glucocorticoids and sulpha-containing antibiotics since they are frequently used in 
dermatological cases, a common clinical feature associated with hypothyroidism.
Glucocorticoids
In human patients receiving glucocorticoid therapy, a number of thyroidal abnormalities 
may occur. Broadly speaking, the effect of therapy is greatest on total T3 concentrations 
but in some patients, total T4 or free thyroid hormone concentrations may also decrease 
(Rosychuk, 1982). Glucocorticoids decrease TBG and TBPA production in humans which 
causes a reduction in the total circulating thyroid hormone pool. This primarily affects total 
T4 concentrations. There is also a direct suppressive effect on pituitary TSH production 
which contributes to the reduction in total T4 (Wilber & Utiger, 1969; Nicoloff, Fisher & 
Appleman, 1970). A similar effect has recently been reported in dogs (Dixon & Mooney, 
1997). A transient 'rebound' period during which TSH is temporarily elevated after the 
cessation o f glucocorticoid therapy is also recognised in humans and may last for up to a 
week after stopping the treatment (Wilber & Utiger, 1969; Nicoloff et al, 1970; Spencer et 
al, 1987). However, similar studies in the dog are lacking and currently the influence that 
this phenomenon may have on the interpretation of endogenous cTSH in the diagnosis of
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canine hypothyroidism is unclear. Glucocorticoids also inhibit the peripheral conversion of 
T4 to T3 and this can have a marked effect on circulating total T3 concentrations. Indeed, 
exogenous glucocorticoid therapy can reduce serum total T3 values by up to 40 % 
(Gambert, 1996).
Woltz, Thompson, Kemppainen, Munnell & Lorenz, (1983) demonstrated that the 
intramuscular administration of 2 . 2  mg/kg body weight prednisone given every other day to 
five healthy dogs significantly decreased plasma T3 within eight hours of therapy although 
total T4 did not significantly decrease until days nine and 11 o f treatment. Kemppainen, et 
al, (1983) administered 2.2 mg/kg body weight prednisone intramuscularly on alternate 
days to 10 healthy adult crossbreed dogs for 21 days. Thyroid function was evaluated 
throughout the experiment by measurement of resting total T4 and total T3 concentrations, 
and total T4 response to both TSH and TRH administration. Mean ± s.d. resting total T4 
and total T3 concentrations were significantly decreased in the treated dogs (9.3 ± 2.4 
nmol/L and 0.29 ± 0.04 nmol/L, respectively) compared with control dogs (39.5 ± 5.9 
nmol/L and 0.58 ± 0.06 nmol/L, respectively). The dogs given prednisone had significantly 
reduced total T4 and total T3 concentrations (23.8 ± 3.9 nmol/L and 0.37 ± 0.03 nmol/L 
respectively) four hours after intravenous administration of 250 jag TRH compared with the 
control dogs (55.5 ± 6.0 nmol/L and 0.87 ±0.1 nmol/L, respectively). However, results 
were not significantly different between the treated and untreated dogs four hours after 
intravenous administration of 0.4 i.u./kg body weight exogenous TSH. Laurberg & Boye, 
(1984) administered a single dose o f 12 mg dexamethasone to 12 healthy mixed breed dogs 
weighing between 18 and 24 kg. The route of drug administration was not indicated. There 
was no significant effect on total T4 concentrations within 48 hours after drug 
administration. A transient decrease in total T3 values occurred which was statistically 
significant at 24 hours but which had returned to near pre-treatment values by 48 hours. 
There was also a marked and statistically significant increase in total rT3 concentration after 
the drug administration which lasted for more than 48 hours. Torres et al, (1991) 
confirmed that basal total T4 and total T3 concentration, and total T4 response to TSH 
administration were significantly decreased within 24 hours o f oral administration of 1.1 
mg/kg body weight prednisolone twice daily to 12 healthy beagle dogs. However, the same 
drug used orally at 0.55 mg/kg body weight twice daily for a month did not significantly 
alter serum total T4 concentration although it did significantly reduce total T3 values 
(Moore, Ferguson & Hoenig, 1993).
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It is clear from these studies that the steroid type, dose, length o f therapy and route 
of administration can profoundly influence the magnitude and duration of these effects in 
both humans and dogs.
Sulphonamide Antibiotics
Panciera & Post, (1992) evaluated the effect of sulphadiazine-containing antibiotics at a 
therapeutic dose rate (12.5 mg/kg) on circulating thyroid hormones in six clinically healthy 
dogs. There was no apparent effect of the medication on mean total T4 , total T3 or free T4 
concentration at any time during the study period. Neither was there any effect of the drug 
on total T4 response to TSH administration.
Hall et al, (1993) evaluated the effect of administration of sulphamethoxazole- 
containing antibiotics at a standard therapeutic dose (30mg/kd twice daily) to 2 1  dogs with 
pyoderma and normal baseline thyroid hormone concentrations. Six weeks after starting 
therapy, there was a significant suppression o f mean basal total T4 concentration. In three 
dogs a TSH response test was performed and in each case there was a reduction in post- 
TSH total T4 concentration was reported although the data were not provided. The serum 
total T3 concentrations were reduced in 13 of the 21 dogs six weeks after starting therapy 
but the reduction was not statistically significant in the group as a whole.
Using the same drug and dosing regime as Hall et al, (1993), Campbell et al, 
(1996) demonstrated suppression of both total T4 and total T3 and elevations in cTSH 
concentrations in 12 clinically healthy dogs within three weeks of starting therapy. The 
cTSH values returned to normal three weeks after the cessation of treatment. Total rT3 
concentrations were also reduced by therapy, suggesting that the effects on thyroid 
hormone concentrations most likely resulted from direct thyroidal suppression. The authors 
concluded that the drug can cause a temporary iatrogenic hypothyroidism and has the 
ability to produce confusing diagnostic test results.
Torres, McKeever & Johnston, (1996) reported the development of clinical signs 
and biochemical abnormalities consistent with hypothyroidism in a dog receiving 
sulphadiazine therapy at approximately 50 mg/kg for 18 weeks. Severe suppression of 
baseline thyroid hormone concentrations, and a complete absence of response to exogenous 
TSH administration was reported which resolved within seven days o f cessation of therapy.
Gookin, Trepanier & Bunch, (1999) reported the development of iatrogenic clinical 
hypothyroidism in a dog as a result of chronic trimethoprim-sulphadiazine therapy.
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However, the true role of this drug in that case was complicated by the concurrent 
administration of exogenous THRT.
Hall et al, (1993) investigated the mechanism of action of sulphonamides on 
thyroid hormone metabolism by radionuclide imaging and suggested it to be interference 
with iodide metabolism causing failure of thyroid hormone synthesis. The mechanism has 
been reported to be inhibition of TPO activity, an enzyme integral to several of the 
production steps in thyroid hormone synthesis (Gupta, Eggo, Uetrecht, Cribb, Daneman, 
Reider, Shear, Cannon & Spielberg, 1992; Doerge & Decker 1994). Clearly, based on the 
above studies, there is variation in the effect of sulphonamide preparations depending on 
both the preparation and dose used and the duration of therapy.
Phenobarbital Drugs
Gaskill, Burton, Gelens, Ihle, Miller, Shaw, Brimacombe & Cribb, (1999) evaluated serum 
total T4 and cTSH concentrations from 126 dogs with a provisional diagnosis of epilepsy. 
Seventy eight of the dogs were being medicated with phenobarbital whilst 48 were not. 
Mean total T4 was significantly decreased and mean cTSH results were significantly 
increased in the treated compared with the untreated dogs. However, the increase in cTSH 
concentration resulted in a mean value (0 . 2 2  ng/ml) which remained well within the 
reference range. Dogs who had suffered seizure activity within the 24 hours prior to blood 
testing had significantly depressed total T4 concentrations compared to those which had 
not. Kantrowitz, Peterson, Trepanier, Melian & Nichols, (1999) also evaluated the effect of 
phenobarbital administration on indices of thyroid function in 78 dogs with seizure 
disorders compared with 150 clinically healthy dogs receiving no medication. Of the seizure 
disorder cases, 55 were receiving phenobarbital alone, 15 received phenobarbital and 
bromide, and eight were treated with bromide alone. Total and free T4 (measured by 
equilibrium dialysis) concentrations were significantly lower in the dogs receiving 
phenobarbital compared with the healthy dogs. There was no significant difference in mean 
total T3 or cTSH concentrations between the two groups. One possible explanation for the 
difference in cTSH results reported between these two studies, is that in the report of 
Gaskill et al., (1999) the dogs who were not receiving phenobarbital were epileptic, and 
many ( 6 6  %) had had seizure activity within the previous 24 hours. This may have reduced 
the cTSH concentration within these “control” dogs. In contrast the unmedicated dogs 
studied by Kantrowitz et al, (1999) were clinically healthy. The difference in results may 
therefore be partly related to the difference in the “control” groups used.
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8.2 INTRODUCTION
The effect of NTI and commonly used drug therapies on tests of thyroid function is poorly 
understood in dogs compared to humans. Many of the reports evaluating thyroid function 
in dogs with NTI have principally studied the effect of hyperadrenocorticism on these tests, 
which is not necessarily representative o f the effects of other NTI. Most recent studies of 
thyroid function tests in dogs have been principally concerned with those cases in which 
hypothyroidism was a diagnostic consideration. However, little information exists on the 
performance of these tests in various other types o f NTI. Specifically, very limited data has 
been reported on the effect of various NTI on the more recently released kits for cTSH, 
free T4 by dialysis and TgAb estimation in dogs. In contrast to humans and cats, little is 
known about the role of thyroid hormone estimations as prognostic markers in dogs with 
NTI. The objective of this study was to investigate a number of clinical parameters and a 
comprehensive range of thyroid function-related tests in dogs with varying NTI, to identify 
clinical and endocrine markers of prognostic value in dogs with NTI.
8.3 MATERIALS AND METHODS 
Case Material and Sample Collection
A random selection of canine serum and plasma samples submitted to the diagnostic 
biochemistry and haematology laboratory for routine analysis were used for the study. 
Samples had been collected as part of the routine investigation of clinical cases at the 
DVCS. Samples used in the study therefore included those taken from cases suffering from 
a broad range of disease types and severity. Once aliquots of the samples had been removed 
for their primary analysis, the remainder was frozen and stored as described in Chapter 2. 
Breeds were categorised in the same manner as Chapter 5.
Data Storage and Handling
Case details corresponding to each of the samples were collected by conducting multiple 
interviews with the relevant clinicians in the DVCS. Data were manually recorded to hard 
copy at the time of interview and subsequently transferred to a computerised database 
(Microsoft Access for Windows 95, version 7.0, Microsoft Corporation) to facilitate 
permanent storage and data analysis. An example of a completed form is shown in 
Appendix 5. The data recorded included reference, signalment, clinical and historical 
features including the recent known drug therapies in each case prior to sampling. The 
fields containing data for disease category, disease course, diagnostic method and outcome
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had a limited number of options from which clinicians were requested to select only one. 
These categories are detailed in Tables 27 to 30. If more than one disease category applied 
to a particular case, the clinician was instructed to select the one which was considered to 
be the principal complaint. In cases in which multiple diagnostic methods were employed to 
establish the diagnosis, the method producing the most definitive information was selected.
Each case was assigned a clinical disease score (CDS) corresponding to each 
sample by the relevant clinician. The CDS was a number between one and 10, chosen by 
the clinician to indicate his or her opinion o f the “metabolic severity” of the dogs illness at 
the time the sample was collected. A value of one indicated a “normal” dog and a value of 
1 0  corresponded to a dog which the clinician considered “on point of natural death due to 
profound disease”. Clinicians were requested to use a linear scale between these limits to 
assign the CDS corresponding to each sample. The eventual outcome of cases were usually 
recorded weeks or months after sample collection by repeated interview with the relevant 
clinician or by referral to case notes.
For the purposes o f this study, drugs capable of suppressing thyroid function were 
considered to be NSAID’s, anticonvulsants, steroids, potentiated sulphonamides and 
THRT.
Sample Analysis
All samples were analysed for total T 4 ,  free T 4 ,  total T 3 ,  cTSH and TgAb as described in 
Chapter 2. It was not possible to measure each analyte in every case. Samples with a result 
less than the assay LoD (Chapter 3) were assigned a value equal to that LoD.
Data Analysis
The ages of the dogs in each of the outcome groups were compared using analysis of 
variance techniques with post hoc pairwise comparison of means using Newman-Keuls 
multiple range tests. The effect o f thyroid suppressive medication on hormone results was 
evaluated with Mann-Whitney U tests. The effect o f disease category and duration of 
illness on eventual outcome was evaluated by chi squared analysis. In any analysis in which 
chi squared testing was performed, only categories which had data cells from more than 
one variable, with five or more cases in each cell were included in the statistical analysis. In 
the case of dogs from which samples were obtained on more than one occasion, analyses 
were only performed using the first sample received from that animal. DPR analysis of the 
CDS results was performed as described in Chapter 2. Hormone results were considered
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abnormal if they were below (total T4, free T4 and total T3) or above (cTSH) the diagnostic 
limits identified in Chapter 4 otherwise they were considered “normal”.
Disease Category
Cardiovascular
Congenital
Dermatological
Endocrine
Gastrointestinal
General Medicine
Immune Mediated
Infectious
Neoplastic
Neurological
Ophthalmological
Orthopaedic
Other
Respiratory 
Soft Tissue 
Trauma 
Urogenital 
Unknown
Table 27. Disease categories from which clinicians selected the grouping which in their 
opinion best represented the primary disease.
Disease Course
Acute
Chronic
Table 28. Disease course options from which clinicians selected the grouping which in 
their opinion best represented the duration of the primary disease.
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Diagnostic Method
Clinical
Clinicopathology
Histopathology
Imaging
Other
Post mortem examination
Table 29. Diagnostic methods from which clinicians selected the technique which in their 
opinion provided the most definitive diagnostic data.
Outcome Description
Died The dog died during the hospitalisation period.
Euthanatised The dog was euthanatised, or the clinician’s 
recommendation to the owner was that the dog be 
euthanatised, as a result of the primary complaint.
Survived-partial recovery The dog survived and was discharged. However, the 
disease was not cured and/or required permanent 
medication to control the clinical signs.
Survived-fiill recovery The dog survived and was discharged. A full clinical 
recovery occurred without the need for continuing 
therapy.
Table 30. Classification of patient outcomes and their corresponding definitions.
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8.3 RESULTS 
Clinical M aterial
A total of 233 samples were collected from 205 dogs. Twenty one, six and one dogs had 
two, three and four samples collected, respectively. The mean ± s.d. age (range) o f all the 
dogs studied was 6 . 8  ± 4.0 (0.3 to 16.5) years. There were 87 female (46 neutered) and 
118 male (24 neutered) dogs. The most commonly represented breeds and breed-types are 
summarised in Table 31.
Breed Number of cases
Retriever 41
Spaniel 24
Terrier 23
Collie 2 0
German shepherd dog 15
Crossbreed 15
Boxer 6
Bullmastiff 5
Rottweiler 5
German shorthaired pointer 4
Akita 3
Bernese mountain dog 3
Great Dane 3
Lurcher 3
Poodle 3
Setter 3
St Bernard 3
Other 26
Total 205
Table 31. Distribution of the most common breeds and breed types investigated. The 
“other” category corresponds to 2 0  other breeds each represented by either one or two 
individuals.
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The number of cases in each of the disease categories and their eventual outcome 
are detailed in Table 32.
Disease Category Cases Died Euthanatised
Partial
Recovery
Full
Recovery
Cardiovascular 11 (5.4%) 0 1 8 2
Congenital 2 ( 1 .0 %) 0 1 0 1
Dermatological 5 (2.4 %) 0 0 5 0
Endocrine 8  (3.9 %) 0 1 6 1
Gastrointestinal 24(11.7% ) 0 3 9 1 2
General Medicine 13 (6.3 %) 0 3 4 6
Immune Mediated 9 (4.4 %) 0 0 5 4
Infectious 2 ( 1 .0 %) 0 0 1 1
Neoplastic 47 (22.9 %) 0 23 16 8
Neurological 16(7.8% ) 0 3 1 0 3
Ophthalmological 11 (5.4%) 0 0 4 7
Orthopaedic 29(14.1 %) 1 1 8 19
Other 4(1 .9% ) 0 0 0 4
Respiratory 9 (4.4 %) 0 2 6 1
Soft Tissue 2 ( 1 .0 %) 0 0 1 1
Trauma 6  (2.9 %) 0 0 1 5
Urogenital 5 (2.4 %) 0 1 2 2
Unknown 2 ( 1 .0 %) 0 0 1 1
Total 205 1 39 87 78
Table 32. Classification o f cases by principal disease category and eventual outcome.
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The principal diagnostic methods used to confirm the diagnosis in each case are 
outlined in Table 33. The diagnostic modalities which were most commonly used to 
confirm the diagnosis were clinical opinion, clinicopathological data, histopathological data 
and imaging techniques, each of which were of similar diagnostic utility.
Only one of 205 dogs died during the study. This case unexpectedly died whilst 
anaesthetised during surgery for orthopaedic disease, and was not expected to have died as 
a consequence o f the primary complaint. Of the 39 cases which were euthanatised, it was 
considered likely that the majority of them would have ultimately died of their primary 
disease if euthanasia had not been performed.
Diagnostic Method Cases
Clinical 45 (21.9%)
Clinicopathological 51 (24.9 %)
Histopathological 39(19.0% )
Imaging 63 (30.7 %)
Post mortem 6  (2.9 %)
Other 1 (0.5 %)
Total 205
Table 33. Classification of cases by the diagnostic method which was most heavily relied 
upon to achieve the final diagnosis.
Only neoplasia, gastrointestinal and orthopaedic disease categories had sufficient 
cases to evaluate any effect of disease category on eventual outcome. Dogs with neoplasia 
were significantly less likely to make a full recovery but significantly more likely to make a 
partial recovery compared with the other groups. Orthopaedic cases were significantly 
more likely to make a full recovery and less likely to make a partial recovery. Analysis of 
the likelihood o f euthanasia depending on disease category was not possible, since only one 
disease category (neoplasia) had a sufficient number of cases which were euthanatised to 
allow statistical analysis. However, approximately half of the cases in this group were
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euthanatised which is markedly more than in other groupings. Chi squared analysis o f the 
neoplasia group compared to all other dogs when considered as a single group, revealed a 
highly significant (p<0 .0 0 0 1 ) increase in the likelihood of euthanasia in the dogs with 
neoplasia compared with those with non-neoplastic illness.
Classification of individual cases by disease course and details of their respective 
outcomes are summarised in Table 34.
Disease Course Died Euthanatised
Partial
Recovery
Full
Recovery Total
Acute 0 15 9 19 43
Chronic 1 24 78 59 162
Total 1 39 87 78 205
Table 34. Number of dogs in each outcome category classified by disease course.
There was a significant difference in the outcome of cases depending upon the 
duration of illness, with acute cases being significantly more likely to be euthanatised but 
significantly less likely to make a partial recovery than chronic cases which were 
significantly less likely to be euthanatised.
The CDS results categorised by eventual outcome are detailed in Table 35. and 
displayed in Figure 26. Statistical analysis of the CDS result from the “died” category was 
not performed. The CDS was significantly different between each of the remaining three 
outcome groups. DPR analysis identified an optimal CDS cut-off value of 6.0 for the 
prediction of euthanasia. This value was associated with a sensitivity, specificity and DPR 
of 0.67, 0.86 and 0.53, respectively for predicting euthanasia. The mean (± s.d.) CDS was 
significantly increased in the acutely diseased patients (5.1 ± 2.7) compared with the 
chronically ill patients (3.4 ± 2.2).
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Clinical Disease 
Score (CDS)
Died Euthanatised
Partial
Recovery
Full
Recovery
Total
1-2 0 4 34 45 83
3-4 1 6 23 21 51
5-6 0 7 20 8 35
7-8 0 15 10 4 29
9-10 0 7 0 0 7
Mean ± s.d. 3.0 ± 0 6.36 ±2.55 3.63 ±1.98 2.67 ± 1.70 3.78 ±2.39
Table 35. Number o f dogs in each outcome category categorised by clinical disease score 
(CDS) groupings. A CDS value o f one indicates a “normal” healthy dog and a value o f 10 
corresponds to a dog “on point o f death due to profound disease”. A linear scale is 
interpolated between these values.
Percent
100% H
90%  - 
80% - 
70%  - 
60%  - 
50%  - 
40% - 
30% - 
20% - 
10% - 
0% JZJ
1-2 3-4 5-6 7-8
Clinical Disease Score (CDS)
□  Euthanatised
□  Partial recovery
□  Full recovery
9-10
Figure 26. Clinical disease scores (CDS) for 205 dogs categorised by eventual outcome. 
The columns in each CDS banding total 100 %. A CDS value o f one indicates a “normal” 
healthy dog and a value o f 10 corresponds to a dog “on point of death due to profound 
disease”. A linear scale is interpolated between these values.
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The outcome of cases categorised by age and gender is summarised in Table 36. 
Cases which made a full recovery were significantly younger than both those which were 
euthanatised and those which made a partial recovery. There was no significant difference 
in age between those dogs which were euthanatised and those which made a partial 
recovery. There was no significant difference in outcome of dogs based on either gender or 
neutering status.
Outcome
Age 
(mean ± s.d.)
Male
entire
Male
neutered
Female
entire
Female
neutered
Died 9.42 ± 0 0 0 0 1
Euthanatised 7.66 ±3.57 19 4 7 9
Partial Recovery 7.51 ±3.70 39 9 18 2 1
Full Recovery 5.64 ± 4.33 36 1 1 16 15
All Cases 6.84 ± 4.02 94 24 41 46
Table 36. Age and gender distribution o f cases categorised by eventual outcome.
Thyroid Hormones
The results of all analyses are detailed in Appendix 36. Of the first samples collected from 
each of the 205 cases, six were collected from dogs which were receiving or recently had 
received THRT. These six samples were excluded from all further analyses of all thyroid 
hormone parameters. Of the remaining 199 samples, 62 (31.2 %) were collected from dogs 
that had not recently received any medication at all. A total of 6 8  (34.2 %) samples were 
collected from dogs which had recently received medications capable o f suppressing 
thyroid function. The remaining 69 (34.7 %) samples were collected from dogs which had 
received other medications. There was no significant difference in eventual outcome of 
cases when those which had received any type of thyroid suppressive medication were 
compared with those which had not received these drugs. There was no significant 
difference in outcome of cases when those which had received some form of therapy were 
compared with those which had not received any type of medication. Results of analysis of
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total T4, free T4, total T3 and cTSH are summarised in Table 37. Combined results of all 
analyses are presented both before and after exclusion of cases which had recently received 
thyroid suppressive therapies.
Dogs receiving thyroid 
suppressive therapies
Dogs not receiving thyroid 
suppressive therapies
Combined
results
Total T4 (nmol/L) 16.93 (17.04) 20.65(15.47) 19.97(15.90)
Free T4 (pmol/L) 19.52(13.14) 22.75 (11.79) 21.55 (12.80)
Total T3 (nmol/L) 1.26 (0.58) 1.39(0.77) 1.35 (0.74)
cTSH (ng/ml) 0.12(0.20) 0.13 (0.22) 0.12(0.21)
Table 37. Median (semi-interquartile range (SIR)) circulating total T4, free T4, total T3 and 
cTSH concentration from 199 dogs with various diseases. Results are shown for dogs 
receiving thyroid suppressive therapies, for dogs not receiving thyroid suppressive therapies 
and for both groups of dogs combined.
Total T4 and free T4 concentrations were both significantly decreased in dogs 
receiving thyroid suppressive therapy compared to dogs which were not receiving such 
therapies. There was no effect of these drugs on circulating total T3 or cTSH 
concentrations.
Results of total T4, free T4, total T3 and cTSH analyses categorised according to 
eventual case outcome are summarised in Table 38. Dogs which were euthanatised had 
significantly decreased total T4, free T4 and total T3 concentrations compared to those 
which made a full recovery and significantly decreased total T3 concentrations compared to 
those which made a partial recovery. No other hormone parameters were significantly 
different between dogs with different outcomes. The data for total T4, free T4 and total T3 
categorised by outcome are displayed in Figures 27 to 29.
C hapter 8 234
Full Recovery Partial Recovery Euthanatised
Total T4 (nmol/L) 22.46(13.49)' 18.11 (19.34) 12.65 (14.58)2
Free T4 (pmol/L) 24.40(12.04)' 20.61 (11.44) 18.42 (15.65)2
Total T3 (nmol/L) 1.45 (0.76)' 1.40 (0.81)' 0.99 (0.50)2
cTSH (ng/ml) 0.09 (0.20) 0.15 (0.23) 0.11 (0.25)
Table 38. Median (semi-interquartile range (SIR)) circulating total T4, free T4, total T3 and 
cTSH concentrations in 198 dogs with various illnesses, categorised by their eventual 
outcome. Hormone results with a different superscript are statistically different from each 
other.
Percent D Euthanasia
□  Partial recovery
□  Full recovery
< 5 5-10 10-15 15-20 20-25 > 25
Total T4 (nmol/)
Figure 27. Circulating total T4 concentrations in dogs with various diseases, categorised by 
eventual outcome. Results are grouped in 5 nmol/L bandings. The columns in each banding 
total 100 %.
C hapter 8 235
Percent
60 -i
50 -
40 -
30 -
20 -
10  -
<5 5-10 10-15 15-20
Free T4 (pmol/)
20-25
□  Euthanasia
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Figure 28. Circulating free T4 concentrations in dogs with various diseases, categorised by 
eventual outcome. Results are grouped in 5 pmol/L bandings. The columns in each banding 
total 100 %.
□  Euthanasia
Percent
□  Partial recovery
□  Full recovery
0-0.5 0.5-1.0 1.0-1.5 1.5-2.0 2.0-2.5 > 2 .5
Total T3 (nmol/)
Figure 29. Circulating total T3 concentrations in dogs with various diseases, categorised by 
eventual outcome. Results are grouped in 0.5 nmol/L bandings. The columns in each 
banding total 100 %.
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Including the dogs which had received thyroid suppressive therapy, total T4 , free T4 
and total T3 concentrations were decreased in 70 of 197 (35.5 %), eight of 179 (4.5 %) and 
149 of 196 (76.0 %) cases, respectively. Total T4 alone was reduced in three (1.5 %), total 
T3 alone was reduced in 83 (42.3 %) and both hormones were concurrently reduced in 6 6  
(33.7 %) of these dogs. Of the dogs which had not received thyroid suppressive therapies, 
total T4, free T4 and total T3 were reduced in 39 of 131 (29.8 %), two of 120 (1.7 %) and 
96 o f 131 (73.3 %) cases, respectively. Total T4 alone was reduced in two (1.5 %), total T3 
alone was reduced in 83 (45.0 %) and both hormones were concurrently reduced in 37 
(28.2 %) of these dogs.
Since thyroid suppressive therapies were demonstrated to significantly alter total 
and free T4 concentrations, analysis o f the patterns of change of these parameters was 
performed after exclusion of those cases which had received these drugs. Circulating total 
T4 concentrations were subnormal in 39 cases. These cases encompassed a wide range of 
disease types which are summarised in Table 39. Of these cases, 13 (33.3 %) were 
euthanatised, 16 (41.0 %) made a partial recovery and 10 (25.6 %) made a full recovery. 
Dogs with subnormal total T4 values were significantly more likely to be euthanatised than 
dogs with normal total T4 results. Free T4 values were estimated in 36 of these 39 cases and 
were subnormal in only one (2.8 %) animal. This dog was ultimately euthanatised. Total T3 
was measured in 39 of the cases with subnormal total T 4 ,  and was decreased in 37 (94.9 %) 
of them.
Two dogs had decreased circulating free T4 concentrations and both of these cases 
were ultimately euthanatised. Circulating free T4 values were at the low end of normal (less 
than 10 pmol/L) in nine dogs representing seven disease categories. Three of these cases 
were euthanatised, three made a partial recovery and three made a full recovery.
Of the 149 dogs with subnormal total T3 values, one (0.7 %) died, 37 (24.8 %) 
were euthanatised, 57 (38.2 %) made a partial recovery and 54 (36.2 %) made a full 
recovery. Of these cases, 96 had not received thyroid suppressive therapy and total T4 was 
decreased in 37 (38.5 %) of them whilst two (2.1 %) had concurrent subnormal free T4 
values. Only one dog with a normal total T3 concentration was euthanatised. Dogs with 
subnormal total T3 values were significantly more likely to be euthanatised than dogs with 
normal values.
Circulating cTSH concentrations were not significantly different between dogs with 
different outcomes. Circulating cTSH results were increased in six of 182 (3.3 %) cases 
which were suffering from orthopaedic, neoplastic or neurological diseases. The total T4
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concentration was concurrently decreased in two cases. Both of these cases had systemic 
neoplasia. All six dogs with elevated cTSH results had normal free T4 values and were 
negative for TgAb.
Circulating TgAb were negative in 181 and equivocal in 18 dogs. No dogs were 
positive for TgAb. The distribution o f TgAb results between case outcome groups is 
summarised in Table 40. The TgAb result was of no discriminatory value in assessing the 
likely outcome of cases.
Disease category Number of dogs
Neoplasia 1 2
Gastrointestinal 7
Cardiovascular 3
Ophthalmological 3
Endocrine 2
General Medical 2
Neurological 2
Respiratory 2
Infectious 1
Immune mediated 1
Orthopaedics 1
Trauma 1
Urogenital 1
Unknown 1
Total 39
Table 39. Most common disease categories encountered amongst 39 dogs with subnormal 
total T4 concentrations.
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Positive
TgAb Result 
Equivocal Negative
Died 0 0 1
Euthanased 0 2 36
Partial recovery 0 7 76
Full recovery 0 9 6 8
Table 40. Circulating TgAb results obtained from 199 dogs with various disorders 
categorised by eventual outcome.
8.4 DISCUSSION
The results o f this study provided extensive data on the association of both clinical and 
endocrinological factors with the severity of illness and provide an insight into their use as 
prognostic indicators in dogs. To the author’s knowledge, correlation of many of the 
features studied with eventual case outcome have not been previously reported in dogs.
The signalment of cases including age, gender and breed-type was similar to those 
of corresponding cases presented in Chapter 5. Approximately 19 % of all cases were 
ultimately euthanatised, compared to approximately 42 and 38 % which made partial or full 
recoveries, respectively. The low percentage of cases making a full recovery presumably 
reflects the type of cases referred for investigation. The author is unaware of corresponding 
outcome data for other referral institutions and these results provide data with which future 
studies can be compared.
It was clear that cases with neoplasia were more likely to be euthanatised than those 
with non-neoplastic disorders. Similarly less than 20 % o f cases with neoplasia made 
complete recoveries. By contrast, orthopaedic cases were significantly more likely to make 
a full recovery. However, inadequate cases within the remaining disease categories 
hindered statistical evaluation and further studies evaluating a larger number of dogs are 
certainly warranted.
The duration of disease was of value in predicting the eventual case outcome and 
revealed that acute cases were significantly more likely to be euthanatised. However, as 
evidenced by the increased CDS in the acutely ill patients compared to those with chronic
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conditions, those cases referred more rapidly after the development of signs were 
apparently suffering from more serious diseases and therefore this finding may be partly a 
consequence of dealing with a referral population. It is unclear if these results are 
applicable in first opinion practice where it is possible that more chronically affected cases 
may be less likely to recover. However, this issue is currently unclear and a similar 
evaluation of equivalent cases in a first opinion practice would be valuable and allow 
comparison with the results of the present study. As occurred during the analysis of the 
data presented in Chapter 5 and Appendix 31, the complicating effect introduced by 
analysis of purely referral data was acknowledged as a limitation of the present study. 
However, the results obtained in this study remain of value and provide novel data with 
which future studies can be compared.
The CDS was clearly a useful tool in predicting the eventual outcome of cases. The 
clinical value of this test was demonstrated by the sensitivity and specificity of 0.67 and 
0.86, respectively for predicting euthanasia. Whilst clinical evaluation is normally a routine 
part o f case assessment, it is usually performed in a fairly subjective manner. The 
assignment of an actual value for monitoring purposes may therefore assist in a more 
comprehensive and objective means of case evaluation.
It was clear from the results that younger dogs are more likely to make a full 
recovery than are older dogs. Whilst this may reflect an improved ability of the younger 
animal to cope during systemic illness, it is likely that these results are influenced by the 
nature of diseases which younger animals commonly suffer from, fewer of which are 
typically life-threatening. The results o f the present study indicated that orthopaedics was 
more commonly associated with a full recovery than were the other disciplines. However, 
the data presented in Chapter 5 demonstrated that juvenile dogs are over-represented in 
certain referral disciplines including orthopaedics. This may explain the high recovery rates 
in young animals in the present chapter. As was advocated in the discussion in Chapter 5, a 
dedicated detailed study of population and disease demographics of referred dogs is a 
neglected area o f research and is undoubtedly worthy of future study.
The effect of thyroid suppressive medication on circulating total and free T4 
concentrations was obvious in this study and supported the findings of previous studies 
(Woltz et al, 1983; Torres et al, 1991). Median total and free T4 values were decreased 
by approximately 18 and 14 %, respectively compared to the values from dogs not 
receiving thyroid suppressive medications. However, there was no significant effect of 
these drugs on total T3 or cTSH concentrations which is in contrast to the results of
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previous reports (Rosychuk, 1982; Woltz et al., 1983). The variation in some results of the 
present study with these reports may reflect variation in drug doses and duration of 
therapy, since it was not considered practical to evaluate these issues in detail in the present 
study. Clearly, o f principal importance is the effect that commonly used drug regimes have 
on thyroid hormone parameters in a working clinical environment. Therefore, although a 
variety of drugs have been experimentally demonstrated to alter thyroid function, the 
results of this study indicate that these effects on total T3 specifically may be o f less 
importance in practice. The eventual outcome of cases in the present study was not 
significantly different between cases which had not been medicated, those which had 
received thyroid suppressive therapies, and those which had received other therapies prior 
to referral. Therefore, the demonstration of a strong correlation between total and free T4 
concentrations and the likelihood of recovery was not due to the complicating effect of 
previous therapies on thyroid hormone concentrations.
The most common pattern of thyroid abnormalities encountered was a reduction in 
total T3 alone which occurred in over 40 % of patients studied. Concurrent reduction of 
both total T4 and total T3 was also common occurring in approximately one third o f dogs. 
However the prevalence of subnormal total T4 alone was very low. These results are 
interesting and are broadly similar to the changes which occur in the low T3 syndrome in 
humans with NTI (Bermudez et al, 1975; Nicolofif & LoPresti, 1996). The reduced 
frequency of subnormal total T4 compared to total T3 values may indicate that the T4 
depression associated with systemic illness in dogs occurs later in the course o f disease. In 
support of this was the finding that the frequency of subnormal total T3 in cases with 
depressed total T4 values was nearly 100 % whereas only approximately 40 % of dogs with 
subnormal total T3 values had a concurrent decrease in total T4 concentration. However, 
this remains unclear and longitudinal case studies evaluating the change in hormone 
concentrations with disease progression would be of considerable value in this regard. 
These results are interesting since most previous studies in dogs have reported that total T3 
is less consistently decreased in NTI than is total T4 (Peterson et al., 1984; Larsson, 1988; 
Elliot et al., 1995; Peterson et al., 1997). There are several possible explanations for the 
discrepancy of these reports with the present study. Many of the previous reports of canine 
thyroid function in NTI have evaluated specific types o f illness, usually either diseases 
mimicking hypothyroidism (Larsson, 1988; Peterson, 1997) or frequently, dogs with 
hyperadrenocorticism (Peterson et al., 1984). Unlike the present study or contemporary 
human reports, it has been rare for canine studies to evaluate wide ranging disease
Chapter 8 241
categories. Differences in the cases evaluated may therefore partly account for the 
difference in results. This is certainly supported by the data presented in Chapter 4, in 
which less than 20 % o f cases with NTI which clinically mimicked hypothyroidism, had 
subnormal total T3 concentrations. In particular, the reliance on dogs with 
hyperadrenocorticism which is largely mediated by glucocorticoid excess is unlikely to truly 
represent the pattern of thyroid hormone abnormalities in general NTI. This is supported by 
the increased prevalence of subnormal total T3 values reported in this disease (Peterson et 
al., 1984) compared with dogs with a wider range of illnesses (Larsson, 1998; Peterson et 
al, 1997). The frequent reduction in total T3 values in hyperadrenocorticism are 
presumably a consequence of the reduced peripheral conversion of T4 to T3 associated with 
glucocorticoid excess (Gambert, 1996). As outlined previously, the high prevalence of 
subnormal total T4 concentrations in hyperadrenocorticism is likely related to a 
combination o f abnormalities including suppression of thyrotropin secretion and altered 
affinity and concentration o f hormone binding proteins. The frequent use of 
hyperadrenocorticism as a model of metabolic disease must certainly be in question. The 
report by Elliot et al., (1995) which evaluated a wide range of diseases was more 
comparable to the present study and correspondingly the reported frequency of 
abnormalities of total T4 and particularly total T3 values were closer to those found in the 
present study. An alternative explanation includes the reference ranges used to identify 
“normal” from “abnormal” values in different studies. Commonly, previous studies have 
compared bormope results with those obtained from a putatively healthy group o f dogs 
(Larsson, 1988; Peterson et al., 1997). However, in the present study, the cut-off value 
used to classify total T3 results as abnormal was the concentration which most reliably 
distinguished between hypothyroidism and NTI identified in Chapter 4. Whilst both 
approaches are justifiable, the advantage of the limits used in the present study, are that the 
cut-off used was generated using a “control” population of dogs which all had various NTI. 
Therefore, the identification of a subnormal value in the dogs with NTI in the present 
chapter, is genuinely separating those dogs based on the severity of their illness, rather than 
simply the presence or absence o f illness as occurs in most other studies. This was 
considered to be a more appropriate approach to this problem, and typifies the complexities 
involved in selecting an appropriate control group as highlighted in Chapter 5.
The correlation of thyroid hormone concentrations with eventual outcome 
demonstrated that both total and free T4 and total T3 concentrations decrease in NTI and 
the magnitude of depression is strongly associated with the likelihood of euthanasia. This is
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similar to reports in humans and cats (Slag et al, 1981; Mooney et al., 1996). O f all the 
parameters of thyroid function evaluated, total T3 concentrations were most strongly 
correlated with eventual outcome. In the dogs that were euthanatised the mean value was 
reduced to only approximately 60 % of that in the dogs which survived. Identification of a 
normal total T3 value was highly predictive of survival although like all the parameters 
studied, this could not differentiate between the likelihood o f a partial or full recovery. 
However, identification of a subnormal total T3 result was associated with a mortality rate 
which was similar to that of all dogs in the study. Therefore, at the cut-off value selected in 
this study, total T3 estimation can apparently be used as a specific predictor of recovery.
The effect of NTI on total T4 values was also marked, with values being reduced in 
the patients that were subsequently euthanatised to approximately half that of the dogs 
which made a full recovery. Total T4 values were subnormal in 29.8 % of cases which had 
not received any thyroid suppressive therapy compared to 35.5 % of all cases including 
those which had received these drugs. Euthanasia was significantly more likely in dogs with 
a subnormal total T4 concentration compared to dogs with normal values. This is similar to 
reports in other species (Slag et al, 1981; Mooney et al, 1996) but is in contrast to the 
report by Elliot et al, (1995) in which no correlation of total T4 and outcome was 
identified. The reason for the discrepancy of the present study with that of Elliot et 
a l,(1995) probably reflects an increased incidence of subnormal total T4 values in the 
surviving dogs reported by Elliot et al, (1995) which may have been present due to the 
type of cases studied as previously discussed. The dogs with depressed total T4 
concentrations in the present study encompassed a wide range of disease categories 
indicating that the use of thyroid hormone estimation as a prognostic marker is of value in a 
wide range of clinical illnesses.
Although also significantly reduced in non-surviving compared with surviving 
patients, the free T4 concentration was less markedly affected by NTI decreasing by 
approximately one third in those dogs which were euthanatised compared with dogs which 
made a full recovery This is similar to the results o f human studies but has not been 
previously reported in dogs with wide ranging illnesses. Analysis of the likelihood of 
euthanasia in dogs with subnormal free T4 values could not be evaluated due to an 
inadequate number o f cases. Subnormal free T4 values occurred in only 1.7 % of cases 
which had not received thyroid suppressive therapy supporting the conclusion in Chapter 4 
that identification of a subnormal free T4 is a specific indicator o f thyroid disease. Because 
only two cases had subnormal free T4 values interpretation of these results must be
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performed cautiously. However, both cases were ultimately euthanatised suggesting that 
although uncommon, a subnormal free T4 concentration may be a very poor prognostic 
indicator in NTI. Further studies with additional cases are clearly required.
Measurement of circulating TgAb was of no prognostic utility in the cases studied. 
The absence of a positive TgAb result in any of the samples collected supports the 
conclusions in Chapter 7, that measurement of this analyte is a highly specific method for 
the identification of thyroid disease.
In conclusion, this study has demonstrated that the most common pattern o f thyroid 
hormone changes in dogs with a wide range of NTI is depression o f total T3 alone. 
Reduction of both total T4 and total T3 concentrations is also common. It is clear that the 
severity of illness in dogs as assessed by the likelihood o f recovery, can be inferred from 
estimation of thyroid hormone concentrations. Specifically, the maintenance of total T3 
concentrations in the face of illness, is a highly specific indicator that recovery is likely. 
However a reduction in total T3 is not uncommon in cases which ultimately survive. 
Circulating total T4 concentrations decrease in approximately 30 % of cases irrespective of 
the type of illness and more marked depressions in this hormone are associated with 
reduced likelihood of recovery. In contrast, although free T4 is also usually decreased by 
illness, the reduction is less than for total T4 and subnormal values are only rarely 
encountered. However, it is possible that a subnormal free T4 concentration is a veiy poor 
prognostic indicator. The clinical impression of the severity of illness correlates well with 
eventual outcome as does the age of dog and duration of illness, with older and more 
acutely ill patients having a markedly poorer prognosis. Not surprisingly, cases with 
neoplasia are much more likely to die as a result of their illness than cases with non­
neoplastic diseases.
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CHAPTER 9
GENERAL CONCLUSIONS AND FUTURE RESEARCH 
9.1. INTRODUCTION
The objectives of this study were outlined in Chapter 1 and the relevant conclusions have 
been detailed in the appropriate chapters. This chapter serves to summarise the most 
significant findings and highlight the areas which have been recognised as areas worthy of 
further research.
9.2 ASSAY VALIDATION
Assays for total and free T4, total T3, cTSH and TgAb were successfully validated for use 
with canine serum. In the case of the total T4 assay, this was achieved despite modification 
to allow determination of the lower concentrations typically encountered in dogs compared 
with humans. The confirmation that the cTSH assay is a valid canine method is a major 
advancement in the study of canine thyroid disease. The ability to accurately determine 
cTSH has been awaited for several decades, and the importance of the release of this assay 
has been highlighted by the large number of publications in this area since the present study 
commenced. However, it was recognised that the current cTSH assay remains too 
insensitive to allow the identification of subnormal cTSH values therefore reducing its 
utility in the confirmation of central hypothyroidism or in accurate therapeutic monitoring. 
As occurred with the equivalent human TSH assays more than 20 years ago, further 
commercial development of this assay is anticipated in the future and appropriate studies in 
these areas will be required at that time. The confirmation of a valid TgAb assay is arguably 
the most significant step forward in the study of canine thyroid disease since the 
development o f methods for the estimation o f the thyroid hormones themselves. The ability 
to identify developing thyroid disease in its earliest stages, potentially prior to the 
occurrence of clinical abnormalities, has profound implications for the management of both 
healthy dogs and those with suspected hypothyroidism in veterinary practice in the coming 
years. The opportunity to make informed breeding decisions in healthy dogs based on 
TgAb results is one example of the role that this test is likely to assume in the future. 
However, many questions in this area still exist. The association, if any, between 
autoimmune thyroiditis and idiopathic atrophy needs to be clarified and it is likely that 
TgAb estimation will greatly facilitate this. The time taken for disease progression in
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individuals is currently unclear and also requires longitudinal case studies and TgAb 
monitoring programmes will be invaluable. Study of the underlying genetic predisposition 
to canine hypothyroidism will also be assisted by monitoring TgAb within particular 
families of dogs.
9.3 DIAGNOSIS OF CANINE HYPOTHYROIDISM
This study has reported the diagnostic utility of total T4, free T4, total T3 and cTSH for the 
confirmation of canine hypothyroidism. The use of DPR analysis and ROC curve 
generation have also been shown to be dynamic statistical methods which can be practically 
applied to this type of study. It is clear that as previously reported, total T4 and total T3 are 
poorly specific indicators of thyroid status and are frequently affected by NTI and drug 
therapy. In contrast, the estimation o f free T4 has been shown to be the single most 
accurate test and a more specific indicator of thyroid function. The role o f cTSH 
estimation, not as a solitary diagnostic test, but as a supporting test has also been proven to 
significantly enhance the ability of the clinician to reliably confirm hypothyroidism. Features 
which in practice are prone to interfering with these tests have been identified and include 
recovery from NTI and the use of sulphonamide-containing drug therapies. Consequently, 
diagnostic guidelines to facilitate the accurate diagnosis of hypothyroidism have now been 
established which can be widely applied in practice. Whilst many questions regarding the 
diagnosis of hypothyroidism were answered in this study, just as many became apparent 
during the course of the work. The reason for normal cTSH concentrations in a substantial 
number of dogs with hypothyroidism remains unclear and requires further study. Various 
explanations have been summarised previously but research into both technical causes 
related to the assay itself and biological causes will be undoubtedly be rich sources of 
future studies.
9.4. EPIDEMIOLOGY AND ROUTINE CLINICAL PATHOLOGY
For the first time in the UK the epidemiological characteristics of hypothyroidism, 
confirmed using a reliable diagnostic method, have been identified. The breeds and ages of 
affected dogs were similar to those identified in other parts o f the world including the USA 
and Australia. However, limitations of the present study due to the nature o f the referral 
population studied were acknowledged, and future studies to minimise the effect of such 
errors are required. However, this was a conclusion which applied not simply to the 
identification of breed or pedigree predilections for hypothyroidism since the complexities
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associated with identification of suitable control populations were also apparent in the 
estimation of endocrine parameters and routine biochemical and haematological analytes. It 
became evident that even some of the most basic information on the demographics of the 
UK canine population is currently unclear, hindering epidemiological analysis of canine 
disease in general. It is hoped that this area will be comprehensively evaluated in the near 
future, since it has implications for many areas of clinical study in dogs. The routine 
clinicopathological features associated with hypothyroidism were identified and in some 
cases confirmed previous reports. However, the use of newer biochemical tests such as 
fructosamine in dogs with hypothyroidism revealed the potential for improved performance 
o f routine tests in this condition. The limitations of routine biochemistry and haematology 
evaluation were also clearly demonstrated by use of a novel approach based on 
measurement of these parameters in dogs with clinically similar NTI. Consequently, 
guidelines on routine diagnostic testing were produced which will be of considerable value 
in routine practice.
9.5. THERAPEUTIC MONITORING
Previous reports concerning therapy and therapeutic monitoring for hypothyroidism have 
produced conflicting guidelines and consequently this area has previously been a source of 
debate. The results of this study demonstrated that once daily THRT using a synthetic T4 
preparation is a successful method for resolution of clinical and clinicopathological 
abnormalities. The need for twice daily therapy has been shown to be rare thus the 
guidelines produced improve the likelihood of client compliance and facilitate a more 
economic approach to therapy. The use of six hour post-pill peak total T4 concentrations as 
a monitoring tool has been confirmed, but unlike the variation in guidelines for therapeutic 
monitoring which has previously been a common difficulty, objective hormone 
concentrations which are correlated with clinical outcome have been identified and 
reported. Circulating cTSH estimation during therapeutic monitoring has been shown to be 
o f limited value but as identified previously, this is an area which may assume greater 
importance in the future as commercial assays are progressively modified. Novel data on 
the biochemical and haematological changes which occur in dogs receiving THRT have 
been reported for the first time. This study has therefore provided a basis from which future 
studies can develop and be compared. The potential for use o f routine clinicopathological 
parameters such as creatinine in therapeutic monitoring has been investigated and based on 
the results clearly warrants further evaluation. It is quite possible that this section of the
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study alone has therefore identified an area which may ultimately become of substantial 
economic and practical benefit to veterinary practitioners and dog owners alike.
9.6. THYROGLOBULIN AUTO ANTIBODIES
The reliable determination of circulating TgAb in healthy dogs, those with hypothyroidism 
and those with clinically similar NTI has been evaluated in detail for the first time. The 
results confirm the high specificity o f a positive TgAb result for thyroid disease, and as 
discussed previously have revealed that research in this area is necessary and justified.
9.7. THYROID FUNCTION IN NON-THYROIDAL ILLNESS
The role of thyroid hormone parameters in NTI has been studied in detail in humans and 
briefly in cats. However, previously only one limited study had evaluated the role of tests of 
thyroid function in dogs with NTI. The results of the present study have, for the first time, 
clearly demonstrated the marked association between total and free thyroid hormone 
concentrations and the likelihood o f recovery in a wide range of diseases. The use of 
thyroid hormones as prognostic markers in dogs is therefore clearly an area which may 
have profound implications for canine welfare and is undoubtedly worthy of future study. 
In addition, the identification of clinical parameters which are of prognostic relevance has 
also been reported. Whilst this was almost an incidental finding in the principal study, it 
revealed an area which is largely unstudied and based on the findings requires further and 
more detailed consideration. The pattern of thyroid hormone abnormalities encountered in 
NTI has also been identified and in some respects differs from previously held assumptions. 
The limitations of previous studies have been highlighted and it is expected that the 
publication o f the results of the present study will stimulate considerable interest and future 
research in this area over the coming years.
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Appendix 1
Registration information recorded to the hospital computer system (Dataflex).
Field Comments
Hospital Number
Animal Name
Species
Breed 1 e.g. terrier, collie etc.
Breed 2 e.g. west highland white, rough etc.
Date of Birth
Age Updated by hospital system
Sex Including neutering status
Date First Seen
Date Last Seen
Visit Number
Owner Reference Unique to owner
Key Owner name and initials
Name Owner name and title
Address Owner address
Town
Code Owner address postal code
Home Tel Owner home telephone number
Bus Tel Owner business telephone number
Fax Owner home facsimile number
Email Owner electronic mail address
Vet Ref Unique numerical reference of referring veterinary surgeon
Key Referring veterinary surgeon’s name and initials
Name Referring veterinary surgeon's name
Address Referring veterinary surgeon's address
Town
Code Referring veterinary surgeon's postal code
Tel Referring veterinary surgeon's telephone number
Fax Referring veterinary surgeon's facsimile number
Email Referring veterinary surgeon's electronic mail address
Clin Ref Unique numerical reference of clinician
Key Clinician's unique text code e.g. RMD, CTM etc.
Name Clinician's name
Dept Division within Department o f Veterinary Clinical Studies
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Measured and calculated routine haematology parameters.
Param eter Units Comments
RBC X  1012/L Red blood cell count
Hb g/dl Haemoglobin
HCT % Haematocrit
MCV fl Mean red cell volume
MCH Pg Mean red cell haemoglobin
MCHC g/dl Mean red cell haemoglobin concentration
PLT x 107L Platelet count
MPV fl Mean platelet volume
PCT % Plateletcrit
PDW Platelet distribution width measured in arbitrary units 
at 20% of the maximum height of the platelet
x 109/L
histogram
WBC White blood cell count
Band Neutrophils x 109/L
Neutrophils x 109/L
Lymphocytes x 109/L
Monocytes x 109/L
Eosinophils x 109/L
Basophils x 109/L
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Appendix 3
Measured routine biochemical parameters.
Param eter Units Analyser Methodology
Alanine IU/L Axon L-alanine and a-ketoglutarate coupled to
Aminotransferase lactate dehydrogenase activity
Albumin g/L Axon Bromocresol green dye binding with rapid 
absorbance
Alkaline IU/L Axon p-nitrophenol phosphate in DEA buffer
Phosphatase
Aspartate IU/L Axon L-aspartate and a-ketoglutarate coupled to
Aminotransferase malate dehydrogenase activity
Bilirubin jamol/L Axon Diazotised sulphanilic acid
Calcium mmol/L Axon Cresolphthalein complexone
Chloride mmol/L Axon Ferric thiocyanate
Cholesterol mmol/L Axon Cholesterol esterase, cholesterol oxidase and 
peroxidase
Creatine Kinase IU/L Mira N-acetylcysteine, hexokinase and glucose-6- 
phosphate dehydrogenase
Creatinine pmol/L Axon Picric acid
Fructosamine pmol/L Mira Nitroblue tetrazolium
y-Glutamyl IU/L Axon y-Glutamyl-p-nitroanilide and glycylglycine
Transferase
Globulin g/L Axon Arithmetic subtraction (total protein minus 
albumin)
Glucose mmol/L Axon Glucose hexokinase and D-glucose-6- 
phosphate dehydrogenase
Inorganic mmol/L Axon Ammonium molybdate
Phosphorus
Magnesium mmol/L Axon Xylidyl blue
Potassium mmol/L Axon Ion selective electrode
Sodium mmol/L Axon Ion selective electrode
Total Protein g/L Axon Biuret reagent
Triglycerides mmol/L Axon Lipoprotein lipase, glycerol kinase, glycerol 
phosphate oxidase and peroxidase
Urea mmol/L Axon Urease and glutamic dehydrogenase
Axon Technicon Axon (Bayer) 
Mira Cobas Mira (Roche)
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Appendix 4
Data categories used to store additional case information at each dog-visit
Category Comments
Hospital Number Unique six figure hospital number
Stim Clinical biochemistry laboratory identification relating to bovine 
thyrotropin stimulation test (if performed on that visit)
Stim Date Date of thyrotropin stimulation test (if performed on that visit)
Routine Clinical biochemistry laboratory identification relating to routine
profile (if performed on that visit)
Routine Date Date o f routine profile (if performed on that visit)
Name Owner name
Age Animal age
Sex Sex and neutering status
Breed Breed
Weight Weight
HypoT4 Numerical coding (1-hypothyroid, O-euthyroid)
Other Diagnosis Other relevant clinical information
Visit No Visit number since first visit
Wks on Tx Number of weeks on L-thyroxine therapy (if appropriate)
Basal T4 Basal or pre-thyrotropin total thyroxine concentration
Post TSH T4 Post-thyrotropin total thyroxine concentration
cTSH Endogenous thyrotropin concentration
6 hr post pill Six hour post-L-thyroxine total thyroxine concentration 
(hypothyroid dogs on treatment only)
fT4d Free thyroxine concentration
fT4d Date Date o f free thyroxine assay
Box Serum sample storage location identification
Drug Tx Current or recent drug therapy
Urea Routine profile result (urea)
Na Routine profile result (sodium)
K Routine profile result (potassium)
Cl Routine profile result (chloride)
Ca Routine profile result (calcium)
Mg Routine profile result (magnesium)
p o 4 Routine profile result (inorganic phosphate)
Glue Routine profile result (glucose)
Choi Routine profile result (cholesterol)
Crea Routine profile result (creatinine)
Tbil Routine profile result (total bilirubin)
ALKP Routine profile result (alkaline phosphatase)
AST Routine profile result (aspartate aminotransferase)
ALT Routine profile result (alanine aminotransferase)
TP Routine profile result (total protein)
Alb Routine profile result (albumin)
Glob Routine profile result (globulin)
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Appendix 4 (continued)
Category Comments
A:G Routine profile result (albumin to globulin ratio)
CK Routine profile result (creatine kinase)
Trig Routine profile result (triglycerides)
GGT Routine profile result (y-glutamyl transferase)
Fruct Routine profile result (fructosamine)
RBC Routine profile result (red blood cell count)
Hb Routine profile result (haemoglobin)
HCT Routine profile result (haematocrit)
MCV Routine profile result (mean red blood cell volume)
MCH Routine profile result (mean red blood cell haemoglobin)
MCHC Routine profile result (mean red blood cell haemoglobin 
concentration)
PLT Routine profile result (platelet count)
MPV Routine profile result (mean platelet volume)
WBC Routine profile result (white blood cell count)
Band N Routine profile result (band neutrophils)
Neut Routine profile result (neutrophils)
Lymp Routine profile result (lymphocytes)
Mono Routine profile result (monocytes)
Eosin Routine profile result (eosinophils)
Baso Routine profile result (basophils)
Misc Miscellaneous comments field
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Appendix 5
Example of completed template used to record historical and clinical data from hospitalised 
cases with various disorders.
Unique ID: 24 Date Sampled j” 25/01/99 Breed jst Bernard
Case Number j 132521
Clinician jRuth Willis
. Doq Name: f?iggy
Sample Number: [*** 1 Years: j  ~ 2  Months: 0 J... . ....-...... ...... ........P Owner Name: jGentwhite
Disease Category I[Cardiovascular None @  Anticonvulsants □  Cardiac □
Diagnostic method j[Imaging Steroids □  PotSulphs □  Thyroid Therapy □
Disease Course j[Chronic NSAIDS □  Other antimicrobials D Other □
Clinical Disease Score 
Comments
thyroid suppressive drugs ?
Idiopathic pericardial effusion
Outcome jSurvived-complete recover T4 J 2035 T3 1.05 fT4d j 21.55
Date of Outcome j 08/10/99 cTSH j 0.66 TGAA | n e g
Clinical Details Complete ? 0  Outcome Complete ? @
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Appendix 6
Construction of the Receiver Operating Characteristic (ROC) curve and calculation of the 
area under the ROC curve (W)
The calculation of the area under the ROC curve (W) and the calculation of the standard 
error of W as exemplified by cut-off values of T4 for the confirmation of hypothyroidism.
7.6 8.2
Cut-Off Value (nmoI/L)
8.3 8.5 9.1 9.6 9.8 10.1 10.2
Nx 0 1 2 1 0 0 1 2 1
Nax 85 84 82 81 81 81 80 78 77
Ax 1 0 0 0 1 1 0 0 0
Abx 36 37 37 37 37 38 39 39 39
W partial 0 37 74 37 0 0 39 78 39
Q 1 partial 0 1369 2738 1369 0 0 1521 3042 1521
Q 2  partial 7225 0 0 0 6561 6561 0 0 0
Nx Number o f dogs without hypothyroidism having a test result at the cut-off value 
Nax Number of dogs without hypothyroidism having a test result above the cut-off value 
Ax Number of dogs with hypothyroidism having a test result at the cut-off value 
Abx Number of dogs with hypothyroidism having a test result below the cut-off value
At each cut-off value the partial terms o f the area under the ROC curve (W parti a i )  and of the 
intermediate probabilities Q1 p a rtiai and Q2 partjai are calculated using the formulae:
W partial = (Nx * Abx) + (V2 * Nx * Ax)
Q1 partiai = Nx * [(Abx * Abx) + (Abx * Ax) + (Ax * Ax / 3)]
Q2 partiai = Ax * [(Nax * Nax) + (Nax * Nx) + (Nx * Nx / 3)]
When W partial, Q1 partial, and Q2 partial have been calculated for each cut-off value, the final 
value o f W and of the intermediate probabilities Q1 and Q2 are calculated using the
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following formulae in which Nd represents the number of dogs with hypothyroidism and 
Nn represents the number of dogs without hypothyroidism.
W = (X W partial) / (Nd * Nn)
Q1 = (X Q1 p a r t ia l)  / (Nd * Nd * Nn)
Q2 = (X Q2 p a r t ia l)  / (Nn * Nn * Nd)
The standard error of the area under the ROC curve (SEw) is then calculated as:
j  (w * ri-wp + oNd-n * roi-w2p + dNn-n * ro2-w2i>
\ J  Nd * Nn
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Appendix 7
Total thyroxine (T4) intra-assay precision.
Duplicate
Total T4 Concentration (nmol/L) 
Low Intermediate High
1 15.1 37.2 95.1
2 16.7 31.7 91.1
3 16.2 34.7 92.9
4 16.7 35.1 98.4
5 15.5 32.5 92.3
6 16.6 36.5 90.7
7 16.8 40.2 91.7
8 15.0 37.4 87.9
9 15.6 36.6 93.7
1 0 15.7 42.6 96.0
Mean 16.0 36.5 93.0
s.d. 0.7 3.3 3.0
c.v. (%) 4.3 9.0 3.2
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Total thyroxine (T4) inter-assay precision.
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Total T4 Concentration (nmol/L)
Assay Run Low Intermediate High
1 5.5 14.0 172.0
2 5.1 13.8 170.8
3 4.3 11.4 155.9
4 5.7 11.5 169.9
5 6 . 2 15.8 168.0
6 4.5 13.3 156.0
7 4.8 13.6 168.8
8 6.7 16.9 179.4
9 5.1 10.3 158.9
1 0 6.3 13.5 164.6
Mean 5.4 13.4 166.4
s.d. 0 . 8 2 . 0 7.6
c.v. (%) 14.8 14.9 4.6
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Total thyroxine (T4) linearity study using the supplied zero standard as the diluent.
Progressive 20% Dilutions
Total T4 concentration (nmol/L) 
Observed (O) Expected (E) % O/E
Undiluted 2 1 . 2
Dilution 1 17.9 17.0 105.5
Dilution 2 16.0 14.3 111.7
Dilution 3 13.4 1 2 . 8 104.7
260
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Appendix 10
Total thyroxine ( T 4 )  limit of detection.
Replicate CPM
1 50350
2 50259
3 50000
4 50257
5 50508
6 49739
7 50559
8 50124
9 50154
1 0 50600
1 1 50935
1 2 50455
13 50536
14 50320
15 50350
16 50320
17 50210
18 50358
19 51232
2 0 50241
Mean 50375
s.d. 318
Mean - 2.6 s.d. 49549
Equivalent total T4 limit o f detection 4.7 nmol/L
CPM: Counts Per Minute
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Free thyroxine measured by dialysis intra-assay precision.
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Free T4 Concentration (pmol/L)
Duplicate Low Intermediate High
1 9.4 25.3 42.7
2 9.8 20.9 45.9
3 9.7 2 0 . 2 45.6
4 8.7 17.7 44.4
5 11.9 20.3 46.1
6 11.5 2 0 . 1 44.5
7 1 0 . 2 20.3 45.9
8 9.2 20.4 50.2
9 9.6 18.6 45.5
1 0 14.1 18.2 48.4
Mean 10.4 2 0 . 2 45.9
s.d. 1 . 6 2 . 1 2 . 1
c.v. (%) 15.7 10.3 4.6
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Free thyroxine measured by dialysis inter-assay precision.
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Free T4 Concentration (pmol/L)
Assay Run Low Intermediate High
1 11.3 2 2 . 6 164.6
2 13.4 25.6 223.2
3 1 1 . 2 22.3 179.9
4 10.3 24.7 197.1
5 13.0 25.2 185.3
6 14.7 26.3 2 0 1 . 8
Mean 12.3 24.4 192
s.d. 1.7 1 . 6 2 0 . 2
c.v. (%) 13.5 6.7 10.5
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Appendix 13
Free thyroxine by dialysis linearity study using the supplied zero standard as the diluent.
Free T4 concentration (pmol/L)
Dialysate Dilution Observed (O) Expected (E) % O/E
Undiluted 126.6
1:1 58.1 63.3 91.8
1:3 29.4 29.0 101.2
1:7 15.9 14.7 108.2
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Free thyroxine measured by dialysis limit of detection.
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Replicate CPM
1 11549
2 11452
3 11965
4 11260
5 11898
6 11126
7 11728
8 10861
9 12358
1 0 12292
1 1 12259
1 2 11197
13 12356
14 11677
15 12409
16 11804
17 12477
18 11798
19 12009
2 0 11399
Mean 11793
s.d. 477
Mean + 2.6 s.d. 13036
Equivalent free T4 limit o f detection 3.22 pmol/L
CPM: Counts Per Minute
Appendices
Appendix 15
Total triiodothyronine (T3 ) intra-assay precision.
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Duplicate
Total T3 Concentration (nmol/L) 
Low Intermediate High
1 1.24 2.40 4.38
2 1.21 2.23 4.45
3 1.42 2.35 4.33
4 1.34 2.39 4.54
5 1.15 2.17 4.46
6 1.27 2.28 4.48
7 1.26 2.30 4.42
8 1.28 2.38 4.50
9 1.25 2.50 4.47
10 1.30 2.27 3.74
Mean 1.27 2.33 4.38
s.d. 0.07 0.10 0.23
c.v. (%) 5.7 4.1 5.3
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Total triiodothyronine (T3) inter-assay precision.
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Total T3 Concentration (nmol/L)
Assay Run Low Intermediate High
1 1.59 2.23 3.80
2 1.46 1.92 4.00
3 1.77 2.19 4.14
4 1.59 1.91 not done
Mean 1.60 2.06 3.98
s.d. 0.13 0.17 0.17
c.v. (%) 7.9 8.3 4.3
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Appendix 17
Total triiodothyronine (T3) linearity study using the supplied zero standard as the diluent.
Total T3 concentration (nmol/L)
Dilution Observed (O) Expected (E) % O/E
Undiluted 4.40
1:1 2.08 2.20 94.6
1:3 0.98 1.04 94.2
1:7 0.55 0.49 112.2
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Total triiodothyronine ( T 3 )  limit of detection.
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Replicate CPM
1 18158
2 18412
3 17880
4 18479
5 18259
6 18922
7 18296
8 18177
9 18233
1 0 17865
1 1 18126
1 2 18127
13 18315
14 18154
15 18088
16 18430
17 17623
18 18244
19 17732
2 0 18161
Mean 18184
s.d. 282.5
Mean - 2.6 s.d. 17450
Equivalent total T3 limit of detection 0.14 nmol/L
CPM: Counts Per Minute
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Thyrotropin (cTSH) intra-assay precision.
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cTSH Concentration (ng/ml)
Duplicate Low Intermediate High
1 0 . 1 2 0.84 2.13
2 0.14 0 . 8 6 2.06
3 0.13 0.87 217
4 0.14 0.82 2 . 2 1
5 0.13 0.83 2 . 2 2
6 0.14 0.89 2 . 2 1
7 0.16 0.84 2 . 2 0
8 0.13 0 . 8 6 2.13
9 0.14 0.83 2.16
1 0 0.14 0.84 2.18
Mean 0.137 0.848 2.167
s.d. 0 . 0 1 1 0 . 0 2 1 0.049
c.v. (%) 7.7 2.5 2.3
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Appendix 20
Thyrotropin (cTSH) inter-assay precision.
cTSH Concentration (ng/ml)
Assay Run Low Intermediate High
1 0.14 0.44 1.34
2 0.15 0.42 1.40
3 0.16 0.46 1.27
4 0 . 1 2 0.43 1.28
5 0.16 0.38 1.18
6 0.15 0.43 1.24
7 0.15 0.39 1.19
8 0.08 0.37 1.34
9 0 . 1 0 0.37 1 . 2 2
1 0 0 . 1 1 0.28 1.24
Mean 0.132 0.396 1.27
s.d. 0.029 0.052 0.07
c.v. (%) 21.9 13.2 5.6
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Appendix 21
Thyrotropin (cTSH) linearity study using the supplied zero standard as the diluent.
Dilution Observed (O) Expected (E) % O/E
(ng/ml) (ng/ml)
Undiluted 2.84
1:1 1.26 1.42 88.7
1:3 0.68 0.63 107.9
1:7 0.30 0.34 88.2
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Thyrotropin (cTSH) limit of detection.
Replicate CPM
1 51
2 60
3 49
4 56
5 42
6 52
7 42
8 39
9 60
1 0 52
1 1 51
1 2 42
13 46
14 41
15 52
16 58
17 42
18 44
19 44
2 0 43
Mean 48.3
s.d. 6.7
Mean + 2.6 s.d. 65.7
Equivalent cTSH limit o f detection 0 . 0 1  ng/ml
CPM: Counts Per Minute
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Appendix 23
Quantitative thyroglobulin autoantibody (TgAb) intra-assay precision results. Figures shown are 
optical density values expressed as a percentage of the negative control sample optical density.
Sample 1 Sample 2
(positive) (negative)
967 108
938 94
904 99
896 97
907 98
892 90
876 95
908 82
1075 91
1 0 0 1 82
1 0 0 0 105
999 87
1006 117
941 105
1045 98
1055 84
958 91
1007 94
1048 99
1084 104
Mean 975 96
s.d. 65.9 9.06
c.v. (%) 6.75 9.44
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Appendix 24
Quantitative thyroglobulin autoantibody (TgAb) inter-assay precision results. Figures shown 
are optical density values expressed as a percentage o f the negative control sample optical 
density.
Assay Run Positive Equivocal Negative
1 1105 136 58
2 1139 2 0 0 1 0 0
3 1491 161 76
4 983 192 58
5 1080 130 59
6 975 96 42
Mean 1129 152 6 6
s.d. 189 39.6 2 0 . 1
c.v. (%) 16.8 26.0 30.7
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Qualitative thyroglobulin autoantibody (TgAb) intra-assay precision.
Duplicate Sample 1 Sample 2
1 Negative Positive
2 Negative Positive
3 Negative Positive
4 Negative Positive
5 Negative Positive
6 Negative Positive
7 Negative Positive
8 Negative Positive
9. Negative Positive
1 0 Negative Positive
Qualitative
Precision 1 0 0 % 1 0 0 %
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Appendix 26
Qualitative thyroglobulin autoantibody (TgAb) inter-assay precision.
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Assay Run Sample 1 Sample 2 Sample 3
1 Negative Equivocal Positive
2 Negative Equivocal Positive
3 Negative Equivocal Positive
4 Negative Equivocal Positive
5 Negative Equivocal Positive
6 Negative Negative Positive
Qualitative
Precision 1 0 0 % 83% 1 0 0 %
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Appendix 27
Classification of cases with equivocal TSH response test results
Three hypothyroid and nine euthyroid dogs exhibited an equivocal response to bovine TSH 
administration. The initial hormone results from these cases are detailed in Tables 41 and 
42, respectively.
In one of the three dogs ultimately confirmed as hypothyroid (130239) there was a 
further decline in total T4 (from 13.8 to 3.0 nmol/L) and increase in cTSH concentration 
(from 0.94 to 1.32 ng/ml) over a period of 14 weeks. In another of these cases (122647) 
there was evidence of lymphocytic thyroiditis on histopathological examination of thyroid 
tissue. In the third (129912), the owner circumstances were such that T4 replacement 
therapy was the only available method for supporting or refuting hypothyroidism. In this 
and the other two cases there was an unequivocal response to T4 supplementation without 
the need for other therapy.
Of the nine euthyroid dogs with equivocal TSH response test results, there was a 
complete resolution from non-thyroidal illness following appropriate therapy in eight cases 
(121319, 125089, 127515, 127978, 129496, 132278, 132320 and 132467). In the 
remaining case (129960) there was a return of total T4 and cTSH to normal at a later date. 
There was no need for thyroid hormone replacement therapy in any of these cases. The 
non-thyroidal illnesses are summarised in Table 42. There was no firm diagnosis reached in 
case number 127515 who presented with a two week history of anorexia and dullness. 
However, this dog responded to non-specific therapy without the need for T4 replacement 
therapy.
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Case
Number
Age
tyre)
Sex Breed Basal total 
T4 (nmol/L)
Post-TSH total 
T4 (nmol/L)
Free T4 
(pmol/L)
Total T3 
(nmol/L)
cTSH
(ng/ml)
122647 1 0 . 8 M Boxer 12.4 25.4 10.98 2.61 3.32
129912 1 1 F Pug 9.6 21.9 9.46 1.03 0.73
130239 9 FN Doberman 13.8 22.4 12.37 1.54 0.94
Table 41. Hormone results from three hypothyroid dogs with equivocal TSH response test 
results.
Case
Number
Age
(yrs)
Sex Breed Diagnosis
Basal
Total
t 4
Post TSH 
Total T4 Free
t 4
Total
t 3
cTSH
121319 5 M Chow
Obesity and 
Musculoskeletal 
disease
8.5 24.7 ND ND 0.03
125089 13 FN WHWT
Golden
Allergic Skin 
Disease 
Temporary
1 0 . 8 25.6 33.29 1.46 0.24
127515 1 0 MN retriever anorexia and 
lethargy
1 0 . 1 23.9 ND ND 0.18
127978 8 FN Bearded
collie
Addisons
Disease
10.5 22.5 8 . 0 0.99 2.65
129496 1 1 FN Boxer
Retriever
HAC
Chronic
4.7 2 0 . 6 5.81 1.90 0.13
129960 9 MN cross hyperplastic
dermatitis
1 0 . 8 2 2 . 1 8.95 2.82 0.26
132278 3 MN Labrador
retriever
HAC 1 2 . 1 25.2 13.75 1.18 0.28
132320 1 2 M Golden
retriever
Homer’s
Syndrome
8.3 24.0 5.19 2.51 0.47
132467 1 2 M Crossbreed Testicular
Neoplasia
15.4 23.4 5.0 2.46 0.50
Table 42. Hormone results and clinical details from nine euthyroid dogs with equivocal 
TSH response test results.
ND Analysis not done HAC Hyperadrenocorticism
WHWT West Highland White Terrier
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Appendix 28
Further Investigation of Case Number 133791
Concurrent NTI was confirmed and may have been responsible for “normal” cTSH 
concentrations in eight of the 11 hypothyroid dogs. Of the remaining three cases the cTSH 
concentration approached the assay LoD in only one case, a 7.5 year old male entire 
miniature schnauzer (case number 133791). Further investigation of this case was 
performed to evaluate the possibility of central hypothyroidism. The initial hormone 
concentrations from this dog are detailed in Table 43. Routine biochemistry and 
haematology results are detailed in Table 44.
The pituitary responsiveness to TRH administration was assessed by estimation of 
circulating cTSH concentration at five, 10, 20, 30 and 60 minutes following the intravenous 
administration of 200 pg synthetic TRH (p-GLU-HIS-PRO amide, Sigma Chemical Co.) 
These results are detailed in Table 45. There was no significant change in cTSH 
concentration following TRH administration. This is consistent with a provisional diagnosis 
of central hypothyroidism. Alternative explanations include the presence of undetectable 
isomeric forms of cTSH (Peterson et al, 1997) or long-standing hypothyroidism associated 
with pituitary “exhaustion” (Scott-Moncrieff et al, 1998). In both these situations no 
measurable cTSH response to TRH administration would also be expected.
Clinical evaluation did not reveal any neurological abnormalities suggestive of a 
pituitary mass. Further investigations to confirm central hypothyroidism would have 
consisted of pituitary imaging techniques such as magnetic resonance imaging (MRI). After 
considerable discussion with the owners of this case, THRT was instituted without any 
further diagnostic evaluation. The dog responded well and is reported to be clinically 
healthy after a follow up period of 2 2  months.
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Case
Number
Age Sex Basal 
Total T4
Post-TSH 
Total T4
Free T4 Total T3 cTSH
133791 7.5 M 5.1 6 . 2 3.22 2.57 0 . 0 2
Table 43. Routine endocrine results from a 7.5 year old hypothyroid male miniature 
schnauzer (case number 133791). For key see Appendix 4.
Analyte Result Analyte Result
Urea 6.7 CK 85
Na 141 Trig 5.13
K 4.2 GGT 1 2
Cl 108 Fruct 324
Ca 2.73 RBC 5.06
Mg 0.76 Hb 1 2
P04 1.48 HCT 34
Glue 5.6 MCV 67
Choi 33.07 MCH 23.7
Crea 8 8 MCHC 35.2
Tbil 1 PLT 530
ALKP 60 MPV 7
AST 17 WBC 5.7
ALT 76 BandN 0
TP 78 Neut 3.591
Alb 37 Lymp 1.824
Glob 41 Mono 0 .2 2 &
A:G 0.9 Eosin 0.057
Table 44. Routine biochemistry and haematology results from a 7.5 year old hypothyroid 
male miniature schnauzer (case number 133791) with an unexpectedly low circulating 
cTSH concentration. For key and units see Appendices 2 and 4.
Appendices 282
Time post TRH 
(minutes)
cTSH
(ng/ml)
0 0 , 0 2
5 0.03
1 0 0.03
2 0 0 . 0 2
30 0 . 0 2
60 0.03
Table 45. Endogenous cTSH concentrations immediately prior to and at following the 
intravenous administration o f200 pg TRH in case number 133791.
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Appendix 29
Signalment and hormone data from 52 hypothyroid dogs
Case
Number
Age
(yrs)
Sex Breed Basal 
Total T4 
(nmol/L)
Post-TSH 
Total T4 
(nmol/L)
Free T4 
(pmol/L)
Total T3 
(nmol/L)
cTSH
(ng/ml)
116865 7.2 M Scottie 7.6 4.7 3.22 0.81 3.30
131136 6 MN Cocker sp. 4.7 6 . 0 3.22 1.33 0.91
131132 1 1 FN WHWT 11.4 1 0 . 0 5.41 3.88 12.3
131486 1 0 . 2 FN WHWT 14.0 19.6 10.34 1.05 3.25
124413 6 F Labrador 14.8 1 1 . 0 11.78 1.09 1.74
126382 6 M Sheltie 4.7 4.7 3.22 0 . 6 6 1.57
129827 4.5 M Cocker sp. 4.7 4.7 3.22 1.25 1.89
133137 1 0 FN Crossbreed 4.7 4.7 3.22 1.32 3.57
133791 7.5 M Miniature
schnauzer
5.1 6 . 2 3.22 2.57 0 . 0 2
124684 1 0 FN G Ret. 5.8 8.7 4.11 0.25 0.94
115099 6.9 F Bearded
collie
10.4 10.5 ND ND 2.84
130239 9 FN Doberman 13.8 22.4 12.37 1.54 0.94
109711 9 M Miniature
schnauzer
12.9 19.3 3.22 0.70 0.15
133026 3 M GSD cross 13.8 15.7 3.22 23.49f 8.52
130794 1 0 F Crossbreed 5.2 13.1 3.22 1.47 0.96
129292 5 MN Akita 1 0 . 8 8 . 0 3.22 1.61 0.43
109116 7 F Clumber sp 4.7 5.6 ND ND 1.29
131646 1 1 FN Border
terrier
4.7 4.7 8.85 0 . 8 6 0.73
132396 4 F G-Ret 1 2 . 8 13.7 4.93 2 . 8 8 4.34
122647 10.75 M Boxer 12.4 25.4 10.98 2.61 3.32
134214 8 M Lab-Ret 5.3 4.7 3.22 2.32 2 . 1 0
119760 4 M Hovawart 9.1 8.5 3.22 1 . 1 1 6.31
133399 5 M Lab-Ret 4.7 4.7 3.22 1.13 1 . 8 8
130375 8 FN Crossbreed 4.7 4.7 3.22 0.91 1.42
127889 9 F Shetland
sheepdog
4.7 4.7 3.22 0.81 2.90
129912 1 1 F Pug 9.6 21.9 9.46 1.03 0.73
134156 3 F Eng sp sp 4.7 4.7 3.22 1.50 1.18
127391 8 FN Rough
collie
4.7 4.7 ND ND 0.23
129838 4 FN Eng sp sp 5.6 6 . 6 3.22 1.35 2.48
130866 1 0 M Labrador 4.7 4.7 3.22 1 . 2 2 1 . 6 8
129976 7 FN WHWT 4.7 4.7 3.22 1.65 5.98
130656 6 FN Akita 4.7 13.2 3.22 1.43 0.69
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Appendix 29 continued
Case
Number
Age
(yrs)
Sex Breed Basal 
Total T4 
(nmol/L)
Post-TSH 
Total T4 
(nmol/L)
Free T4 
(pmol/L)
Total T3 
(nmol/L)
cTSH
(ng/ml)
132798 8 M Border
terrier
4.7 5.0 3.22 1.16 0.03
130431 1 2 F St Bernard 2 1 . 2 29.4 12.39 1 . 8 8 0.57
128082 9 FN Crossbreed 4.7 4.7 3.22 0.96 2.67
127111 7 F Lab-Ret 5.5 4.7 3.22 1.04 2.17
124283 6 M Rottweiler 4.7 4.7 ND ND 1 . 0 2
133778 3 M Bassett
hound
4.7 4.7 3.22 2.23 0.08
133641 4 FN Flat coated 
retriever
4.7 4.7 3.22 1.77 2.13
125877 4 MN Crossbreed 4.7 4.7 ND ND 1.45
132391 13 FN Doberman 4.8 1 0 . 0 3.22 1.59 1.52
127627 9 M Poodle 4.7 4.7 ND ND 0 . 0 1
134019 1 1 F English
setter
17.8 18.8 6 . 6 6 3.57 6.30
131249 1 0 F Cocker sp 4.7 4.7 ND ND 1.17
131426 9 F Lab-Ret 4.7 4.7 3.22 1 . 2 1 1.77
127135 9.5 M Retriever 6.4 9.2 ND ND 0.15
133668 7 M Hungarian
vizsla
4.7 4.7 3.22 1.82 0.26
127940 6 FN Doberman 4.7 4.7 3.22 1.08 0.98
129565 4 MN Cocker sp 14.5 17.4 11.90 ND 0.84
135542 9 MN Labrador
cross
4.7 4.7 3.22 1.91 134
122424 9.75 M Rottweiler 4.8 15.2 ND ND 0.76
131438 7 F GSP 4.7 4.7 3.22 1 . 0 2 0.03
Elevated result attributed to the presence of T3Ab.
WHWT West Highland White Terrier GSP German shorthaired pointer
GSD German Shepherd Dog Eng sp sp English springer Spaniel
Cocker sp Cocker Spaniel Clumber sp Clumber Spaniel
G-Ret Golden retriever Lab-Ret Labrador retriever
ND Analysis not done
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Signalment and hormone data from 88 euthyroid dogs with non-thyroidal illness
Case
Number
Age
(yrs)
Sex Breed Basal 
Total T4 
(nmol/L)
Post- 
TSH 
Total T4 
(nmol/L)
Free T4 
(pmol/L)
Total T3 
(nmol/L)
cTSH
(ng/ml)
124709 1 0 M Crossbreed 16.9 63.9 12.04 2.62 0.16
132320 1 2 M Golden retriever 8.3 24.0 5.19 2.51 0.47
130370 2 M Bull terrier 32.1 63.9 13.70 3.09 0 . 6 6
132582 7 M Dachshund 15.2 46.5 13.71 ND 1 . 0 0
130929 10.5 M PMD 10.7 46.0 7.51 1.90 0 . 1 2
132476 1 2 M Crossbreed 15.4 23.4 5.00 2.46 0.50
124980 7.5 F Gordon setter 4.90 37.3 4.68 0.94 0.08
131778 4 M Bull mastiff 19.3 34.4 9.99 2.37 0.06
132904 9 MN Cocker spaniel 23.7 73.3 11.28 2.94 0.72
130754 1 1 F Golden retriever 27.1 63.8 1 2 . 0 0 2 . 6 8 0.18
126582 5.5 M Golden retriever 2 1 . 6 72.4 31.44 1.54 0.06
127405 5 FN Golden retriever 29.5 51.7 17.88 2.47 0 . 2 2
122827 2.5 FN Shitsu 20.4 50.3 24.74 1.47 0.09
131049 9.5 FN Crossbreed 18.7 75.3 9.96 2.96 0 . 1 1
127416 1 1 M Sheltie 28.9 85.7 ND ND 0.34
131930 10.25 M Labrador 18.8 46.8 11.03 2.27 0.44
130820 1.5 M BMD 1 2 . 6 55.5 6.75 ND 0.18
124776 7 FN Boxer 23.3 45.8 28.46 1 . 8 6 0 . 2 1
134192 9 M Rottweiler 13.5 39.3 10.49 2.53 0.57
131408 7 M Labrador
retriever
8 . 2 31.2 9.75 2.03 0.24
130143 8 M Eng sp sp 19.4 66.9 13.74 3.01 0.87
128293 5 F Rotty 23.7 46.3 22.46 1.31 0.07
121319 5 M Chow chow 8.5 24.7 ND ND 0.03
131579 1 0 MN Border collie 14.8 67.7 1 2 . 0 1 2.25 0.67
131484 1.5 FN Bichon frise 60.5 187.6 35.44 3.11 0 . 1 2
119621 7 F Bearded collie 26.0 45.1 10.73 3.31 1.37
130680 7.5 M Bearded collie 21.4 75.1 13.10 ND 0.87
124358 2 M Labrador-
retriever
27.5 45.0 2 1 . 0 0 1.93 0.32
130075 3 M Chow-chow 23.0 72.9 2 0 . 8 6 2.43 0 . 0 2
132502 1 0 M Golden retriever 17.8 57.8 15.41 1.78 0.07
129205 14 FN Pekinese 16.3 37.8 19.54 1.26 0.28
127911 5 M Dachshund 2 1 . 0 54.0 23.7 1.80 0.14
127163 1 2 M Collie cross 29.6 53.7 32.34 0.78 0 . 0 1
129960 9 MN Retriever cross 1 0 . 8 2 2 . 1 8.95 2.82 0.26
126068 9 M Doberman 1 1 . 0 42.9 16.06 1.82 0.31
110826 1 0 F Labrador
retriever
15.2 31.5 11.50 2.38 0.45
132446 1 0 FN Crossbreed 4.7 34.7 3.22 2.71 0 . 0 2
Appendices 286
Appendix 30 continued
Case
Number
Age
(yrs)
Sex Breed Basal 
Total T4 
(nmol/L)
Post- 
TSH 
Total T4 
(nmol/L)
Free T4 
(pmol/L)
Total T3 
(nmol/L)
cTSH
(ng/ml)
130040 6 FN CKCS 18.4 77.7 15.19 3.02 0.04
126932 7.5 FN Irish Setter 27.5 70.9 23.83 1.93 0.27
134203 5 F Yorkshire terrier 49.8 127 ND ND 0.17
134197 1.5 FN Golden retriever 17.8 67.2 8.29 2.58 0 . 1 0
131217 2 M Dalmation 31.1 85.6 20.16 2.65 0.54
126385 5 FN Labrador 26.6 52.7 32.78 1.16 0.37
130364 6.5 M Irish setter 1 0 . 1 34.6 7.49 1.27 0.29
132278 3 MN Labrador 1 2 . 1 25.2 13.75 1.18 0.28
131932 5 MN Boxer 33.0 72.0 16.17 3.27 0.95
131280 13 M Wire haired fox 
terrier
27.6 8 6 . 1 14.83 2.69 0.19
130350 4 FN Bull terrier 
cross
41.4 113.4 15.35 4.71 0.51
131783 3 M CKCS 21.3 190 8 . 0 0 3.24 0 . 0 2
133497 9.5 M Border collie 13.4 80.2 26.94 1.85 0 . 8 8
133293 1 0 F GSD 8.3 31.3 ND ND 1.13
129581 5 MN Doberman 21.9 45.5 1 1 . 8 8 2.19 0.90
127515 1 0 MN Retriever 1 0 . 1 23.9 ND 0.18
131428 1 1 M Golden retriever 13.8 40.3 1 1 . 0 1 2 . 1 2 0.50
127978 8 FN Bearded collie 10.5 22.5 8 . 0 0 0.99 2.65
129496 1 1 FN Boxer 4.7 2 0 . 6 5.81 1.90 0.13
130120 1 2 FN Scottie 2 0 . 0 35.0 13.94 2.91 0.61
127729 4.5 M Bull terrier 25.6 45.9 22.16 2.78 1.04
130021 9 F Sheltie 27.4 130.8 24.25 3.10 0.07
130963 4 F Doberman 2 0 . 2 53.0 9.00 2.33 0 . 6 8
132168 8 F Jack russell 
terrier
50.8 121.4 24.43 3.22 0.31
124329 2 M Golden retriever 13.9 33.8 ND ND 0.30
130849 6 F Crossbreed 31.4 164.6 14.45 2.07 0.14
132239 11.5 FN Cocker spaniel 19.3 47.8 1 2 . 6 6 1.93 0.53
124911 4.5 F Gordon setter 35.0 83.0 51.25 1.41 0.37
131528 1 1 F Border collie 17.8 50.0 17.52 2.19 0.43
132510 1 0 FN Golden retriever 1 2 . 8 32.3 1 0 . 2 ND 0 . 0 2
131182 7 F Belgian
shepherd
54.4 82.2 11.44 4.59 0.29
131258 8 F Borzoi 11.7 36.7 9.01 2.72 0.80
130406 7 M Flat coated 
retriever
17.3 51.5 12.29 2 . 8 6 1.63
131785 4 M Eng SpSp 36.1 70.5 15.50 2.82 0.18
131709 1 1 MN Lhasa apso 25.4 97.4 23.56 2.34 0.23
133780 9.5 MN Cairn terrier 34.9 94.7 16.49 2 . 6 8 0.17
131288 4 FN Lhasa apso 26.6 76.7 15.34 2.56 0.16
124766 3.5 F Min schnauzer 46.5 1 0 0 . 8 19.99 3.38 0 . 2 0
132385 14.5 M Labrador 9.8 32.4 4.39 2.92 0.13
126035 1 M Scottish terrier 33.0 65.0 31.21 1.26 0 . 1 0
129797 5 M Golden retriever 1 0 . 2 52.3 10.64 1.52 0.03
129161 4 M Golden retriever 27.5 63.3 17.85 2.67 0.05
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Appendix 30 continued
Case
Number
Age
(yrs)
Sex Breed Basal 
Total T4 
(nmol/L)
Post- 
TSH 
Total T4 
(nmol/L)
Free T4 
(pmol/L)
Total T3 
(nmol/L)
cTSH
(ng/ml)
125089 13 FN WHWT 1 0 . 8 25.6 33.29 1.46 0.24
127258 1 1 M English setter 2 2 . 2 58.2 41.75 1.82 0.34
125949 7 FN Rottweiler 23.2 67.2 18.40 1.95 0.17
130548 1 1 MN Doberman 13.1 48.7 7.77 2.63 0.89
117757 5.25 M Newfoundland 35.9 59.1 22.64 1.38 0.17
131276 7 FN Samoyed 28.4 63.9 10.59 2.93 2 . 1 0
130897 6 F Cairn terrier 15.7 45.5 11.40 2.24 0.77
132249 7 M WHWT 19.3 59.2 16.12 2.80 0.37
126513 5 FN Bearded collie 29.6 63.7 23.27 ND 0.47
WHWT West Highland White Terrier BMD Bernese Mountain Dog
GSD German Shepherd Dog PMD Pyrenean Mountain Dog
CKCS Cavalier King Charles Spaniel ND Analysis not done
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Appendix 31
Analysis o f breed and specialty distributions within the hospital control group.
Dogs within the hospital control group were grouped according to the specialty to which 
they were referred. The distribution of breeds within these groups were then determined 
and are detailed in Table 46. A selection of these data are displayed in Figure 30. The 
hospital computer breed coding used for case grouping is detailed in Table 47.
As can be appreciated from Table 46 and Figure 30 a small number of disciplines 
accounted for a relatively large percentage of the total referral group. The most common 
disciplines to which cases were referred were general medicine (n=1047, 18.2 %), 
orthopaedics (n=829, 14.4 %), ophthalmology (n=828, 14.4 %) and soft tissue surgery 
(n=691, 12.0 %). The specialties which accounted for the largest relative referrals of 
individual breeds are detailed in Table 48. It can be seen from these data that certain breeds 
were more commonly referred to particular specialties. For example 20 of 50 (40.0 %) 
daschunds and 12 of 27 Pekinese (44.4 %) were referred to neurology, and 27 of 99 (27.3 
%) poodles were referred to ophthalmology. These biases are unlikely to significantly 
damage the control data if the actual number of animals of each breed involved remains 
small in relation to the total number of control cases.
In addition to evaluating the percentage of each breed referred to each specialty, the 
percentage of each specialty accounted for by individual breeds was examined. The 
specialties in which an individual breed accounted for greater than 15 % of the total 
referrals to that specialty are detailed in Table 49. It can be seen from these data that 
certain specialties were composed predominantly o f one or two breeds of dog. For 
example, of the 69 cases within the pathology specialty, 66 (95.6 %) were German 
shepherd dogs. This is potentially much more damaging to the validity of the control group 
due to the introduction of a large number of a particular breed. Closer investigation of the 
pathology groups revealed that these were dogs actively recruited to the University of 
Glasgow Veterinary School for a particular study on chronic degenerative 
radiculomyelopathy (CDRM). The categorisation of breeds and specialties in this manner 
allowed the identification of such biases.
From the data presented it is clear that there is the potential for certain breeds 
referred in disproportionately high numbers to particular specialties, to influence the
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makeup of the hospital control group as a whole. Prior to interrogating the database, it had 
been the intention to statistically analyse the distribution of breeds within specialties by chi 
squared analysis. This would have allowed identification and removal of offending subsets 
of dogs. However, as is illustrated by the data in this appendix, multiple breeds across 
multiple disciplines were present in sufficiently large numbers to make statistical evaluation 
of the data extremely complicated. In addition, chi squared analysis became inappropriate 
since the appropriate R x C contingency tables had numerous cells which were either empty 
or below a value considered statistically safe (usually five) for analysis.
An alternative approach which was considered, was to compare the distribution of 
breeds within a specialty, to the distribution of that breed within all other specialties as a 
single group. This approach would have allowed simple chi squared analysis and has been 
applied previously in a similar situation (Graham, 1995). However, after consideration that 
approach was rejected since any overrepresentation of a breed within a discipline would in 
itself, when included in the control group, reduce the likelihood of identifying over-referral 
of that breed within any other specialty. The detail involved in analysing the hospital group 
for the purpose of producing a valid control was consequently considered beyond the scope 
of this thesis. The hospital group was subsequently used unaltered as the control. It was felt 
that its comparative value with other studies who have used equivalent control cases, 
alongside recognition of the inherent problems associated with this approach justified its 
inclusion in this study.
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Appendix 31 (continued)
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Code Breed Code Breed Code Breed Code Breed
1 Affenpinscher 26 Doberman 51 Lowchen 76 Rottweiler
2 Akita 27 Elkhound 52 Lundehund 77 St Bernard
3 Anatolian
karabash
28 Estrela
Mountain
Dog
53 Lurcher 78 Saluki
4 Basenji 29 Fila Brasiliero 54 Malamute 79 Samoyed
5 Beagle 30 Foxhound 55 Maltese 80 Schipperke
6 Belgian
Shepherd
31 French
Bulldog
56 Maremma
Sheepdog
81 Schnauzer
• 7 Bernese
Mountain
Dog
32 German 
Shepherd Dog
57 Mastiff 82 Sennenhund
8 Bichon Friese 33 Great Dane 58 Mexican
hairless
83 Setter
9 Bloodhound 34 Greyhound 59 Munsterlander 84 Sheltie
10 Borzoi 35 Griffon 60 Newfoundland 85 Shih Tzu
11 Bouvier des 
Flandres
36 Hamilton
Stovare
61 Norwegian
Buhund
86 Sloughi
12 Boxer 37 Harrier 62 Old English 
Sheepdog
87 Spaniel
13 Briard 38 Lancashire
Heeler
63 Papillon 88 Spinone
14 Bulldog 39 Lancashire
Heeler
64 Pekinese 89 Spitz
15 Bullmastiff 40 Hovawart 65 Pinscher 90 Staghound
16 Canaan Dog 41 Husky 66 Pointer 91 Swedish
Vallhund
17 Chihuahua 42 Italian
Greyhound
67 Pomeranian 92 Terrier
18 Chinese
Crested
43 Japanese Chin 68 Poodle 93 Tosa
19 Chow Chow 44 Karelian Bear 
Dog
69 Portugese 
Water Dog
94 Trailhound
20 Collie 45 Keeshond 70 Pug 95 Viszla
21 Coonhound 46 Kelpie 71 Puli
Hungarian
96 Weimeraner
22 Corgi 47 Komondor 72 Pumi 97 Whippet
23 Dachshund 48 Kuvasz 73 Pyrenean 
Mountain Dog
98 Sharpei
24 Dalmation 49 Leonberger 74 Retrievers 99 Crossbreed
25 Deerhound 50 Lhasa Apso 75 Rhodesian
Ridgeback
Table 47. Hospital computer codes used to categorise individual breeds
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Specialty Breed
Number 
of dogs
Percentage of total 
referrals of that breed
Cardiology Boxer 33 18.5%
Dermatology Terriers 100 10.6 %
General Medicine Retrievers 198 19.5 %
Terriers 155 16.5 %
Spaniels 100 15.8%
GSD 95 19.6%
Collies 88 18.0%
Crossbreeds 73 16.3 %
Rottweiler 35 24.5 %
Doberman 30 31.2%
Boxer 28 15.7%
Greyhound 20 39.2 %
Setters 14 17.7%
Great Dane 13 18.3%
Shetland 13 26.5 %
Sheepdogs
Dachshunds 12 24.0 %
Poodles 11 11.1 %
Neurology Dachshund 20 40.0 %
Doberman 19 19.8%
Pekinese 12 44.4 %
Great Dane 11 15.5%
Ophthalmology Terriers 190 20.2 %
Retrievers 139 13.7%
Spaniels 127 20.1 %
Crossbreeds 67 15.0%
Collies 55 11.2%
Poodles 27 27.3 %
Boxer 22 12.4%
Tosa 11 13.9%
Table 48.
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Specialty Breed Number 
of dogs
Percentage of total 
referrals of that breed
Orthopaedics Retrievers 200 19.7%
Terriers 103 10.9%
Collies 85 17.4%
Spaniels 69 10.9%
GSD 64 13.2 %
Crossbreeds 51 11.4%
Rottweiler 30 21.0%
Newfoundland 14 32.6 %
Bernese 
Mountain Dog
12 30.0 %
BullmastifF 12 21.4%
Great Dane 12 16.9%
Poodle 12 12.1 %
Pathology GSD 66 13.6%
Soft Tissue Surgery Terriers 111 11.8%
Retrievers 103 10.1 %
Collies 88 18.0%
GSD 86 17.8%
Crossbreeds 68 15.2%
Spaniels 64 10.1 %
Boxer 19 10.7 %
Setters 15 19.0%
Table 48 (continued) Specialties in which individual breeds constituted more than 10 
percent of the total referrals o f that breed (only groups with more than 10 individuals are 
included)
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Appendix 31 (continued)
Specialty Breed Number 
of dogs
Percentage of total referrals to that 
specialty accounted for by that breed
Cardiology Retrievers 64 17.4%
Dermatology Terriers 100 23.0 %
Retrievers 66 15.2%
Endocrinology Terriers 57 18.5%
General Medicine Retrievers 198 18.9%
Oncology Retrievers 69 26.3 %
Ophthalmology Terriers 190 22.9 %
Retrievers 139 16.8 %
Spaniels 127 15.3 %
Orthopaedics Retrievers 200 24.1 %
Pathology GSD 66 95.6 %
Reproduction Terriers 26 20.2 %
Soft Tissue Surgery Terriers 111 16.1 %
Others Terriers 65 19.3%
Retrievers 56 16.7%
Table 49. Breeds of dog within each referral specialty in which the particular breed 
represented more than 15 % of the total referrals to that specialty.
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Appendix 32
Further evaluation of case number 127627. A case with concurrent hypothyroidism and 
hyperadrenocorticism
A nine year old entire male poodle was referred with a history of lethargy, flank alopecia, 
superficial pyoderma, abdominal distention and more recently, polydipsia and polyphagia. 
Subsequently, neurological abnormalities developed, most notably right peripheral 
vestibular syndrome and bilateral facial nerve paralysis. Abnormal routine and endocrine 
clinicopathological findings including results o f ACTH stimulation and low dose 
dexamethasone suppression testing are detailed in Tables 50 and 51. Based on the clinical 
and clinicopathological findings, a diagnosis of pituitary dependent hyperadrenocorticism 
(PDH) was made.
Analyte Result Comment
Cholesterol (mmol/L) 17.81 Increased
ALKP (Lu/L) 1774 Increased
ALT (i.u./L) 256 Increased
Lymphocytes (x 109/L) 0.889 Decreased
Table 50. Routine clinicopathological abnormalities in case number 127627.
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Test Time Result Comment
ACTH Stimulation Pre ACTH cortisol 
Post ACTH cortisol
130 nmol/L 
670 nmol/L
Consistent with 
hyperadrenocorticism
Low Dose
Dexamethasone
Suppression
Basal cortisol
Three Hours post ACTH
Eight Hours post ACTH
121 nmol/L 
9 nmol/L 
37 nmol/L
Consistent with 
pituitary dependent 
hyperadrenocorticism
TSH stimulation
Basal Total T4 
Six Hours post TSH 
Basal cTSH
LoD 
LoD 
0 . 0 1  ng/ml
Consistent with 
hypothyroidism but with 
discordant cTSH
Table 51. Dynamic endocrine test results in case number 127627.
LoD: result at or below the assay limit of detection
Due to the suppressive effect of NTI on thyroid function, the diagnosis of hypothyroidism 
remained provisional and thyroid function was monitored following treatment for 
hyperadrenocorticism. Mitotane treatment was commenced and resulted in partial 
resolution of the clinicopathological and clinical abnormalities within 10 days. However the 
metabolic clinical signs, and total T4 concentration in particular remained abnormal despite 
otherwise adequate therapy confirmed by monitoring ACTH stimulation tests (Table 52). 
Following six weeks of mitotane therapy there was no change in thyroid hormone 
parameters and a diagnosis of concurrent hypothyroidism was made.
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Date Total T4 
(nmol/L)
cTSH
(ng/ml)
Basal
cortisol
(nmol/L)
Post-ACTH
cortisol
(nmol/L)
Comment
26/3/97 LoD LoD 130 670 Therapy for
hyperadrenocorticism starts
1/4/97 LoD (pre) 
LoD (post)
LoD TSH stimulation test
10/4/97 4.9 0.03 LoD LoD
17/4/97 LoD LoD
13/5/97 LoD LoD No change in thyroid status
Table 52. Endocrine results with time in case 127627.
LoD: result at or below the assay limit of detection
Since the cTSH concentration in this dog remained at the cTSH assay LoD, a TRH 
stimulation test was performed the results o f which are detailed in Table 53. These were 
consistent with a diagnosis o f central hypothyroidism.
Time cTSH (ng/ml) Comment
0  minutes 0.03 No response to TRH
1 0  minutes 0 . 0 2 administration consistent
2 0  minutes 0.03 with central
30 minutes 0 . 0 2 hypothyroidism
Table 53. Response of cTSH to exogenous TRH administration in case number 127627.
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Following the start of thyroid hormone replacement therapy, there was a good 
clinical response associated with appropriate therapeutic concentrations of the hormone 
(results not shown). To minimise the interpretation o f clinical signs resulting from the 
hyperadrenocorticism as being due to hypothyroidism only those signs which either 
developed or persisted following therapy for the hyperadrenocorticism were used in the 
analysis of clinical signs associated with hypothyroidism outlined in Chapter 5.
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Appendix 33
Endocrinological case details recorded from 31 dogs receiving thyroid hormone 
replacement therapy.
Dog Hospital
number
Date Days on 
therapy
Visit Weight
(kg)
Percent
starting
weight
Total
t 4
cTSH
1 116865 17-06-96 0 1 7.6 3.3
1 116865 16-07-96 29 3 56.4 0.01
1 116865 16-09-96 91 4 41.7 0.1
2 131136 23-02-98 0 1 22.5 100 4.7 0.91
2 131136 12-03-98 17 2 21.4 95.1 50 0.07
2 131136 23-04-98 59 3 19.4 86.2 38.4 0.03
2 131136 15-06-98 112 4 20.2 89.8 67.9 0.01
3 131132 06-01-97 0 1 9.8 100 11.4 12.3
3 131132 27-01-97 21 2 9.8 100 13.3 1.65
3 131132 03-03-97 56 3 9.4 95.9 63.7 0.01
3 131132 15-04-97 99 4 9.2 93.9 60.7 0.01
4 131486 03-07-97 0 1 7.3 100 14 3.25
4 131486 04-08-97 32 3 7.5 102.7 26.8 0.54
4 131486 18-09-97 77 4 7.5 102.7 48.4 0.51
5 129827 03-06-96 0 1 22 100 4.7 1.89
5 129827 12-06-96 9 2 62.6 0.02
5 129827 11-07-96 38 3 20.2 91.8 43.5 0.01
5 129827 23-09-96 112 4 53.6 0.02
6 133137 16-10-97 0 1 4.7 3.57
6 133137 30-10-97 14 2 95.1 0.02
6 133137 27-11-97 42 3 52.9 0.02
6 133137 05-02-98 112 4 64.6 0.01
7 133791 20-01-98 0 1 10 100 5.1 0.02
7 133791 09-02-98 20 2 9.1 91 39.6 0.01
7 133791 12-03-98 51 3 9.1 91 37 0.01
8 133026 02-10-97 0 1 55 100 13.8 8.52
8 133026 27-11-97 56 3 48 87.3 58.3 0.32
8 133026 08-01-98 98 4 50.5 91.8 49.2 0.18
9 130794 11-11-96 0 1 32 100 5.2 0.96
9 130794 25-11-96 14 2 32.5 101.6 100.5 0.05
9 130794 24-12-96 43 3 31.7 99.1 77.2 0.05
9 130794 03-02-97 84 4 31.2 97.5 116.5 0.04
10 132396 16-07-97 0 1 33.2 100 12.8 4.34
10 132396 04-08-97 19 2 31.5 94.9 81.1 0.01
10 132396 11-09-97 57 3 31 93.4 103.5 0.01
10 132396 13-10-97 89 4 30 90.4 12.6 0.01
11 122647 24-07-97 0 1 37 100 12.4 3.32
11 122647 08-08-97 15 2 42.3 0.14
11 122647 25-09-97 63 3 36 97.3 42.6 1.62
11 122647 06-11-97 105 4 34.4 93.0 39.9 0.25
12 134214 30-03-98 0 1 39.25 100 5.3 2.1
12 134214 23-04-98 24 2 38.5 98.1 74.6 0.1
12 134214 21-05-98 52 3 36.1 92.0 76 0.02
13 130375 07-10-96 0 1 16 100 4.7 1.42
13 130375 21-10-96 14 2 14.4 90 54.2 0.31
13 130375 02-12-96 56 3 14.1 88.1 49.2 0.39
13 130375 20-01-97 105 4 14.5 90.6 50.7 1
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Appendix 33 (continued)
Dog Hospital
number
Date Days on 
therapy
Visit Weight
(kg)
Percent
starting
weight
Total
t 4
cTSH
14 134156 09-03-98 0 1 21.5 100 4.7 1.18
14 134156 26-03-98 17 2 20.5 95.3 52 0.25
14 134156 22-04-98 44 3 20.9 97.2 45 0.19
14 134156 01-06-98 84 4 19.5 90.7 31.4 0.15
15 129838 03-06-96 0 1 23.5 100 5.6 2.48
15 129838 01-07-96 28 2 81.1 0.01
15 129838 19-08-96 77 4 22 93.6 60.8 0.02
16 130866 18-11-96 0 1 46 1 4.7 1.68
16 130866 05-12-96 17 2 44 95.6 52.1 0.15
16 130866 06-01-97 49 3 40.5 88 46.7 0.02
16 130866 17-02-97 91 4 39.3 85.4 51.1 0.03
17 129976 20-06-96 0 1 11.8 100 4.7 5.98
17 129976 16-07-96 26 2 11.3 95.8 76.6 0.02
17 129976 26-08-96 67 3 11 93.2 86.1 0.05
17 129976 07-10-96 109 4 10.7 90.7 62.7 0.06
18 130656 22-10-96 0 1 36 100 4.7 0.69
18 130656 30-12-96 69 3 34.5 95.8 54.2 0.05
18 130656 27-01-97 97 4 33.5 93 50.8 0.01
19 132798 03-09-97 0 1 9.5 100 4.7 0.03
19 132798 12-09-97 9 2 8.9 93.7 47.4 0.01
20 128082 05-03-96 0 1 22.4 100 4.7 2.67
20 128082 29-04-96 55 3 23 102.7 42.3 02
21 127111 04-06-96 0 1 32 100 5.5 2.17
21 127111 17-06-96 13 2 33.5 104.7 38.7 0.07
21 127111 09-09-96 97 4 30.5 95.3 95.9 0.19
22 133778 19-01-98 0 1 22.7 100 4.7 0.08
22 133778 05-02-98 17 2 22.5 99.1 79.3 0.03
22 133778 09-03-98 49 3 22.8 100.4 39.8 0.01
22 133778 16-04-98 87 4 22 96.9 71.1 0.01
23 133641 29-12-97 0 1 30.5 100 4.7 2.13
23 133641 12-01-98 14 2 28 91.8 29.3 0.75
23 133641 09-02-98 42 3 29.4 96.4 32 0.01
23 133641 23-03-98 84 4 27.1 88.8 27.7 0.01
24 132391 03-07-97 0 1 30 100 4.8 1.52
24 132391 24-07-97 21 2 27.5 91.7 8.3 0.02
24 132391 01-09-97 60 3 27.5 91.7 41.9 0.01
24 132391 02-10-97 91 4 26.3 87.7 40.9 0.01
25 127627 13-05-97 0 1 4.7 0.01
25 127627 06-06-97 24 2 29.1 0.01
26 134019 18-02-98 0 1 17.8 6.3
26 134019 11-03-98 21 2 26.3 0.02
27 131426 13-02-97 0 1 38.7 1 4.7 1.77
27 131426 27-02-97 14 2 37.2 96.1 90.3 0.04
27 131426 18-03-97 33 3 35.3 91.2 38.5 0.05
27 131426 02-06-97 109 4 29.5 76.2 57.2 0.01
28 127940 30-04-96 0 1 31.5 100 4.7 0.98
28 127970 22-05-96 22 2 31 98.4 36.8 0.1
28 127940 18-06-96 49 3 60.7 0.09
29 129565 07-05-96 0 1 24.2 100 14-5 0.84
29 129565 28-05-96 21 2 22 90.9 53.8 0.03
29 129565 15-08-96 100 4 21 86.8 88 0.03
30 129757 07-11-97 0 1 4.7 134
30 129757 21-11-97 14 2 39.4 0.66
30 129757 11-12-97 34 3 31.4 0.22
31 131438 17-02-97 0 1 32.8 100 4.7 0.03
31 131438 06-03-97 17 2 31.5 96.0 67.3 0.01
31 131438 07-04-97 49 3 30 91.5 49.9 0.01
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ABBREVIATIONS
% Percent
± Plus or minus
p Micro
pi Microlitre
jlxTJ Microunits
3,5-T2 3,5-diiodothyronine
5-D 5-deiodinase
Ab Antibody
ACTH Adrenocorticotropin
AITD Autoimmune thyroid disease
BSA Bovine serum albumin
cpm Counts per minute
c.v. Coefficient of variation
cAMP Cyclic adenosine monophosphate
CCH Chromic chloride passive haemagglutination
CDS Clinical disease score
cTSH Canine thyroid stimulating hormone
DCM Dilated cardiomyopathy
DIT Diiodothyrosine
dl Decilitre (100 mililitres)
DPR Differential positive rate
DVCS Department of Veterinary Clinical Studies
ECG Electrocardiographic
EDTA Tri-potassium ethylenediamine tetra-acetic acid
ELISA Enzyme-linked immunosorbent assay
FSH Follicle stimulating hormone
fT4I Free thyroxine index
g Grams
GCH Glutaraldehyde
GnRH Gonadotropin releasing hormone
HDL High density lipoproteins
h d l 2 High density lipoprotein-2
HIV Human immunodeficiency virus
HRP Horseradish peroxidase
Lu. International unit
IFCC International Federation of Clinical Chemistry
IgG Gammaglobulin
IRMA Immunoradiometric assay
KBq Kilo Becquerels
KC The Kennel Club
kg Kilogram
L Litre
lbs Pounds (weight)
LDL Low density lipoproteins
LH Leutenising hormone
LMN Lower motor neurone
LoD Limit o f detection
mg Milligrams
Abbreviations
MHC Major histocompatability complex
MIT Monoiodotyrosine
ml Millilitre
N Normal (molar strength)
ng Nanogrames
nmol Nanomoles
NSAID Non-steroidal anti inflammatory drugs
NSB Non-specific binding
NTI Non-thyroidal illness
o.d. Optical density
o.r. Odds ratio
°c Degrees celcius
P Statistical probability value
PBS Phosphate buffered saline
PC Personal computer
PEG Polyethyleneglycol
PFMA Pet Food Manufacturers Association
pmol Picomoles
PTU Propylthiouracil
QC Quality control
RIA Radioimmunoassay
ROC Receiver operating characteristic
rT3 3,3’,5'-T3 (reverse-T3)
s.d. Standard deviation
s.e.m. Standard error of the mean
SIBO Small Intestinal Bacterial Overgrowth
SIR Semi-interquartile range
S.I. Systeme International d’Unites
t 3 3,5,3 '-T riiodothyronine
T3Ab T3 autoantibodies
t 3-s T3 sulphates
t 4 3,5,3,,5,,tetraiodothyronine (thyroxine)
T4Ab T4 autoantibodies
TBG Thyroid hormone binding globulin
TBPA Thyroid hormone binding prealbumin
TC Total counts (of radioactivity)
TCH Tanned cell haemagglutination
Tg Thyroglobulin
TgAb Thyroglobulin autoantibodies
THBI Thyroid hormone protein binding inhibitors
THBR Thyroid hormone binding ratio
THRT Thyroid hormone replacement therapy
TMB 3,3,,5,5'-tetramethylbenzidine
TPO Thyroid peroxidase
TPOAb Thyroid peroxidase autoantibodies
TRAb Thyrotropin receptor antibodies
TRH Thyrotropin releasing hormone
TSH Thyroid stimulating hormone
UK United Kingdom
USA United States of America
VLDL Very low density lipoproteins
Abbreviations
W Area under the ROC curve
5-D 5-deiodinase
3,3'-T2 3,3,-diiodothyronine
125I 125radioiodine
131I 13'radioiodine
Note that abbreviations for all clinicopathological parameters are detailed 
Appendices 2 and 4.
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